Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Involving virus or bacteriophage

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130045474DEVICES AND METHODS FOR DETECTING AND MONITORING HIV AND OTHER INFECTIONS AND DISEASES - Disclosed herein are bio-nanosensor devices and methods suitable for blood assays. The bio-nanosensors are based on thickness shear mode transducer capable of transmitting a shear wave into a biofluid adjacent to a bio-functionalized sensing interface of a piezoelectric crystal. The bio-functionalized sensing interface includes one or more antibodies and/or biomarker-specific ligands capable of sensing HIV. The disclosed bio-nanosensors are capable of defecting the presence of HIV virus at picogram sensitivities using no more than 10 μl of blood in less than 15 minutes.02-21-2013
20110177495CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS - The present invention discloses generalizable methods of evolving nucleic acids and proteins utilizing continuous directed evolution. The invention discloses methods of passing a nucleic acid from cell to cell in a desired function-dependent manner. The linkage of the desired function and passage of the nucleic acid from cell to cell allows for continuous selection and mutation of the nucleic acid.07-21-2011
20120202192HYPER-SPECTRAL IMAGING AND ANALYSIS OF A SAMPLE OF MATTER, FOR IDENTIFYING AND CHARACTERIZING AN OBJECT OF INTEREST THEREIN - Method for hyper-spectral imaging and analysis of a sample of matter, for identifying and characterizing an object of interest therein. Preparing test solution or suspension of the sample, including adding thereto a spectral marker specific to object of interest, such that if object of interest is in test solution or suspension, object of interest becomes a hyper-spectrally active target which is hyper-spectrally detectable and identifiable; adding to test solution or suspension a background reducing chemical, for reducing background interfering effects caused by presence of objects of non-interest in test solution or suspension, thereby increasing hyper-spectral detectability of hyper-spectrally active target in test solution or suspension; generating and collecting hyper-spectral image data and information of test solution or suspension; and, processing and analyzing thereof. Exemplary objects of interest are biological agents—bacteria (08-09-2012
20120202190DETECTION OF HEPATITIS B VIRUS IN BLOOD USING LAMP METHOD - A method for detection blood borne pathogen in whole blood, comprising collecting a blood sample from a subject, heating said sample for a period of time, adding said heated sample to a pre-mixed LAMP solution comprising one or more LAMP primer set, and Bst DNA polymerase to create a reaction mixture, incubating said reaction mixture for a period of time and determining the presence of blood born pathogen.08-09-2012
20100075299DETECTION AND USE OF ANTIVIRAL RESISTANCE MUTATIONS - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.03-25-2010
20080286751Dispensing Device For Microfluidic Droplets Especially For Cytometry - The invention relates to a dispensing device for droplets comprising a first channel (11-20-2008
20090181365NOROVIRUS DETECTION REAGENT - The present invention provides a combination of oligonucleotides preferable for composing a gene testing reagent capable of detecting all subtypes of norovirus rapidly and with high sensitivity. More specifically, the present invention provides a detection method in which only norovirus is specifically amplified and an oligonucleotide that binds to a specific site of norovirus, by using a primer having a sequence that is homologous or complementary to a base sequence specific for norovirus and is located at a position subject to minimal mutation according to subtype.07-16-2009
20100015597PRODUCTION OF BIOLOGICAL CARRIERS FOR INDUCTION OF IMMUNE RESPONSE AND INHIBITION OF VIRAL REPLICATION - This application provides a method to form non-infectious Biological Carrier that may be used to deliver signals to cells either in vitro or in vivo. The Biological Carriers are inactivated virus particles that have been specifically modified to give biological properties different from the virus particles deriving from an unmodified host cell that (i) expresses at least one co-stimulatory molecule and (iia) at least one antigen that can initiate an immune response, and/or (iib) express surface molecules that suppress viral replication.01-21-2010
20080268424Glut-1 as a Receptor for Htlv Envelopes and its Uses - The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.10-30-2008
20100143882IMPROVED MULTIPLEX NUCLEIC ACID AMPLIFICATION USING BLOCKED PRIMERS - The present invention is in the field of nucleic acid amplification, and in particular in transcription-based amplification, providing improvements thereof. Specifically, the present invention provides primers, and methods for using them, that improve transcription-based amplification reactions, in particular multiplex reactions.06-10-2010
20080261202Tagged Polyfunctional Reagents Capable of Reversibly Binding Target Substances in a pH-dependent Manner - Polyfunctional reagents are disclosed that are capable of reversibly binding to target substances, for example nucleic acid, proteins, polypeptides, cells, cell components, microorganisms or viruses, for use in purifying or otherwise manipulating them. The reagents comprise a tagging group for manipulating and/or detecting the target substance when bound to the polyfunctional reagent. The polyfunctional reagents work by binding the target substance at a first pH and then releasing it at a second pH, usually higher than the first. Examples of tagging groups include tagging group members of a specific binding pair which is capable of binding to a specific binding partner and/or a label.10-23-2008
20090325147MOLECULARLY IMPRINTED POLYMERS FOR DETECTING MICROORGANISMS - The invention described herein provides molecularly imprinted polymers (MIPs) that are capable of binding to a microorganism, and methods for detecting and/or identifying microorganisms utilizing Molecularly Imprinted Polymers (MIPs). The microorganisms of the invention include prokaryotes, eukaryotes, virus and prions. The methods of the invention comprise detecting all or part, including epitopes, of macromolecules associated with the microorganisms. The macromolecules of the invention include polysaccharides, proteins, glycoproteins, peptidoglycans, lipoproteins, peptides, polypeptides, and polynucleotides, associated with said microorganisms. The invention also provides for methods of diagnosing a subject infected with the microorganisms utilizing MIPs, in addition to diagnostic kits.12-31-2009
20100055674UTILIZING LIVER CELL LINE QSG-7701 TO BE INFECTED WITH HEPATITIS B VIRUS - The use of the liver cell line QSG-7701 for HBV infection includes the following steps: directly infecting QSG-7701 cells with purified HBV particles and facilitating the infection by DMSO and/or PEG treatment. The easily available QSG-7701 liver cell line may not require pre-differentiation induction and is naturally susceptible for HBV infection. This cell line provides near normal physiological conditions for HBV infection, especially the infection conditions that are characterized with Chinese origin. This cell line is suitable for investigating the life cycle of HBV. Therefore, this cell line is useful for the investigation of viral infection processes and for the development of drugs that specifically target these processes.03-04-2010
20090311669SIGNAL FOR PACKAGING OF INFLUENZA VIRUS VECTORS - The invention provides a packaging (incorporation) signal for influenza virus vectors, and methods of using the signal to transmit and maintain influenza viral and foreign nucleic acid in virus and cells.12-17-2009
20110189651Method and Device for Detecting Feline Immunodeficiency Virus - A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV polypeptides and determining the binding of antibodies in the sample to the polypeptides. The determination of whether an animal is infected with FIV or has been vaccinated against FIV can be determined by measuring the animal's immune response to an FIV env polypeptide. A device for detecting FIV antibodies is provided.08-04-2011
20090155772Method for detecting nanbv associated seroconversion - The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors are transformed into host cells and used in a method to express large quantities of these antigens. The invention also provides compositions containing certain of the isolated antigens, diagnostic systems containing these antigens and methods of assaying body fluids to detect the presence of antibodies against the antigens of the invention.06-18-2009
20100151446METHOD FOR COUNTING AND SEGMENTING VIRAL PARTICLES IN AN IMAGE - The method is for intracellular counting and segmentation of viral particles in an image. An image is provided that has a plurality of items therein. A radius range of viral particles is determined. Round items in the image having a radius within the predetermined radius range are identified. Elliptical items that are formable from the predetermined radius range are determined. The round and elliptical items identified into groups are sorted. The viral particles among the round and elliptical items are identified. For example, the method may be used for intracellular counting and segmentation of siRNA treated human cytomegaloviral particles in TEM images.06-17-2010
20120183951COMPOSITIONS FOR USE IN IDENTIFICATION OF ARENAVIRUSES - The present invention relates generally to the detection and identification of arenaviruses and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.07-19-2012
20120183950TISSUE ANALYSIS - The present invention provides a method of tissue analysis, disease modelling or drug development comprising the steps of providing a tissue sample comprising cells of at least two different cell types; exposing cells in the tissue sample to an agent ex vivo; exposing the cells to three or more detection means arranged to distinguish between three or more different cell types and/or different cell states; detecting the detection means in order to determine the different cell types and/or different cell states in the sample. The invention further provides a kit for performing the method of the invention and uses of the method of the invention.07-19-2012
20120183949Method, device, or system using lung sensor for detecting a physiological condition in a vertebrate subject - Devices, systems, and methods are disclosed herein for detecting one or more physiological conditions in lungs of a vertebrate subject. A method is described for administering at least one microparticle to lungs of a vertebrate subject, wherein the at least one microparticle includes one or more markers; wherein the one or more markers is configured to be released in response to one or more physiological conditions in the vertebrate subject; and detecting the one or more markers in a lung exhalant of the vertebrate subject.07-19-2012
20090325148Bead Array Reader Based-Hemagglutination and Hemagglutination Inhibition Assay - Hemagglutination assays and hemagglutination inhibition assays were introduced in medical and virology practice more than 60 years ago. Since then, these assays have become important tools for measuring concentrations and strengths of viral cultures, the efficacy of the anti-viral immunization, and for studying the neutralizing capacity of virus-specific antibodies. The present invention comprises an improved hemagglutination inhibition assay (HAI), with at least about a 10-fold increase in sensitivity versus the traditional the HAI, to provide more accurate measurements of components in, for example, fluids from the in vitro MIMIC® system when assessing the effects of anti-viral vaccines (e.g., for seasonal influenza).12-31-2009
20100009344LIQUID CRYSTAL BASED ANALYTE DETECTION - The present invention relates to the field of detection of viruses, and in particular to detection of viruses using a liquid crystal assay format. In the present invention, virus binding in a detection region is identified by changes in liquid crystal orientation caused by virus binding independent orientation caused by any topography associated with the detection region.01-14-2010
20100159440METHODS FOR IDENTIFYING AGENTS THAT MODULATE p44 - The present invention provides methods for identifying evolutionarily significant polynucleotide and polypeptide sequences in human and/or non-human primates which may be associated with a physiological condition, such as enhanced resistance to HCV infection. The invention also provides methods for identifying evolutionarily significant polynucleotides with mutations that are correlated with susceptibility to diseases, such as BRCA1 exon 11. The methods employ comparison of human and non-human primate sequences using statistical methods. Sequences thus identified may be useful as host therapeutic targets and/or in screening assays.06-24-2010
20100159443DISEASE MODEL INCORPORATION INTO AN ARTIFICIAL IMMUNE SYSTEM (AIS) - The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.06-24-2010
20100159439Method for combined sequential agent delivery and electroporation for cell structures and use thereof - Disclosed is a method for sequential delivery of agents to and/or into a cell structure, wherein an electrolyte-filled tube is provided together with a counter electrode, said tube is connected to a voltage or current generator, at least two agents are introduced in a discrete mode into the electrolyte solution contained in the tube, which is placed close to the cell structure, one agent at the time being transported through the tube to and/or into said cell structure in which a pore has been formed by application of an electric field focused on the cell structure, resulting in electroporation of the cell structure. Also different applications of the method is disclosed, e.g. us of the method in order to transfer cell-impermeant solutes, such as drugs or genes, into the cell structure or out of the cell structure.06-24-2010
20100143888ENZYMATIC DIAGNOSTIC TEST FOR SARS AND OTHER VIRAL DISEASES - The present invention is directed towards methods, compositions and kits for testing for a virus in a sample. The methods determine the presence of a viral enzyme by contacting the sample with a peptidal compound capable of being cleaved by the viral enzyme to form peptidal compound fragments. Detection of a peptidal compound fragment confirms the presence of the virus.06-10-2010
20080213753METHOD FOR THE VERIFICATION OF THE REMOVAL OF VIRUSES TO VALIDATE FILTERS AND FILTERING PROCESSES - Disclosed is a method for verification of the removal of viruses to validate filters, filtering processes, physical and chemical inactivation processes, or adsorptive removal processes in predefined process conditions that are simulated on a small scale. According to said method, viruses are cultured in suitable cell lines in a first step, a virus suspension is obtained after solubilizing cells in a second step, the virus suspension obtained is added in a third step to a protein solution that is to be analyzed, and the virus-containing protein solution is filtered through the filter that is to be validated, and the removal of viruses is then analyzed in a fourth step. The virus suspension is first processed via a membrane adsorber following step two, the viruses being bonded to the membrane adsorber and contaminants being removed with the aid of a detergent buffer solution, while the bonded, purified viruses are eluted from the membrane adsorber area and are added to the protein solution that is to be analyzed as a concentrated virus suspension in step three.09-04-2008
20090191540Markers for Viral Infections and Other Inflammatory Responses - Compositions and methods for the detection, diagnosis and treatment of BVDV are provided.07-30-2009
20090191538Selective detection of oncogenic HPV - Compositions and methods for discriminately detecting the presence of a set of related genes from target organisms while avoiding detection of closely similar genes in non-target organisms. The present invention achieves this objective by a variety of novel nucleic acid constructs and methods. The nucleic acid constructs of the present invention are able to carry out this objective by virtue of the selected sequences of the compositions and by methods of use of such compositions.07-30-2009
20100081127System and Method of Chemical Imaging Using Pulsed Laser Excitation and Time-Gated Detection to Determine Tissue Margins During Surgery - System and method for differentiating tissue margins in a biological sample using pulsed laser excitation and time-gated detection. A region containing a biological tissue is irradiated with substantially monochromatic pulsed laser light to thereby produce Raman scattered photons. The Raman scattered photons are detected using time-gated detection to thereby obtain a Raman spectroscopic image from the irradiated region characteristic of either a neoplastic portion or a non-neoplastic portion of the region containing the biological tissue. A boundary between a neoplastic portion and a non-neoplastic portion is differentiated and the boundary location in the Raman spectroscopic image is displayed.04-01-2010
20100120017RAPID IMMUNE CHROMATOGRAPHIC DETECTION BY AMPLIFICATION OF THE COLLOIDAL GOLD SIGNAL - The present invention relates to a rapid immunochromatographic test device suitable to detect more than one target in a single assay at the same time, uses of said device for detecting diseases in a sample, a method for the production of said device as well as a kit comprising the device.05-13-2010
20100120021HPV E6, E7 MRNA Assay and Methods of Use Thereof - Provided is an HPV E6, E7 mRNA assay, referenced herein as the “In Cell HPV Assay,” that is capable of sensitive and specific detection of normal cervical cells undergoing malignant transformation as well as abnormal cervical cells with pre-malignant or malignant lesions. The In Cell HPV Assay identifies HPV E6, E7 mRNA via in situ hybridization with oligonucleotides specific for HPV E6, E7 mRNA and quantitates the HPV E6, E7 mRNA via flow cytometry. The In Cell HPV Assay can be carried out in less than three hours directly from liquid-based cervical (“LBC”) cytology specimens. The In Cell HPV Assay provides an efficient and highly sensitive alternative to the Pap smear for determining abnormal cervical cytology.05-13-2010
20100120020FLUORESCENT NEUTRALIZATION AND ADHERENCE INHIBITION ASSAYS - The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.05-13-2010
20100112549Microorganism Detection Method and Apparatus - Embodiments of the present invention relate to selective organism detection, and, more particularly to recombinant bacteriophages and the use of such recombinant bacteriophages to detect target bacteria and to detect specific nucleic acid sequences within said target bacteria thus allowing for the detection of phenotypic characteristics of said bacteria such as determining drug(s) to which such target bacteria are resistant. The present invention further relates to sample preparation apparatuses for preparing samples for detection and analysis using bacteriophage-based techniques, that are low in cost, easy to use, and do not require technical expertise or any additional laboratory infrastructure to perform.05-06-2010
20100112546NANOSCALE SENSORS - Various aspects of the present invention generally relate to nanoscale wire devices and methods for use in determining analytes suspected to be present in a sample, and systems and methods of immobilizing entities such as reaction entities relative to nanoscale wires. In one aspect, a nucleic acid, such as DNA, may be immobilized relative to a nanoscale wire, and in some cases, grown from the nanoscale wire. In certain embodiments, the nucleic acid may interact with entities such as other nucleic acids, proteins, etc., and in some cases, such interactions may be reversible. As an example, an enzyme such as telomerase may be allowed to bind to DNA immobilized relative to a nanoscale wire. The telomerase may extend the length of the DNA, for instance, by reaction with free deoxynucleotide triphosphates in solution; additionally, various properties of the nucleic acid may be determined, for example, using electric field interactions between the nucleic acid and the nanoscale wire. In another aspect, the invention provides systems and methods for attaching entities such as nucleic acids, receptors such as gangliosides, or surfactants to a nanoscale wire, for example, using aldehyde-producing reactions or hydrophobic interactions. In some aspects, certain systems and methods of the present invention may be used to determine an analyte suspected to be present in a sample, for example, a toxin, a virus, or a small molecule. Systems and methods of using such nanoscale wires are disclosed in other aspects of the invention, for example, within a microarray. Still other aspects of the invention include assays, sensors, kits, and/or other devices that include such nanoscale wires, methods of making and/or using functionalized nanoscale wires (for example, in drug screening or high-throughput screening), and the like.05-06-2010
20130078620DEVICE AND METHOD FOR DETECTION AND IDENTIFICATION OF IMMUNOLOGICAL PROTEINS, PATHOGENIC AND MICROBIAL AGENTS AND CELLS - The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD03-28-2013
20130078619SAMPLE PREPARATION DEVICE - A sample preparation device is disclosed. The sample preparation device includes a housing defining a passage way between a first opening and a second opening; and a sample filter occupying a section of said passage way. The sample filter contains a monolith adsorbent that specifically binds to nucleic acids. Also disclosed are sample filters containing glass frit is coated with an capture agent that binds specifically to an analyte of interest, sample filters containing a hydrophilic matrix with impregnated chemicals that lyses cell membranes, a cartridge base and an integrated sample preparation cartridge.03-28-2013
20130078618COMPOSITIONS, REACTION MIXTURES AND METHODS FOR DETECTING NUCLEIC ACIDS FROM TYPE A1 AND/OR TYPE C1 HUMAN PAPILLOMAVIRUS - Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.03-28-2013
20130078615Device and Method for Detection and Quantification of Immunological Proteins, Pathogenic and Microbial Agents and Cells - The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD03-28-2013
20130078616METHOD AND SYSTEM FOR AMPLIFICATION OF NUCLEIC ACIDS IN MICROFLUIDIC VOLUME HYDROGELS - The present invention provides for a novel method and system for amplification of nucleic acids within a hydrogel of microfluidic volume using a hydrocarbon wax as a support substrate.03-28-2013
20130078617SAMPLE ANALYZER AND METHOD FOR CONTROLLING SAMPLE ANALYZER - A sample analyzer transports a first rack and a second rack, the first rack including a first number of supporters for supporting containers that contain biological samples of subjects, and the second rack including a second number of supporters for supporting containers that contain standard samples. The sample analyzer determines whether a transport object is the first rack or the second rack. When it has been determined that the transport object is the second rack, the sample analyzer performs a transporting operation according to the second rack and measure the standard samples in the containers supported by the second rack in a predetermined order, and prepares a calibration curve used for analyzing a measurement result of a biological sample, based on a plurality of measurement results of the standard samples.03-28-2013
20130078613Selection of HCV Treatment - The present invention is based on the discovery of an association between the SNP genotype at the rs12979860 locus in the IL28B gene promoter and the probability of achieving a SVR in HC V-infected patients that are given a triple therapy treatment that contains peginterferon alfa-2a, ribavirin, and a HCV NS5B polymerase inhibitor.03-28-2013
20130078614PROBE FOR HPV GENOTYPE DIAGNOSIS AND ANALYSIS METHOD THEREOF - The present invention relates to a probe for diagnosing HPV genotype and to a method of analyzing the same.03-28-2013
20130078611METHOD FOR DETECTING MICROORGANISMS AND A KIT THEREOF - The present invention provides a method for detecting microorganisms comprising steps of PCR, magbead, complex forming, blocking and washing and reporting, in which microorganisms, particular to HBV, can be easily detected via a time-saving and user-friendly process, with high sensitivity and stability. Furthermore, according to the method for detecting microorganisms, a kit for detecting microorganisms is also provided in the present invention, so that the detection of HBV can be achieved conveniently and easily.03-28-2013
20130078612METHOD FOR DETECTING MICROORGANISMS AND A KIT THEREOF - The present invention provides a method for detecting microorganisms comprising steps of PCR, magbead, complex forming, blocking and washing and reporting, in which microorganisms, particular to HBV, can be easily detected via a time-saving and user-friendly process, with high sensitivity and stability. Furthermore, according to the method for detecting microorganisms, a kit for detecting microorganisms is also provided in the present invention, so that the detection of HBV can be achieved conveniently and easily.03-28-2013
20100075301Methods for Generation of Reporter Phages and Immobilization of Active Bacteriophages on a Polymer Surface - Novel reporter bacteriophages are provided. Provided are compositions and methods that allow bacteriophages that are used for specific detection or killing of 03-25-2010
20100075300ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF ANTI-VIRAL IMMUNE RESPONSE - A sensor chip for detecting an immune response against a virus, the sensor chip including a substrate having a surface and a plurality of virus-like particles or capsid fragments bound to discrete locations on the surface of the substrate. Detection devices containing the sensor chip and methods of detecting anti-viral immune responses are also described herein.03-25-2010
20100075298Method for rapid identification and quantification of microorganisms - Method for unamplified, selective identification of a microorganism comprising obtaining a sample comprising the microorganism, wherein the sample comprises unseparated genetic material of the microorganism; adding to the sample a molecular beacon comprising an nucleic sequence which is complementary to at least one nucleic acid sequence in the microorganism; and heating the sample; wherein the molecular beacon hybridizes with said nucleic acid sequence to produce a detectable signal.03-25-2010
20130084560ANALYSIS OF A MICRONEUTRALIZATION ASSAY USING CURVE-FITTING CONSTRAINTS - A method and apparatus are disclosed for analyzing a microneutralization assay. Specifically, an automated process can be used to read the optical density of multiple samples in a microneutralization assay and plot the results using one or more constraints. A particular constraint that can be used is a maximum optical density that is read from a sample. Using the plotted curve, a neutralization titer is determined, which is the highest dilution at which a virus is effectively blocked. Other constraints can also be used. For example, a constraint can be based on using a cell control optical density as a lower asymptote and a virus control optical density as an upper asymptote. When multiple constraints are used, analysis is performed to determine which constraint provided the most accurate curve fit.04-04-2013
20100047767PATHOGEN BINDING - Provided is a method for determining the presence or absence of a pathogen in a sample, which method comprises: a) contacting the sample with a whole or a part of a cell surface receptor protein capable of binding the pathogen; b) allowing the cell surface receptor protein or part thereof to bind the pathogen; c) determining the presence or absence of the pathogen bound to the receptor protein or part thereof.02-25-2010
20130137084Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses - The present invention is based on the discovery of associations that exist between single nucleotide polymorphisms (SNPs) on chromosome 15 and virological outcomes in a diverse population of patients with hepatitis C virus (HCV) who received interferon-based treatment.05-30-2013
20130034844ASSAY FOR MEASURING CELL-MEDIATED IMMUNORESPONSIVENESS - The present invention relates generally to the field of immunological-based diagnostic assays. More particularly, the present invention contemplates a method for measuring cell-mediated immunoresponsiveness. The present invention further enables determination of the immunosuppressive effects of disease conditions, therapeutic agents and environmental contaminants. The assay of the present invention is also capable of integration into pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.02-07-2013
20130034845BARRIERS FOR FACILITATING BIOLOGICAL REACTIONS - The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes.02-07-2013
20130034843Molecular Determinants Associated with Enhanced Ability to Enter Cells Expressing CXCR4 - The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acids in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIV's ability to enter such cells is enhanced relative to a reference HIV, e.g., an HIV that does not comprise such amino acid(s).02-07-2013
20080311557DEVICE, KIT AND METHOD FOR HOOKWORM ANTIGEN CAPTURE AND DETECTION - A device, kit and method for detecting the presence or absence of hookworm antigens. The device, kit and method of the present invention may be used to confirm the presence or absence of hookworm in a fecal sample that may be infected with one or more of roundworm, whipworm, tapeworm and heartworm, and whether or not hookworm ova are present in the sample. Further, the device, kit and method of the present invention may be used to confirm the presence or absence of hookworm in a fecal sample excreted by a canine animal as early as nine days after the animal first becomes infected with hookworm.12-18-2008
20130040289BREAST MILK ETHANOL SCREENING SYSTEM AND METHOD - A test kit detects the presence of a target analyte in a fluid sample. In particular, the test kit includes reagents capable of detecting the target analyte of interest in breast milk. More particularly, the test kit is capable of detecting the presence of alcohol, caffeine, nicotine, drugs of abuse, therapeutic drugs, triglycerides, lactose, capsaicin, and gluten, for example, in breast milk.02-14-2013
20130040290METHODS AND SYSTEMS FOR ULTRA-TRACE ANALYSIS OF LIQUIDS - A monitoring assembly (02-14-2013
20130040287Methods for Detection and Typing of Nucleic Acids - Disclosed are methods and kits for identifying and characterizing polynucleotide sequences in a sample which may include a heterogeneous sample. Some of the methods and kits are directed to the identification and characterization of a virus in a sample, which may include HIV capable of cause AIDS or AIDS-like symptoms. The virus may be HIV-1, and may also include drug resistant mutations. The methods may include reacting a mixture that includes, in addition to nucleic acid isolated from the sample, at least one oligonucleotide capable of specifically hybridizing to HIV nucleic acid where the oligonucleotide includes at least one non-natural base. In addition, the methods may include detection of one or more mutations in HIV nucleic acid that are associated with drug resistance.02-14-2013
20130040284HBV DRUG RESISTANCE METHODS - New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD→YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.02-14-2013
20130040286Rapid Diagnostic Device, Assay and Multifunctional Buffer - A rapid diagnostic device, assay and multifunctional buffer reagent are provided for the detection of a target analyte in a fluid test sample. The 2-step assay utilizes a dual component flow-through device comprising a test unit and a dried indicator reagent delivery unit for receiving the fluid sample and multifunctional buffer, respectively. The test unit comprises a reaction zone containing immobilized capture reagent that can bind to the target analyte, an absorbent zone supporting the reaction zone, and optionally, a blood separation zone in lateral fluid communication with the reaction zone. The delivery unit comprises a label zone permeated with a dried indicator reagent which can be placed in transient fluid communication with the reaction zone of the test unit during the assay procedure. The rapid diagnostic assay system reduces the number of assay reagents, method steps and time required for performance compared to other conventional assays.02-14-2013
20130040288Biological Specimen Collection and Transport System and Method of Use - Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.02-14-2013
20130040285Saliva Polymerase Chain Reaction Assay for Cytomegalovirus Infection - Congenital cytomegalovirus (CMV) infection is an important cause of disease in infants and immune-compromised adults. Most infants infected with CMV are not promptly identified because of the absence of symptoms. It has been discovered that an assay based on the polymerase chain reaction (PCR) for testing of saliva specimens for CMV is rapid, accurate, and inexpensive. Some versions of the assay employ primers that are specific for sequences flanking the highly conserved major envelope glycoprotein B or the highly conserved immediate early 2 exon 5 genes. The assay exceeds the standard rapid culture technique in accuracy, speed, and economy. When the assay is performed on dried saliva, it loses no significant amount of accuracy, and is surprisingly much more sensitive than a PCR assay using dried blood. This assay will permit broader testing to detect and intervene in congenital CMV infection, potentially avoiding numerous cases of associated disease.02-14-2013
20130040283GRAPHENE COMPOSITION, METHOD OF FORMING A GRAPHENE COMPOSITION AND SENSOR SYSTEM COMPRISING A GRAPHENE COMPOSITION - A method of forming a composition includes oxidation of graphene oxide to form holey graphene oxide having defects therein and reduction of the holey graphene oxide.02-14-2013
20100099079Non-dividing cell-based assay for high throughput antiviral compound screening - The present invention features a cell-based assay that recapitulates all aspects of a viral lifecycle for use in identifying antiviral agents. The assay employs synchronized, non-dividing host cells and a fluorescence resonance energy transfer peptide substrate for monitoring endogenous viral protease activity, which is indicative of viral infection kinetics.04-22-2010
20080293042Detection of Contamination of Municipal Water Distribution Systems - A system for the detection of contaminates of a fluid in a conduit. The conduit is part of a fluid distribution system. A chemical or biological sensor array is connected to the conduit. The sensor array produces an acoustic signal burst in the fluid upon detection of contaminates in the fluid. A supervisory control system connected to the fluid and operatively connected to the fluid distribution system signals the fluid distribution system upon detection of contaminates in the fluid.11-27-2008
20090269733Devices and Methods for the Rapid Analysis of Pathogens in Biological Fluids - The present invention relates to devices and methods for rapidly determining whether a biological fluid contains a suspect Gram positive bacterial, a Gram negative bacterial or a viral pathogen. The invention particularly pertains to such devices and methods wherein the biological fluid is cerebrospinal fluid, and wherein the suspect pathogen is a causative agent of meningitis.10-29-2009
20130137090NUCLEIC ACID APTAMER-BASED DIAGNOSTIC METHODS WITH NOVEL TECHNIQUES FOR SIGNAL ENHANCEMENT - The present invention concerns methods for the detection of target molecules in a sample including several steps of signal amplification allowing the detection of a very low number of target molecules in the tested sample. The detection assay is based on the use of a universal probe which enables the signal amplification. The specific recognition of the target molecule is achieved by using a specific binding agent, preferably an aptamer. The invention further concerns kits and methods for the diagnosis of pathological conditions.05-30-2013
20090155774Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell - This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD406-18-2009
20090155773High-Risk Human Papillomavirus Detection - This invention provides compositions and methods for detecting HPV in a sample. This invention also provides related kits, systems, and computers.06-18-2009
20090155771HEPATITIS B VIRUS DNA POLYMERASE AND SURFACE ANTIGEN VARIANTS AND METHODS OF USING SAME - The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.06-18-2009
20090155770IMPLANTABLE DEVICES FOR FIBER OPTIC BASED DETECTION OF NOSOCOMIAL INFECTION - Disclosed are methods and devices for continuous in vivo monitoring of a potential infection site. Disclosed devices may be utilized to alert patients and/or health care providers to the presence of a pathogen at an early stage of a hospital acquired infection, thereby providing for earlier intervention and improved recovery rates from bacterial infection. Disclosed methods utilize implantable devices for location at an in vivo site. The implantable device is held in conjunction with an optical fiber that detects and transmits an optically detectable signal generated in the presence of a pathogen. Upon generation of the emission, the optically detectable emission signal may be transmitted to a portable detection/analysis device. Analysis of the characteristics of the emission signal produced may be used to determine the presence or concentration of pathogens at the site of inquiry, following which real time information may be transmitted to medical personnel, for instance via a wireless transmission system.06-18-2009
20090155768Reporter plasmid phage packaging system for detection of bacteria - The invention is related to a transducing particle that comprises a bacteriophage coat and a DNA core that comprises plasmid DNA comprising: a) a host-specific bacteriophage packaging site wherein the packaging site is substantially in isolation from sequences naturally occurring adjacent thereto in the bacteriophage genome, b) a reporter gene, c) a bacteria-specific promoter operably linked to said reporter gene, d) a bacteria-specific origin of replication, and optionally e) an antibiotic resistance gene. The invention includes phage transducing particles, methods of making transducing particles, and methods of using the transducing particles in bacterial detection.06-18-2009
20100041015COMPETITIVE ENZYME LINKED IMMUNOSORBENT ASSAY (C-ELISA) FOR THE DETECTION OF A FLAVIVIRUS SPECIFIC ANTIBODY - A competitive enzyme-linked immunosorbent assay (C-ELISA), using flavivirus member specific immunological agents was developed to detect antibody specific to members of the flaviviruses indicative of exposure to flavivirus. The test is based on a competition for epitope binding on the envelope protein of the flavivirus antigen captured using anti-flavivirus IgA in the presence of flavivirus positive serum. This test has comparable sensitivity specificity and speed to the virus neutralization assay (VNT). C-ELISA is a versatile technique, which could have various applications. Slight modifications of this protocol could lead to a C-ELISA-based detection method of secondary infection or one that could be used for serotype specific sero-epidemiological studies and/or vaccine evaluation. The protocol developed for C-ELISA was demonstrated using dengue lysate antigen and dengue specific monoclonal antibody. This can be used against other flaviviruses and the results for Japanese encephalitis illustrates this.02-18-2010
20100041022Novel assay for the separation and quantification of hemagglutinin antigens - Described are methods for separating hemagglutinin (HA) antigens, comprising the steps of applying a reduced and derivatized antigen preparation comprising solubilized HA antigens and a detergent in a pH controlled solution, on a Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) column; and eluting the HA antigens from the column with an ion pairing agent in an organic mobile phase. The invention further relates to quantifying methods using the methods for separating the antigens with the further step of measuring the peak area of the eluted antigen in a chromatogram resulting from the elution step.02-18-2010
20100041021APPARATUS AND METHOD FOR MEASURING CONCENTRATION OF MOLECULES THROUGH A BARRIER - An apparatus and method for detecting the presence and measuring the concentrations of molecules through a barrier and/or at a distance utilizes the principle of chemical/electrostatic attraction (hereinafter “affinity”), i.e., the affinity between charged atoms and molecules that cause their chemical interactions and reactions, to infer, based on the behavior of molecules on one side of the barrier, the presence and concentration of corresponding molecules on the other side of the barrier. The invention is useful, by way of example and not limitation, in non-invasively measuring glucose levels of diabetic patients.02-18-2010
20100041018METHOD TO DETECT VIRUS RELATED IMMUNOLOGICAL MARKERS FOR THE DIAGNOSIS OF HEPATITIS C VIRUS INFECTION - This invention discloses using SPR technology to simultaneously and qualitatively measure the presence of HCV-associated immunological markers in a serum sample for the diagnosis of HCV infection. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of HCV related antigen proteins used for the diagnosis of HCV infection.02-18-2010
20100041017FLUORESCENT SEMICONDUCTOR MICROPARTICLE ASSEMBLY, FLUORESCENT LABELING AGENT ASSEMBLY FOR BIOLOGICAL SUBSTANCE, AND BIOIMAGING METHOD AND BIOLOGICAL SUBSTANCE ANALYSIS METHOD USING THE ASSEMBLIES - Disclosed is a fluorescent semiconductor microparticle assembly comprising at least three kinds of fluorescent semiconductor microparticles with an average particle size of from 1 to 10 nm, having the same chemical composition, a different average particle size and a different emission maximum wavelength in the emission spectra, wherein a standard deviation of emission intensity in each of the at least three kinds of fluorescent semiconductor microparticles is not more than 15%.02-18-2010
20100041013ASSAY FOR A HEALTH STATE - The invention relates to an assay for determining a health state of a subject using a combination of detecting the presence of a virus and detecting the presence of a genomic target or marker indicative of a health state.02-18-2010
20100041019Methods of Screening for Respiratory Synctial Virus and Human Metapneumovirus - Provided are nucleic acid primers and probes for use in diagnostic assays to screen for respiratory infections, such as respiratory syncytial virus (“RSV”) and human metapneumovirus (hMPV). The primers and probes may be used to screen for RSV or hMPV in a singleplex assay or they may be used in a multiplex assay to simultaneously screen for RSV and hMPV, or RSV and/or hMPV and any of the following viruses: influenza A, and influenza B, parainfluenza viruses, adenovirus, coronavirus, and rhinoviruses.02-18-2010
20100041014Biological targeting compositions and methods of using the same - Modified red blood cells are described. In an embodiment, the modified red blood cell includes a target-binding agent. Targeted delivery of imaging agents, drugs, and peptide and protein pharmaceuticals using modified red blood cells are described. Processes for preparing the modified red blood cells, pharmaceutical and diagnostic compositions containing the same and methods of diagnosis and treatment involving the modified red blood cells are described.02-18-2010
20100028855DETECTION OF INFLUENZA VIRUS TYPE B - The invention provides methods for detecting influenza B from its NS1 protein. The NS1 protein is present in detectable levels in clinical samples and can be detected using antibodies that are panspecific for influenza B without binding to influenza A or other viruses.02-04-2010
20090130655Detection method using nanoaggregate-embedded beads and system thereof - The invention discloses a detection method using nanoaggregate-embedded beads and system thereof, which are characterized in that the nanoaggregate of Raman dye and metal nanoparticles is coated by an inorganic oxide to form a nanoaggregate-embedded bead, and which is then conjugated with a probe molecule to form a sensor bead. The Raman spectra of the product formed by binding of the sensor bead and an analyte in a sample is detected for determining whether the analyte exists in the sample. In embodiment, the pH of the solution of metal nanoparticles is controlled to keep at 10, and the concentration of the Raman dye is controlled to keep between 1×1005-21-2009
20090130653Interference Control Panel for Evaluation of Analytical Assays for Samples Derived from Blood - The invention relates to quality control of analytical assays, particularly NAT assays of blood samples containing nucleic acids. A control panel containing quantified amounts of substances known to interfere with an analytical assay is used and compared with a reference sample in the analytical assay. A comparison of the assay results interference panel validates the assay and can serve as a periodic quality control check for the analytical assay as well as related methods and protocols. The use of the control panel of the invention can also determine whether interfering substances are present and establish under what conditions the analytical assay reliable.05-21-2009
20100105026Optical measurement method for molecular detection using relaxation measurement in optically anisotropic nanoparticles and device for performing the method - Optical measurement methods are described that are suitable for determining the relaxation behavior of nanoparticles dispersed in a solution. The particles have optically anisotropic properties and are alignable by an external stimulus, for example, an electric or magnetic field. In this manner the optical detection of certain molecules that can bind specifically to the surface of the nanoparticles and thus change the relaxation behavior of the nanoparticles as well as to provide devices for carrying out the methods is possible.04-29-2010
20100105027DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUSES - Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.04-29-2010
20100105025DEVICES FOR GENERATING DETECTABLE POLYMERS - This document provides systems, devices, and methods involved in generating detectable polymers. For example, diagnostic systems, diagnostic devices, primer systems, and collections of primer systems are provided.04-29-2010
20100105024RAPID TEST INCLUDING GENETIC SEQUENCE PROBE - A rapid test kit may have a genetic probe, and antibody detecting probe or a combination of a genetic probe and an antibody detecting probe disposed within one or more test windows of the test kit. A cellulose filter paper membrane with a flow rate selected in a range of about 0.04 to about 0.4 ml/min/cm04-29-2010
20130029321SAMPLE PROCESSING DEVICE AND METHOD - A sample processing device is disclosed, which sample processing device comprises a first substrate and a second substrate, where the first substrate has a first surface comprising two area types, a first area type with a first contact angle with water and a second area type with a second contact angle with water, the first contact angle being smaller than the second contact angle. The first substrate defines an inlet system and a preparation system in areas of the first type which two areas are separated by a barrier system in an area of the second type. The inlet system is adapted to receive a sample liquid comprising the sample and the first preparation system is adapted to receive a receiving liquid. In a particular embodiment, a magnetic sample transport component, such as a permanent magnet or an electromagnet, is arranged to move magnetic beads in between the first and second substrates.01-31-2013
20130029322ANTI-HPV E7 ANTIBODIES - Monoclonal anti-HPV (human papillomavirus) E7 antibodies are capable of specifically recognizing an epitope of the C-terminal or the N-terminal region of a HPV E7 protein.01-31-2013
20130029317METHOD FOR EARLY DIAGNOSIS OF LIVER CANCER AND PREDICTION OF METASTASIS - Disclosed is a method for early diagnosis of liver cancer. The method comprises the steps of: (A) providing a sample obtained from a subject; (B) assessing the expression level of four subtypes of α-mannosidase genes consisting of MAN1C1 in the sample; (C) comparing the expression level of α-mannosidase genes in the sample with a normal control; and (D) determining whether the subject having a risk of suffering liver cancer in accordance with the result of step (C); wherein while the MAN1C1 expression level of the sample is lower than that in the normal control, the subject is determined to have a risk of suffering liver cancer. Additionally, while MAN1A1, MAN1A2 and MAN1B1 expression levels in the sample are higher than those in control group, the subject is determined to suffer from liver cancer and has a risk of metastasis.01-31-2013
20130029320DEVICE AND METHOD FOR DETECTING BIOMOLECULE - Disclosed are a method for detecting a biomolecule including: immobilizing a nucleic acid aptamer capable of specifically binding to a biomolecule to be detected on the surface of a bead on which fluorophores are arranged; hybridizing the nucleic acid aptamer with a guard nucleic acid (g-nucleic acid) labeled with a quencher to quench fluorescence; and reacting a sample including the biomolecule to be detected with the nucleic acid aptamer and detecting a fluorescence signal emitted as the biomolecule binds with the nucleic acid aptamer and the g-nucleic acid labeled with the quencher is separated, and a device for detecting a biomolecule for conducting the detection method. The present disclosure allows for effective, convenient and fast detection of the biomolecule to be detected, enables quantitative analysis, and enables detection of even a trace amount of sample.01-31-2013
20130029319MEANS AND METHODS FOR PREDICTING THE RISK OF MORTALITY OF PATIENTS WITH HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CANCER - The present invention relates to the field of diagnostic measures. In particular, the present invention relates to a method for predicting the risk of mortality in a subject suffering from low viral load HPV (human papillomavirus) positive oropharyngeal squamous cell cancer. The method is based on the determination of the amount of an E6* gene product and the amount an E1̂E4 gene product of HPV in a sample from said subject. Moreover, the method is based on determining the presence of absence of an E1C gene product of HPV. The present invention further relates to a method for predicting the risk of mortality in a subject suffering from HPV (human papillomavirus) positive oropharyngeal squamous cell cancer based on the determination of copy number of HPV per cancer cell.01-31-2013
20130029318Microchips and Methods for Testing a Fluid Sample - Systems and methods for medical diagnosis or risk assessment for a patient are provided. A fluid-testing microchip is described which includes a filter compartment configured to receive a fluid sample from an inlet port, wherein the filter compartment comprises a plurality of beads coated with a defoaming agent, a micro-pump configured to transfer the fluid sample from the filter compartment to a test compartment, and the test compartment comprising a test component configured to test the fluid sample. The systems include an instrument for reading or evaluating the test data. These systems and methods are designed to be employed at the point of care, such as in emergency rooms and operating rooms, or in any situation in which a rapid and accurate result is desired.01-31-2013
20130029316METHOD FOR REAL-TIME DETECTION OF WEST NILE VIRUS USING A CLEAVABLE CHIMERIC PROBE - A method is described for the real-time detection of West Nile Virus in samples taken from humans or potential carriers of the virus such as mosquitoes or birds. Real-time detection of West Nile Virus is performed in a PCR reaction using gene specific primers and a cleavable chimeric fluorescent probe. The method is amenable to medium and high throughput analysis.01-31-2013
20090123910Method of efficient extraction of protein from cells - Methods for producing a protein extract from cells, such as cells or cellular samples containing viral proteins, are provided. In general terms, the methods may involve: increasing the pH of the cells to a pH of at least about pH 10.0 to produce an intermediate composition, and then, in the presence of a non-ionic detergent such as a polyoxyethylene alkyl ether, neutralizing the pH of the intermediate composition to produce the protein extract. Such methods can be used in conjunction with methods for detecting one or more target proteins in a sample, such as viral proteins. Systems, kits and compositions for practicing the subject methods are also provided.05-14-2009
20090123909Rapid, Informative Diagnostic Assay For Influenza Viruses Including H5N1 - A rapid diagnostic assay for influenza virus, particularly avian influenza and more particularly H5N1, is described. The assay is based on amplification of a significant portion of the hemagglutinin (HA) gene and sequencing of several loci within the HA gene, using techniques which can obtain real time sequence information from multiple sites of a target DNA, in particular pyrosequencing and bioluminescence regenerative cycle. The assay contemplates the use of information-rich subsequences within the HA gene, e.g., (1) a glycosylation sequon; (2) receptor binding site; and (3) HA1/HA2 cleavage site. Other subsequences for sequencing include strain and clade markers, which vary among H5N1 strains.05-14-2009
20130137088FACTOR INVOLVED IN LATENT INFECTION WITH HERPESVIRUS, AND USE THEREOF - Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder.05-30-2013
20130137087SYSTEM AND METHOD INCLUDING ANALYTICAL UNITS - Systems and methods for processing and analyzing samples are disclosed. The system may process samples, such as biological fluids, using assay cartridges which can be processed at different processing locations. In some cases, the system can be used for PCR processing. The different processing locations may include a preparation location where samples can be prepared and an analysis location where samples can be analyzed. To assist with the preparation of samples, the system may also include a number of processing stations which may include processing lanes. During the analysis of samples, in some cases, thermal cycler modules and an appropriate optical detection system can be used to detect the presence or absence of certain nucleic acid sequences in the samples. The system can be used to accurately and rapidly process samples.05-30-2013
20130052637OPTICAL FLUORESCENT IMAGING IN HISTOLOGY - Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to the negligible animal autofluorescence.02-28-2013
20130089855METHOD OF CHARACTERIZING VASCULAR DISEASES - Embodiments of the invention relate generally to methods of diagnosing diseases and measuring homeostatic states. In particular, the methods described here are used to characterize RNA from vesicles for expression of disease related markers. Embodiments of the invention also relate generally to the characterization of RNA by using sensitive techniques such as PCR to internally sample organ health using whole blood.04-11-2013
20100003665Real-time HPV PCR Assays - The present invention relates a fluorescent multiplex PCR assay for detecting the presence of an HPV type in a sample using multiple fluorophores to simultaneously detect a plurality of HPV genes of the same HPV type, wherein the HPV type is selected from the group consisting of: HPV33, HPV35, HPV39, HPV51, HPV56, and HPV59. The present invention also relates to oligonucleotide primers and probes specific to said HPV types for use in the methods of the present invention.01-07-2010
20100136517MATRIX STABILIZATION OF AGGREGATION-BASED ASSAYS - Methods and apparatus for stabilization of aggregation-based assays are described. In various embodiments, anti-analytes are dispersed within a matrix. A solution containing analytes brought into contact with the matrix, so that analytes may permeate throughout at least a portion of the matrix. In some embodiments, the anti-analytes and analytes are mobile within the matrix. As aggregates form and increase in size, the aggregates become substantially immobile within the matrix. As a result, signals representative of an amount of aggregation within the matrix can remain substantially constant. In various aspects, matrix-stabilized aggregation-based assays provide for reliable quantitative analysis of analyte concentration with test solutions.06-03-2010
20090042181Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene - The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.02-12-2009
20130089854KIT FOR DOT IMMUNOGOLD DIRECTED FILTRATION ASSAY AND USE THEREOF - A kit for dot immunogold directed filtration assay including a dot immunogold directed filtration card, a detection probe labeled by nano colloidal gold or latex beads, a negative standard, a positive standard, and a cleaning solution.04-11-2013
20130089853FLUORESCENT DYES - Provided are various compounds comprising the formula04-11-2013
20110003279Monitoring devices and processes based on transformation, destruction and conversion of nanostructures - A large number of properties of nanostructures depend on their size, shape and many other parameters. As the size of a nanostructure decreases, there is a rapid change in many properties. When the nanostructure is completely destroyed, those properties essentially disappear. Systems based on changes in properties of nanostructures due to the destruction of nanostructures are proposed. The systems can be used for monitoring the total exposure to organic, inorganic, organometallic and biological compounds and agents using analytical methods.01-06-2011
20090305232Peptides for Detection of Antibody to Porcine Reproductive Respiratory Syndrome Virus - The invention provides compositions and methods for the detection and quantification of PRRSV antibodies and antibody fragments using polypeptides.12-10-2009
20090305230Real Time Detection of Molecules, Cells and Particles Using Photonic Bandgap Structures - Provided herein is a photonic bandgap (PBG) detector effective to detect inorganic molecules, organic biomolecules or biopolymers, cells, subcellular organelles, and particles. The PBG detector utilizes photonic crystals having a binding agent attached to channel surfaces comprising the crystals to selectively bind a molecule, cell or particle of interest so that an increase in light transmission is detectably induced within the photonic bandgap upon binding. Also provided are methods of optically detectiing an analyte and of identifying the presence of a cell or a particle in a biological sample.12-10-2009
20090305229MULTIPLEX DETECTION OF RESPIRATORY PATHOGENS - Described are kits and methods useful for detection of respiratory pathogens (influenza A (including subtyping capability for H1, H3, H5 and H7 subtypes) influenza B, parainfluenza (type 2), respiratory syncytial virus, and adenovirus) in a sample. Genomic sequence information from the respiratory pathogens was analyzed to identify signature sequences, e.g., polynucleotide sequences useful for confirming the presence or absence of a pathogen in a sample. Primer and probe sets were designed and optimized for use in a PCR based, multiplexed Luminex assay to successfully identify the presence or absence of pathogens in a sample.12-10-2009
20090305228Potentiation of Apoptosis by Monoclonal Antibodies - The present invention relates to the use of an antibodies composition, the fucose content of which is less than 65%, for indicating apoptosis in vitro.12-10-2009
20090305227HIV-1 LATENCY MODEL FOR HIGH THROUGHPUT SCREENING - Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.12-10-2009
20090305226Biomolecular Recognition of Crystal Defects - Discrete and diffuse defects in a surface are detected. Discrete defects that may compromise the performance may be repaired.12-10-2009
20090305231Sensitive Immunoassays Using Coated Nanoparticles - Coated nanoparticles comprising a core surrounded by a shell that increases the reflectance of the nanoparticle, wherein the coated nanoparticle does not include a Raman-active molecule, are provided. Test devices and immunoassay methods utilizing the coated nanoparticles are provided.12-10-2009
20130071833MEANS AND METHODS FOR DISTINGUISHING FECV AND FIPV - The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.03-21-2013
20130071834COMPOSITIONS AND METHODS USEFUL FOR HCV INFECTION - The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.03-21-2013
20090092965Method and Apparatus for Target Detection Using Electrode-Bound Viruses - A biosensor capable of detecting the presence and/or concentration of an analyte or biomarker includes at least one electrically conductive electrode operatively coupled to an impedance analyzer for measuring the change in the resistive impedance of the electrode in response to an applied alternating current at a plurality of frequencies. In one embodiment, at least one electrode is covered with a self-assembled monolayer that is chemically bonded to a surface. A plurality of virus particles such as phage viruses are immobilized on the self-assembled monolayer and may be exposed to a test or sample solution. The virus particles may be obtained from phage-displayed libraries to detect a wide variety of targets including, for example, DNA, RNA, small molecules, and proteins or polypeptides. In another embodiment, the virus particles are electrostatically bound to a substrate in between a pair of elongated electrodes disposed on a substrate.04-09-2009
20090092963Method for combined parallel agent delivery and electroporation for cell structures an use thereof - Disclosed is a method for parallel delivery of agents to and/or into a cell structure, wherein at least two electrolyte-filled tubes are provided together with a counter electrode, the tubes being connected to a voltage or current generator, said agents being introduced into the electrolyte solution contained in the tubes, which are placed close to the cell structure, whereupon the agents are transported through the tubes to said cell structure and into the said structure through pores which have been formed by application of an electric field focused on the cell structure, resulting in electroporation of the cell structure. Also different applications of the method is disclosed, e.g. use of the method in order to transfer cell-impermeant solutes, such as drugs or genes, into the cell structure or out of the cell structure.04-09-2009
20090092962METHOD FOR DETECTING SARS CORONAVIRUS - This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.04-09-2009
20130059289ADENO-ASSOCIATED VIRUS SEROTYPE I NUCLEIC ACID SEQUENCES, VECTORS AND HOST CELLS CONTAINING SAME - The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.03-07-2013
20130059294IDENTIFICATION OF POLYMORPHIC HEPATITIS B VIRUSES AND KRAS ONCOGENE MUTATIONS AND CLINICAL USE - The present application provides a method of monitoring patients of chronic hepatitis B virus (HBV) infection undergoing nucleoside/nucleotide analogue antiviral treatment for treatment efficacy and for risk of drug-resistance, by simultaneous determination of quantities of viral DNA and identification of mutant viruses responsible for drug-resistance. This invention also provides methods and reagents for highly sensitive identification/quantification of KRas oncogene mutations from body fluids or tumor tissues and the use of these methods for cancer risk assessment, cancer early detection, treatment outcome prediction, and treatment monitoring.03-07-2013
20130059293MAGNETIC RESONANCE SYSTEM AND METHOD TO DETECT AND CONFIRM ANALYTES - A system and method are provided to detect target analytes based on magnetic resonance measurements. Magnetic structures produce distinct magnetic field regions having a size comparable to the analyte. When the analyte is bound in those regions, magnetic resonance signals from the sample are changed, leading to detection of the analyte.03-07-2013
20130059292METHOD OF DETECTING A TARGET USING APTAMER-MEDIATED PROTEIN PRECIPITATION ASSAY - The present invention relates to a method and detection kit for determining a presence of one or more proteins using aptamer-mediated pull-down assays. Specifically, a reproducible a protein precipitation (Co-AP/AP) method is provided to identify physiologically relevant protein-protein interactions by using target protein-specific aptamers, and to confirm its superior performance over antibody based protein precipitation (Co-IP/IP) methods in terms of its protein pull-down performance.03-07-2013
20130059291COMPOSITIONS AND METHODS FOR IDENTIFYING DENGUE VIRUS - The invention generally relates to compositions and methods for identifying dengue virus. In certain embodiments, the invention provides methods for identifying a dengue virus serotype that involve obtaining a sample comprising at least one dengue virus protein; digesting the protein to produce peptides; ionizing the peptides; detecting a parent and associated fragment ion of the peptides; and identifying the serotype based on results of the detecting step.03-07-2013
20130059290DETECTION OF NUCLEIC ACIDS IN CRUDE MATRICES - A method includes contacting a crude matrix with components of an isothermal nucleic acid amplification reaction for a target nucleic acid species, thereby providing a mixture; incubating the mixture under conditions sufficient for the isothermal nucleic acid amplification reaction to proceed, thereby providing a product; and determining whether an indicator of the target nucleic acid species is present in the product.03-07-2013
20100009341METHODS AND MEANS FOR ASSESSING HIV GAG/PROTEASE INHIBITOR THERAPY - The present invention relates to methods and means for the evaluation of HIV treatment. In particular, molecular events at the HIV gag and protease proteins and their effect on therapeutic efficacy of drugs are determined The methods rely on providing HIV gag and protease nucleic acid material and evaluating a treatment either through genotyping or phenotyping. Said method may find use in multiple fields including diagnostics, drug screening, pharmacogenetics and drug development.01-14-2010
20110014600Microfluidic Magnetophoretic Device and Methods for Using the Same - A microfluidic device may employ one or more sorting stations for separating target species from other species in a sample. The separation is driven by magnetophoresis. A sorting station generally includes separate buffer and sample streams. A magnetic field gradient applied to the sorting station deflects the flow path of magnetic particles (which selectively label the target species) from a sample stream into a buffer stream. The buffer stream leaving the sorting station is used to detect or further process purified target species labeled with the magnetic particles.01-20-2011
20110014599Novel Fluorescent Dyes and Uses Thereof - The present invention provides fluorescent dyes that are based on firefly luciferin structure. These dyes are optimally excited at shorter wavelengths and have Stokes shift of at least 50 nm. The fluorescent dyes of the invention are useful for preparation of dye-conjugates, which can be used in detection of an analyte in a sample.01-20-2011
20110014598OPTIMIZED PROBES AND PRIMERS AND METHOD OF USING SAME FOR THE DETECTION OF HERPES SIMPLEX VIRUS - Described herein are primers and probes useful for detecting and typing variant HSV strains, and methods of using the described primers and probes.01-20-2011
20100015595Phage Particle Diagnostic Reagents - The present invention relates to novel methods for detecting a member of a known binding pair in a sample, including a cell, where one member of the pair (termed the “receptor”) is expressed by a bacteriophage, which phage is then used to detect the presence of the other member of the pair (termed the “ligand” or “target”). Rather than detecting the binding of the phage using antibody-based technology, the present invention relates to detecting marker molecule associated with the phage. In one aspect, the invention relates to identifying an antigen-bearing moiety (e.g., a red blood cell antigen) of interest present on a cell, e.g., a red blood cell, using antibody-displaying bacteriophage, as well as detecting anti-red blood cell auto- or alloantibodies and/or complement in a sample, using antiglobulin reagent-displaying bacteriophage and detecting a marker molecule associated with the phage. In one aspect, the phenotype of the phage is not linked with the genotype of the phage.01-21-2010
20090280471METHODS FOR RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND ANIMALS - The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.11-12-2009
20090148830IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI) - The present invention relates to a method for the detection of acute respiratory tract infection (ARI) comprising the simultaneous amplification of several target nucleotide sequences present in a biological sample by means of a primer mixture comprising at least one primer set from each one of the following gene regions: the F1 subunit of the fusion glycoprotein gene for RSV, the hemagglutininneuraminidase gene for PIV-1, the 5′ noncoding region of the PIV-3 fusion protein gene, 16 S rRNA sequence for 06-11-2009
20090269734METHOD FOR DETERMINATION OF RECOGNITION SPECIFICITY OF VIRUS FOR RECEPTOR SUGAR CHAIN - A method in which the recognition specificity of a virus for a receptor sugar chain can be easily determined with a simple instrument or apparatus is provided. In a method for determining the recognition specificity of a virus for a receptor sugar chain or for determining the change in a host infected in accordance with the mutation of virus comprising, a sample of the virus is brought into contact with a support having a polymer with sialo-oligosaccharide immobilized on the surface thereof; and the degree of binding therein is assayed to determine the recognition specificity of said virus for said receptor sugar chain and to determine the change in a host range. The method is suitable for the surveillance of virus.10-29-2009
20090269732Methods for Diagnosing Oncogenic Human Papillomavirus (HPV) - Methods for diagnosis of HPV infection in a subject are provided. HPV infection in a subject can be determined by generating mass profile data for a biological sample from the subject and correlating the mass profile data with reference mass profiles to detect the presence or absence, and/or quantity of at least one biomarker associated with HPV infection. Methods for detecting at least one biomarker associated with HPV infection in a biological sample are also provided.10-29-2009
20120225424Device and Method for Electroporation-Based Delivery of Molecules Into Cells and Dynamic Monitoring of Cell Responses - The present invention includes devices and methods for transfecting a cell or cell population and dynamic monitoring of cellular events. A variety of microelectronic devices are provide that incorporate functions such as electroporation, modulation of a transmembrane potential and dynamic monitoring of cellular functions and mechanisms.09-06-2012
20120225423PATHOGEN DETECTION BIOSENSOR - The invention described herein provides methods for the detection of target particles, such as pathogens, soluble antigens, nucleic acids, toxins, chemicals, plant pathogens, blood borne pathogens, bacteria, viruses and the like. Also described is an emittor cell comprising a receptor, wherein the receptor can be an antibody or an Fc receptor, and an emittor molecule for the detection of a target particle in a sample wherein the target particle to be detected is bound by one or more receptors on the emittor cell. Also provided are optoelectronic sensor devices for detecting a target particle in a sample, including in a plurality of samples.09-06-2012
20130065223Universally Applicable Lysis Buffer and Processing Methods for the Lysis of Bodily Samples - The present invention provides a universally applicable lysis buffer comprising a chaotropic 5 agent, a reducing agent, and a proteolytic enzyme suitable for processing a wide variety o different sample types, such as different types of bodily samples relevant for the diagnosis o a respiratory disease. Furthermore, the present invention provides the use of a chaotropic agent, a reducing agent, and a proteolytic enzyme for the lysis of a broad spectrum of bodily samples. Moreover, the present invention provides a method for processing bodily samples which is universally applicable to the lysis of a variety of different types of bodily samples. Furthermore, the present invention provides methods for analyzing a bodily sample or for detecting the presence of a pathogen in a bodily sample, preferably, for diagnosing a respiratory disease, such as pneumonia or tuberculosis. Preferably, these methods are universally applicable to a variety of sample types, are applicable as one-tube-processes, are 15 suitable for performance in a high-throughput setting, and are automatable.03-14-2013
20130065221HMGB1 AND ANTI-HMGB1 ANTIBODIES FOR THE PROGNOSTIC OF NEUROLOGICAL DISORDERS - The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.03-14-2013
20130065222COMPOSITIONS, METHODS AND REACTION MIXTURES FOR THE DETECTION OF MURINE LEUKEMIA VIRUS-RELATED VIRUS - The present invention relates to the detection of infectious agents, more specifically to the detection of murine leukemia viruses and other highly related viruses, including but not limited to ecotropic murine leukemia viruses, xenotropic murine leukemia viruses, and polytropic murine leukemia viruses. Compositions, methods, reaction mixtures and kits are described for the detection of MLV by using in vitro nucleic acid amplification techniques.03-14-2013
20130065224PERSONAL GLUCOSE METERS FOR DETECTION AND QUANTIFICATION OF A BROAD RANGE OF ANALYTES - A general methodology for the development of highly sensitive and selective sensors that can achieve portable, low-cost and quantitative detection of a broad range of targets using only a personal glucose meter (PGM) is disclosed. The method uses recognition molecules that are specific for a target agent, enzymes that can convert an enzyme substrate into glucose, and PGM. Also provided are sensors, which can include a solid support to which is attached a recognition molecule that permits detection of a target agent, wherein the recognition molecule specifically binds to the target agent in the presence of the target agent but not significantly to other agents as well as an enzyme that can catalyze the conversion of a substance into glucose, wherein the enzyme is attached directly or indirectly to the recognition molecule, and wherein in the presence of the target agent the enzyme can convert the substance into glucose. The disclosed sensors can be part of a lateral flow device. Methods of using such sensors for detecting target agents are also provided.03-14-2013
20130065220METHOD OF RAPIDLY DETECTING MICROORGANISMS USING NANOPARTICLES - The present invention relates to a method of rapidly detecting microorganisms using nanoparticles, and more particularly to a method and device of rapidly detecting microorganisms by adding, to the microorganisms to be detected, nanoparticles having immobilized thereon an antibody that binds specifically to the microorganisms to be detected, subjecting the mixture to an immune reaction to form a reaction solution, passing the reaction solution through a microorganism-concentrating film to concentrate the microorganisms, capturing microorganisms, which was immune-reacted with the antibody-immobilized nanoparticles, by a microorganism-capturing filtration membrane, and determining the presence and concentration of the microorganisms.03-14-2013
20110020791Methods and Materials for Detecting Mutations in Quasispecies Having Length Polymorphisms - The present invention is directed to a method for detecting the presence or absence of a mutation of interest in the nucleic acid of a pathogen, wherein the mutation of interest is located adjacent to a length polymorphism defining multiple quasispecies of the pathogen.01-27-2011
20110020790USE OF REGULATORY SEQUENCES FOR SPECIFIC, TRANSIENT EXPRESSION IN NEURONAL DETERMINED CELLS - The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells. Additionally, methods for screening of compounds capable of regulating neuronal determined cell activity, neurogenesis, stimulating proliferation of neuronally committed precursor cells and/or neuronal differentiation are provided and the invention also relates to methods for the detection and analysis of neuronal differentiation, neuronal migration and/or neuronal determination processes. Finally, the invention relates to diagnostic and pharmaceutical compositions comprising the regulatory sequences, recombinant nucleic acid molecules, host-cells or isolated neuronal determined cells described herein.01-27-2011
20110020788NMR DEVICE FOR DETECTION OF ANALYTES - This invention relates generally to detection devices having one or more small wells each surrounded by, or in close proximity to, an NMR micro coil, each well containing a liquid sample with magnetic nanoparticles that self-assemble or disperse in the presence of a target analyte, thereby altering the measured NMR properties of the liquid sample. The device may be used, for example, as a portable unit for point of care diagnosis and/or field use, or the device may be implanted for continuous or intermittent monitoring of one or more biological species of interest in a patient.01-27-2011
20090233269Detection of a Target in a Preservative Solution - This invention relates to methods, articles and compositions useful in detecting target substances in an alcoholic preservative solution, and for identifying sensors useful for binding to such targets. The methods allow for the simultaneous performance of sufficient fixation of a sample and binding of a detectable sensor to a target of interest in the sample. In one aspect, a method is provided that comprises contacting a sample suspected of containing a target with a detectable sensor molecule known to bind to such target in an alcoholic preservative solution. The method maybe performed in multiplex form to permit simultaneous analysis of a plurality of targets. Methods for identifying a sensor capable of binding to a desired target in an alcoholic preservative solution are also provided. An alcoholic preservative solution comprising one or more such detectable sensors is also provided. Also provided is a sample comprising a bound sensor provided by such a process. Also provided are kits useful for such methods.09-17-2009
20090233268DETECTION OF BIOMARKERS AND BIOMARKER COMPLEXES - The invention features methods and devices for the detection of biomarker complexes and their components and for the sequential detection of multiple epitopes of a biomarker. The invention also features methods for diagnosing disease and evaluating the efficacy of treatment of a subject with a disease.09-17-2009
20090233267Methylated Tat Polypeptides and Methods of Use Thereof - The present invention provides isolated methylated Tat peptides; and compositions comprising the peptides. The present invention further provides isolated antibodies specific for a Lys-51-methylated Tat polypeptide. Also provided are methods of identifying agents that inhibit Lys-51 methylation of a Tat polypeptide. The present invention further provides methods of treating an immunodeficiency virus infection in a mammalian subject.09-17-2009
20090233266STRUCTURE OF THE HEPATITIS C VIRUS NS2 PROTEIN - The present invention provides a crystallized C-terminal domain of an NS2 protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the C-terminal domain of hepatitis C virus NS2 protein, and methods of inhibiting hepatitis C virus infection, replication and/or pathogenesis, by interacting with the same.09-17-2009
20130164734METHODS AND MATERIALS FOR THE DETECTION OF DENGUE VIRUS INFECTION - The present invention provides monoclonal antibodies that are specific for the Dengue non-structural glycoprotein NS1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including ELISA and lateral flow assays, that employ the disclosed antibodies for the early detection of Dengue virus infection. Diagnostic kits for the detection of Dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies.06-27-2013
20130164735METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.06-27-2013
20130164736METHOD FOR DETECTING MOLECULAR INTERACTIONS - The present invention relates to a method for detecting molecular interactions in a solution. In particular, the present invention relates to a method for detecting interactions between two substances that are likely to interact with one another. The present invention can be used in particular in the field of scientific research and in the field of medical analysis.06-27-2013
20100068697PIEZOELECTRIC MICROCANTILEVER SENSORS FOR BIOSENSING - A piezoelectric microcantilever for sensing compounds or molecules. The piezoelectric microcantilever, may include at least one electrode, an insulation layer, a receptor, an immobilization layer, a non-piezoelectric layer and a piezoelectric layer The sensor is capable of self actuation and detection. The piezoelectric layer may be constructed from a highly piezoelectric thin lead magnesium niobate-lead titanate film, a highly piezoelectric thin zirconate titanate film, a highly piezoelectric lead-free film. Methods of using the sensors and flow cells and arrays including the sensors are also described.03-18-2010
20090047665COMPOSITIONS FOR USE IN IDENTIFICATION OF ADENOVIRUSES - The present invention provides compositions, kits and methods for rapid identification and quantification of adenoviruses by molecular mass and base composition analysis.02-19-2009
20090047663Methods and Compositions For Identifying and Characterizing Hepatitis C - The invention provides novel methods and compositions for amplifying portions of the HCV genome. The nucleic acid sequences set forth as SEQ ID NOS:1-64 derived from HCV cDNA and functional equivalents thereof, kits containing same, and methods employing same, are useful for the identification and characterization of HCV in biological samples.02-19-2009
20090047662HETERODUPLEX TRACKING ASSAY - A change in viral tropism occurs in many HIV positive individuals over time and may be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus may be shifted back to CCR5-mediated entry soon after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment and clinical management of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CCR5- or CXCR4-specific strains. The diagnostic methods may be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. The methods of the invention include cell-based methods, including cell fusion assays, and molecular-based methods, including heteroduplex tracking assay, to both quantitatively and qualitatively analyze patient-derived HIV for coreceptor usage.02-19-2009
20090047661QUANTITATIVE HIV PHENOTYPE OR TROPISM ASSAY - The present invention concerns a method for predicting quantitative phenotype, e.g. gag-phenotype, integrase phenotype or tropism in a patient infected by Human Immunodeficiency Virus (HIV).02-19-2009
20090047659AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF SEQUENCES ASSOCIATED WITH DRUG-RESISTANCE MUTATIONS - Sequences of nucleic acid oligonucleotides for amplifying different portions of gag and pol genes of HIV-1 and for detecting such amplified nucleic acid sequences are disclosed. Methods of amplifying and detecting HIV-1 nucleic acid in a biological sample using the amplification oligonucleotides specific for gag and pol target sequences are disclosed.02-19-2009
20090047657Detection Method For Latent Viral Infections and Its Kit For Examination - The subject of the present invention is to provide a detection method for latent viral infections by detecting a gene product related to latent infections without going through an invasive procedure involving pain and bleeding, caused by skin biopsy and blood collection. Further, the subject of the present invention is to provide a kit for examination using in the detection of latent viral infections described above. As crusts and scales in a lesion contain large amounts of virus-infected cells which are in a state of dry necrosis, the method collects crusts and/or scales for a test sample and detects a gene product related to latent infections which may be present in the test sample. The kit for examination comprises (1) antisense oligonucleotide for reverse transcription of a gene product related to latent viral infections, (2) a primer set for amplifying a gene product related to latent viral infections and (3) a primer set for amplifying a housekeeping gene.02-19-2009
20090047656Molecular analysis of primary cells - The present invention provides a method of propagating cells of interest obtained from a biological specimen by a) enriching the cells under conditions that maintain sufficient cell viability; and b) propagating the cells under conditions effective to allow cell viability, proliferation and integrity.02-19-2009
20120115126Compositions and Methods for Rapid, Real-Time Detection of Influenza A Virus (H1N1) Swine 2009 - Disclosed are oligonucleotide amplification primers and detection probes specific for the amplification and detection of pathogenic organisms, including for example, specific Influenza A H1N1 viral isolates. Also disclosed is a biological organism identification kit including the disclosed nucleic acid probes and primers, as well as thermal cycling reagents that is both portable and durable, and may also be self-contained for remote, or in-field analysis and identification of particular influenza isolates from a variety of biological specimen types.05-10-2012
20120115125ASSAY FOR DETECTING AND QUANTIFYING HIV-1 - Method of detecting HIV-1 nucleic acids using nucleic acid amplification and a molecular torch hybridization probe. The invented method is characterized by high levels of precision in the quantitation of HIV-1 targets at low copy numbers, and by accurate detection of different HIV-1 subtypes, including M group and O group variants.05-10-2012
20100003666Microfluidic Methods for Diagnostics and Cellular Analysis - Methods for detection of molecular recognition and analysis of cells are provided. Both optical and non-optical methods are presented. Methods utilize capture of particles in semi-permeable structures. Specific microfluidic system architectures for conducting biomolecule and cell assays are described.01-07-2010
20120231444Microfabricated Crossflow Devices and Methods - This invention provides microfabricated devices and methods for detecting, analyzing and sorting biological materials and particles. Droplets containing the particles are provided in an extrusion fluid, passed through a detection region, and then directed into a branch channel according to predetermined characteristics. For example, cells or viral particles contained in droplets of aqueous solvent are flowed past a detector in the nonpolar extrusion fluid decane, and routed into a selected branch channel for subsequent analysis or use.09-13-2012
20090011402BIOSENSORS BASED ON DIRECTED ASSEMBLY OF PARTICLES - A sensor system for detecting an effector or cofactor comprises (a) a nucleic acid enzyme; (b) a substrate for the nucleic acid enzyme, comprising a first polynucleotide; (c) a first set of particles comprising a second polynucleotide at least partially complementary to the substrate, where the polynucleotide is attached to the particles at its 3′ terminus; and (d) a second set of particles comprising a third polynucleotide at least partially complementary to the substrate, where the polynucleotide is attached to the particles at its 5′ terminus.01-08-2009
20100086908METHODS FOR THE DETECTION OF RESPIRATORY VIRUSES - The present invention relates generally to the field of nucleic acid detection and more specifically to the detection of human respiratory viruses in a patient sample. In some aspects, the invention relates to the detection of multiple respiratory viral groups, including rhinovirus, respiratory syncytial virus, parainfluenza virus, influenza virus, metapneumovirus, adenovirus, coronavirus, and enterovirus.04-08-2010
20080286752Methods for the production of HCV, assaying HCV entry, and screening drugs and cellular receptors for HCV - The invention provides cell culture methods that efficiently produce new infectious HCV virions where such methods are based on the unexpected finding that culturing cells at lower temperatures, i.e., from about 20° C. to about 34° C., enables efficient methods dependent upon HCV E1E2 mediated fusion. The invention also provides fusion assay methods that are robust and reliable because of, at least in part, specific pH conditions, and HCV E1 and E2 proteins that contain a dimerization domain. The present methods are useful for propagating infectious HCV, for improved diagnostics, drug screening and basic research efforts relating to HCV receptor binding, HCV entry (binding (attachment) and fusion), replication, virion assembly and release. In another respect, the present invention provides methods for detecting HCV E1E2 mediated fusion, and related methods for identifying drugs or other molecules that can inhibit HCV fusion and for identifying mutations that can inhibit HCV fusion.11-20-2008
20130164733HEPATITIS-C VIRUS TESTING - New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping.06-27-2013
20130164737Method for Separating Target Molecules or Particles from Fibrinogen-Containing Samples Including Blood Components - A method for separating target molecules or particles from a fibrinogen containing sample comprises: (a) trapping the said target molecules or particles in a fibrin network by converting at least partially the fibrinogen contained in the sample into fibrin; (b) retracting the said fibrin network to form a fibrin clot; (c) separating the said fibrin clot from the surrounding sample medium.06-27-2013
20120237923Lateral Flow Immunoassay Controls - Rapid lateral flow immunoassays have an extensive history of use in both the clinical and home settings. These devices are used to test for a variety of analytes, such as drugs of abuse, hormones, proteins, urine or plasma components and the like. The present invention provides an improved procedural control that indicates to the test user that at least a portion of the applied sample has passed through the test result zone of the test strip, and optionally that the test is complete and the test results may be read.09-20-2012
20120237922Viral Diagnostics - The present disclosure provides methods for determining whether a subject is infected with lymphocytic choriomeningitis virus (LCMV). These methods include obtaining a sample from a subject with increased susceptibility to LCMV infection, contacting the sample with one or more compositions for detecting LCMV, and determining whether the one or more compositions for detecting LCMV is associated with a marker of LCMV from the sample, wherein detection of an association indicates that that the subject is infected with LCMV.09-20-2012
20120237921FULL GENOME DNA OF HUMAN CYTOMEGALOVIRUS STRAIN JHC ISOLATED FROM KOREAN PATIENT AND OPEN READING FRAMES THEREOF - Provided are a full genome DNA of a human cytomegalovirus (HCMV) strain JHC isolated from Korean patients and open reading frames (ORFS) thereof and, more particularly, UL1, UL119 and RL6.09-20-2012
20110033837IMMORTALIZED HUMAN CD4-POSITIVE CELL AND ITS USE FOR DETERMINING THE PHENOTYPE OF A HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - The invention relates to an immortalized CD4-positive cell. According to the invention, this cell comprises a gene encoding a CXCR4 chemokine receptor that is capable of serving as a coreceptor for entry of a Human Immunodeficiency Virus Type 1 (HIV-I) into the cell, and a gene encoding a CCR5 receptor that is not capable of serving as a coreceptor for entry of a Human Immunodeficiency Virus Type 1 into the cell. The invention furthermore relates to a method for the phenotypical characterization of a HIV-I, comprising providing such a cell, adding an HIV-I to the cell under conditions that allow for the entrance of the HIV-I into the cell and the replication of the virus in the cell, and measuring the replication of the HIV-I in the cell.02-10-2011
20090170069Cell free methods for detecting protein-ligand binding - Provided are rapid and sensitive cell-free assay methods for detecting and/or measuring specific bimolecular or higher order interactions via reassembly of a split monomeric reporter protein, and methods of detecting or identifying modulators of such interactions by the effect on the signal provided by the reassembled split reporter protein. This methodology is adaptable to protein-protein, protein-peptide, protein-nucleic acid, protein-methylated or nonmethylated nucleic acid and other small or large molecule ligands and binding proteins.07-02-2009
20100279277METHODS OF EVALUATING A TEST AGENT IN A DISEASED CELL MODEL - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.11-04-2010
20120183952COMPOSITIONS FOR USE IN IDENTIFICATION OF CALICIVIRUSES - The present invention relates generally to the detection and identification of caliciviruses and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.07-19-2012
20090068638PHAGE-BASED METHOD FOR THE DETECTION OF BACTERIA - The present invention relates to the field of biosensors useful for detecting bacteria. More particularly, the present invention relates to an electrochemical cell or biosensor and its use in a phage-based method and kit for the detection of bacteria.03-12-2009
20110129816DEVICE FOR DETECTION OF INFLUENZA VIRUS - A device for detecting or quantifying influenza viruses in a sample, which comprises a detection region having a human anti-influenza virus nucleoprotein antibody immobilized onto a support, a sample supply region, and a sample-migrating region; and a kit for detecting or quantifying influenza viruses, which comprises a solid phase in which a human anti-influenza virus nucleoprotein antibody is fixed onto a carrier.06-02-2011
20100167264Quantitative analyte assay device and method - The present invention relates to an assay device and a method for using such for the quantitative determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains a test site having immobilized thereon a ligand capable of reacting with the analyte and binding such to the test site, and two standard band sites having immobilized thereon known high and low concentrations of a calibrator agent capable of reacting with a label conjugate and binding such to the standard sites, wherein the upstream membrane has a site for the application of a sample to be analyzed, and has a site downstream from the sample application site for depositing label conjugates capable of reacting with the analyte and label conjugates capable of reacting with the immobilized calibrator agents in the standard bands to provide a known label response in the standards bands, and the downstream membrane is capable of absorbing said sample and providing the capillary flow for the sample through the upstream and test membrane.07-01-2010
20090176201MICROBUBBLES FOR AFFINITY SEPARATION - The present invention relates to methods, compositions and kits for affinity isolation, affinity purification and affinity assay based on microbubbles coated with an affinity molecule. Particularly, the invention provides protein microbubbles coated with an affinity molecule. In addition, the invention provides glass microbubbles coated with an affinity molecule. Methods of using the microbubbles of the invention for isolating analytes and cells are specifically provided.07-09-2009
20110086338Bacteriophage/Quantum-Dot (Phage-QD) Nanocomplex to Detect Biological Targets in Clinical and Environmental Isolates - The invention is related to a non-biotinylated bacteriophage that comprises a nucleic acid sequence encoding a biotinylation domain, a complex that comprises a biotinylated bacteriophage and a biotin-specific ligand conjugated bioconjugate, and a method of detecting a bacterial cell in a sample comprising contacting the sample with a non-biotinylated bacteriophage that comprises a nucleic acid sequence encoding a biotinylation domain, wherein the bacteriophage is specific to the bacterial cell.04-14-2011
20100227313Methods and Compositions for Determining Altered Susceptibility of HIV-1 to Protease Inhibitor Treatment - This invention relates to methods for determining altered susceptibility of HIV-I viruses to protease inhibitors (PIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding protease and/or gag of the HIV-I, the presence of mutations correlated with altered susceptibility to amprenavir and/or darunavir.09-09-2010
20110076671USE OF SYNTHETIC PEPTIDE DERIVED FROM ZEBRA PROTEIN FOR THE IN VITRO DIAGNOSIS OF THE EPSTEIN-BARR VIRUS (EBV) REACTIVATION - Method of using polypeptide derived from ZEBRA protein, or variants or isoforms of the polypeptide for the in vitro and ex vivo screening of the EBV virus reactivation in a biological sample of a subject afflicted by a pathology associated with EBV infection.03-31-2011
201101298132'-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION - The present invention discloses a method for the treatment of Flaviviridae infection that includes the administration of a 2′-branched nucleoside, or a pharmaceutically acceptable prodrug and/or salt thereof, to a human in need of therapy in combination or alternation with a drug that directly or indirectly induces a mutation in the viral genome at a location other than a mutation of a nucleotide that results in a change from serine to a different amino acid in the highly conserved consensus sequence, XRX06-02-2011
20090029346Detection of human papilloma virus - An assay for detecting HPV comprising treating the viral nucleic acid with an agent that modifies cytosine to form derivative viral nucleic acid, amplifying at least a part of the derivative viral nucleic acid to form an HPV-specific nucleic acid molecule, and looking for the presence of an HPV-specific nucleic acid molecule, wherein detection of the HPV-specific nucleic acid molecule is indicative HPV.01-29-2009
20100143884DETECTION OF INFLUENZA VIRUS - The present application describes methods for detecting influenza A and/or influenza B and/or distinguishing between pathogenic and seasonal influenza A subtypes. Many of these preferred formats employ pan-specific antibodies (i.e., that react with all or at least multiple strains within an influenza type) to detect presence of influenza A and/or influenza B and PDZ domains in combination with panspecific antibodies to influenza A to distinguish pathogenic and seasonal influenza A subtypes.06-10-2010
20110300528Methods for Bacteriophage Design - Methods for designing and breeding phages are described. The methods include methods to design phages for previously resistant bacterial strains. The methods described do not use genetic manipulation techniques.12-08-2011
20090087833ADIPOGENIC ADENOVIRUSES AS A BIOMARKER FOR DISEASE - This invention relates to the relationship between infection with an adipogenic adenovirus, such as adenovirus-36, and obesity-related disease. In particular, this invention relates to assaying a subject to determine the adipogenic adenovirus infection status and then determining the subject's predisposition to developing an obesity-related disease based on the adipogenic adenovirus infection status.04-02-2009
20090142747Development of Diagnostic Kit for the Detection of Chrysanthemum Virus B - The present invention provides a method for detection of 06-04-2009
20110300529DETECTION OF IFI16 IN BODY FLUIDS - The present invention relates to methods for the qualitative and/or quantitative determination of interferon inducible protein 16 (IFI 16) in an extracellular form.12-08-2011
20110070574METHOD FOR VIRUS DETECTION - A method of determining the concentration of a virus or antigen thereof in a sample comprises the steps of: providing a sensor surface having immobilized thereto a virus antigen or a virus antigen analogue, mixing the sample with a known amount of antibody to the virus antigen to obtain a predetermined concentration of antibody to the antigen in the sample mixture, contacting the sample mixture with the sensor surface to bind free antibody in the mixture to the sensor surface, measuring the response of the sensor surface to the binding of free antibody, and determining the concentration of the virus or antigen in the sample from a calibration curve prepared by measuring the responses obtained for mixtures containing the predetermined concentration of antibody and different concentrations of virus.03-24-2011
20090004644METHODS AND COMPOSITIONS FOR PROCESSES OF RAPID SELECTION AND PRODUCTION OF NUCLEIC ACID APTAMERS - Embodiments herein relate to compositions and methods for making and using aptamers, for example, DNA aptamers (DCEs) and/or RNA aptamers. In some embodiments, methods relate to making and amplifying target DCEs. In certain embodiments, methods for making capture elements or aptamers concern using a reporter moiety and signal reducing moiety prior to amplifying a target-specific capture element. In some embodiments, methods disclosed herein may be used to rapidly generate large quantities of aptamers such as DCEs directed to a particular target agent. Some embodiments relate to systems for performing automated generation of aptamers.01-01-2009
20130022963DIRECT AMPLIFICATION AND DETECTION OF VIRAL AND BACTERIAL PATHOGENS - Provided herein are methods for identifying the presence or absence of a target nucleic acid from a microorganism using direct amplification without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids.01-24-2013
20110136101Immortalized Human Fetal Liver Cells - The present invention provides immortalized fetal liver cells that express the oncogene Simian virus (SV 40) large T-antigen and specific hepatocyte markers and a method for producing same.06-09-2011
20130022962METHOD AND APPARATUS FOR DIAGNOSTIC ANALYSES - A method for diagnostic analyses, in particular to identify pathogens, such as viruses, bacteria or other micro-organisms present in a biological sample, comprises a first step of measuring and continuously monitoring the turbidity and/or the concentration of the pathogens, by means of an instrumental reading technique, of a liquid culture medium into which the sample to be analyzed has been inoculated and in which the replication of the pathogens possibly present occurs, said measuring and monitoring being carried out dynamically during the replication of the pathogens growing in the culture medium; and a second step of identifying the pathogens, carried out by taking at least an aliquot of the liquid culture medium containing the biological sample directly obtained from the first step, which has reached a desired value of turbidity according to a standardized value scale, such as the McFarland turbidity scale, and/or of concentration of the pathogens, and using said aliquot directly in mass spectrophotometric identification means (01-24-2013
20080233557PNA Probes, Kits, and Methods for Detecting Lamivudine-Resistant Hepatitis B Viruses - Disclosed are peptide nucleic acid (PNA) probes to detect lamivudine resistant mutants of hepatitis B virus (HBV), which causes acute and chronic hepatitis, kits for detecting lamivudine resistant HBV comprising the PNA probes, and methods for detecting lamivudine resistant HBV by using the kits. They can accurately detect mutations of rtL180M, rtM204V, rtM204I and rtV2071 within B and C domains of HBV DNA polymerase gene, the main cause of lamivudine resistance, as well as mixed mutants of more than one mutant. They can detect lamivudine resistant HBV with high specificity and sensitivity.09-25-2008
20130022960RAPID TEST FOR DETECTING INFECTION - Test kit has a cellulose filter paper with a flow rate of about 0.04 to about 0.4 ml/min/cm01-24-2013
20100136520DETECTING HEPATITIS B VIRUS - This invention is related to methods for detecting hepatitis B virus by determining the level of hepatitis B virus surface antigen protein. This invention is also related to methods for detecting mutant hepatitis B virus surface antigen protein and kits for detecting hepatitis B virus.06-03-2010
20120088228METHODS OF PRODUCING HIGH TITER, HIGH PURITY VIRUS STOCKS AND METHODS OF USE THEREOF - The purity and titer of virus stocks used for virus clearance studies have a significant influence on study outcome, and impact how well the scale-down model represents the production-scale process. Impurities in virus stocks are particularly important in the testing of small virus retentive filters because these impurities may cause a filter to foul prematurely, leading to underestimation of the true throughput capability of the filter and consequent inappropriate sizing of the production scale unit. In addition, impurities can also affect the levels of virus clearance observed by altering the fouling mechanisms and subsequent fluid passage through the virus filter. Described herein are methods for making, producing and using high purity virus stocks having high titer.04-12-2012
20120003627Portable Fluorescence Reader Device - The present invention describes a device for performing a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The device also includes a compatible slide comprising sample wells. The device detects emitted fluorescence signal through a camera and optics assembly that is controlled by a user interface assembly.01-05-2012
20120107794Cross-Coupled Peptide Nucleic Acids for Detection of Nucleic Acids of Pathogens - The present invention concerns methods for detecting a nucleic acid comprising (i) contacting a solution comprising a first PNA having a first cross-reactive functional group with a substrate having a second PNA affixed thereto, the second PNA having a second first cross-reactive functional group, wherein the first PNA has a reporter molecule attached thereto and the first and second PNAs being complementary to different portions of a target DNA; (ii) contacting a sample suspected of containing the nucleic acid with the first and second PNAs; and (iii) determining the presence of the reporter molecule on the substrate.05-03-2012
20110300530IN VITRO TEST SYSTEM FOR VIRAL INFECTIONS - The invention relates to a multi-layered biological in vitro tissue containing: dermis layer, containing a collagen biomatrix with fibroblasts embedded therein and epidermis layer, containing epithelial cells. It is provided that latently virally infected neuronal cells are integrated at least into the dermis layer.12-08-2011
20110300531METHOD AND DEVICE TO DETECT THE PRESENCE OF ANALYTES IN A SAMPLE - Disclosed are methods and apparatus useful for determining the presence or absence of one or more analytes in a liquid sample, such as a biological or environmental sample. In some embodiments, the method can use an indirect competitive immunochromatographic test strip.12-08-2011
20110287410HEPATITIS-C VIRUS TESTING - New styles of hepatitis C virus (HCV), referred to as HCV-3 and HCV-4, have been identified and sequenced. Antigenic regions of HCV-2, HCV-3 and HCV-4 polypeptides have been identified. Immunoassays for HCV and antibodies thereto are described, which allow more complete screening of blood samples for HCV, and allow HCV genotyping.11-24-2011
20110287409DIAGNOSTIC DEVICE AND METHOD - Diagnostic devices and methods involve comparison of relative levels of first and second components and/or characteristics of a fluid sample (e.g., saliva), preferably using bound antibodies arranged to interact with selected components, and colorimetric indicators that are released in proportion to relative concentration or amount of the components or characteristics, as indicative of a health condition such as dehydration state, shock state, stress state, disease state, drug consumption, and drug metabolization. Amylase and IgA may be selected as specific salivary components of interest.11-24-2011
20110287408Preparation of Micro-Porous Crystals and Conjugates Thereof - A conjugate comprising a dye-labeled microporous crystal, a stop-cock moiety, and covalently bound thereto an affinity binding agent is disclosed. The dye-labeled microporous crystal is a zeolite crystal, such as a zeolite L crystal, having a large number of channels in its interior into which the dye is loaded. The stop-cock moiety can be functionalized with an amino group to which a carboxyester group can be attached. The affinity binding agent allows for the binding to a biological moiety. The conjugate of the moiety can be used in in-vivo and/or in-vitro imaging applications.11-24-2011
20110287406Novel HCV core+1 protein, methods for diagnosis of HCV infections, prophylaxis, and for screening of anti-HCV agents - The present invention relates to a novel form of core+1 protein of Hepatitis C virus (HCV), designated shorter form core+1 protein. The shorter form core+1 protein of Hepatitis C virus is the product of translation of a coding sequence consisting of all or part of a nucleotide sequence extending from nucleotide 598 to nucleotide 920 within the core+1 ORF of HCV represented on FIG. 11-24-2011
20100015596RS VIRUS DETECTING KIT USING ANTI-RS VIRUS MONOCLONAL ANTIBODY, IMMUNO-CHROMATOGRAPHIC TEST DEVICE, AND NEW ANTI-RS VIRUS MONOCLONAL ANTIBODY - A kit or an immuno-chromatographic test device for detection of respiratory syncytial virus (RSV), comprising at least an RSV F protein-recognizing anti-RSV monoclonal antibody produced by hybridoma RSF2-412. An anti-RSV monoclonal antibody recognizing an RS virus F protein, which is selected from the group consisting of an antibody produced by hybridoma RSF2-412, an antibody produced by hybridoma RSF1-1565, and an antibody produced by hybridoma RSF6-255.01-21-2010
20090162832Functional viral vectors for the overexpression or extinction of particular genes in plants, and applications - The invention relates to the use of genes which, in plants, encode proteins with a functional diversity in terms of silencing, comprising the selection of the gene with the level of effectiveness in order to construct a plant viral vector having the function of overexpressing or silencing particular genes.06-25-2009
20110143335METHODS AND SYTEMS TO CAPTURE COMPETITIVE MOLECULES - Methods and systems to capture competitive molecules, such as to reduce false positives in an assay. Competitive molecules may be captured in a fluid moving through a portable point-of-care diagnostic assay system.06-16-2011
20110143333ANTI-CHIKUNGUNYA MONOCLONAL ANTIBODIES AND USES THEREOF - The present invention relates to the field of arbovirosis caused by Chikungunya virus (CHIK). The present invention specifically concerns anti-CHIK monoclonal antibodies (MAbs), and more specifically anti-CHIK.E2 MAbs and their use as diagnostic products in methods for detecting the presence or absence of a CHIK strain.06-16-2011
20110143337UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION - Embodiments of the present invention provide methods and nucleic acid reporter molecules for the detection of nucleic acid in a sample. The nucleic acid reporter molecule comprises two unsymmetrical cyanine monomer moieties, which may be the same or different, that are covalently attached by a linker comprising at least one aromatic, heteroaromatic, cyclic or heterocyclic moiety comprising 3-20 non-hydrogen atoms selected from the group consisting of O, N, S, P and C. The linker may be rigid, relatively flexible or some degree thereof. The unsymmetrical cyanine monomer moieties comprise a substituted or unsubstituted benzazolium moiety and a substituted or unsubstituted pyridinium or quinolinium moiety that is connected by a methine bridge that is monomethine, trimethine or pentamethine. The linkers form the cyanine dimer compounds by attaching to the pyridinium or quinolinium moiety of the monomer moieties. The present nucleic acid reporter molecules find utility in forming a nucleic acid-reporter molecule complex and detecting the nucleic acid. In particular, present nucleic acid reporter molecules with a rigid linker and monomer moieties with a monomethine bridge find utility in detecting RNA in the presence of DNA.06-16-2011
20110143336MARKER FOR ESTIMATING THE DIAGNOSIS OF CERVICAL ADENOCARCINOMA OR FOR ESTIMATING THE PROGNOSIS OF CERVICAL CANCER - To provide a novel biomarker for estimating the diagnosis of cervical adenocarcinoma or for estimating the prognosis of cervical cancer. An antibody against Villin 1 is employed as a biomarker.06-16-2011
20110143334MICROBIOLOGICAL SYSTEMS AND METHODS OF FLUID SAMPLE ANALYSIS - Methods and systems for detecting the presence of a target microorganism in a liquid sample are provided. Methods comprise the steps of passing the liquid sample through a surface filter, placing the surface filter into contact with a culture device, incubating the culture device for a period of time and detecting the presence of a target microorganism. Methods may be used with an automated detection system.06-16-2011
20110143332METHOD FOR IDENTIFYING MICROORGANISM OR DETECTING ITS MORPHOLOGY ALTERATION USING SURFACE ENHANCED RAMAN SCATTERING (SERS) - The present invention relates to a method for producing a profile identifying a microorganism based on surface enhanced Raman scattering (SERS) and an apparatus thereof. The method comprises: (1) placing the microorganism on a SERS-active substrate; (2) mounting the microorganism with a mounting solution; (3) obtaining a SERS spectrum of the microorganism in step (2); and (4) analyzing the SERS spectrum to produce the profile.06-16-2011
20110294110SET OF MAGNETIC LABELS - Provided is a label for an analyte, which label is attached to a magnetic or magnetisable substance, the label comprising: 12-01-2011
20090053688 METHOD AND DEVICE FOR ULTRASOUND ASSISTED PARTICLE AGGLUTINATION ASSAY - Ultrasound-assisted particle agglutination assay methods and apparatuses are described based on first providing a standing wave ultrasound field at a resonance frequency of a test liquid in a resonator cell containing microparticles covered with a binding agent with high affinity to an analyte sought to be detected by the assay test. Formation of the specifically-bound and nonspecifically-bound aggregates of these microparticles is then followed by effective stirring of the liquid with swept-frequency sonication causing disintegration of nonspecifically-bound aggregates and leaving specifically-bound aggregates in place for further detection and measurement. The methods and devices of the invention allow significant improvement in the sensitivity and specificity of agglutination tests and are advantageously applicable to detecting various proteins, DNA, RNA and other biologically active substances. Specific examples are provided.02-26-2009
20110294112METHODS FOR POINT-OF-CARE DETECTION OF NUCLEIC ACID IN A SAMPLE - Provided herein are methods and apparatus for detecting a target nucleic acid in a sample and related methods and apparatus for diagnosing a condition in an individual. The condition is associated with presence of nucleic acid produced by certain pathogens in the individual.12-01-2011
20110294113DETECTION DEVICE FOR DETECTING BIOLOGICAL MICROPARTICLES SUCH AS BACTERIA, VIRUSES, SPORES, POLLEN OR BIOLOGICAL TOXINS, AND DETECTION METHOD - A device for the detection of micro particles that can be marked by probes or antibodies capable of being detected by radiation has a filter, a supply system, and a detection system. Fluid to be examined is passed over a filter to filter out the micro particles and to perform the marking steps by supplying corresponding marking substances to the filter12-01-2011
20110294109METHODS FOR DETECTING AN ANALYTE - Methods of decreasing non-specific binding in solid phase assays for an analyte are disclosed. In the methods, the solid phase apparatus (lateral flow solid phase apparatus or capillary flow solid phase apparatus) is subjected to elevated heat. The elevated heat can be applied subsequent to application of a test sample to the solid phase apparatus.12-01-2011
20110294111METHOD OF DETERMINING AND CONFIRMING THE PRESENCE OF AN HPV IN A SAMPLE - Methods are provided for genotyping a target nucleic acid in a sample. In various aspects, the methods comprise generating nucleic acid hybrids between probes specific for the genotypes of interest and the target nucleic acid and detecting hybridization in the sample. In other aspects, the methods comprise using multi-probe mixtures to reduce the volume of sample necessary to determine the genotype of the target nucleic acid.12-01-2011
20090136917Systems and methods for viral therapy - Diagnostic methods and compositions associated with viral therapy are provided. In particular, methods, compositions, and kits to measure markers and therapeutic indicator predictive of viral efficacy in antitumor therapy are provided. Therapeutic viruses and combinations and kits for use in the practicing the methods also are provided.05-28-2009
20090286230Methods, Devices, Kits and Compositions for Detecting Roundworm - Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.11-19-2009
20080280284Nucleic Acid Sequences That Can Be Used as Primers and Probes in the Amplification and Detection of Hsv Dna and Method for the Amplification and Detection of Hsv Dna Using a Transcription Based Amplification - The present invention is related to a pair of oligonucleotide primers for the amplification of HSV nucleic acid comprising: a) an oligonucleotide, 10-50 nucleotides in length, preferably 10-35 nucleotides in length, comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of: 5′-ACGTTCACCAAGCTGCTGCT-3′, or its complementary sequence and b) an oligonucleotide, 10-50 nucleotides in length, preferably 10-35 nucleotides in length, comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of: 5′CCAGGGCCCTGGAGGTGCGG-3′, or its complementary sequence. The invention also relates to probes, method for amplifying an HSV DNA target, method of specific ou aspecific detection of HSV type 1 and 2 and test kit to do possible the detection of HSV. The present invention is especially useful in methods for practicing nucleic acid test.11-13-2008
20100035229METHODS, PLASMID VECTORS AND PRIMERS FOR ASSESSING HIV VIRAL FITNESS - The present invention relates to methods and means for the evaluation of HIV replicative capacity in a given environment. In particular, the invention provides a growth competition assay that can determine relative viral fitness using a recombinant tagged HIV-1 virus system. The methods rely on plasmid vectors, amplicons, primers and probes, and the generation of replication-competent viruses therefrom. Said methods and materials may find use in multiple fields including diagnostics, drug screening, pharmacogenetics and drug development.02-11-2010
20100035236ENRICHMENT METHOD FOR VARIANT PROTEINS WITH ALTERED BINDING PROPERTIES - A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.02-11-2010
20100035235USE OF FOCUSED LIGHT SCATTERING TECHNIQUES IN BIOLOGICAL APPLICATIONS - Methods for using focused light scattering techniques for the optical sensing of biological particles suspended in a liquid medium are disclosed. The optical sensing enables one to characterize particles size and/or distribution in a given sample. This, in turn, allows one to identify the biological particles, determine their relative particle density, detect particle shedding, and identify particle aggregation. The methods are also useful in screening and optimizing drug candidates, evaluating the efficacy and dosage levels of such drugs, and in personalized medicine applications.02-11-2010
20100035233Triggered RNAi - The present application relates to methods and compositions for triggering RNAi. Triggered RNAi is highly versatile because the silencing targets are independent of the detection targets. In some embodiments, methods of silencing or modulating the expression of a marker gene are provided. The methods generally comprise providing an initiator to a cell comprising a detection target and a silencing target gene, wherein the detection target is different from the silencing target gene, wherein binding of the detection target to the initiator initiates formation of an inactivator double-stranded RNA (inactivator dsRNA). The inactivator dsRNA can silence the silencing target gene to modulate the expression of a marker gene.02-11-2010
20100035232TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR IDENTIFICATION OF PATHOGENS - The methods disclosed herein relate to methods and compositions for amplifying nucleic acid sequences, more specifically, from nucleic acid sequences of pathogens by targeted whole genome amplification.02-11-2010
20100035227Compositions for use in identification of alphaviruses - The present invention provides oligonucleotide primers and compositions and kits containing the same for rapid identification of alphaviruses by amplification of a segment of viral nucleic acid followed by molecular mass analysis.02-11-2010
20100035228Monitored separation device - A device for separating and purifying useful quantities of particles comprises: 02-11-2010
20110217695BETAG1-IgG INTRON FOR ENHANCED ANTI-IGF1R EXPRESSON - The present invention provides polynucleotides for enhanced expression of a target gene such as an immunoglobulin. Methods of expressing a target gene using the polynucleotides of the invention are also covered.09-08-2011
20120088227Devices and Process for Separating Plasma From a Blood Sample - The present invention pertains to a device for separating plasma from a blood sample comprising a stacked structure which is provided with a first portion including a separating member having a first surface for applying or receiving the blood sample, wherein the separating member is adapted to permit the passage of plasma but to inhibit the passage of cells, and a second portion including an absorptive member for absorbing the plasma, which has a second surface in contact with the separating member for receiving the plasma, wherein the absorptive member is adapted to generate a capillary pressure so as to draw plasma from the separating member to the absorptive member. The first portion is fixed to the backing member in a manner to be removed without destroying the absorptive member. The absorptive member is fixed to the backing member in a manner to be removed without destroying the absorptive member.04-12-2012
20100028859Hyper-Spectral Imaging and Analysis of a Sample of Matter, and Preparing a Test Solution or Suspension Therefrom - Method for hyper-spectral imaging and analysis of a sample of matter, for identifying and characterizing an object of interest therein. Preparing test solution or suspension of the sample, including adding thereto a spectral marker specific to object of interest, such that if object of interest is in test solution or suspension, object of interest becomes a hyper-spectrally active target which is hyper spectrally detectable and identifiable; adding to test solution or suspension a background reducing chemical, for reducing background interfering effects caused by presence of objects of non-interest in test solution or suspension, thereby increasing hyper spectral detectability of hyper spectrally active target in test solution or suspension; generating and collecting hyper-spectral image data and information of test solution or suspension; and, processing and analyzing thereof. Exemplary objects of interest are biological agents—bacteria (02-04-2010
20100028857Method for Detecting and for Removing Endotoxin - The invention relates to a method for identifying endotoxins for eliminating said endotoxins from a sample, with the aid of bacteriophage tail proteins.02-04-2010
20090215028Methods and Compositions for Determining Anti-HIV Drug Susceptibility and Replication Capacity of HIV - This invention relates, in part, to methods and compositions for determining the susceptibility of an HIV to an anti-HIV drug or the replication capacity of an HIV. In certain embodiments, the methods comprise culturing a host cell in the presence of the anti-HIV drug, measuring the activity of the indicator gene in the host cell; and comparing the activity of the indicator gene as measured with a reference activity of the indicator gene. In certain embodiments, the difference between the measured activity of the indicator gene relative to the reference activity correlates with the susceptibility of the HIV to the anti-HIV drug, thereby determining the susceptibility of the HIV to the anti-HIV drug. In certain embodiments, the difference between the measured activity of the indicator gene relative to the reference activity indicates the replication capacity of the HFV, thereby determining the replication capacity of the HIV. In certain embodiments, the host cell comprises a patient-derived segment and an indicator gene. In certain embodiments, the patient-derived segment comprises a nucleic acid sequence that encodes integrase or RNAse H.08-27-2009
20090275016ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE - A sensor chip for detecting an immune response against an influenza virus, the sensor chip including a substrate having a surface and a plurality of hemagglutinin polypeptides bound to discrete locations on the surface of the substrate, each hemagglutinin polypeptide having a hemagglutinin epitope. Detection devices containing the sensor chip and methods of detecting influenza immune responses are also described herein.11-05-2009
20110217693Generation of Replication Competent Viruses for Therapeutic Use - The present invention relates to the generation of replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.09-08-2011
20100209905PROTEIN D - AN IGD-BINDING PROTEIN OF HAEMOPHILUS INFLUENZAE - A novel surface exposed protein of 08-19-2010
20090098531DETECTING HEPATITIS B VIRUS - This invention is related to methods for detecting hepatitis B virus by determining the level of hepatitis B virus surface antigen protein. This invention is also related to methods for detecting mutant hepatitis B virus surface antigen protein and kits for detecting hepatitis B virus.04-16-2009
20090098529Methods for attenuating virus strains for diagnostic and therapeutic uses - Modified or attenuated viruses and methods for preparing the modified viruses and modulating attenuation are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The viruses also can be used in diagnostic methods.04-16-2009
20090098527BIOLOGICAL ORGANISM IDENTIFICATION PRODUCT AND METHODS - A biological organism identification product, and methods of using the same, that include a collection device to collect one or more sample organisms, a fixing and transporting composition present in an amount sufficient to kill the sample organism(s) associated with the collection device, an extraction member to extract a sufficient amount of genomic nucleic acid from the sample organism(s) to facilitate identification; and a polymerase chain reaction component into which the sufficient amount of genomic nucleic acid can be dissolved. The amplified genomic material is exposed to molecules that bind to predetermined genomic sequences, providing the identification feature of the product. The biological organism identification product may be portable, durable, and self-contained.04-16-2009
20100330548Nucleic Acid Primers and Probes for Detecting Human and Avian Influenza Viruses - Provided are nucleic acid sequences that are used to prepare primers and probes that are used in a kinetic polymerase chain reaction (kPCR) assay to detect influenza viruses in a human or animal subject. The starting material for the kPCR assays may be DNA or RNA and the assays may be conducted in a singleplex assay to detect a single influenza virus or in a multiplex assay to detect multiple influenza viruses. The primers and probes have utility in the detection and quantification of type A and type B influenza viruses (INFA and INFB, respectively) and have been shown to be effective for the detection and quantification of all the known INFA subtypes, namely, H1, H2, H3, H4, H5, H6, H7, H8, and H9.12-30-2010
20100209903Method for measuring resistance of a patient HIV-2 to protease inhibitors - A search method in a biological sample containing an HIV-2 viral strain for possible resistance of said strain to treatment by an anti-protease agent, and nucleotide probes for the implementation thereof. According to methods known per se, the presence of at least one mutation at certain, specified, particular positions of the proteinic sequence of the protease of said viral strain from a biological sample taken from a patient contaminated by HIV-2 is searched. If said mutation is observed, the existence of a resistance to said anti-protease agent is assumed in the patient.08-19-2010
20100209904Antibodies for oncogenic strains of HPV and methods of their use - The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.08-19-2010
20100112548KIT FOR DETECTING NON-PATHOGENIC OR PATHOGENIC INFLUENZA A SUBTYPE H5 VIRUS - Current methods for detecting influenza A subtype H5 virus, for example cell culture, haemagglutination-inhibition, fluorescent antibody and enzyme immunoassay, and reverse transcriptase polymerase chain reaction (RT-PCR) may have the disadvantages of low sensitivity and low specificity. Furthermore, such methods are relatively difficult to use, and may not be suitable for routine detection on a daily basis. The kit for detecting H5 virus of this invention may provide a user-friendly alternative that is relatively more sensitive and specific to H5 virus. The detection kit utilizes two specially designed primers A and B for the replication of H5 virus, and a specific capture probe for immobilizing the amplified viral RNA. An additional primer C is also designed for the detection of pathogenic H5 virus. The detection of H5 virus by the detection kit may be accomplished within one day if desired.05-06-2010
20080311556Sense Antiviral Compound and Method for Treating Ssrna Viral Infection - The invention provides sense antiviral compounds and methods of their use in inhibition of growth of viruses of the Flaviviridae, Picornoviridae, Caliciviridae, Togaviridae, Coronaviridae families and hepatitis E virus in the treatment of a viral infection. The sense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of (12-40) subunits, including at least (12) subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 3′-terminal end (40) bases of the negative-sense RNA strand of the virus.12-18-2008
20080311560Oligonucleotides For Detecting Human Papilloma Virus In A Test Sample - Oligonucleotides targeted to HPV Type 16 and/or Type 18 nucleic acid sequences which are particularly useful to aid in detecting HPV type 16 and or 18 are described. The oligonucleotides can aid in detecting HPV Type 16 and/or Type 18 in different ways such as by acting as hybridization assay probes, helper probes, and/or amplification primers.12-18-2008
20080311558Methods For Rapid Identification Of Pathogens In Humans And Animals - The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.12-18-2008
20090170066METHODS AND MATERIALS THEREFOR - The present invention relates to a method for detecting or detecting and identifying rotavirus in a biological sample. In particular, the invention relates to a detection method comprising contacting the nucleic acids from the sample or derived from the sample with at least one VP4 and/or VP7 universal probes in the context of a solid support and detecting any type-specific hybridisation. The invention further relates to a detection or detection followed by typing method comprising contacting the nucleic acids from the sample or derived from the sample with at least one P type-specific and G type-specific probes in the context of a solid support and detecting any type-specific hybridisation. The invention also relates to primers and probes used therein and to diagnostic kits.07-02-2009
20090317796Indirect immunofluorescence assay typing kit for coxsackievirus A group and method for typing coxsackievirus A group - An indirect immunofluorescence assay typing kit for coxsackievirus, comprising: a first reagent comprising a mixture of an anti-coxsackievirus A2 polyclonal antibody, an anti-coxsackievirus A4 polyclonal antibody, an anti-coxsackievirus A5 polyclonal antibody, an anti-coxsackievirus A6 polyclonal antibody, and an anti-coxsackievirus A10 polyclonal antibody; a second reagent comprising the anti-coxsackievirus A2 polyclonal antibody; a third reagent comprising the anti-coxsackievirus A4 polyclonal antibody; a fourth reagent comprising the anti-coxsackievirus A5 polyclonal antibody; a fifth reagent comprising the anti-coxsackievirus A6 polyclonal antibody; a sixth reagent comprising the anti-coxsackievirus A10 polyclonal antibody; and a seventh reagent comprising a secondary antibody labeled with a fluorescence compound, wherein the secondary antibody is used for detecting the antibody anti-coxsackieviruses A2, A4, A5, A6 and A10 polyclonal antibodies and a titer of the anti-coxsackieviruses A2, A4, A5, A6 or A10 polyclonal antibody is about 1:5000-151:70000.12-24-2009
20100035237NOVEL ANTIGEN CONSTRUCTS USEFUL IN THE DETECTION AND DIFFERENTIATION OF ANTIBODIES TO HIV - Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.02-11-2010
20110195394SYSTEMS AND METHODS FOR DIAGNOSING VIRAL INFECTIONS - Systems and methods for diagnosing viral infections. According to at least one embodiment of a stabilizing system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for a viral infection in a body fluid comprising the diagnostic marker and a detection agent capable of detecting the diagnostic marker08-11-2011
20100112550Microfluidic Assay for Characterization of the Leukocyte Adhesion Cascade - An apparatus and method for identifying and screening for agents affecting the leukocyte adhesion cascade (LAC) encompassing rolling, adhesion and migration comprises an optically clear, plastic microfluidic chip comprising flow channels with diameters in the range of 10-500 μm. The flow channels are coated with endothelial cells and at least a portion of the flow channels contains 1-30 μm sized openings, optionally filled with a native or synthetic extracellular matrix, that allow leukocyte migration into one or more tissue spaces.05-06-2010
20100112547METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF INFLUENZA - The invention provides method and compositions for determining the presence and amount of an influenza virus in a sample including high risk strains of Influenza A. Also provided are methods for determining whether a subject is infected with a influenza virus, as well as, the type and strain of the influenza virus. The methods involve contacting a sample from the subject with a PDZ polypeptides (PDZ) and/or PDZ ligands (PL) and determining whether binding interactions occur between PDZ and PL. Assays for identifying anti-viral agents are also provided, as well as, methods for using the compositions to alter PDZ binding to PL in influenza infected cells.05-06-2010
20090311667RAPID DIAGNOSIS METHOD SPECIFIC TO AVIAN INFLUENZA VIRUS - The present invention relates to a method for detecting an avian influenza virus by an immunological assay using an anti-influenza virus antibody being unreactive to human influenza type-A virus subtypes H1, H2 and H3 and a human influenza type-B virus and being reactive to plural subtypes of avian influenza viruses, and an immunochromatographic test tool for use in the method. According to the present invention, an avian influenza virus can be detected specifically, rapidly and in a simple manner, as distinguishing an avian influenza virus from a human influenza virus.12-17-2009
20110269115Heated Assays for Influenza - Methods of increasing specific binding, decreasing non-specific binding, and reducing false-positive interaction in solid phase assays for influenza are disclosed. In the methods, the solid phase apparatus (lateral flow solid phase apparatus or capillary flow solid phase apparatus) is subjected to elevated heat subsequent to application of a test sample to the solid phase apparatus.11-03-2011
20080311559DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUSES - Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.12-18-2008
20090148828VIRAL DETECTION LIPOSOMES AND METHOD - A method of generating pathogen detecting liposomes includes a step of providing molecular beacons with fluorescing components. The molecular beacons include either strands of RNA or DNA and the fluorescing components include an emitter and a quencher. The method further uses nanodroplet technology to encapsulate the molecular beacons within a lipid membrane. Subsequently, receptors are assembled in association with the membrane.06-11-2009
20100062415Pathogen Detection Biosensor - The invention described herein provides methods for the detection of target particles, such as pathogens, soluble antigens, nucleic acids, toxins, chemicals, plant pathogens, blood borne pathogens, bacteria, viruses and the like. Also described is an emittor cell comprising a receptor, wherein the receptor can be an antibody or an Fc receptor, and an emittor molecule for the detection of a target particle in a sample wherein the target particle to be detected is bound by one or more receptors on the emittor cell. Also provided are optoelectronic sensor devices for detecting a target particle in a sample, including in a plurality of samples.03-11-2010
20090061412Methods for Detecting Papillomavirus DNA in Blood Plasma and Serum - This invention relates to the detection of extracellular papillomavirus DNA in blood plasma or serum from a human or animal. In particular, the invention relates to the detection, identification, evaluation, or monitoring of neoplastic, premalignant or malignant disease associated with a papillomavirus. The invention thereby provides methods for the identification of individuals at risk for, or having, cervical dysplasia, cervical intraepithelial neoplasia, or cervical cancer.03-05-2009
20090148831NS5A nucleotide sequence variation as a marker for interferon response - Methods and reagents for determining a nucleotide variation at position 937 of the HCV-1a NS5A gene useful in predicting an individual's response to interferon treatment are presented.06-11-2009
20090148829Methods For Rapid Identification Of Pathogens In Humans And Animals - The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.06-11-2009
20080311561Kits and Method For Detecting Human Papilloma Virus With Oligo Nucleotide Bead Array - Provided are determining methods of human papillomavirus (HPV) genotypes with a high sensitivity. The method includes performing two-step PCRs on an HPV L1 gene in a sample to be analyzed as a biotin-labeled, single-stranded L1 gene, performing a hybridization reaction on the biotin-labeled, single-stranded L1 gene with a HPV genotype detection probe, reacting the hybridization reaction product with fluorescent substance combined with streptavidine, and measuring a fluorescent substance level to identify the HPV genotype. The detection method has high sensitivity enough to detect an extremely small amount of HPV in the sample. In addition, the high specificity exhibited by the detection method enables accurate diagnosis specific to HPV type.12-18-2008
20100267010Method and Apparatus for Real-Time Analysis of Chemical, Biological and Explosive Substances in the Air - A device for real-time analysis of airborne chemical, biological and explosive substances has at least a gas analysis sensor, fluorescence/luminescence sensor and a sensor for determining the particle size and number of particles. Each of the sensors is connected to a multireflection cell (multipass laser cell) as an open measurement path. In addition, the device also includes an evaluation unit for the real-time analysis of chemical, biological and explosive substances.10-21-2010
20100267009METHOD FOR THE IN VITRO DIAGNOSIS AND/OR IN VITRO THERAPY MONITORING OF INFECTIONS - A method for in-vitro diagnosis and/or in-vitro therapy monitoring of infections and/or infectious diseases and differentiation between acute infections and latent or overcome infections comprising incubating eukaryotic cells with an antigen; and testing for cells (ASCs) secreting antigen-specific antibodies, the secreted antibodies of which are directed specifically against the antigen.10-21-2010
20100267005Crosslinking Within Coordination Complexes - Crosslinked proteins, proteins and polymers, and polymers and methods of making the same are disclosed. In one illustrative embodiment, a method is provided comprising the steps of attaching a chelator to one or more polymers; creating a coordination complex between the first protein, the second protein, and a metal ion; and crosslinking the first and second proteins by exposing the coordination complex to an oxidant.10-21-2010
20080293039VP7 gene of human rotavirus and composition for diagnosis of human rotavirus infection comprising primer or probe specific to thereof - The present invention relates to a VP7 gene of human rotavirus and a composition for diagnosis of human rotavirus infection comprising primer or probe specific to thereof, and more particularly to a VP7 gene encoding the amino acid sequence set forth in SEQ ID NO:2 and a composition for diagnosis of human rotavirus infection comprising primer or probe specific to thereof. The human rotavirus VP7 gene according to the present invention will be useful for diagnosis of novel G11 type human rotavirus infection, and will be used for development of rotavirus vaccine.11-27-2008
20100035234VACCINE ASSAYS - The present invention is directed to methods, assays and compositions for implementing such methods and assays for assessing efficacy of individual components in multi-component vaccines and for assessing efficacy of a vaccine against a pathogen. In one aspect, the method of assessing efficacy of a vaccine against a pathogen is a quick assay that tests for an activity correlated with efficacy such as binding in an ELISA rather than requiring the time and expense of an assay that detects actual bactericidal activity. In another aspect, the method for testing the efficacy of an individual component in a multi-component vaccine includes obtaining an immune sample from a subject inoculated with the multi-component vaccine; blocking the portion of the immune sample that recognizes the individual component such as by addition of the individual component, and testing the efficacy of the immune sample to respond to the pathogen.02-11-2010
20110262897IMAGING TECHNIQUES USING A TRIDENTATE LIGAND - The present invention relates to microscopy and, in particular, Time-resolved Emission Imaging Microscopy (TREM). The Invention relates to the use of a transition metal complex having a tridentate ligand in an imaging technique. The transition metal is preferably platinum.10-27-2011
20110262896SYSTEM AND METHOD FOR MULTI-ANALYTE DETECTION - The present invention provides a system and method for the simultaneous detection of multiple analytes in a sample. The detection system includes a housing that holds a reagent carousel rotatably coupled thereto. Further included in the housing is an incubator carousel rotatably coupled thereto. The housing also includes magnetic material that is associated with the incubation carousel for assisting in separation beads from reagent and wash solution. A robot, associated with the housing is configured to manipulate at least either the reagent carousel or the incubator carousel and transfer materials therebetween. Reaction vessels hold samples and reaction vessels handlers move the reaction vessels. Sample analysis is determined by at least one laser based detector.10-27-2011
20110262895METHODS FOR THE DIAGNOSIS OF VARICELLA ZOSTER VIRUS INFECTION - The present invention relates to methods and devices for the rapid assessment of saliva for the presence of varicella zoster virus (VZV) particles. The methods and devices permit rapid, simple and cost-effective diagnosis of primary VZV infection.10-27-2011
20110262893SEPARATING TARGET ANALYTES USING ALTERNATING MAGNETIC FIELDS - The invention generally relates to using magnetic particles and alternating magnet fields to separate a target analyte from a sample. In certain embodiments, methods of the invention involve contacting a sample with magnetic particles including first moieties specific for a target analyte, thereby forming target/particle complexes in the sample, flowing the sample through a channel including second moieties attached to at least one surface of the channel, applying alternating magnetic fields to the flowing sample to result in target/particle complexes being brought into proximity of the surface to bind the second moieties and unbound particles remaining free in the sample, binding the target/particle complexes to the second moieties, and washing away unbound particles and unbound analytes of the sample.10-27-2011
20110262892METHODS FOR DETECTION OR MEASUREMENT OF VIRUSES - A method for treating a virus-containing sample, characterized by treatment of a virus-containing sample with a treatment solution containing (1) an anionic surfactant and (2) an amphoteric surfactant, nonionic surfactant or protein denaturant; a virus assay method using said treating method; a method for treating a virus-containing sample, characterized by treatment of a virus-containing sample with a treatment solution containing (1) a chaotropic ion and (2) an acidifying agent; a virus assay method using said treating method; a virus assay method, characterized in that a virus antigen and a virus antibody are measured based on their binding to their probe in the presence of a surfactant with an alkyl group of 10 or more carbon atoms and a secondary, tertiary or quaternary amine, or a nonionic surfactant, or of both of them; and a monoclonal antibody and a hybridoma producing the same for carrying out said method.10-27-2011
20100041016METHODS FOR DETECTING ORGANISMS AND ENZYMATIC REACTIONS USING RAMAN SPECTROSCOPY AND AROMATIC COMPOUNDS COMPRISING PHOSPHATE - The present disclosure provides systems for the rapid and sensitive detection of organisms and molecules in samples. Reactants that produce Raman-active products are used in combination with Raman light scattering. Such compounds may comprise phosphates permitting the detection of phosphatases. The present disclosure can also be used to measure enzyme-kinetics.02-18-2010
20100279271Sample collection apparatus - A sample collection apparatus which measures biological samples and can be used to provide the early detection of respiratory diseases, for example tuberculosis induced by the pathogen 11-04-2010
20100120019Detection, screening, and diagnosis of HPV-associated cancers - Embodiments of the invention provide methods, polyclonal antibodies, monoclonal antibodies, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Monoclonal antibodies are used to detect oncogenic high risk and low risk HPV types in a single assay, which is not limited to assay type or format. Useful tools for specific detection of various HPV associated cancers are provided. HPV associated cancer biomarkers are identified and can be used in a screening method for early stage precancerous lesions as well as late stage cancer progression.05-13-2010
20090280472Method for Detection of Antigens - The field of the invention relates generally to the detection of antigens, including, but not limited to, quantum dots (Qdots) and metal oxide nanoparticles. More specifically, the invention relates to the detection of antigens on a surface or in a source, which antigens include bacteria, viruses, and small proteins. In some embodiments, the invention can be used to detect biological warfare agents, such as anthrax and ricin. In some embodiments, the invention can be used for early detection of diseases in human and animals. The invention may utilize a swab-test and may further utilize a filtration process, such as with a syringe-disc.11-12-2009
20100129785AGENTS AND METHODS FOR SPECTROMETRIC ANALYSIS - Disclosed herein are agents, methods, and kits for determining the presence or concentration of a target, or multiple targets, in a sample, in a uniplexed or multiplexed fashion. In general, the methods enable the analysis of small molecules produced or consumed in liquid-phase that may be analyzed using gas or vapor phase detection methods.05-27-2010
20120034598Real-Time Detection of Influenza Virus - The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.02-09-2012
20120034597METHODS OF MONITORING TREATMENT OF AVIREMIC HIV-INFECTED PATIENTS - Methods of monitoring the efficacy of intensified highly active anti-retroviral therapy (HAART) treatment in aviremic Human Immunodeficiency Virus (HIV)-infected patients.02-09-2012
20100099076SENSITIVE AND RAPID DETECTION OF VIRAL PARTICLES IN EARLY VIRAL INFECTION BY LASER TWEEZERS - The present system and methods allow for low level detection of as little as single pathogen particles, such as viral or bacterial particles, during the early stage of infection. An optical trapping system, such as laser tweezers, are used to trap a substrate to which an analyte has been bound to detect and record the thermal motion of an antibody-antigen interaction that may occur between an anti-viral antibody-coated microsphere and a viral particle for example. The system may be equipped with a detection system such as a position sensitive photodetector (PSD) to record the thermal motion of a trapped microsphere and particle at a certain frequency. The thermal motion data may be Fourier transformed into a power spectrum, which may be transformed into an output value using a Lorentzian equation. The power spectrum of the trapped microsphere may be recorded before and after binding of the pathogenic particle to determine the presence thereof.04-22-2010
20100120018Integrated Active Flux Microfluidic Devices and Methods - The invention relates to a microfabricated device for the rapid detection of DNA, proteins or other molecules associated with a particular disease. The devices and methods of the invention can be used for the simultaneous diagnosis of multiple diseases by detecting molecules (e.g. amounts of molecules), such as polynucleotides (e.g., DNA) or proteins (e.g., antibodies), by measuring the signal of a detectable reporter associated with hybridized polynucleotides or antigen/antibody complex. In the microfabricated device according to the invention, detection of the presence of molecules (i.e., polynucleotides, proteins, or antigen/antibody complexes) are correlated to a hybridization signal from an optically-detectable (e.g. fluorescent) reporter associated with the bound molecules. These hybridization signals can be detected by any suitable means, for example optical, and can be stored for example in a computer as a representation of the presence of a particular gene. Hybridization probes can be immobilized on a substrate that forms part of or is exposed to a channel or channels of the device that form a closed loop, for circulation of sample to actively contact complementary probes. Universal chips according to the invention can be fabricated not only with DNA but also with other molecules such as RNA, proteins, peptide nucleic acid (PNA) and polyamide molecules.05-13-2010
20100120016METHODS AND SYSTEMS FOR DETECTION OF CONTAMINANTS - An impedance biosensor for detecting a contaminant in a starting material, the biosensor comprising a housing, an input device supported by the housing, an output device supported by the housing, a microfluidic cell supported by the housing, the starting material being engagable with the microfluidic cell, and an impedance analyzer supported by the housing and operable to measure impedance of the starting material to detect the presence of a contaminant.05-13-2010
20100081124PRIMERS AND PROBES FOR DETECTING HUMAN PAPILLOMAVIRUS AND HUMAN BETA GLOBIN SEQUENCES IN TEST SAMPLES - The present invention relates to primers, probes, primer sets, primer and probe sets, methods and kits for detecting human papillomaviruses, human beta globin sequences and human papillomaviruses and human beta globin sequences in a test sample.04-01-2010
20120141979OLIGONUCLEOTIDES FOR DETECTING CHICKEN ASTROVIRUS - There is provided an oligonucleotide sequence capable of binding to a portion of a CAstV genome, wherein the oligonucleotide sequence has binding specificity to the precapsid region of CAstV or to cDNA of the precapsid region. The oligonucleotide sequence can be one of a primer pair for use in a method for detecting the presence of CAstV in a biological sample by reverse transcription followed by amplification of the reverse transcription products using such primer pair, or a method for amplifying CAstV cDNA using such primer pair.06-07-2012
20090081638Immobilisation of Antigenic Carbohydrates to Support Detection of Pathogenic Microorganisms - The invention relates to the field of chemistry and diagnosis, more in particular to diagnosis of current and/or past and/or symptomless infections or of a history of exposure to, a gram-negative-bacterium (such as an enterobacteriaceae or a legionella). Even more in particular, the invention relates to the screening of animals or animal products for the presence of unwanted/undesired microorganisms. The invention further relates to a method for screening samples for the presence of antibodies directed against unwanted/undesired microorganisms and preferably such a method is performed with help of a biosensor. The invention also relates to a method for immobilizing polysaccharides to solid surfaces. The invention furthermore provides solid surfaces with immobilized polysaccharides as well as applications of such surfaces.03-26-2009
20090191539Primers for isothermal amplification of hepatitis C virus - The present application relates to primers for isothermal amplification of HCV each include at least eighteen consecutive bases corresponding to a 3′ end region of one selected from base sequences of SEQ ID NOs: 1-10, 21 and 22. The primers are specific to HCV subtypes 1a, 1b, 2a, 2b and 3a, respectively and enable genotyping of HCV by isothermal amplification.07-30-2009
20100092942Method and apparatus for detection of biological organisms using Raman scattering - A system for the detection of compounds, including a target biological organism or component from a sample, using one or more reactant that will bind to the biological organism or compound forming a Raman active product, concentrating the Raman active product, and detecting the Raman active product using Raman light scattering.04-15-2010
20110200986BIO-ASSAY USING LIQUID CRYSTALS - There is provided a method, an in vitro method and a detection system for detecting the presence of at least one biological molecule in at least one sample. The method can include, for example, providing a sample and/or a binding agent to a contact portion of a surface by way of at least one microfluidic channel; disposing a liquid crystal at the contact portion; determining whether the orientation of the liquid crystal changes after the sample contacts the binding agent, indicating the presence of the biological molecule; and determining length of bright region of the liquid crystal and/or change in interference color of said liquid crystal, and consequently indicating the quantity of said biological molecule. Also disclosed are methods of detecting biological molecules using at least one 4′-pentyl-biphenyl-4-R, where R may be at least one functional group selected from carboxylic acid, amine, aldehyde, and oligopeptide.08-18-2011
20090286228Methods, Devices, Kits and Compositions for Detecting Roundworm - Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a mammalian sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.11-19-2009
20100081126PROCESS FOR DESIGNING INHIBITORS OF INFLUENZA VIRUS STRUCTURAL PROTEIN-1 - Disclosed are methods and compositions useful in identifying inhibitors of influenza virus, such as influenza A and B virus. Also disclosed are methods for preparing compositions for administration to animals, including humans infected with or to protect against influenza virus.04-01-2010
20100081125 AMPLIFICATION FOR SOLID PHASE IMMUNOASSAY - The present invention is directed to immunoassays for detecting one or more target analytes in a fluid sample wherein the detection reaction occurs on a solid support and involves an amplification system. In particular, the invention is directed to making and using a test device having at least one site for detecting the presence of at least one target analyte, wherein a conjugate comprising dextran-polystreptavidin is immobilized at the test site(s) as a capture reagent for a complex containing the target analyze.04-01-2010
20100081123Devices and methods for analyte detection using distorted liquid crystals - The present invention provides devices and methods for detection of analytes based on measuring the anchoring strength of liquid crystals having distorted geometries. Methods for detecting an analyte in a sample include the steps of: (a) capturing an analyte on a substrate surface wherein the substrate surface defines an easy axis when in contact with a liquid crystal. Substrate surface and liquid crystal are brought into contact and an analyte-dependent departure in the orientation of the liquid crystal from the easy axis of the substrate surface is measured. This departure indicates the presence of the analyte in the sample.04-01-2010
20120107798SINGLE MOLECULE SENSITIVE PROBES FOR DETECTING RNA - The various embodiments of the present disclosure relate generally to single molecule sensitive probes for detecting RNA, and more particularly to multivalent fluorescent probes for detecting a single molecule of RNA in a cell. The present invention includes a RNA imaging probe comprising: a multivalent core comprising a plurality of attachment sites; a plurality of RNA/DNA chimeric oligonucleotides having a specificity for a target RNA, wherein a RNA/DNA chimeric oligonucleotide is bound to an attachment site of the multivalent core; and a plurality of fluorophores, wherein a fluorophore is bound to the RNA/DNA chimeric oligonucleotide.05-03-2012
20120107797GENOTYPING OF BOVINE PAPILLOMAVIRUS GENOTYPES - The present invention is concerned with the provision of diagnostic means and methods. Specifically, it relates to a composition comprising oligonucleotides selected from at least two different groups of oligonucleotides, said groups comprising at least one pair of oligonucleotides being capable of specifically amplifying polynucleotides comprised by a Bovine Papillomavirus (BPV), said BPV being selected from the group consisting of BPV-1, BPV-2, BPV-3, BPV-4, BPV-5, BPV-6, BPV-7, BPV-8, BPV-9, BPV-10, and BAPV-11 as well as uses based on said composition and kits comprising it. Moreover, contemplated is a method for the simultaneous detection and/or identification of BPV types in a sample.05-03-2012
20120107796METHODS AND KITS TO DETECT NEW H1N1 "SWINE FLU" VARIANTS - Methods and kits used in the detection of the H1N1/09 influenza virus are disclosed. The methods comprise methods of using the nucleic acids to detect H1N1/09 generally as well as H1N1/09 variants resistant to antiviral compositions.05-03-2012
20120107795Methods For Concurrent Identification And Quantification Of An Unknown Bioagent - The present invention provides methods for the quantification of an unknown bioagent in a sample by amplification of nucleic acid of the bioagent, and concurrent amplification of a known quantity of a calibration polynucleotide from which are obtained a bioagent identifying amplicon and a calibration amplicon. Upon molecular mass analysis, mass and abundance data are obtained. The identity of the bioagent is then determined from the molecular mass of the bioagent identifying amplicon and the quantity of the identified bioagent in the sample is determined from the abundance data of the bioagent identifying amplicon and the abundance data of the calibration amplicon.05-03-2012
20090263788EFFICIENT ALGORITHM FOR PCR TESTING OF BLOOD SAMPLES - Systems, processes, and devices are provided which are useful for testing blood or plasma donations to detect those specific donations which are contaminated by a virus above a predetermined level. Samples are formed into pools which are subsequently tested for virus contamination by a high-sensitivity test such as PCR. The pools are tested in accordance with an algorithm by which a sample from each donation is mapped to each element of an N-dimensional matrix or grid. Each element of the matrix is identified by a matrix identifier, X10-22-2009
20090263787 METHOD FOR SCREENING OF INFECTIOUS AGENTS IN BLOOD - This invention discloses using SPR technology to simultaneously and qualitatively detect the presence of infectious agent related antibodies and/or antigens in a serum sample, which can be used to screen for infectious agents in blood. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antigens and antibodies used for the screening of infectious agents in blood.10-22-2009
20090263785Modified HIV-1 Peptides and Use Thereof in the Detection of Anit-HIV Antibodies - The invention relates to synthetic peptides having sequence (III), which are derived from HIV-1 virus gp41 and which can be used in immunoassays for the detection of infections caused by HIV-1 viruses. The invention also relates to the method of preparing said peptides, to compositions and kits containing same and to the use thereof for diagnostic purposes. The invention further relates to immunoassays which use said peptides for the detection of anti-HIV virus antibodies.10-22-2009
20090263786Mass spectrometric analysis method - Methods of using mass spectrometry and in particular matrix assisted laser Ligand-Complex from Target and desorption-ionization (MALDI) mass spectrometry to analyze, or otherwise detect the presence of or determine the identity of intact ions of undigested, unfragmented covalently stabilized supramolecular target-ligand-complexes, as well as the use of these methods in various biological application such as characterization of antibodies, drug discovery, and complexomics including automated or higher throughput applications.10-22-2009
20090170071SERUM BIOMARKERS OF HEPATITIS B VIRUS INFECTED LIVER AND METHODS FOR DETECTION THEREOF - The invention provides a method for detecting the presence of altered serum proteins in an Hepatitis B Virus (HBV)-infected patient with liver inflammation, comprising: obtaining a sample of serum from the patient; subjecting the sample to protein gel electrophoresis to separate proteins contained therein; staining proteins separated on the electrophoresis gel with silver nitrate solution; scanning the images of stained proteins into an image analysis scanner to obtain gel images; comparing the gel images to control samples of electrophoresis gels prepared from serum of normal patient and serum of HBV-infected patient with liver inflammation to determine whether the sample of serum from the patient contains specific serum proteins. This invention also provides serum protein biomarkers for the diagnosis of patients with HBV infection and liver inflammation.07-02-2009
20130217002HIV-1 IGG3 RESPONSE IN ACUTE HIV-1 - The present invention relates, in general, to HIV-1 and, in particular, to methods of detecting incident HIV-1 infection.08-22-2013
20100099077STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION - Chemiluminescent acridinium esters are provided which are fast light emitting and hydrolytically stable. The chemiluminescent acridinium esters are useful labels in assays for detecting or quantifying analytes.04-22-2010
20100099078METHOD FOR DESIGNING A DRUG REGIME FOR HIV-INFECTED PATIENTS - The instant disclosure describes a novel genotype and phenotype assay to elucidate and/or evaluate new potential HIV integrase inhibitors, but also currently approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This assay allows studying linked mutations and mutational patterns that occur under HAART and experimental therapies.04-22-2010
20110200985COMPOSITIONS FOR USE IN IDENTIFICATION OF HERPESVIRUSES - The present invention relates generally to identification of herpesviruses and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.08-18-2011
20110200983METHODS AND MATERIALS FOR DETECTING VIRAL OR MICROBIAL INFECTIONS - This document provides methods and materials for detecting target nucleic acid. For example, methods and materials for detecting the presence or absence of target nucleic acid, methods and materials for detecting the amount of target nucleic acid present within a sample, kits for detecting the presence or absence of target nucleic acid, kits for detecting the amount of target nucleic acid present within a sample, and methods for making such kits are provided.08-18-2011
20110200982GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., 08-18-2011
20090130649Methods for Genotyping HVC - The present invention relates to methods for differentiating Hepatitis C virus (HCV) group A genotypes from HCV group B genotypes. The invention finds application in determining prognosis, and in the selection of treatment regimes, for patients infected with HCV.05-21-2009
20110171629NANOSTRUCTURED DEVICES INCLUDING ANALYTE DETECTORS, AND RELATED METHODS - The present invention provides compositions and devices comprising nanostructure networks, and related methods. The compositions may exhibit enhanced interaction between nanostructures, providing improved device performance (e.g., improved conductivity). In some embodiments, the devices are capable of interacting with various species to produce an observable signal from the device. In some cases, the compositions and devices may be useful in the determination of analytes, including—biological analytes (e.g., DNA, ebola virus, other infective agents, etc.), small, organic analytes, and the like. The embodiments described herein may exhibit high sensitivity and specificity to analytes and may be capable of analyte detection at femtomolar concentrations (e.g., 10 fM).07-14-2011
20120295249Instrument And Method For The Automated Thermal Treatment Of Liquid Samples - An instrument and a method for the automated thermal treatment of liquid samples are disclosed. An inter-distance between a temperature-controlled receptacle for loading with a plurality of vessels for containing the samples and end portions of optical fibers can be varied, wherein the receptacle is configured to form a thermal communication with the loaded vessels and wherein the optical fibers have first and second end portions. The first end portion and the second end portion of each optical fiber is fixed with respect to each other for transmitting light, wherein the variation of the inter-distance allows the vessels to be loaded to or unloaded from the receptacle and to enable detection of light from the samples contained in the one or more receptacle-loaded vessels.11-22-2012
20120295250Microchip, Measurement System and Method Using the Same, and Test Reagent to be Used for Microchip - A microchip to be used for measuring a plurality of types of objects to be measured. The microchip includes at least a reagent retaining portion and a detecting portion. The test reagent retaining portion includes a plurality of types of test reagents corresponding respectively to the plurality of types of objects to be measured. A plurality of time courses for a change in detected value at the detecting portion caused by a reaction between the test reagents and the objects to be measured corresponding respectively thereto are all different from each other.11-22-2012
20120295251DETERMINING CODON DISTRIBUTION AND/OR BASE PAIR DISTANCE BETWEEN CODONS IN A NUCLEIC ACID - The present invention relates to methods for the design and/or production of a probe or primer that is capable of hybridizing to a plurality of sites in a sample comprising nucleic acid. Furthermore, the present invention provides methods for detecting and amplifying nucleic acid using such a probe or primer, for example, for identification of a strain, species or genera. Probe or primer sequences are determined by reference to codon usage bias of a target nucleic acid. In addition, the present invention provides methods for determining codon distribution and/or base pair distance between codons in a nucleic acid.11-22-2012
20090286232METHOD AND APPARATUS FOR ENHANCED SENSITIVITY IN BACTERIOPHAGE-BASED DIAGNOSTIC ASSAYS - A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: (a) combining with the sample an amount of bacteriophage capable of attaching to the target microorganism to create a bacteriophage-exposed sample; (b) providing conditions to the bacteriophage-exposed sample sufficient to allow the bacteriophage to attach to the target microorganism while inhibiting phage replication in a potentially cross-reactive, non-target microorganism; and (c) assaying the bacteriophage-exposed sample to detect the presence or absence of a bacteriophage marker to determine the presence or absence of the target microorganism; wherein the amount of the bacteriophage is between 10% to 70% of the threshold number of bacteriophage that the assay can detect, or between 1×1011-19-2009
20090286231Methods, Devices, Kits and Compositions for Detecting Roundworm, Whipworm, and Hookworm - Methods, devices, kits and compositions for detecting the presence or absence of one or more helminthic coproantigens in a sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm, whipworm and/or hookworm in a fecal sample from a mammal and may also be able to distinguish between one or more helminth infections. Confirmation of the presence or absence of roundworm, whipworm and/or hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.11-19-2009
20090286224Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist - A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.11-19-2009
20090286222Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes And Enteric Viruses - The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.11-19-2009
20090291430Electrophoretic Interactive Spectral Methods and Devices for the Detection and/or Characterization of Biological Particles - Methods for identifying a biological particle in a sample medium include generating an Electrophoretic Quasi-elastic Light Scattering (EQELS) spectrum for the biological particle in the sample medium. The EQELS spectrum is compared to a reference database comprising a plurality of spectra, and each of the plurality of spectra correspond to an EQELS spectrum for one of a plurality of known biological particles. The biological particle in the sample medium is identified from the comparison.11-26-2009
20090291428COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF POXVIRAL INFECTIONS - The invention encompasses an antibody that binds to and substantially inhibits the activity of at least one poxvirus complement inhibitor. Additionally, the application encompasses methods of detecting a poxvirus complement inhibitor and methods of decreasing the activity of a poxvirus complement inhibitor.11-26-2009
20080206741Virus Recovery Medium, Use Thereof and Viral Diagnostic Kit Including Same - The present invention relates to a virus recovery medium and a viral diagnostic kit comprising the same. The virus recovery medium is supplemented with a hormone and an enzyme. The hormone is preferably a glucocorticoid hormone, more preferably dexamethasone. The enzyme is preferably a protease, more preferably trypsin.08-28-2008
20080206742Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1 (INI1)/hSNF5 - Peptides comprising an Rpt1 domain of an INI1/hSNF5 which inhibit HIV-1 production in a human cell, and vectors encoding those peptides are provided. Also provided are methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by treating the cells with the above peptides or vectors. Other methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by inhibiting production of INI1/hSNF5 are provided. Additionally, methods of determining whether a test compound inhibits HIV-1 virion production in a mammalian cell, or spread of the HIV-1 to another cell, are provided. Those methods comprise determining whether the test compound inhibits the production of INI1/hSNF5 or disrupts the interaction of HIV-1 integrase with INI1/hSNF5.08-28-2008
20090104597ADVANCED CERVICAL CELL SCREENING METHODS - Advanced cervical cancer screening methods that provide a molecular based process of detecting HPV-integration. The disclosed methods allow for a streamlined approach of conducting a Pap test and immunohistochemical test on the same slide. The disclosed methods provides an inexpensive, highly sensitive, specific, and detailed test that is easy to evaluate and follow-up.04-23-2009
20090104596Noninvasive Measurement and Identification of Biomarkers in Disease State - The invention is methods and related kits for diagnosing a disease state of cachexia by measuring biomarker profiles from a biological sample. Rapid measurement of early onset or progression of the disease in a subject is determined by measuring biomarker levels from the subject and optionally comparing the biomarker levels to a standard biomarker profile or metabolome phase portrait for the disease. The biomarkers measured in the assay and related kit for cachexia progression include biomarkers selected from the group consisting of lactate, citrate, formate, acetoacetate, 3-hydroxy butrate, alanine, glutamine, glutamate, valine, isoleucine leucine, thrionine, lysine, arginine, tyrosine, phenyl alanine, histidine and tryptophan.04-23-2009
20090104595Methods for determining the sensitivity or resistance of retrovirus isolates to therapeutic retroviral treatments based on viral protease inhibitors and diagnostic kits - A method for determining sensitivity or resistance of isolates of HIV (human immunodeficiency virus) retroviruses to chemical molecules having an inhibiting activity on a viral protease or to therapeutic treatments based on inhibitors of the viral protease, including causing cell lysis of at least one yeast by expression of the retrovirus protease.04-23-2009
20110171628CERVICAL SCREENING ALGORITHMS - This invention describes new protocols for screening for cervical carcinomas or high-grade premalignant cervical lesions based on combinations of testing for the presence of high-risk HPV, HPV genotyping, marker analysis, and/or cytology. With these protocols the number of women that have to undergo follow-updiagnostic testing and/or clinical examinations will decrease. Further, the number of false positives and false negatives will decrease.07-14-2011
20090280473Inhibition of membrane fusion proteins - Methods of inhibiting viral infection of a eukaryotic cell by a target virus having a class II virus fusion protein are provided. Also provided are methods of screening a test compound for the ability to inhibit infection by a virus having a class II viral fusion protein. Additionally provided herewith are aqueous-soluble proteins comprising a portion of a class II viral fusion protein comprising a Domain III of the viral fusion protein.11-12-2009
20090269735SAMPLE PRETREATMENT SOLUTION FOR IMMUNOLOGICAL TEST AND METHOD FOR USING THE SAME - Sample pretreatment solutions for influenza virus tests by immunochromatography are described.10-29-2009
20090286227Methods, Devices, Kits and Compositions for Detecting Whipworm - Methods, devices, kits and compositions for detecting the presence or absence of whipworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of whipworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, roundworm, and heartworm. Confirmation of the presence or absence of whipworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.11-19-2009
20090286229Methods, Devices, Kits and Compositions for Detecting Roundworm - Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.11-19-2009
20100279273NUCLEIC ACID SEQUENCES FOR THE AMPLIFICATION AND DETECTION OF RESPIRATORY VIRUSES - The present invention relates to methods of detection, as well as assays, reagents and kits for the specific detection of 15 clinically important respiratory viruses including influenza A and B viruses, human respiratory syncytial viruses, human metapneumoviruses, human enteroviruses, all serotypes of rhinoviruses, 7 serotypes of adenoviruses, parainfluenza viruses types 1, 2, 3, and 4, as well as coronaviruses NL, 229E, OC43, and SARS-CoV. The present invention allows for the detection of each of these respiratory viruses in a single assay.11-04-2010
20100279275HUMAN GASTROINTESTINAL STEM CELL-DERIVED PRIMARY INTESTINAL EPITHELIAL CELL SYSTEM AND METHODS OF USE THEREOF - The present invention relates to an intestinal primary epithelial cell system for detecting gastrointestinal segment-specific activation or suppression of a Toll-like receptor (TLR) by a target agent. The cell system includes an isolated human intestinal primary epithelial cell (HIPEC) line that expresses at least one TLR, where the HIPEC line is derived from a differentiable adult human gastrointestinal stem cell (ahGISC) line. Also disclosed are various methods of using the cell system, a kit that includes the cell system, and an isolated cell culture including an isolated HIPEC line derived from a differentiable ahGISC line.11-04-2010
20090291429SUBSTANCES CAUSING DIFFERENTIATION - A DNA construct is described which contains a fusion gene under the control of a promoter. The fusion gene comprises at least one resistance gene and at least one reporter gene and is slightly toxic to a host cell transfected with that DNA construct. That DNA construct can be encoded on a plasmid or a virus. Further, a method is described for using the DNA construct to identify substances that may cause a differentiation in eukaryotic cells.11-26-2009
20090298051Test Kit and Method for Detecting Bacteriophage - Phages can be detected as rapid indicators of the hygienic quality of a sample. Both continuous flow methods and devices, single sample methods and devices, of various volumes, can be used. Single samples may be tested by single or multi-step testing methods. Test kits can be provided in easy-to-use formats. Certain phages, such as coliphage, are useful as indicators of fecal contamination.12-03-2009
20110171627ZCYTOR19 HETERODIMERIC CYTOKINE RECEPTOR POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS - Novel methods are disclosed for forming a heterodimeric receptor complex with IL-28R and CRF2-4. The methods may be used for detecting and treating viral infections in in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.07-14-2011
20100279274Method of Pooling and/or Concentrating Biological Specimens for Analysis - The present invention provides methods for concentrating and pooling liquid suspensions of biological specimens containing analytes of interest in a dry state. The dried biological specimens containing analytes of interest are reconstituted and released from the matrix for subsequent analysis in concentrated form.11-04-2010
20100279272MULTIPLEXED ANALYSIS METHODS USING SERS-ACTIVE NANOPARTICLES - Methods are described for performing a multiplexed analysis of a level of target analyte in a sample, employing an identifier and a labeling reagent. Either or both of the identifier and the labeling reagent comprises a SERS-active nanoparticle associated with a SERS-active reporter with a uniquely identifiable spectroscopic signature. Interrogation of the identifier and the labeling reagent is conducted by serial coincident detection. Such methods can provide enhanced multiplexed analysis of analytes in a sample, especially with regards to improving the type of identifying reagents that are employed.11-04-2010
20100041020Methods for detecting the presence, location or quantity of targets using novel dyes - The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified by the addition of charged and polar groups to provide beneficial properties.02-18-2010
20130217001METHOD FOR MONITORING A STERILIZATION PROCESS - The disclosed invention relates to a method for monitoring a sterilization process. The method comprises: (A) exposing an article to be sterilized and a biological indicator to a sterilization medium during a sterilization process, the biological indicator comprising a cell with a plasma membrane in which the biological indicator is positioned on part or all of an electronically conductive material positioned on a substrate; and (B) measuring the membrane potential of the cell to detect the viability of the cell.08-22-2013
20130216999METHODS AND KITS FOR THE DETECTION OF AN INFECTION IN SUBJECTS WITH LOW SPECIFIC ANTIBODY LEVELS - This invention relates to methods that enable the detection of antibodies against a latent infection, a chronic infection, a re-infection, and/or a breakthrough infection; enable the diagnosis of a latent infection, a chronic infection, a re-infection, and/or a breakthrough infection; and increase low anti-viral antibody levels, and a kit for the detection of virus-specific antibodies expressed at low levels.08-22-2013
20110269116Cell Line From Rousettus As Host Cell For Pathogen Amplification - The present invention relates to permanent cell lines from chiropterans suitable for amplification and production microbial agents, preferably viruses, and its use for diagnostic or therapeutic purposes.11-03-2011
20090170062Device and method for detecting analytes by visualization and separation of agglutination - The invention relates to a device for detecting one or several analytes in a sample, characterized in that it comprises one or more reaction chambers and/or one or more reagent application channels, and one or more capillary systems and one or more negative vessels. The invention also relates to a method for detecting one or more analytes in a sample fluid by visualization of agglutination, characterized in that a) the sample fluid is brought into contact with a reagent, b) the reaction mixture is exposed to the effects of gravitation or magnetism, wherein the reaction mixture is strained through the capillary system of the inventive device with a negative vessel connected to the inventive device, and c) the reaction between the analyte and the reagent is determined. The invention also relates to one such method wherein the reaction mixture is brought into contact with another reagent during step b). The invention further relates to a method wherein the order of the individual steps consisting of a) and b) are reversed, particularly when the sample fluid is brought into contact with a reagent only during the effects of gravitation or magnetism.07-02-2009
20090170070INCREASED SPECIFICITY OF ANALYTE DETECTION BY MEASUREMENT OF BOUND AND UNBOUND LABELS - The present invention describes the provision of an internal control in analytical techniques involving labeling of analytes, such as SERRS, for detection of an analyte, particularly a biomolecule in a sample, with improved accuracy.07-02-2009
20110207115METHODS AND MATERIALS FOR DETECTING CONTAMINATED FOOD PRODUCTS - This document provides methods and materials for detecting contaminated food products. For example, methods and materials for using an enzymatic amplification cascade of restriction endonucleases to detect nucleic acid of a microorganism or virus (e.g., a pathogen) within a sample (e.g., food product sample) being tested, thereby assessing a food product for possible contamination are provided.08-25-2011
20100143890PEPTIDE COMPOUNDS FOR CAPTURING OR INHIBITING AVIAN INFLUENZA VIRUS AND APPLICATION THEREOF - Disclosed herein are peptide, particularly dipeptide compounds and the application thereof to the detection or inhibition of AI virus. The peptide compounds are more stable and easier to synthesize and store than are antibodies. In addition, having strong binding forces for the H5 protein of AI virus, the peptide compounds are useful as capturers or inhibitors of AI virus.06-10-2010
20090035750METHOD OF DETECTING HUMAN PAPILLOMA VIRUS BY USING NUCLEIC ACID AMPLIFICATION METHOD AND NUCLEIC ACID CHAIN-IMMOBILIZED CARRIER - Provided is a nucleic acid primer for LAMP amplification for use in the detection of human papilloma virus and identification of its genotype. The present invention also provides a method of detecting human papilloma virus and identifying its genotype, includes a step of amplifying the nucleic acid chains in a sample in LAMP reaction by using multiple primers including at least one primer selected from the nucleic acid primers according to the present invention and a step of detecting presence of amplified products after the amplification reaction and identifying their genotypes.02-05-2009
20110200984USING NUCLEIC ACIDS FOR CLINICAL MICROBIOLOGY TESTING - A process for analysing a biological sample, comprising the steps of: (a) identifying a micro-organism present within the sample; and (b) determining the effect of one or more antimicrobial(s) on a micro-organism from the sample, wherein steps (a) and (b) are performed by analysing the micro-organism's nucleic acid. Steps (a) and (b) will generally occur in that order, but they may take place concurrently. The steps may advantageously be performed within a single apparatus. Conveniently, the nucleic acid analyte used for step (a) is the same as that used in step (b) e.g. the same PCR amplicon. A micro-organism's nucleic acids can thus be used both to identify the presence of the micro-organism within a sample and then to assess the effect of antimicrobials on its growth.08-18-2011
20100136521Devices And Methods For Detection Of Microorganisms - The present invention features methods and devices for microorganisms through detecting Mie light scattering from immunoagglutinated beads. The methods feature providing a first bead suspension with antibody specific for the microorganism conjugated to beads; mixing the first bead suspension with a sample to form a first mixture; irradiating the first mixture with first incident light; detecting forward light scattering at a first angle with respect to the first incident light, where the first angle being between about 30 to 60 degrees; determining l from the light scattering; providing a second bead suspension with no antibody and simultaneously measuring l06-03-2010
20080274450Methods and applications of molecular beacon imaging for identifying and validating genomic targets, and for drug screening - A method for characterizing the gene expressions of a sample of cells of a living subject, where the sample of cells is characterized by one or more marker sequences. In one embodiment, the method includes the steps of providing one or more types of molecular beacons, each type of molecular beacons designed to have a corresponding probe sequence complementary to one of the one or more marker sequences and an emitter capable of emitting photons of a unique color such that when one of the type of molecular beacons targets the one of the one or more marker sequences the sample of cells, the emitter of the molecular beacon emits photons of the unique color, thereby generating a photon signal of the unique color; treating the sample of cells with the one or more types of molecular beacons; and detecting photon signals of one or more colors of the sample of cells so as to characterizing the gene expressions of the sample of cells, wherein the one or more types of molecular beacons are designed such that the photon signals of the one or more colors are detectable without a need of signal amplification.11-06-2008
20080233558Inhibitors of viral entry screening method - In one aspect the invention relates to a method for identifying inhibitors or viral entry comprising providing an indicator cell wherein said cell expresses a reporter gene and wherein said cell is capable of supporting entry by an effector particle, providing a candidate inhibitor of viral entry, co-compartmentalizing said candidate inhibitor and said indicator cell, contacting said indicator cell with an effector particle, incubating to allow any effector particle entry to take place, and assaying said indicator cell for reporter gene activity, wherein detection of reporter gene activity identifies the candidate inhibitor as an inhibitor for viral entry. Preferably the effector particle is HIV, preferably the reporter gene is a CD09-25-2008
20100015594HUMAN PAPILLOMA VIRUS (HPV) DETECTION USING NUCLEIC ACID PROBES, MICROBEADS AND FLUORESCENT-ACTIVATED CELL SORTER (FACS) - The present invention relates generally to the field of diagnostic and detection assays. More particularly, the present invention provides methods, and reagents including biochips for detecting the presence of, or distinguishing between, one or more analytes in a sample.01-21-2010
20090170064ISOTHERMAL SCREENING OF HUMAN PAPILLOMAVIRUS RELATED NUCLEIC ACIDS - The presently described technology relates generally to the art of molecular diagnostics and more particularly to point-of-care diagnostic methods and materials. The diagnostic methods and materials of the presently described technology are suitable for a variety of uses including but not limited to the bedside or field diagnosis of infectious or noninfectious diseases.07-02-2009
20090170065METHOD FOR TRANSPORT OF MAGNETIC PARTICLES AND DEVICES THEREFOR - The present invention is related to a method for re-enabling transport by means of a magnetic field gradient transport mechanism of magnetic beads comprising a ligand in a solution on top of a surface comprising a receptor bound with said ligand, comprising the step of changing the properties of said solution such that dissociation occurs between said ligand and said receptor, and such that a sufficient repulsive interaction is created between said surface and said bead to allow transport of said bead.07-02-2009
20090170068Molecular Identification Through Membrane-Engineered Cells - The present invention relates to the development of analytical devises based on one or more cells (cellular biosensors) the surface of which has been modified by the artificial insertion of molecules that can react specifically with analytes under determination. These receptor molecules may be proteins (such as enzymes, antigens or antibodies), nucleic acids, carbohydrates, lipids or belong to any other chemical group able to react specifically with target molecules (<>) under determination in one or more samples. The introduction of these molecules into the cell surface can be achieved by electroinsertion or any other appropriate method. Different types of molecules can be inserted into the surface of the same cell, particularly if this contributes to the selectivity of the reaction with the analytes under determination. The method includes the use of an appropriate biosensor containing the modified cellular material in free state or immobilized in a gel or on a substrate made of appropriate material, so that the measurement of the selective reaction with the analyte under determination is ensured. The measurement of the reaction can be achieved by any appropriated method related to a physical chemical property of the sensor, such as the measurement of the change of the electric potential or various optical properties (such as fluorescence, chemiluminescence or electrogenerated chemiluminescence). Consequently, the determination of a chemical or biological compound is possible provided that the pattern of a certain physical chemical property of the biosensor in response to various concentrations of this compound is known, relative to other compounds of similar structure or function.07-02-2009
20100151442METHOD FOR DETECTING EMERGING PANDEMIC INFLUENZA - A method for detecting emerging pandemic influenza strains is provided. RT-PCR is used to detect HPAI followed by pyrosequencing to detect codons defining human or avian influenza signatures. This method screens for avian influenza viruses containing mutations suspected of making the virus more infective or virulent to humans.06-17-2010
20120288849METHOD AND SYSTEM FOR ROBUST AND SENSITIVE ANALYSIS OF BEAD-BASED ASSAYS - Computer-implemented methods and systems are provided for the analysis of multiplex fluorescent-dyed microsphere assays. The methods of the invention provide for determination of differences in analyte quantities between samples obtained from multiplex fluorescent-dyed microsphere assays by analysis of individual bead fluorescence and adjusting for variance; variance-stabilization of the data, and determining significance with hypothesis testing with tolerance determined by power estimation. The methods of the invention provide a benefit in allowing access to low signal or poor quality data, increased statistical power and decreased variability compared to standard curve methodology.11-15-2012
20080280285Systems and Methods For Testing using Microfluidic Chips - Disclosed are methods, devices and systems for biological and chemical sample processing using microfluidic chips. The disclosed microfluidic chips contain at least two detection zones for interacting with pre-selected RNA sequences, DNA sequences, antibodies, or antigens to determine their presence in the sample. Systems are also described comprising a cassette having at least one port and a sample inlet in fluid communication with a detection zone for interacting with pre-selected RNA sequences, DNA sequences, antibodies, or antigens, or mixtures thereof, if present, in a sample. Methods for concurrent testing of at least two of RNA, DNA, antibody, and antigen in a sample are also described, as are methods for testing for pre-selected pathogens and microfluidic methods.11-13-2008
20080286756COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) - The present invention relates to the fields of immunochemistry and pharmacology. Methods and compositions are described for the diagnosis and treatment of SARS CoV infection. More specifically, the application discloses nucleic acids and peptides of the spike glycoprotein of SARS CoV that provide prognostic and therapeutic compositions in treatment of individuals contracting, or in danger of contracting SARS CoV. The peptides of the invention are also useful in producing antibodies against the SARS CoV glycoprotein.11-20-2008
20080286754Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance - The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis.11-20-2008
20080286758REAGENTS AND KITS FOR DETECTION OF INFLUENZA VIRUS AND THE LIKE - The present invention relates to reagents and methods for influenza virus detection. These reagents and methods disclosed in the present invention enable simple, rapid, specific and sensitive detection of influenza virus types A and B. These reagents are N-acetylneuraminic acid-firefly luciferin conjugates which can be cleaved by influenza virus neuraminidase.11-20-2008
20080286757Method and Apparatus for Identification of Microorganisms Using Bacteriophage - A sample is tested for the presence of bacteria, such as in an automatic blood culturing apparatus. If bacteria are determined to be present, a bacteriophage-based bacteria identification process is performed to identify the bacteria present. A plurality of bacteria detection processes, such as a blood culture test and Gram stain test may be carried out prior to the bacteria identification process. A bacteriophage-based antibiotic resistance test or antibiotic susceptibility test is also conducted on the sample.11-20-2008
20080293037Sequences Diagnostic For Shrimp Pathogens - Primers have been isolated that are diagnostic for the detection of the infectious hypodermal and hematopoietic necorsis virus (IHHNV). The primers are based on a new portion of the IHHNV genome and may be used in primer directed amplification or nucleic acid hybridization assay methods.11-27-2008
20080293040INFLUENZA B VIRUSES WITH REDUCED SENSITIVITY TO NEURAMINIDASE INHIBITORS - An isolated influenza B virus which has reduced sensitivity to one or more neuraminidase (NA) inhibitors, wherein the reduced sensitivity to one or more NA inhibitors is associated with a residue in NA other than Ile at position 222, a residue in NA other than Ser at a position 250, or a residue in NA other than Gly at position 402, as well as methods to detect such a virus or determine agents that inhibit the infection or replication of such as virus, are provided.11-27-2008
20080293038Method for Determining Resistance of Hiv to Nucleoside Reverse Transcriptase Inhibitor Treatment - The present invention provides methods and devices for predicting whether an HIV-1 is resistant to an antiviral drug based on the HIV-1's genotype. In one aspect, the invention provides methods comprising determining whether a mutation or combination of mutations associated with NRTI resistance are present, as disclosed herein, thereby assessing the effectiveness of FTC therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV-1 resistance are provided.11-27-2008
20080293041Methods and Devices for Detection of the Strain of a Pathogen - Provided are methods and devices for determining the strain of a pathogen in a sample.11-27-2008
20100143887BIOSENSOR AND METHOD FOR DETECTING BIOMOLECULES BY USING THE BIOSENSOR - Provided are a biosensor and a method for detecting biomolecules by using the biosensor. The biosensor includes a detection unit and a fluid channel. The detection unit is disposed on a substrate and has a surface to which detection target molecules binding specifically to probe molecules are immobilized. The fluid channel is configured to provide an analysis solution containing the probe molecules to the detection target molecules. The probe molecules bind specifically to the target molecules and the detection target molecules.06-10-2010
20090311665Methods, compositions, and kits for collecting and detecting oligonucleotides - Methods, pharmaceutical compositions, and kits are provided which includes accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, atherosclerotic disease, or neurological disease in the animal. A method is provided which includes administering at least one compound to an animal wherein the at least one compound is configured to prevent the cleavage of at least one tissue RNA by a ribonuclease. The method further includes collecting a sample of at least a portion of tissue from the animal.12-17-2009
20120045747KIT FOR DETECTING HEPATITIS B VIRUS AND METHOD FOR DETECTING HEPATITIS B VIRUS USING THE SAME - A kit for detecting HBV in a test sample is disclosed. In addition a method is described for the real-time detection of HBV in a test sample using the kit. According to method of detection, the results of the detection can be rapidly identified with a reduced number of copies of a sample in real-time.02-23-2012
20080213750HCV Variants and Related Methods - HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication.09-04-2008
20080261203Detection of Epstein-Barr Virus - The invention provides methods to detect EBV in biological samples using real-time PCR. Primers and probes for the detection of EBV are provided by the invention.10-23-2008
20080268425METHODS AND KITS FOR DETECTING CLASSICAL SWINE FEVER VIRUS - The present invention provides methods and kits for detecting CSFV. The present invention also provides oligonucleotides for detecting CSFV.10-30-2008
20080268427DETECTION OF BOVINE VIRAL DIARRHEA VIRUS IN HAIR SAMPLES - The present invention relates to a method of detecting whether a target animal is Bovine Viral Diarrhea Virus (BVDV) positive or negative by determining whether a gp48 protein-specific reagent binds to a gp48 Bovine Viral Diarrhea Virus protein or protein fragment, which retains antigenic specificity, from a target animal's hair sample.10-30-2008
20080268426IDENTIFYING VIRALLY INFECTED AND VACCINATED ORGANISMS - This document provides methods and materials related to assessing organisms for the presence or absence of anti-virus antibodies. For example, this document provides methods and materials that can be used to determine whether or not an organism (e.g., a member of a swine species such as a pig) contains anti-PRRS virus antibodies. In other embodiments, this document provides methods and materials that can be used to determine if a particular organism received a vaccine version of a virus, was infected with a naturally-occurring version of the virus, or is naïve with respect to the virus.10-30-2008
20100273143DISCRIMINATORY POSITIVE/EXTRACTION CONTROL DNA - The present teachings generally relate to methods and kits incorporating a discriminating positive control for determining whether a particular microorganism or group of microorganisms are present in a sample, for example but not limited to a food, environmental, agricultural, biopharmaceutical, pharmaceutical, or water sample. According to certain methods, at least part of a starting material, for example but not limited to, a food, environmental, agricultural, biopharmaceutical, pharmaceutical, or water sample can be combined with a culture medium and incubated under conditions suitable for microbial growth followed by extracting microorganism and added control nucleic acids for analysis. The extracted nucleic acids are amplified and the amplified nucleic acids are detected, directly or indirectly, and the fidelity of the methods and the presence or absence of the corresponding microorganism is determined because the discriminating positive control provides both confirmatory results for the methods used but eliminates false positive results.10-28-2010
20120141978PRRSV GP5 BASED COMPOSITIONS AND METHODS - The disclosure includes compositions and methods for the production of an immune response against porcine reproductive and respiratory syndrome (PRRS) virus, or PRRSV. The disclosure is based in part on the use of two or more peptide domains, each with a different sequence, from the PRRSV GP5 protein ectodomain. Compositions and methods comprising polypeptides containing the two or more domains, or nucleic acids encoding them, are described.06-07-2012
20100143886IN VIVO HCV RESISTANCE TO ANTI-VIRAL INHIBITORS - HCV mutations emerged in chimpanzees treated with a N5B polymerase inhibitor (Compound A) or a NS3 protease inhibitor (Compound B). Short term treatment with Compound A was followed by the initial emergence of an HCV with a S282T polymerase mutation following treatment. Short term treatment with Compound B selected for HCV with a R155K or D168T protease mutation.06-10-2010
20100143892USE OF RIBOZYMES IN THE DETECTION OF ADVENTITIOUS AGENTS - The present invention provides a method of detecting adventitious agents in a composition comprising a microorganism by using ribozyme-expressing indicator cells, as well as indicator cells useful in such detection.06-10-2010
20090181364ZINC BINDING COMPOUNDS AND THEIR METHOD OF USE - The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of zinc ions in a sample. The metal chelating moiety of the zinc-binding compound is an analog of the well-known calcium chelator, BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid), wherein the chelating moiety has been modified from a tetraacetic acid moiety to a tri- di- or monoacetic moiety. This change in acetic acid groups on the metal chelating moiety results in the selective bindings of zinc ions in the presence of calcium ions, both of which are present in biological fluids and intracellular cytosolic fluid and organelles.07-16-2009
20090029352Method for detecting the Presence of A Nucleic Acid in A Sample - An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations, or modules, in which discrete aspects of the assay are performed on fluid samples contained in reaction receptacles. The analyzer includes stations for automatically preparing a specimen sample, incubating the sample at prescribed temperatures for prescribed periods, performing an analyte isolation procedure, and ascertaining the presence of a target analyte. An automated receptacle transporting system moves the reaction receptacles from one station to the next. The analyzer further includes devices for carrying a plurality of specimen tubes and disposable pipette tips in a machine-accessible manner, a device for agitating containers of target capture reagents comprising suspensions of solid support material and for presenting the containers for machine access thereto, and a device for holding containers of reagents in a temperature controlled environment and presenting the containers for machine access thereto. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte. The process is performed by automatically moving each of a plurality of reaction receptacles containing a solid support material and a fluid sample between stations for incubating the contents of the reaction receptacle and for separating the target analyte bound to the solid support from the fluid sample. An amplification reagent is added to the separated analyte after the analyte separation step and before a final incubation step.01-29-2009
20090029351METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.01-29-2009
20090130650Methods for the production of highly sensitive and specific cell surface probes - A system and method for producing an oligonucleotide having a high affinity for extracellular or cell surface markers on a target cell. The resultant oligonucleotide probe can be used to detect a target biomolecule, in particular a cancer cell or infectious agent such as a bacterium, virus, or fungus, comprising an aptamer having a high affinity for the biomolecule, wherein at least one labeled dye is attached to the aptamer. The labeled dye causes the aptamer to emit a baseline, non-visible emission. When the aptamer (also referred to herein as a probe) of the invention interacts with a target biomolecule, the fluorescence emission changes from the baseline emission to an emission that is visually detectable.05-21-2009
20090136915Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs - This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.05-28-2009
20110269118METHODS FOR IDENTIFYING CELLS BY COMBINATORIAL FLUORESCENCE IMAGING - A method of identifying the taxonomic or functional classification of cells in situ involves labeling the cells with a set of nucleic acid probes and performing combinatorial fluorescence microscopic imaging. The set of probes contains groups of either two or three probes that bind to a taxon-specific or function-specific nucleotide sequence. Each probe of a group of probes is labeled with a distinct fluorescent label, and each group corresponds to a unique combination of labels, which can be detected across the image and serves to identify cells having a single target sequence, or a set of target sequences, that are characteristic of a unique taxonomic or functional classification. The combinatorial labeling and spectral imaging approach greatly expands the number of different classifications that can be identified simultaneously in a single image of a collection of cells. The methods and probe sets of the invention can be used to rapidly identify microbes, study their ecological relationships, screen for novel antibiotics, and identify pathogens.11-03-2011
20090298050IMMUNOCHROMATOGRAPHIC DEVICE - The present invention provides an immunochromatographic device, which contains the following (a) and (b): (a) a first device part holding a first insoluble carrier used for developing a complex formed with an analyte and a labeling substance comprising a metal labeled with a first binding substance that can bind to the analyte and capturing the analyte and the labeling substance at a reaction portion containing a second binding substance that can bind to the analyte, and (b) a second device part holding a second insoluble carrier used for developing a liquid and a third insoluble carrier used for absorbing a liquid, in such a way that the first insoluble carrier does not come into contact with the second insoluble carrier and the third insoluble carrier.12-03-2009
20090162834MOLECULAR SEQUENCE OF SWINE RETROVIRUS AND METHODS OF USE - Purified nucleic acid which can specifically hybridize with the sequence of swine retroviruses.06-25-2009
20090186337N PROTEIN OF A VIRUS OF THE PARAMYXOVIRIDAE FAMILY-PROTEIN OF INTEREST FUSION PROTEINS - The invention relates to N protein-protein of interest fusion proteins, optionally in the form of soluble N protein-protein of interest/P protein complexes, the N and P proteins being proteins of a virus of the Paramyxoviridae family. When the protein of interest is an antigen, the invention relates also to vaccinal compositions and diagnostic reagents comprising those N protein-antigen fusion proteins or those N protein-antigen/P protein complexes. The N protein-protein of interest fusion protein can also be used as a “vector” for transporting into cells therapeutic molecules of interest, such as antivirals or anticancer agents.07-23-2009
20090186338OLIGONUCLEOTIDES ORIGINATING FROM SEQUENCES CODING FOR THE SURFACE COMPONENT OF PTLV ENVELOPE PROTEINS AND THEIR USES - The invention relates to the use of oligonucleotides from the nucleotide sequences coding for the amino-terminal region of the surface component (SU) of envelope proteins of PTLV viruses in order to perform methods of detecting every PTLV strain or PTLV-related viruses, e.g. for the detection of novel PTLV variants or viruses comprising sequences related to PTLV SUs. The invention also relates to primer pairs which are used to perform said detection methods and the novel PTLV variants thus detected.07-23-2009
20090162831 HUMAN PARVOVIRUS - The present invention relates to the discovery of a new human parvovirus, methods of detecting the parvovirus and diagnosing parvovirus infection, methods of treating or preventing parvovirus infection, and methods for identifying anti-parvoviral compounds.06-25-2009
20090130652Optimization of West Nile Virus Antibodies - The invention relates to the production of binding molecules. In particular, the invention relates to methods for producing binding molecules having an improved functionality of interest.05-21-2009
20090004643METHODS FOR CONCURRENT IDENTIFICATION AND QUANTIFICATION OF AN UNKNOWN BIOAGENT - The present invention provides methods for the quantification of an unknown bioagent in a sample by amplification of nucleic acid of the bioagent, and concurrent amplification of a known quantity of a calibration polynucleotide from which are obtained a bioagent identifying amplicon and a calibration amplicon. Upon molecular mass analysis, mass and abundance data are obtained. The identity of the bioagent is then determined from the molecular mass of the bioagent identifying amplicon and the quantity of the identified bioagent in the sample is determined from the abundance data of the bioagent identifying amplicon and the abundance data of the calibration amplicon.01-01-2009
20090047658Methods and compositions for determining the pathogenic status of infectious agents - Methods and compositions for the detection of disease caused by infectious agents and microbes are provided. In particular, methods and compositions comprising novel combinations of nucleic acid amplification and drug susceptibility technologies are provided. In certain embodiments, the present invention enables the detection of infectious agents and microbes as well as providing information concerning the viability status of the agent or microbe. In one embodiment, the present invention is used for the detection of mycobacterial infections, including, but not limited to, tuberculosis.02-19-2009
20090142748MICROPOROUS MATERIALS, METHODS OF MAKING, USING, AND ARTICLES THEREOF - Described herein are methods for separating one or more analytes present in a fluid sample. The methods involve passing the fluid through or into a microporous material, wherein the analytes are localized near the surface of the microporous material. Additional processing steps such as hybridization and amplification can be performed once the analyte is localized. In one method, once the analyte is localized, the analyte can be detected, counted, and correlated in order to determine the concentration of the analyte in the sample. In another method, the localized analyte is destabilized to make the localized analyte more accessible for chemical manipulation. Modified microporous materials and composite materials are also disclosed that can be used in any of the methods and articles described herein. The composite is composed of a microporous material and a pigment, wherein the pigment is incorporated in the microporous material. The pigments alter the optical properties of the microporous material, which enhances the detection of analyte once it is localized. Methods for making pigmented composites are also disclosed. In a further aspect, various kits and articles such as filtration devices containing any of the microporous materials described herein are provided.06-04-2009
20080318207SEQUENCE COVARIANCE NETWORKS, METHODS AND USES THEREFOR - Methods of identifying targets for designing a therapeutic agent are disclosed. These methods comprise: determining an amino acid sequence of one or more polypeptides of each isolate of a plurality of isolates of a biological system; identifying covariance pairs of amino acid residues; establishing a network comprising the covariance pairs; and identifying one or more hub residue positions, wherein a hub residue position comprises a target for designing a therapeutic agent if the hub residue position has a rank order in the 4012-25-2008
20080318208Dengue Reporter Virus and Methods of Making and Using the Same - The present invention relates to the production and uses of Dengue virus replicons and Dengue reporter virus particles. The present invention relates to methods of identifying inhibitors of Dengue virus infection, inhibitors of Dengue virus replication, and inhibitors of Dengue virus assembly.12-25-2008
20080318204Highly-Sensitive Genomic Assays Employing Chimeric Bacteriophage Standards - Methods are provided for sensitively quantitating at least one pre-selected DNA sequence in a biological sample utilizing hybridization methodology, the method employing as an internal standard an infectious bacteriophage particle comprising a detectable target DNA sequence other than that present in the pre-selected DNA sequence or in DNA quantitated from the biological sample, and as an external standard, an infectious bacteriophage particle comprising at least the pre-selected DNA sequence.12-25-2008
20090325146Method of determining susceptibility of a tumor cell to a chemotherapeutic agent: novel use of herpes - The present invention provides a method of determining if a tumor cell is susceptible to killing by a chemotherapeutic agent, comprising: (a) providing a tumor cell; (b) infecting said tumor cell with a herpes simplex virus or a herpes simplex virus defective in an immediate early gene selected from the group consisting of ICP27, ICP4, and ICP22; and (c) determining the presence of apoptotic killing of said tumor cell, wherein the presence of apoptotic killing is indicative of susceptibility to said chemotherapeutic agent. Chemotherapeutic agent may include doxorubicin, etoposide, paclitaxel, cisplatin, or 5-fluorouracil. The present invention also provides a herpes simplex virus promoter construct having a lacZ gene to assess tumor resistance to chemotherapeutic agents.12-31-2009
20090325149DETECTION AND DISTINGUISHING INFECTIONS BURSAL DISEASE VIRUS (IBDV) STRAINS BY MOLECULAR BIOLOGY METHOD - The present invention relates to a novel method to detect and differentiate different strains of infectious bursal disease virus (IBDV) in a chicken and other bird sample. RNA was obtained from said samples by using a pair of primer (Primer FVVC & RVVC) in a reverse transcriptase-polymerase chain reaction. Two different primer combinations (Primer IF & IVIR) and (Primer IF & RCLA) and real-time polymerase chain reaction conditions were designed and optimized for rapid differentiation of very virulent and vaccine strains of IBDV based on detection of signatory threshold cycle (Ct) and melting temperature (Tm) values.12-31-2009
20090325145METHODOLOGY FOR ANALYSIS OF SEQUENCE VARIATIONS WITHIN THE HCV NS5B GENOMIC REGION - The current invention relates to a standardized method for amplification of an HCV NS5B nucleic acid fragment of any one of HCV genotypes 1 to 6 as a tool for analysis of sequence variations that may be correlated with HCV drug resistance.12-31-2009
20100267008CHIRAL INDOLE INTERMEDIATES AND THEIR FLUORESCENT CYANINE DYES CONTAINING FUNCTIONAL GROUPS - This invention relates to the functionalized cyanine dyes and more particularly, to the synthesis of chiral 3-substituted 2,3′-dimethyl-3H-indole and its derivatives as intermediates for preparation of cyanine dyes, to methods of preparing these dyes and the dyes so prepared.10-21-2010
20130217003METHOD FOR DETERMINING AN ANALYTE CONTENT OF A LIQUID SAMPLE BY MEANS OF A BIOANALYZER - A method for automated in situ determining an analyte content of a liquid sample by means of a bioanalyzer, wherein a measurement duct has at least one substrate, comprising a repeatedly performable sequence of steps as follows: (i) preparing a sensor matrix, which has a plurality of receptors, which bind the analyte and/or a further target molecule, or bring about a chemical conversion of the analyte or of the further target molecule, leading through the measurement duct a preparation solution of at least a first chemical species, wherein a plurality of the first chemical species are bound on the substrate via the functional group binding on the substrate, wherein the other functional group of the plurality of the first chemical species bound on the substrate serves as a receptor or for subsequent binding of a receptor; (ii) leading the liquid sample, through the measurement duct, wherein analyte contained in the liquid sample or in the liquid to be measured, and/or other target molecules contained in the liquid sample or the liquid to be measured, bind, preferably selectively and specifically, on the receptors or are chemically converted by the receptors, and determining a measured variable correlated with the amount of the target molecules bound or converted by the receptors, and deriving therefrom the analyte content of the liquid sample; and (iii) regenerating, especially clearing, the at least one substrate, wherein the sensor matrix and, in given cases, molecules bound thereto, especially analyte molecules, other target molecules or other molecules, are released from the substrate and/or at least partially decomposed.08-22-2013
20090081637Hepatitis B Viral Variants With Reduced Susceptibility To Nucleoside Analogs And Uses Thereof - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.03-26-2009
20090286226Simple membrane assay method and kit - A simple membrane assay method for detecting or quantitating an analyte in a specimen sample using an assay device equipped with a membrane bound with a capture-substance to capture the analyte, including the steps of filtering a specimen sample using a filter, dropping the filtrate onto said membrane and detecting the presence of the analyte in said specimen sample, as well as a simple membrane assay kit for detecting the presence of an analyte in a specimen sample, including (1) a filter tube, and (2) an assay device equipped with a membrane bound with a capture-substance to capture the analyte. The method or the kit can decrease the occurrence of false positivity and can provide a highly accurate detection of the analyte such as pathogen and antibody in a specimen collected in a medical scene or by an individual.11-19-2009
20080268423Compositions and Methods Related to Flavivirus Envelope Protein Domain III Antigens - The present invention concerns methods and compositions involving flavivirus envelope protein domain III antigens for the detection of virus and detection of antibodies against the virus. Such methods and compositions may be used to detect TBE serocomplex viruses or West Nile virus infection in a subject, patient, animal or biological fluid. The present invention also concerns kits for implementing such methods. In some embodiments, kits contain a recombinant TBE serocomplex virus or West Nile virus envelope protein domain III antigen.10-30-2008
20130216997Methods and Systems for Detection of Microorganisms - Disclosed are methods and systems for the isolation and detection of microbes from a sample. The use of binding agents for isolation of a microbe of interest from a sample are described. In certain embodiments, the methods use ribosome-based and/or bacteriophage-based amplification of the signal in detection of bacteria and other microorganisms. For example, embodiments of the present invention can achieve total amplification of at least 10,000 from a single infected cell.08-22-2013
20100003668Oligonucleotides and Use Thereof for Determining Deletion in HBV Pre-S Region - This invention provides combinations of novel oligonucleotides and their use in detecting a deletion(s) in the Pre-S region of HBV. Such a deletion(s) is associated with an increased risk of developing cirrhosis or hepatocellular carcinoma.01-07-2010
20090170063Hcv rna having novel sequence - A truncated form hepatitis C virus gene wherein part of the gene region encoding from the core protein to the NS2 protein of hepatitis C virus has been deleted while retaining the translation frame. In particular, the gene according to claim 07-02-2009
20090098532Probes and Methods for Hepatitis C Virus Typing Using Single Probe Analysis - This invention provides compositions and methods for HCV typing, e.g., genotyping and/or subtyping. The compositions and methods of the invention can be used to assign an HCV isolate to one of at least five HCV genotypes (for example, selected from genotypes 1, 2, 3, 4, 5 or 6), or assign an HCV isolate to one of at least six subtypes (for example, selected from subtypes 1a/b/c, 2a/c, 2b, 3a, 4a, 5a or 6a), where the methods of the invention use only a single typing probe to make the HCV type assignment.04-16-2009
20100267006METHOD FOR DETECTION OF CIRULENT STRAIN OF INFLUENZA TYPE-A VIRUS - The present invention provides a method for detecting a virulent strain of influenza virus in a specific, rapid and simple manner, and an assay device therefor. A method for detecting a virulent strain of influenza A virus is provided, which comprises providing a first antibody that is reactive with all influenza A virus subtypes and a second antibody that is not reactive with a virulent strain of influenza A virus but is reactive with all influenza A virus subtypes other than the virulent strain, and conducting an immunoassay to detect an antigen that shows a positive response in a reaction with the first antibody and shows a negative response in a reaction with the second antibody.10-21-2010
20090081636Pharmaceutical compositions for and methods of inhibiting HCV replication - The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers.03-26-2009
20090081641Methods and systems for treating disease - Methods and systems described herein are applicable to the identification of pathogens, pathogenic variants and applicable treatments or remedies. In some embodiments, the pathogen or pathogens bears a causal relationship to a disease state.03-26-2009
20090053689DEVICE FOR PROCESSING A BIOLOGICAL AND/OR CHEMICAL SAMPLE AND METHOD OF USING THE SAME - The present invention relates to a device and an apparatus device for processing a biological and/or chemical sample. The device comprises at least one sample processing chamber having an inlet at a first end and a penetrable sealing layer at a second end that forms at least a part of an inner wall of the sample processing chamber. The sealing layer is adapted to seal off the sample processing chamber from the environment until said sealing layer is penetrated to form an outlet. The device and apparatus also includes an absorption layer, wherein upon penetration of said sealing layer, said absorption layer is in fluid contact with said sealing layer and is capable of absorbing fluid released from said sample processing chamber, via the outlet. The present invention also relates to a fluid separation device. The fluid separation device comprises a penetrable sealing layer adapted to form a wall of a sample processing chamber of the device of the invention. The fluid separation device also comprises an absorption layer that is in fluid contact with the sealing layer and capable of absorbing fluid released from a sample processing chamber of the device.02-26-2009
20110229875METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that anon-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.09-22-2011
20110229874COMPOSITIONS AND METHODS USEFUL FOR HCV INFECTION - The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.09-22-2011
20110223585ASSAY FOR LOCALIZED DETECTION OF ANALYTES - The present invention relates to a method for detecting an analyte in a sample, said method comprising: (a) contacting said sample with at least one set of at least first and second proximity probes, wherein said probes each comprise an analyte-binding moiety and can simultaneously bind to the analyte, and wherein (i) said first proximity probe comprises a nucleic acid moiety attached at one end to the analyte-binding moiety, wherein a circular or circularizable oligonucleotide is hybridized to said nucleic acid moiety before, during or after said contacting step; and (ii) said second proximity probe comprises an enzyme moiety, attached to the analyte-binding moiety, capable of directly or indirectly enabling rolling circle amplification (RCA) of the circular or, when it is circularized, of the circularizable oligonucleotide hybridized to the nucleic acid moiety of the first proximity probe, wherein said RCA is primed by said nucleic acid moiety of said first proximity probe; (b) if necessary, circularizing said oligonucleotide, to produce a circularized template for RCA; (c) subjecting said circular or circularized template to RCA, wherein if the enzyme moiety of the second proximity probe in step (a)(ii) is a DNA polymerase, this step does not utilize a free DNA polymerase; and (d) detecting a product of said RCA.09-15-2011
20090053692DETECTION OF HIV-1 BY NUCLEIC ACID AMPLIFICATION - Nucleic acid sequences and methods for detecting HIV-1 nucleic acid (LTR and pol sequences) in biological samples by detecting amplified nucleic acids are disclosed. Kits comprising nucleic acid oligomers for amplifying HIV-1 nucleic acid present in a biological sample and detecting the amplified nucleic acid are disclosed.02-26-2009
20090053690SURFACE CHEMISTRY AND DEPOSITION TECHNIQUES - Surface chemistries for the visualization of labeled single molecules (analytes) with improved signal-to-noise properties are provided. To be observed, analyte molecules are bound to surface attachment features that are spaced apart on the surface such that when the analytes are labeled adjacent analytes are optically resolvable from each other. One way to express this concept is that binding elements should be spaced apart such that the Guassian point spread functions of adjacent labels do not overlap. Another way of expressing this concept is that the surface binding elements should be spaced apart by a distance equal to at least the diffraction limit for an optical label attached to the bound analytes.02-26-2009
20090053687METHOD FOR THE DETECTION OF HPV AND PROBES, PRIMERS AND KITS - The invention relates to materials and methods method for detection and/or typing of any HPV nucleic acid possibly present in a biological sample, the method comprising the steps of: (i) amplification of a polynucleic acid fragment comprising or consisting of the B region of any HPV nucleic acid in the sample, said B region being indicated in FIG. 02-26-2009
20090202984SINGLE MOLECULE NUCLEIC ACID SEQUENCE ANALYSIS PROCESSES AND COMPOSITIONS - Improved solid supports and methods for analyzing target nucleotide sequences are provided herein. Certain improvements are directed to efficiently preparing nucleic acids that comprise nucleotide sequences identical to or substantially identical to one or more target nucleotide sequences, or complement thereof. The prepared nucleic acids include a reference sequence that facilitates sequence analysis. The solid supports and methods provided herein minimize the number of steps required by published sequence analysis methodologies, and thereby offer improved sequence analysis efficiency.08-13-2009
20080286759Hepatocyte Bioreactor System For Long Term Culture of Functional Hepatocyte Spheroids - A rotating wall vessel is used as a culture vessel and bioreactor for the cultivation of hepatocytes in the form of spheroids to generate a culture with many properties of the intact liver. These properties include enzyme activity comparable to fresh cells and long-term maintenance of viability and cellular function for periods on the order of months. The cultures may be used to produce hepatocyte products, evaluate metabolism of an agent, propagate Hepatitis C virus and test agents as inhibitors of this virus. Thus, the culture system disclosed herein makes long term functional cultivation of human hepatocytes feasible.11-20-2008
20090220946ADENOVIRUS STATUS AS A PREDICTOR OF BODY COMPOSITION CHANGE, DISEASE STATUS, AND TREATMENT OUTCOMES - Infection with obesifying adenoviruses in animals and humans may be used to predict changes in body weight and disease status. More particularly, infection with certain adenoviruses, such as adenovirus type 36 (Ad-36) and adenovirus type 37 (Ad-37) may cause removal of the normal equilibrium factors that control fat cell metabolism and may make individuals more responsive than normal individuals to perturbations, which cause body composition change including weight gain or weight loss.09-03-2009
20090220941COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND KITS AND METHODS USING SAME - An isolated composition-of-matter comprising a sialic acid bound to a sialic acid binding domain of a polypeptide is provided. Uses thereof and kits comprising same are also provided.09-03-2009
20090246752APPARATUS AND METHOD FOR DETECTING MICROSCOPIC LIVING ORGANISMS USING BACTERIOPHAGE - A method for detecting one or more target bacteria in a raw sample where: 1) bacteriophage(s) specific to each target bacterium are added to the raw sample, 2) the test sample is incubated, and 3) the test sample is tested for the presence of each phage in sufficient numbers to indicate the presence of the associated target bacteria in the raw sample. In one embodiment, each phage is initially added to the raw sample in concentrations below the detection limit of the final phage detection process. In another embodiment, the parent phages are tagged in such a way that they can be separated from the progeny phage prior to the detection process. Preferred phage detection processes are immunoassay methods utilizing antibodies that bind specifically to each phage. Antibodies can be used that bind to the protein capsid of the phage. Alternatively, the phage can by dissociated after the incubation process and the sample tested for the presence of individual capsid proteins or phage nucleic acids. The invention can be used to test target bacteria for antibiotic resistance.10-01-2009
20090246754OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION AND QUANTITATION OF BK VIRUS - Described herein are probes and primers for detecting and quantitating variant BK viral strains and methods and devices of identifying and using the described probes and primers.10-01-2009
20090220945HPV E6, E7 mRNA ASSAY AND METHODS OF USE THEREOF - Provided is an HPV E6, E7 mRNA assay, referenced herein as the “In Cell HPV Assay,” that is capable of sensitive and specific detection of normal cervical cells undergoing malignant transformation as well as abnormal cervical cells with pre-malignant or malignant lesions. The In Cell HPV Assay identifies HPV E6, E7 mRNA via in situ hybridization with oligonucleotides specific for HPV E6, E7 mRNA and quantitates the HPV E6, E7 mRNA via flow cytometry. The In Cell HPV Assay can be carried out in less than three hours directly from liquid-based cervical (“LBC”) cytology specimens. The In Cell HPV Assay provides an efficient and highly sensitive alternative to the Pap smear for determining abnormal cervical cytology.09-03-2009
20080261201Methods and compounds to alter virus infection - The invention provides a method to identify an agent that alters parvovirus transduction of mammalian cells. Also provided is a method to enhance transgene expression in a mammalian cell, as well as a method to identify an agent that alters NADPH oxidase activity in parvovirus transduced mammalian cells.10-23-2008
20080261200Detection of Nucleic Acid Mutations - A method for detecting a mutation in a target nucleic acid sequence in a sample, the target nucleic acid sequence comprising a first DNA strand and optionally the complementary strand thereof, said method comprising: (a) adding a detection primer to the nucleic acid, wherein the detection primer binds to the first DNA strand at a DNA sequence that comprises the mutation site; (b) extending the detection primer to form second DNA strands that are complementary to the first DNA strand; (c) adding an amplification primer to the nucleic acid, wherein the amplification primer binds to the second DNA strand and/or to the complementary strand, at a position away from the mutation site; (d) extending the amplification primer to form third DNA strands that are complementary to the second DNA strands, and/or additional copies of the first DNA strand; (e) annealing the DNA strands by complementary base pairing, to form nucleic acid duplexes, wherein if the two strands of the duplex have a mismatched residue at the mutation site, the duplex is a heteroduplex, and. wherein if the two strands of the duplex do not have a mismatched residue at the mutation site, the duplex is a homoduplex; and (d) detecting the presence of heteroduplexes and/or homoduplexes.10-23-2008
20080261199RAPID DETECTION PROCESSES AND RELATED COMPOSITIONS - An improved detection method is described for an antigen such as a chemical compound, a peptide, or a nucleic acid. The detection time for an antigen can be dramatically reduced relative to conventional technologies. The technology can particularly be used, for example, to modify and reduce the detection time significantly in traditional Western blot, Dot blot, ELISA and Immunohistology methods.10-23-2008
20080261197Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens - An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.10-23-2008
20090253123Hepatitis B variants with reduced sensitivity to therapeutic compounds, their detection and uses thereof - The present invention is a diagnostic kit and materials for: 1) the prediction of the long-term response of a chronic hepatitis B virus (HBV) carrier to treatment with nucleoside/nucleotide analogue, or their combination; 2) the detection of HBV variants that exhibit reduced reactivity to antibody detection; 3) the detection of HBV variants in the precore/core region that negatively affect the course of liver disease; 4) the identification of the HBV genotype.10-08-2009
20120141980METHOD FOR ISOLATING VIRUSES - The present invention relates to a method and kit for the isolation of viruses from a sample. The sample is treated with an extraction solution that comprises at least a divalent chloride salt and/or an ionic liquid.06-07-2012
20090220939Methods for determing resistance or susceptibility to hi entry inhibitors - The invention provides a method for determining whether a human immunodeficiency virus is likely to be more resistant to a viral entry inhibitor than a reference HIV. In certain aspects, the methods comprise comparing the length of one or more variable regions of an envelope protein of the HIV or a number of glycosylation sites on the envelope protein of the HIV to a length of one or more corresponding variable regions of an envelope protein of the reference HIV or a number of glycosylation sites on the envelope protein of the reference HIV, wherein the HIV is likely to be more resistant to the CD4 binding site entry inhibitor than the reference HIV when the HIV has longer variable regions than the reference HIV or the HIV has more glycosylation sites than the reference HIV.09-03-2009
20090220937Compositions for Use in Identification of Adventitious Viruses - The present invention provides compositions, kits and methods for rapid identification and quantification of adventitious contaminant viruses by molecular mass and base composition analysis.09-03-2009
20090220944Method to measure and characterize microvesicles in the human body fluids - This disclosure provides a method to capture, detect, characterize and quantify human exosomes in small volumes of human body fluids by using a sandwich ELISA test. This method allows a full characterization of an exosome preparation, thus providing a tool to distinguish a disease-related condition from a healthy state, by the use of a non-invasive assay. In fact, this method may be useful in screening, diagnosis and prognosis of tumors, with a simple plasma sample. At the same time measurement of circulating exosomes may provide information on the level of tumor mass present in a patient. The method provided here is suitable to evaluate presence of some infectious and/or transmissible agents, such as viral proteins or prion proteins, within circulating exosomes.09-03-2009
20090220940Method for Testing the Integrity of Membranes - A method for evaluating the integrity of microfiltration, ultrafiltration and nanofiltration membranes, which method comprises passing a liquid that contains a substantially mono-dispersed population of nano-probes through said membrane to form a permeate and testing said permeate for the presence of said nano-probes, wherein the non-detection of said nano-probes in said permeate indicates that said membrane is substantially intact.09-03-2009
20090220942ACTIVATED SPLIT-POLYPEPTIDES AND METHODS FOR THEIR PRODUCTION AND USE - The present invention relates to a method to produce activated split-polypeptide fragments that on reconstitution immediately forms an active protein. The method relate to real-time protein complementation. Also encompassed in the invention is a method to split and produce split-fluorescent proteins in an active state which produce a fluorescent signal immediately on reconstitution. The present application also provides methods to detect nucleic acids; non-nucleic acid analytes and nucleic acid hybridization in real-time using the novel activated split-polypeptide fragments of the invention.09-03-2009
20130137082BIOSENSOR, APPARATUS AND METHOD FOR DETECTING A BIOMOLECULE USING THE BIOSENSOR - Provided are a biosensor, an apparatus and a method for detecting a biomolecule using the biosensor. The biosensor may include a supporting substrate, a semiconductor layer spaced apart from a top surface of the supporting substrate by supporting patterns, and a nano-motor array formed on a top surface of the semiconductor layer. The nano-motor array may include a plurality of nano-metal rods configured to exhibit an autonomous propulsion in a fluid.05-30-2013
20090117537METHOD FOR DETECTING SARS CORONAVIRUS - This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.05-07-2009
20090117536METHOD AND DEVICE FOR BACTERIAL SAMPLING - A bacterial detection sampling device comprising: a sampling medium for receiving a bacterial sample; and a plurality of bacteriophage. The bacteriophage are located on or in the sampling medium. Each bacteriophage comprises a nucleic acid encoding a protein capable of emitting light at an output wavelength.05-07-2009
20090258342OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION, QUANTIFICATION AND GROUPING OF HIV-1 - Described herein are optimized primers and probes useful for detecting, quantitating and grouping variant HIV-1 strains, and methods and kits of using the described primers and probes.10-15-2009
20090258340Assay for SARS coronavirus by amplification and detection of the replicase sequence - Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.10-15-2009
20090258339SYSTEMS, METHODS AND COMPOSITIONS FOR DETECTION OF HUMAN PAPILLOMA VIRUS IN BIOLOGICAL SAMPLES - The present invention comprises, without limitation, systems, methods, and compositions for the detection, identification, and quantification, down to the single copy level, of human papillomavirus (HPV) in biological samples, including but not limited to, mammalian body fluids and cervix scrapings, for purposes of detection, treatment and/or management of cancer and dysplasia.10-15-2009
20090220943HCV GENOTYPING AND PHENOTYPING - The present invention includes methods of genotyping and phenotyping HCV. In one embodiment, the methods of the invention can be used to determine whether a HCV isolate is resistant to an antiviral drug. The invention also includes primers for amplifying a HCV NS3 region and kits.09-03-2009
20090246753Detection of Phage Amplification by SERS Nanoparticles - A phage specific antibody presenting particle, devices and methods related to detection of phage amplification are provided.10-01-2009
20100015598Light Emission Modifiers and Their Uses in Nucleic Acid Detection, Amplification and Analysis - The present invention relates to methods and reagents for modifying the emission of light from labeled nucleic acids for the purpose of real time detection, analysis, and quantitation of nucleic acid sequences, e.g., using singly labeled probes. These methods and reagents exploit advantageous properties of thiazine dyes and diazine dyes. Furthermore, the use of these light emission modifiers in background reduction, nucleic acid duplex stabilization and other uses is also described. Related kits, reaction mixtures and integrated systems are described.01-21-2010
20090253122Method for measuring resistance of a patient HIV-2 to protease inhibitors - A search method in a biological sample containing an HIV 2 viral strain for possible resistance of said strain to treatment by an anti-protease agent, and nucleotide probes for the implementation thereof. According to methods known per se, the presence of at least one mutation at certain, specified, particular positions of the proteinic sequence of the protease of said viral strain from a biological sample taken from a patient contaminated by HIV 2 is searched. If said mutation is observed, the existence of a resistance to said anti-protease agent is assumed in the patient.10-08-2009
20090253120DNA VIRUS DETECTION BY DNA CHIP - The disclosure relates to chips containing nucleic acid probes or primers and their use in methods to detect nucleic acid molecules of DNA viruses. The disclosure includes DNA chips in contact with a thermocycler capable of automatically regulating the temperature, temperature cycle times, and number of temperature cycles of the chips to provide genetic diagnosis in one step.10-08-2009
20090253124METHOD FOR DETECTING HUMAN PAPILLOMAVIRUS mRNA - An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.10-08-2009
20120171663System for Detection of Occult Murine Cytomegalovirus (MCMV) - Methods and compositions for detecting, treating, characterizing, and diagnosing cytomegalovirus in mammals using a nested-PCR methodology using specific predesigned primers are described.07-05-2012
20090258341Compositions and Methods for Detecting Bacteria - Genetically modified bacteriophage and methods of using the same to detect bacterial types of interest are provided.10-15-2009
20090253121METHOD FOR AMT-RFLP DNA FINGERPRINTING - An improved method for identifying and classifying organisms is provided. The method comprises the steps of obtaining a sample of DNA, isolating a portion of the sample to be analyzed, cutting the sample portion into at least two fragments, ligating both ends of the fragments with double-stranded linker sequences, adding the fragments to a polymerase chain reaction that amplifies a diagnostic region using a SYBR green-intercalating dye, and analyzing the fragments using a melt-curve analysis.10-08-2009
20090253119LATERAL FLOW SYSTEM AND ASSAY - The present invention relates to a lateral flow assay and system, including a test strip, for detection and quantification of analytes in samples, such as samples containing cells and fluid. In general, according to the present invention, a test strip for a lateral flow assay for detection of at least one analyte in a sample comprises: (1) a chromatographic strip, a sample filter, a fluid-impermeable barrier, and means for providing a mobilizable detectable agent that is capable of binding to the at least one analyte or to the capture agent after capturing the analyte to the chromatographic strip such that the mobilizable detectable agent migrates through the chromatographic strip and contacts sample that has passed through the sample filter and also has migrated through the chromatographic strip. The test strip allows detection with or without quantitation of an analyte in a sample containing whole cells.10-08-2009
20120196277DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF PROTEIN GLYCOSYLATION - Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states.08-02-2012
20120196275MULTICELLULAR ORGANOTYPIC MODEL OF HUMAN INTESTINAL MUCOSA - Disclosed are methods of preparing multi-cellular three-dimensional tissue constructs, that include fibroblasts, endothelial cells, lymphocytes and epithelial cells. The present methods may include embedding fibroblasts and endothelial cells in a matrix enriched with gut basement membrane proteins to form a cell containing matrix that is then added to a bioreactor and exposed to epithelial cells and activated lymphocytes as the cell cultures. Also provided are the tissue constructs formed from such methods, a matrix enriched with gut basement membrane proteins and kits that include the same. Further provided are methods of measuring toxicity of a pathogen or commensal organisms, chemosensitivity of tissues to a toxic material and inflammatory conditions, which use the present multi-cellular three-dimensional tissue constructs.08-02-2012
20120196272Prediction of HCV Viral Kinetics in Interferon-Free Treatment - The present invention is based on the discovery of associations that exist between single nucleotide polymorphisms (SNPs) on chromosome 19 and virological outcomes in a diverse population of patients with hepatitis C virus (HCV) who received interferon-free treatment.08-02-2012
20090246751METHOD FOR THE DETECTION OF VIRUS INFECTED CELLS - The present invention relates to a method for determining one or more stressed cell(s) in a medium. The method comprises the steps of (i) providing a sample from the medium, and (ii) determining a change in the sample relative to a normal sample of non-stressed cell(s).10-01-2009
20120141977HEPATITIS B VIRUS MUTATION STRAIN WITH RESISTANCE TO ADEFOVIR DIPIVOXIL AND THE USES THEREOF - A HBV mutation strain is provided, wherein rtE218G mutation occurs at the polymerase region of the mutation strain. The use of the HBV strain in screening anti-HBV drugs and related detection reagents used to detect rtE218G mutation are also provided.06-07-2012
20090275015NON-INVASIVE RESPIRATORY RAPID DIAGNOSIS METHOD - A non-invasive method for rapidly determining the specific presence or absence of respiratory pathogens and chemical entities.11-05-2009
20130122487DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES - Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.05-16-2013
20100184019Novel Human Virus Causing Severe Acute Respiratory Syndrome (SARS) and Uses Thereof - The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.07-22-2010
20120196273DEVICES AND METHOD FOR ENRICHMENT AND ALTERATION OF CELLS AND OTHER PARTICLES - The invention features devices and methods for the deterministic separation of particles. Exemplary methods include the enrichment of a sample in a desired particle or the alteration of a desired particle in the device. The devices and methods are advantageously employed to enrich for rare cells, e.g., fetal cells, present in a sample, e.g., maternal blood and rare cell components, e.g., fetal cell nuclei. The invention further provides a method for preferentially lysing cells of interest in a sample, e.g., to extract clinical information from a cellular component, e.g., a nucleus, of the cells of interest. In general, the method employs differential lysis between the cells of interest and other cells (e.g., other nucleated cells) in the sample.08-02-2012
20120196276Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes and Enteric Viruses - The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.08-02-2012
20100261157Device and Method for Processing a Sample Contained in a Swab for Diagnostic Analysis - A device for processing a sample contained in a swab for diagnostic analysis, includes a chamber having a first chamber portion and a second chamber portion to receive the swab and a processing fluid, wherein at least one of the first and second chamber portions is flexible. A divider may be positioned in the chamber to facilitate transferring the sample to the second chamber portion, and a delivery channel is disposed in fluid communication with at least one of the first chamber portion and the second chamber portion to deliver a processed sample for diagnostic analysis.10-14-2010
20120034600DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES - Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.02-09-2012
20090098528Method for determining early HCV seroconversion - The present invention concerns a polypeptide which is composed of the amino acids 1207±10 to 1488±10 of a hepatitis C virus and of less than 20 foreign amino acids and the use of this polypeptide as an antigen in an immunological test.04-16-2009
20090047660Antibodies for oncogenic strains of HPV and methods of their use - The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.02-19-2009
20100184016METHODS AND COMPOSITIONS IN THE TREATMENT OF PORCINE CIRCOVIRAL INFECTION - The invention relates generally to the field of virology. More particularly, the present invention relates to methods of diagnosing, prognosis, treatment and prevention of porcine circoviral infection in mammals, in particular of porcine circovirus type 2 (PCV2).07-22-2010
20100184015METHOD FOR DETECTION OF XMRV - The present invention relates to the identification of Xenotropic murine leukemia virus (XMRV) nucleic acid by polymerase chain reaction (PCR) analysis (e.g., real time PCR (RT/PCR); nested RT/PCR using Tth DNA polymerase and Hot start polymerase) and the uses thereof. In particular, the invention provides methods for the detection, and in particular early detection, of XMRV in RNA isolated from samples (e.g., urine samples; expressed prostate secretion (EPS)) of prostate cancer patients and normal individuals.07-22-2010
20100184014Non-M, non-O HIV-1 strains, fragments and uses - Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent.07-22-2010
20100261154PRIMERS AND PROBES FOR DETECTING HEPATITIS C VIRUS - The present invention relates to primers, probes, primer sets, primer and probe sets, methods and kits for detecting Hepatitis C virus in a test sample.10-14-2010
20100261153Methods For Direct Fluorescent Antibody Virus Detection In Liquids - The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.10-14-2010
20100261156REAGENT FOR DETECTING HIV-1 ANTIGEN AND DETECTION METHOD - The present invention provides a reagent for detecting a HIV antigen comprising a first antibody which is a first human monoclonal antibody recognizing HIV-1 p24 antigen and being labeled with a labeling substance, a solid phase and a second antibody which is a second human monoclonal antibody recognizing HIV-1 p24 antigen and to which a substance being capable of binding to the solid phase is bound.10-14-2010
20090017448SCREENING TOOL FOR ANTIVIRAL AGENTS - A method is provided for screening anti-adenovirus agents. The method includes reducing the activation of the immune system of a small mammal, administering a human adenovirus vector to the small mammal, monitoring the tumor cells in the mammal, and analyzing infectious virus units within the tumor cells and the organs of the small mammal. Specifically, the immune system of the small mammal is suppressed using cyclophosphamide. The small mammal may be, but is not limited to, one of the following: mice, rabbits, cotton rats, hamsters, rats, and other small rodents.01-15-2009
20090017447Human Endogenous Retrovirus with Foamy-Like Properties and Uses Thereof - The invention relates to the discovery of a human endogenous retrovirus (HERV) family, Type I HERV-K (HML-2) which appear to be active in vitro and in vivo, infectious, and which have the have the salient features and properties of foamy retroviruses. Based on its natural replication in humans, and that it protects the host from viral and tumor transformation, this non-pathogenic endogenous virus could be developed as a replication competent gene therapy vector. It also is expected to have much higher efficacy than other vectors as it crosses the bloodbrain barrier and infects almost all cell types in the host (proliferating or not). It may naturally lyse tumor cells or infected cells, and thus could even be used without genetic modification. Of course, this vector could be used in traditional ways with it ability to replicate genetically removed. In addition to its value as a vector, as it is reactivated with infection, its detection could also be used to monitor the safety of gene therapy (irrespective of vector type used), as well as other biological therapies including vaccination, blood transfusion, transplantation and xenotransplantation. Finally it may be used to screen for new therapeutic and prophylactic treatments for a wide variety of diseases.01-15-2009
20090017446Method and Set of Tools for Checking the Crystallisation Conditions of Biological Macromolecules - The invention relates to a method and set of tools for checking and ascertaining the crystallisation conditions of biological macromolecules using the counter-diffusion technique which employs precipitating agents, additives and buffers. The concentration of the precipitating agent(s) in the medium (solution or gel) is greater than those currently used with other available checking techniques, such as batch, microbatch or vapour phase diffusion techniques, such that, as a result of the diffusion along the length of the capillary containing the biological macromolecule, a large number of concentrations of the precipitating agent(s) used in one experiment are checked. The set of tools or kit contains the necessary elements for performing said method.01-15-2009
20090017445Method For Detecting And Removing Endotoxin - The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca01-15-2009
20100151441Human Cytomegalovirus Latency Promoting Genes, Related Virus Variants and Methods of Use - Latency promoting genomic sequences from human cytomegalovirus (HCMV) and virus variants lacking function of one or more of the latency promoting genes are disclosed. Also disclosed are methods of using the altered viruses and latency promoting genes and their gene products for the production of vaccines and for identifying antiviral compounds.06-17-2010
20090017443Method for Detection of Hepatitus B Virus - To provide a method for detection or quantification of hepatitis B virus (HBV) antigens in serum and a simple and highly user-friendly method for sample treatment for use in the detection or quantification thereof. The method for treatment of a sample containing hepatitis B virus (HBV) is characterized in that release of HBV antigens and disruption of antibodies that bind to HBV antigens are carried out by treating a sample containing HBV with a treatment agent containing (1) an acidifying agent and (2) a protein denaturant or an amphoteric surfactant or cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within a molecule.01-15-2009
20090017444Screening method for modulators of viral transcription or replication - The invention provides methods to identify modulators of viral transcription or replication.01-15-2009
20120244524METHOD FOR COUNTING AND SEGMENTING VIRAL PARTICLES IN AN IMAGE - The method is for intracellular counting and segmentation of viral particles or infectious agents in an image. An image is provided that has a plurality of items therein. A radius range of viral particles is determined. Items in the image having a radius within the predetermined radius range are identified. Elliptical items that are formable from the predetermined radius range are determined. The round and elliptical items identified into groups are sorted. The viral particles among the round and elliptical items are identified. For example, the method may be used for intracellular counting and segmentation of siRNA treated human cytomegaloviral particles in TEM images.09-27-2012
20110059431NON-ENZYMATIC DETECTION OF BACTERIAL GENOMIC DNA - The present invention relates to methods for detecting for the presence of one or more target analytes, e.g. biomolecules, in a sample. In particular, the present invention relates to a method that utilizes blocking strands to inhibit target rehybridization to detect double stranded genomic DNA.03-10-2011
20110059430CROSS-SPOT - The invention relates to an in vitro method for measuring the presence of an antigen indicative for the presence of an infectious agent, and preferably a medical condition or disease in a sample using an immune effector cell capable of producing an immune effector molecule following stimulation by an antigen.03-10-2011
20120196274MATERIALS AND METHODS FOR GENOTYPING AND QUANTIFYING A HIGH-RISK HUMAN PAPILLOMAVIRUS - Nucleic acids, assays, and methods for the detection and quantification of high risk HPV types are disclosed.08-02-2012
20100221700METHOD OF MONITORING HIV INFECTION - The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to a method of monitoring the intensity of HIV infection and predicting the time to progression to acquired immunodeficiency syndrome (AIDS).09-02-2010
20100151444Detection method for human pappilomavirus (HPV) and its application in cervical cancer - Embodiments of the invention provide methods, assays, and kits for detecting HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with pre-malignant and malignant epithelial cell lesions. Detection of HPV DNAs, genomes, and/or oncoproteins by nucleic acid hybridization assays and immunological assays can be used in early clinical screening for HPV infection and diagnosis for cervical cancer. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.06-17-2010
20100240023METHOD FOR EXTRACTING DEOXYRIBONUCLEIC ACIDS (DNA) FROM MICROORGANISMS POSSIBLY PRESENT IN A BLOOD SAMPLE - The present invention relates to a method for extracting DNA from microorganisms possibly present in a blood sample, comprising the following steps: i) filtration of a blood sample through a filtration membrane, the pores of which have a diameter ranging from 0.01 μm to 50 μm, in particular from 0.1 μm to 10 μm, and most particularly from 0.2 μm to 1 μm; ii)) washing of said filtration membrane; and iii) extraction of the deoxyribonucleic acids from the microorganisms possibly present on said filtration membrane.09-23-2010
20100216116VIRAL LATENCY MODEL - The invention relates generally to the field of virology. More particularly, the present invention relates to in vitro models for viral latency. In particular to latently infected cultures of primary and continuous cell lines, and to the use thereof in methods to identify anti-viral compounds. More in particular to identify compounds which are either able to modulate the induction of viral latency in the aforementioned cell cultures, or which are able to retain the viruses in the aforementioned cells in their latent form. Other aspects of the invention are directed to antiviral compounds identified using the models and methods of the present invention, as well as to the use thereof in treating latent infections such as for example latent Herpes Simplex Virus (HSV) infections.08-26-2010
20100216118Method of Detection/Extraction, and Related Detection/Extraction Device - A method that uses an L-α-dipalmitoleoyl-phosphatidylcholine (DPPC) surfactant based device that reacts with a substance in a known manner, to detect a substance of interest or to extract a substance of interest from a material is provided. The principles of the present invention are particularly useful in detecting/measuring a substance that is harmful to a human, and also to extracting NACL from saltwater.08-26-2010
20100240026KIT AND METHOD FOR DETECTING BOVINE VIRAL DIARRHEA VIRUS IN TISSUE SAMPLES - The present invention relates to the method for treatment of tissue samples with proteolytic/histolytic additive collagenase or other similar protease prior to testing with an antigen capture immunoassay to identify cattle infected with Bovine Viral Diarrhea Virus (BVDV). The use of collagenase or other similar protease in antigen extraction step of the assay drastically increases accuracy of the assay, thus it allows for a more effective, reliable, quick, and cost effective way of identifying and thereby removing infected cattle and/or other animals from an otherwise uninfected herd.09-23-2010
20100227310FLOW CYTOMETRY METHODS AND IMMUNODIAGNOSTICS WITH MASS SENSITIVE READOUT - Mass cytometry method. In one aspect, the method includes providing a sample having at least one cell type and mixing the sample with material such as nanoparticles functionalized with affinity molecules for the at least one cell type. The sample is transported through a suspended microchannel resonator to record a mass histogram and a cell count for the at least one cell type is determined from the histogram.09-09-2010
20100227311TISSUE CULTURE SYSTEM FOR PRODUCTION OF HEPATITIS C VIRUS - A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 209-09-2010
20100255459CONTROL FOR VIRUS DETECTION ASSAYS BASED ON REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTION - A method for the accurate quantification of a virus in a sample, by reverse transcription polymerase chain reaction (RT-PCR), includes: adding a known concentration of a Mengo virus to the sample as control for the nucleic acids extraction step, the Mengo virus being a mutant strain with the same growth properties than those of the wild-type Mengo virus, and with non-pathogenic capacity; performing a nucleic acids extraction to obtain a nucleic acids suspension; analyzing the nucleic acids suspension by RT-PCR with primers and probes; quantifying the amplimers resulting from the RT-PCR; determining the concentration of the virus in the sample by comparison of the value obtained with an appropriate standard curve; and determining the concentration of the Mengo virus by comparison of the value obtained with an appropriate standard curve.10-07-2010
20100240025Bacteriophage with Enhanced Lytic Activity - This invention encompasses an isolated 09-23-2010
20100240024Assays And Kits For Determining HIV-1 Tropism - The present invention relates to assays and kits for determining tropism of HIV-1 for a chemokine receptor in a test sample obtained from a subject.09-23-2010
20080274451Body for flow-through cells and the use thereof - A system of flow-through cells is obtained by assembling a body with a base plate. The body has a first spring element and a first stop, disposed on opposite end sections of the body, at least one second spring element and a corresponding second stop, disposed on opposite faces of the body, and at least one support element and at least one retaining element, which are adapted for the exact positioning of the body in the receiving openings of a support in three directions.11-06-2008
20100159442MAGNETIC RECOGNITION SYSTEM - Provided is a label for an analyte, which label is attached to a magnetic or magnetizable substance, the label comprising: (a) a recognition moiety for attaching the label to the analyte; and (b) a moiety for binding or encapsulating the magnetic or magnetizable substance; wherein the moiety for binding or encapsulating the magnetic or magnetizable substance comprises a metal-binding protein, polypeptide, or peptide.06-24-2010
20100240027Surrogate Markers for Viral Infections and Other Inflammatory Responses - Compositions and methods for the detection, diagnosis and treatment of BVDV and other viruses are provided.09-23-2010
20130216996ELECTRICALLY CONDUCTIVE POLYMER NANOWIRES WITH INCORPORATED VIRUSES - Grafting M13 bacteriophage into an array of poly(3,4-ethylenedioxythiophene) (PEDOT) nanowires generated hybrids of conducting polymers and replicable genetic packages (rgps) such as viruses. The incorporation of rgps into the polymeric backbone of PEDOT occurs during electropolymerization via lithographically patterned nanowire electrodeposition (LPNE). The resultant arrays of rgps-PEDOT nanowires enable real-time, reagent-free electrochemical biosensing of analytes in physiologically relevant buffers.08-22-2013
20130216998METHOD FOR LINKING POINT OF CARE RAPID DIAGNOSTIC TESTING RESULTS TO LABORATORY-BASED METHODS - A method for using a single sample suspected of containing a microorganism for both a local rapid test immunoassay and a remote laboratory test. The sample is collected from a patient at a physician's office or from the environment to be tested. The sample is collected using a swab or other implement, combined with a rapid test processing reagent and a portion of the processed sample is used for the local rapid test. The rapid test processing reagent typically consists of a buffer, a salt, and a detergent and is compatible with the local rapid test immunoassay. Only a portion of the processed sample is used for the local rapid test, leaving a remaining portion of the processed sample to be used in a remote laboratory assay. At least some of the remaining portion of the processed sample is combined with a stabilization agent that preserves at least the nucleic acid in the processed sample for the remote laboratory assay.08-22-2013
20130217000METHOD FOR CHARACTERISING A BIOLOGICALLY ACTIVE BIOCHEMICAL ELEMENT BY ANALYSING LOW FREQUENCY ELECTROMAGNETIC SIGNALS - A method for characterizing a biologically active biochemical element in a sample by prefiltering the sample and analyzing low frequency electromagnetic signals transmitted by the prefiltered solution. The prefiltering may be through a 150 nm or less filter. The prefiltering may be subsequent to a dilution, e.g., between 1008-22-2013
20100255460DEVICE FOR BIOCHEMICAL PROCESSING AND ANALYSIS OF A SAMPLE - A device for biochemical processing and analysis of a measured sample volume of a sample is described. The device is characterised in that it consists of a sealed vessel (10-07-2010
20100143889RHABDOVIRIDAE VIRUS PREPARATIONS - This document involves methods and materials related to obtaining Rhabdoviridae virus preparations. For example, methods and materials for obtaining large volume, high titer, high purity preparations of Rhabdoviridae viruses (e.g., VSV) with low or non-existent levels of contaminants are provided.06-10-2010
20100151443MICROFLUID SYSTEM AND METHOD TO TEST FOR TARGET MOLECULES IN A BIOLOGICAL SAMPLE - A system and method to test for the presence of target molecules in a biological test sample includes test molecules, a microfluidic chip, and irradiating and detection devices. The test molecules include bio-recognition molecules conjugable with the target molecules, and the corresponding conjugates. The microfluidic chip includes sample channels and flow focusing channels adjoining the sample channels. A buffer exiting from the focusing channels directs a single-file stream of the test molecules through one of the sample channels. The irradiating device delivers radiation for absorption by the test molecules in the single-file stream. After absorption, the test molecules emit fluorescence of a distinct fluorescent spectrum for each of the conjugates. The detection device monitors identifies the presence of the conjugates by monitoring for the distinct fluorescent spectrum. Thus, the test system and method identifies the presence of the target molecules in the test sample.06-17-2010
20100143883CAPTURE OF MYCOBACTERIA LIKE MICRO-ORGANISMS - A method for the capture from a sample of micro-organisms having a hydrophobic surface, which method includes contacting the micro-organisms with a capture reagent, which capture reagent has both a hydrophobic character whereby the capture reagent binds the micro-organisms by hydrophobic interaction therewith and a polar character, the capture reagent either being present on a surface and capturing the micro-organisms thereto, or being present in solution, the method then further including capturing the micro-organisms to a surface by binding the capture reagent to the surface by polar interaction between the surface and the capture reagent.06-10-2010
20100216120Rapid infectious virus assay - An assay to detect or quantify HIV infectious virus from clinically relevant cellular compartments, or reservoirs, in anti-retrovirally treated patients whose viral levels are low to undetectable is described. The method detects infectious virus in patients whose plasma viral loads are considered to be below the limit of current PCR based detection methods and thereby is more relevant for guiding treatment. A further advantage is that the method allows viral tropism to be directly determined in the presence of specific inhibitors of CCR5 or CXCR4. Drug sensitivity can also be directly determined without the need to laboriously recover patient virus by culture for extended time periods, a method that allows for viral selection or evolution, which is not desirable. Patient cells, like the blood mononuclear cells, or monocytes, are isolated and cultured in the presence of cytokines like CSF-1/M-CSF or GM-CSF. to promote their differentiation. Cells are activated with lectins, mitogenic antibodies, phorbol esters, Toll Receptor stimulation or inducers of NfKb or NFAT, followed by agents that induce viral release, like ATP or stimulation of autophagy with LiCl, spermidine, or rapamycin. A key aspect of the invention relates to the timing of the addition of these agents for optimal viral release. A further aspect of the invention relates to sensitive detection of released virus which can be accomplished by adding so-called reporter cells which are under control of the HIV TAT protein so that upon infection these cells synthesize proteins or enzymes that allow for the measurement of infectious particles.08-26-2010
20080318205Hiv Type and Subtype Detection - The present invention relates to the detection of HIV by amplification and PCR-based methods.12-25-2008
20100143885DETECTION OF HUMAN PAPILLOMAVIRUS - There is provided an in vitro method of detecting human papillomavirus nucleic acid in a sample, comprising: (a) contacting said sample with forward and reverse oligonucleotide primers, wherein said primers bind to target sites in the human papillomavirus L1 gene, or the complement thereof, under conditions suitable to promote amplification of a portion of said human papillomavirus L1 gene or complement, thereby generating an amplicon; (b) contacting said amplicon with a probe, wherein the probe binds to a target site within said amplicon; and (c) detecting binding of said probe to said amplicon; wherein said forward primer binds to a target site having the sequence SEQ ID NO: 1; and wherein said reverse primer binds to a target site having the sequence SEQ ID NO: 2.06-10-2010
20100143891Method for the Rapid Diagnosis of Targets in Human Body Fluids - More particularly, the present invention relates to a method for the detection of a target, e.g. pathogen in a human body fluid wherein a body fluid sample is collected with a swab member.06-10-2010
20100136514INFECTIOUS CLONE OF HUMAN PARVOVIRUS B19 AND METHODS - The invention relates to infectious clones of parvovirus B19, methods of cloning infectious B19 clones, and methods of cloning viral genomes that have secondary DNA structures that are unstable in bacterial cells. A B19 infectious clone and methods of producing B19 infectious clones are useful for producing infectious virus. Infectious virus is useful for identifying and developing therapeutically effective compositions for treatment and/or prevention of human parvovirus B19 infections.06-03-2010
20100136515COMPOSITIONS FOR USE IN IDENTIFICATION OF PAPILLOMAVIRUS - The present invention relates generally to identification of HPV, and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.06-03-2010
20100136516System and method for detection of HIV integrase variants - An embodiment of a method for detecting low frequency occurrence of one or more HIV sequence variants associated with integrase is described that comprises the steps of: (a) generating a cDNA species from a plurality of RNA molecules in an HIV sample population; (b) amplifying a plurality of first amplicons from the cDNA species, wherein each first amplicon is amplified with a pair of nucleic acid primers; (c) clonally amplifying the amplified copies of the first amplicons to produce a plurality of second amplicons; (d) determining a nucleic acid sequence composition of the second amplicons; (e) detecting one or more sequence variants that occur at a frequency of 5% or less in the nucleic acid sequence composition of the second amplicons; and (f) correlating the detected sequence variants with variation associated with HIV integrase.06-03-2010
20100136519Determination of a specific immunoglobulin using multiple antigens - The invention concerns a process for the immunological determination of a specific antibody in a fluid sample. The process involves incubating the fluid sample in the presence of a solid phase with two antigens directed against the antibody whose presence is to be determined; the first antigen carries at least one marker group, while the second is either (a) bonded to the solid phase or (b) present in a form in which it can bond with the solid phase, and betrays the presence of the antibody being sought by showing the presence of the marker group in the solid phase and/or in the fluid phase. The proposed process is characterised by the fact that at least one of the two antigens has several epitopic regions which react with the antibody to be determined.06-03-2010
20100136518ANTIBODIES USEFUL FOR THERAPY AND DIAGNOSIS OF CANCER - The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.06-03-2010
20100136513Assay for sars coronavirus by amplification and detection of nucleocapsid rna sequence - Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the nucleocapsid gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARSCoV infection.06-03-2010
20090042182DETECTION OF BOVINE VIRAL DIARRHEA VIRUS IN TISSUE SAMPLES - The present invention relates to a method of detecting whether a target animal is Bovine Viral Diarrhea Virus (BVDV) positive or negative by determining whether a gp48 protein-specific reagent binds to a gp48 Bovine Viral Diarrhea Virus protein or protein fragment, which retains antigenic specificity, from a target animal's tissue sample.02-12-2009
20090075250Environmental Sampling and Testing Method - Provided is sampling and testing device for the detection of specific molds, allergens, viruses, bacteria, fungi, and other protein containing substances. Embodiments of the device include a sampling member slideably engaged with a base that contains a lateral flow strip adapted to detect specific analytes of interest. The sampling member defines a solvent reservoir that stores an elution solvent in a fluid-tight manner before the device is used to sample and test environmental surfaces. During slideable withdrawal of the sampling member from the base, the elution solvent stored in the reservoir is automatically released to a wick assembly of the sampling member. The wick assembly includes a wick adapted to receive, distribute, and retain the elution solvent. After a user samples an environmental surface for an analyte of interest with the elution solvent wetted wick, the sampling member is returned to the base where the wick contacts the lateral flow strip contained in the base. The wick transfers at least a portion of analyte and the elution solvent to the lateral flow strip for the calorimetric detection of specific allergens, viruses, bacteria, and other protein containing substances in the sample. The calorimetric results of the test are displayed through a window in the base.03-19-2009
20120141976METHOD FOR DETECTING VIABLE CELLS IN A SAMPLE BY USING A VIRUS - A method for detecting viable cells such as bacterial cells, within a sample, said method comprising (i) incubating said sample with a virus which is able to infect said cells under conditions which allow said virus to infect and replicate within any such cells which are viable; and (ii) detecting any nucleic acid obtained by replication of the virus in said cell.06-07-2012
20120034599SCREENING SYSTEMS UTILIZING RTP801 - RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801.02-09-2012
20090053691Cell Line and Methods for Determining Viral Titer - The present invention relates to cells, methods, compositions and kits for determining the concentration of virus in a stock, i.e., determining the titer of a viral stock.02-26-2009
20100035230METHODS AND AGENTS FOR DETECTING PARECHOVIRUS - The present disclosure provides methods that permit detection of all known species of 02-11-2010
20090170072DEVICE FOR COLLECTION AND ASSAY OF ORAL FLUIDS - A device for collecting and transporting aqueous fluid from the oral cavity to a lateral chromatographic strip for test is disclosed. The lateral chromatographic strip is placed within and extend along a cavity defined in a housing. At least one inspection site to the lateral chromatographic strip is provided to enable inspection of selected sites on the lateral chromatographic strip for test results. A porous wick material protrudes from the housing to a collection site exterior of the housing at one end and communicates to the lateral chromatographic strip at the other end. The porous wick material has particulate construction, the particles adsorbing aqueous oral fluid to transport the fluid from the mouth to the lateral chromatographic strip without substantial absorption. The particles of the porous wick material are bound together to define a continuous interstitial volume for the flow of oral fluid to be transported and are treated to be hydrophilic to the adsorbed oral fluids. The porous wick material readily releases oral fluid to the lateral chromatographic strip. Prevention of reverse flow to the oral cavity from the lateral chromatographic strip naturally occurs due to the circuitous flow path of the porous wick material. A bite plate is coupled to the housing and insertable between the teeth of the patient to position the porous wick in the oral cavity for collecting the oral fluid. The bite plate is typically held in place by the occlusal force of the teeth, preferably the molars and/or the bicuspids, to position the porous wick in the buccal space. By observing the lateral chromatographic strip while the test device is in the mouth immediate test results are obtained.07-02-2009
20110027774HIGHLY SENSITIVE METHOD FOR DETECTION OF VIRAL HIV DNA REMAINING AFTER ANTIRETROVIRAL THERAPY OF AIDS PATIENTS - Methods for detecting polynucleotides, especially the DNA replicated from samples obtained from subjects infected with pathogenic viruses such as human immunodefiency virus, by detecting electromagnetic signals (“EMS”) emitted by such polynucleotides, and methods for improving the sensitivity of the polymerase chain reaction (“PCR”).02-03-2011
20090148832Compositions and Methods for Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes - The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of using the cell line, or HCV 1a virus particles derived from said cell line, to screen for potential therapeutic agents which interfere with HCV 1a virus propagation to treat hepatic disease.06-11-2009
20090111091SPECIMEN PRETREATMENT LIQUID, KIT FOR MEASURING VIRUS, AND METHOD FOR DETECTING VIRUS - The invention provides a pretreatment liquid for preparing a sample for measuring a virus included in rhinorrhea or sputum by an immunoassay method using an antibody specifically binding to the virus, comprising a protease inhibitor for inhibiting an influence of a protease to the virus, as well as a virus measurement kit and a virus detection method using the specimen pretreatment liquid.04-30-2009
20090111089PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES - Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed.04-30-2009
20080274449ASSAY FOR DETECTION OF HUMAN PARVOVIRUS B19 NUCLEIC ACID - Nucleic acid oligomers specific for human parvovirus B19 genomic DNA are disclosed. An assay for amplifying and detecting human parvovirus B19 nucleic acid in biological specimens is disclosed. Compositions for detecting the presence of parvovirus B19 genomic DNA in human biological specimens are disclosed.11-06-2008
20100184017DIFFERENTIAL AMPLIFICATION OF MUTANT NUCLEIC ACIDS BY PCR IN A MIXTURE OF NUCLEIC ACIDS - A method for enriching a mutant nucleic acid in a mixture of nucleic acids, wherein the method comprises: (a) providing a nucleic acid mixture comprising a parental nucleic acid and a mutant nucleic acid of the parental nucleic acid; and (b) amplifying the nucleic acids in the nucleic acid mixture by polymerase chain reaction (PCR); wherein the mutant nucleic acid is a G→A mutant of the parental nucleic acid, which pairs with a fully complementary nucleic acid sequence to form an AT-rich nucleic acid variant of the parental nucleic acid; and wherein the AT-rich nucleic acid variant is denatured and selectively amplified by carrying out PCR using a denaturation temperature 1-3° C. lower than the lowest denaturation temperature (T07-22-2010
20090111088RAPID ASSESSMENT OF UPPER RESPIRATORY CONDITIONS - A method for rapidly assessing upper respiratory conditions is provided. More specifically, the method involves contacting a sample obtained from the upper respiratory tract of a host with a test strip. The test strip contains an indicator that provides a broad spectrum response in the presence of bacteria, mold, yeast, or other microorganisms that is different than its response in the presence of viruses. This allows for a rapid and simple assessment as to whether the test sample is infected with a virus or some other microorganism. To help a clinician identify the proper course of treatment, it may also be desirable to obtain further information about the particular type of microorganism present. In this regard, the test strip contains any array of one or more differentiating indicators that provides a certain spectral response in the presence of different types of microorganisms. For example, the array may provide a certain spectral response in the presence of gram-negative bacteria, but a completely different spectral response in the presence of gram-positive bacteria. Likewise, the array may provide a certain spectral response in the presence of Rhinoviruses (associated with the common cold), but a different response in the presence of Influenza viruses. Detection of the spectral response provided by the indicators may thus allow for rapid differentiation between different types of microorganisms.04-30-2009
20090111092DETERMINATION OF HEPATITIS C VIRUS GENOTYPE - The present invention provides compositions and methods for the detection and characterization of HCV sequences. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, to determine HCV genotype.04-30-2009
20100297603ANALYTE-RELEASING BEADS AND USE THEREOF IN QUANTITATIVE ELISPOT OR FLUORISPOT ASSAY - The present invention relates to a method of quantifying analyte secreted by a cell or released from a drug delivery vehicle, typically by ELISpot or fluorispot assay. Quantification is possible through the use of an analyte-releasing reagent that includes a bead and the analyte releasably bound to the bead, or a container pre-spotted with analyte released from the reagent. The reagent or pre-spotted containers can be used to provide a standard curve for release of the analyte. By detecting analyte secreted by one or more cells or drug released by a drug delivery vehicle, and comparing the detected analyte to the standard curve, it is possible to quantify the amount of analyte released by the one or more cells or drug released by the drug delivery vehicle. Kits and reagents for practicing the methods of the present invention are also disclosed.11-25-2010
20100297608Systems and Methods for CMOS-Compatible Silicon Nano-Wire Sensors with Biochemical and Cellular Interfaces - The systems and methods described herein include a sensor for suitable for sensing chemical and biological substances. The sensor comprises a semiconductor layer formed in or on a substrate and a channel having nano-scale dimensions formed in the semiconductor layer, where the structure creates an electrically conducting pathway between a first contact and a second contact on the semiconductor layer. In certain preferred embodiments, the nano-scale channel has a trapezoidal cross-section with an effective width and exposed lateral faces, where the effective width is selected to have same order of magnitude as a Debye length (L11-25-2010
20110117541Method for Screening of Agents for the Prevention of Hepatitis C Virus Infection with Cell Culture Tool - The invention relates to an improved method of screening of anti-HCV agents that may have an efficacy for prevention of hepatitis C virus. The method involves the isolation and cryopreservation of HCV-infected hepatocytes from multiple infected individuals. The isolated and cryopreserved hepatocytes are stored in a cryopreservation bank made up of HCV-infected hepatocytes representing the different genotypes of HCV. These stored hepatocytes then are co-cultured in a culture medium with uninfected hepatocytes, and anti-HCV screening of the hepatocytes is done by subjecting HCV infected hepatocytes and uninfected hepatocytes in parallel to the actions of different anti-HCV compounds at various concentrations. An effective anti-HCV agent will lead to prevention of increase in concentration of HCV content of uninfected cells in the co-culture.05-19-2011
20110117538BIOREACTORS FOR FERMENTATION AND RELATED METHODS - Bioreactors suitable for housing a predetermined volume of liquid comprising nutrient medium and biological culture comprising: (a) a container having at least one interior wall; (b) at least one nutrient medium inlet; (c) at least one liquid outlet; (d) at least one gas inlet; (e) at least one gas outlet; and (f) at least one cylindrical sparging filter attached to the at least one gas inlet, wherein the sparging filter comprises a plurality of pores along its axis which permit gas to be emitted radially from the sparging filter into the liquid, wherein the diameter of the plurality of pores does not exceed about 50 μm, and wherein the orientation of the at least one sparging filter within the container provides for immersion of the plurality of pores within the liquid and substantially uniform distribution of emitted gas throughout the liquid, and related methods of using said bioreactors to prepare various biological products.05-19-2011
20130130235PROBES AND PRIMERS FOR DETECTION OF DENGUE - The present disclosure gives description of a method used for the detection and quantification of dengue viral infection caused by dengue virus using nucleic acids isolated from blood, plasma or serum samples by employing Oligonucleotide probes. The method employed here for detection is by Real time PCR. The instant disclosure also provides for primers, probes, PCR Reaction mixture and kit thereof.05-23-2013
20100297605Screening method for prophylactic and/or therapeutic agent for disease accompanied by hepatitis c - Provided is a screening method being able to screen an agent useful for prevention and/or treatment of hepatitis C virus-related disease easily and efficiently and a prophylactic and/or therapeutic agent for hepatitis C virus-related disease obtained by the method.11-25-2010
20100297604METHODS AND REAGENTS FOR VIRUS ISOLATION AND DETECTION - The present invention relates to reagents and methods used in virus isolation and analysis.11-25-2010
20100297609VIVO ISOTOPIC LABELING METHOD FOR QUANTITATIVE GLYCOMICS - The present invention relates to a method of isotopically labeling glycans and in facilitating high throughput quantitative/comparative analysis of glycomic compositions of biological cells. The method is applicable inter alia for identifying differentiated cells and their glycomic characteristics, differentiation conditions, disease and/or therapeutic progression, diagnosing disease states, determining drug activity, establishing manufacturing efficiencies and for determining the half-life of glycans in cells.11-25-2010
20100304358METHODS OF IDENTIFYING BIOLOGICAL TARGETS AND INSTRUMENTATION TO IDENTIFY BIOLOGICAL TARGETS - Methods of measuring and/or detecting biological targets, methods of distinguishing among the same type of biological target, single-molecule detection systems, fluorescent/biological target complexes, methods of using fluorescent/biological target complexes, and the like are disclosed.12-02-2010
20080227084ANALYSIS OF HIV-1 CORECEPTOR USE IN THE CLINICAL CARE OF HIV-1-INFECTED PATIENTS - A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time.09-18-2008
20110236881MODULATION OF INFLUENZA VIRUS - The present invention provides, among other things, methods for the identification of compounds that are capable of modulating the activity of the influenza A virus. For example, the present methods provide platforms for identifying small molecule inhibitors that target the proton transport pathway defined at least in part by two or more of the highly conserved channel residues 27, 30, 31, 34, 37, 41, 44, and 45 of the influenza A M2 protein. In one aspect, the present invention is directed to methods comprising comparing spatial models of a plurality of test compounds with the spatial model of the pathway defined by at least two residues from among residues 27, 30, 31, 34, 37 or 41, 44, and 45 on one or more subunits of the M2 transmembrane protein of the influenza A virus to determine the spatial complementarity of each of the test compounds with the pathway; assessing the ability of the test compounds to bind to the pathway; and, based on the assessed ability of the test compounds to bind the pathway, determining the compound that modulates the activity of influenza A.09-29-2011
20100304360GOLD NANOPARTICLE HPV GENOTYPING SYSTEM AND ASSAY - The invention provides oligonucleotides, kits and methods for genotyping HPV.12-02-2010
20100304364Compositions and methods for monosynaptic transport - Disclosed herein are methods of expressing a heterologous nucleic acid sequence, such as a sequence encoding a detectable protein, in a primary neuron (or plurality of primary neurons) and other neurons that are monosynaptically connected to the primary neuron (or plurality of primary neurons). Such methods involve viruses (such as, rabies viruses) defective for transsynaptic transport (TST-defective virus) and in situ complementation of the defect in a manner that permits only monosynaptic transport of the TST-defective virus. The TST-defective virus and, therefore, any heterologous nucleic acid sequence it carries in its genome, are not transmitted to neurons that are not monosynaptically connected to the primary neuron (or plurality of primary neurons). Also disclosed are methods of targeting a TST-defective virus to a genetically defined primary neuron (or plurality of primary neurons). The disclosed technology enables far more specific labelling and/or manipulation of neural networks than has previously been possible.12-02-2010
20100304361METHOD AND DEVICE FOR MONITORING A THERAPEUTIC TREATMENT REGIME - A method for monitoring a therapeutic treatment regime in an individual having a disease, comprises: providing at a first location a solid substrate capable of immobilising a biomarker characteristic of the disease and a therapeutic compound in the biological sample, contacting the biological sample with the solid substrate to immobilise the biomarker and the therapeutic compound; transferring the solid substrate with the immobilised biomarker and therapeutic compound to a second location; performing an extraction step on the solid substrate to extract the biomarker and the therapeutic compound; performing a first detection assay to detect and/or quantify the biomarker, performing a second detection assay to quantify the therapeutic compound; and correlating the detection and/or quantity of the biomarker with the disease state of the individual, and comparing the quantity of the therapeutic compound with a target level for treatment of the disease, thereby to assess the efficacy of the treatment regime.12-02-2010
20100311038NEAR FULL-GENOME ASSAY OF HCV DRUG RESISTANCE - The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.12-09-2010
20110111392INTEGRATED ENHANCED CHEMILUMINESCENCE BIOSENSORS - A method and apparatus for determining the concentration of an analyte in a sample is provided. This method involves combining enhanced chemiluminescence with microchip capillary electrophoresis or microchip liquid chromatography.05-12-2011
20110111389RAPID GENOTYPING ANALYSIS FOR HUMAN PAPILLOMAVIRUS AND THE DEVICE THEREOF - The present invention discloses methods and devices for rapid genotyping. In one embodiment, the present invention is applied to human papillomavirus (HPV) genotyping, comprising the use of viral genotype-specific-oligonucleotide probes, reversed-dot-blotting genotype array format and flow through hybridization process, thereby providing a more efficient, faster and less expensive method for HPV genotyping. The genotyping method further comprises the use of generic probes to expand the detection of HPV genotypes.05-12-2011
20110111387HIGH-EFFICIENCY VIABLE SAMPLER FOR ULTRAFINE BIOAEROSOLS - Exemplary embodiments provide bioaerosol detection systems and methods for detecting bioaerosols. In one embodiment, the bioaerosol detection system can include a humidifier to increase the humidity of a continuously flowing sample volume of a bioaerosol sample using a biologically compatible liquid medium, and an amplifier to deposit vapor on the bioaerosol sample for a particle size amplification process. Bioaerosol(s) can thus be detected and sampled while simultaneously maintaining their viability. The disclosed bioaerosol detection systems and the methods can provide high efficiency for sampling and detecting ultrafine bioaerosol(s) such as viruses and proteins, which can be smaller than 0.3 μm in diameter and can be as small as 20 nm.05-12-2011
20090068636VIRAL PROTEIN - The present invention is directed to an isolated polypeptide containing SEQ ID NO: 1 or an immunogenic fragment thereof. Also disclosed is an isolated nucleic acid encoding the polypeptide or containing a sequence at least 70% identical to SEQ ID NO: 3. Within the scope of this invention are related expression vectors, host cells, and antibodies. Also disclosed are methods of producing the polypeptide, diagnosing coronavirus infection, and identifying a test compound for treating coronavirus infection.03-12-2009
20090068640METHODS FOR DETECTING AND INACTIVATING A PRION - A method for the isolation or detection of a prion in a sample is disclosed. Also disclosed are methods for the disinfection and/or decontamination and/or inactivation of TSE infectivity.03-12-2009
20090068635INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME - Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.03-12-2009
20090035749ANALYSIS OF HIV-1 CORECEPTOR USE IN THE CLINICAL CARE OF HIV-1 INFECTED PATIENTS - A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. 02-05-2009
20090035748BROMELAIN AS A CLINICAL SAMPLE PRE-TREATMENT, LYSIS AGENT AND NUCLEASE INHIBITOR - This invention generally relates to the use of the proteolytic enzyme bromelain for treating samples for diagnostic assays. More specifically, the present invention relates to the use of bromelain in methods for pre-treating clinical samples primarily for the purpose of obtaining extractable and amplifiable DNA or RNA from prokaryotic or eukaryotic cells and/or viruses. The present methods also relate to using bromelain as a nuclease inhibitor. The use of bromelain as a nuclease inhibitor is useful in applications where the destructive nature of nucleases are detrimental to downstream applications. This invention also relates to the use of bromelain as a lysis agent for samples to be used, for example, in a molecular based diagnostic assay. The present methods include treating a sample which contains bacteria, viruses, host cells, fungi or parasites with bromelain, typically extracting nucleic acid from the sample, and subjecting the sample to a nucleic acid-based diagnostic assay.02-05-2009
20110008765USE OF THREE-DIMENSIONAL MICROFABRICATED TISSUE ENGINEERED SYSTEMS FOR PHARMACOLOGIC APPLICATIONS - The present invention generally relates to a combination of the fields of tissue engineering, drug discovery and drug development. It more specifically provides new methods and materials for testing the efficacy and safety of experimental drugs, defining the metabolic pathways of experimental drugs and characterizing the properties (e.g., side effects, new uses) of existing drugs. Preferably, evaluation is carried out in three-dimensional tissue-engineered systems, wherein drug toxicity, metabolism, interaction and/or efficacy can be determined.01-13-2011
20110008768OLIGONUCLEOTIDES AND METHODS FOR DETECTION OF WEST NILE VIRUS - The invention provides methods of detecting West Nile virus and oligonucleotide reagents derived from a West Nile virus consensus sequence that are useful in the methods of the invention.01-13-2011
20110111391NEWLY IDENTIFIED HUMAN RHINOVIRUS OF HRV-C AND METHODS AND KITS FOR DETECTING HRV-CS - The characterization of a new strain of human rhinovirus of genetic group C(HRV-C) as well as methods and kits for detecting the presence of HRV-C by PCR amplification are provided.05-12-2011
20110111386CERVICAL CELL COLLECTION METHOD - The present invention relates to sample collection and preservation. More specifically, the invention provides methods for the collection and preservation of at least one nucleic acid molecule in a test sample comprising one or more cells or tissues obtained from the cervix of a subject.05-12-2011
20110020785Diagnostic Information Generation and Use - This invention relates generally to a process for producing machine readable contextual diagnostic information and use of contextual diagnostic information for generating tangible and useful results. The process provides the highest level of integration of diagnostic information collected in a distributed or centralized system comprising diagnostic devices and a global computer network. More particularly, in certain embodiments, contextual diagnostic information are used in specific diagnostic related applications and business models including ecommerce.01-27-2011
20110033836METHODS FOR DETERMINING THE PRESENCE OF ANTIBODIES BLOCKING VIRAL INFECTION - The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.02-10-2011
20110033839Methods of Detecting Signatures of Disease or Conditions in Bodily Fluids - Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided. Methods and compositions for diagnosing the presence of an infectious agent in an individual and/or for identifying an infectious agent-specific signature in an infected individual are provided. Methods and compositions for diagnosing the presence of a disease in an individual are also provided. Methods and compositions for identifying a disease-specific signature in an individual having the disease are also provided.02-10-2011
20110039254Chromosomal Insertion of Gfp Into Bacteria For Quality Control - An isolated mutated green fluorescent protein (gfp) gene for chromosomal insertion into a bacterium, wherein the gene is capable of being expressed in bacteria and produce sufficient fluorescence under illumination from a UV lamp in a bacterial colony to be seen by the naked eye. A gene cassette for inserting a gene into a chromosome.02-17-2011
20110045458Detection of Enterovirus - This document describes methods and materials relating to viral diagnostics, and more particularly to the detection of enterovirus. For example, primers and probes for the detection of enterovirus are provided. Articles of manufacture containing such primers and probes for detecting enterovirus are further provided.02-24-2011
20110045457ASSAYS FOR ADSORBED INFLUENZA VACCINES - Influenza hemagglutinin (HA) binds to aluminium salt adjuvants and cannot easily be directly assayed directly a single radial immunodiffusion (SRID) test. The invention modifies the SRID protocol for an adsorbed antigen by including a step in which antigen is desorbed prior to diffusion.02-24-2011
20110053139Detection of bioagents using a shear horizontal surface acoustic wave biosensor - Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In preferred embodiments, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV), a member of the genus Hantavirus, family Bunyaviridae, negative-stranded RNA viruses. Rapid detection (within seconds) of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, although the sensor was approximately 50×1003-03-2011
20100151445Multiplex Method for Detecting an Infection - The invention relates to a method for the in vitro diagnostic detection of an infection with a microorganism, comprising placing a biological sample, in a single assay receptacle, in the presence of particles, each carrying at least one specific detectable physical parameter, and belonging to at least two different groups, one of the groups carrying an anti-IgM capture antibody and the other group carrying a capture antigen derived from said microorganism.06-17-2010
20090275013Method for preparing a monoclonal antibody to the common epitope of nonstructural NSs protein of watermelon silver mottle virus and assay for detection of serological related species in the genus tospovirus with the monoclonal antibody - The invention is an assay for detection of Watermelon silver mottle virus (WSMoV)-serogroup tospoviruses using a monoclonal antibody and a method for preparing the monoclonal antibody. A hybridoma cell line that produces a monoclonal antibody against the NSs proteins of WSMoV-serogroup tospoviruses was produced. The hybridoma cell line produces a monoclonal antibody binding with peptide SEQ ID No. 19.11-05-2009
20110212435Antimicrobial Compounds - The compounds disclosed herein are isoxazole derivatives that are useful as antimicrobial compounds, particularly as anti-bacterial compounds. The disclosed methods comprise incubating at least two different substrates in the presence of at least one oxygenase to provide the disclosed compounds, or to prepare and identify compounds that have antimicrobial activity.09-01-2011
20090311670APPARATUS AND METHOD FOR MEASURING CONCENTRATION OF MOLECULES THROUGH A BARRIER - An apparatus and method for detecting the presence and measuring the concentrations of molecules through a barrier and/or at a distance utilizes the principle of chemical/electrostatic attraction (hereinafter “affinity”), i.e., the affinity between charged atoms and molecules that cause their chemical interactions and reactions, to infer, based on the behavior of molecules on one side of the barrier, the presence and concentration of corresponding molecules on the other side of the barrier. The invention is useful, by way of example and not limitation, in non-invasively measuring glucose levels of diabetic patients.12-17-2009
20090087831METHODS FOR EVALUATING A BACTERIOPHAGE PREPARATION - A quality assurance/quality control paradigm for bacteriophage is provided.04-02-2009
20110212434NOVEL HIV-BASED RECOMBINANT VIRAL CLONES AND USE THEREOF IN ANALYTICAL METHODS - The present invention refers to HIV-based recombinant viral clones that possess the general structure represented in FIG. 09-01-2011
20100227314METHOD OF IDENTIFICATION OF GENOTYPE AND SUBTYPE OF HEPATITIS C VIRUS ON A BIOLOGICAL MICROCHIP - The invention relates to molecular biology, virology and medicine and provides a method for identifying a genotype and a subtype of Hepatitis C virus (HCV) on the basis of the analysis of an HCV genome NS5B region using a differentiating biochip. The method of the present invention is based on a two-step PCR, with a fluorescent labeled, preferably single-stranded, NS5B region fragment obtaining, followed by the hybridization of this fragment on a biochip comprising a set of specific discriminating oligonucleotides. HCV genotype and subtype identification is carried out by defining the specific sequences of the segments of the NS5B region fragment. The invention allows one to conduct an assay precisely from a clinical specimen, to determine 6 genotypes and 36 subtypes of hepatitis C virus, including the most virulent and drug resistant forms, and to reduce the cost of assay. Also, the invention deals with a biochip, a design method and a set of oligonucleotide probes usable under the implementation of the method.09-09-2010
20100227312Particle Adhesion Assay for Microfluidic Bifurcations - A method for characterizing particle adhesion in microfluidic bifurcations and junctions comprises at least one idealized bifurcation or junction. Multiple bifurcations and/or junctions can be combined on a single microfluidic chip to create microfluidic networks configured for assays specifically to characterize particle interactions at junctions or to screen particles for desired interactions with microfluidic bifurcations and/or junctions.09-09-2010
20110236880Potentiated Biocidal Compositions and Methods of Use - The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g., a microbial contact kill time of 5 minutes or less. Further, the present technology provides a method of determining biocidally effective concentrations of biocidal compositions comprising at least one biocidal agent and at least one potentiator system.09-29-2011
20110236879METHODS AND COMPOSITIONS FOR ANALYTE DETECTION - The present invention is directed to methods and apparatus for detection of one or more analytes. Analytes include agents or components of infectious agents such as pathogenic virus, as well as enzymes, proteins and biomarkers.09-29-2011
20090029349Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays - Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.01-29-2009
20110086340METHODS, DEVICES, KITS AND COMPOSITIONS FOR DETECTING ROUNDWORM - Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a mammalian sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.04-14-2011
20110136100NON-HUMAN ANIMAL DISEASE MODEL FOR HEPATITIS B VIRUS-ASSOCIATED DISEASE - A non-human animal disease model for hepatitis B virus-associated liver disease is disclosed. The animal disease model is transduced with a hepatitis B virus genome in the liver cells thereof and exhibits the following symptoms: hepatitis B viral particles and hepatitis B viral DNA in the serum, hepatitis B virus (HBV) envelope and HBV e proteins in the serum, expression of HBV core and HBV envelope proteins in the liver but not in the kidney, heart, lung, brain, pancreas, spleen, stomach or intestine tissues. The animal disease model may develop hepatocellular carcinoma, exhibiting an elevated level of alanine aminotransferase as compared to a control animal without the hepatitis B virus genome in the liver cells thereof, and liver pathological symptoms such as tumor nodules, dysplasia, inflammatory infiltrates, necrosis and fibrosis.06-09-2011
20110086339ELIMINATION OF PATHOGENIC INFECTION IN FARMED ANIMAL POPULATIONS - Animal husbandry has always been susceptible to the ravages of pathogenic infections. Poultry flus and cattle diseases are but two examples that have dire consequences for animals and adversely affect the economic fortunes of farmers. A testing and culling methodology is presented that can eliminate pathogens from an infected herd. The sensitivity of PCR to detect very low levels of nucleic acid of an infecting pathogen is utilized to identify infected animals. In addition, it has been discovered that PCR analysis of manure samples can accurately identify infected animals and offspring for those species that consume placental remains after birth. Mink Aleutian Disease Virus (mADV) is one of several deadly DNA parvoviruses that can quickly reach epidemic proportions in a mink herd. PCR primers have been developed that generate amplicons to detect and identify the mADV. In addition, a previously unidentified strain of mADV has been discovered, genomically sequenced, and substantially detailed.04-14-2011
20110086341FLUORINATED RESORUFIN COMPOUNDS AND THEIR APPLICATION - The invention provides novel fluorinated resorufin compounds that are of use in a variety of assay formats. Also provided are methods of using the compounds and kits that include a compound of the invention and instructions detailing the use of the compound in one or more assay formats.04-14-2011
20110244445Mass spectroscopy analysis of mutant polypeptides in biological samples - The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partner into the elution solution; subjecting a portion of the elution solution to liquid chromatography to segregate a plurality of molecules in the portion of the elution solution to obtain sorted molecules; determining the measured accurate mass of at least one sorted molecule present in the elution solution; and determining the presence of the at least one distinct polypeptide in the biological sample when a measured accurate mass of at least one molecule is substantially equal to the predetermined peptide measured accurate mass.10-06-2011
20090311664Method for Detection of Cancer Cells Using Virus - The invention relates to compositions and methods for cancer cell detection in bodily samples wherein a cancer cell can be detected within a mixed population of cancer cells and non-cancer cells. The invention also relates to compositions and methods that may be used in cancer cell detection, specifically viruses that are replication-competent conditional to a cancer cell, in particular an oncolytic herpes virus, such as NV 1066 and a vaccinia virus, such as GLV-1h68. Provided are methods and kits for using these viruses that preferentially replicate in cancer cells and may also preferentially infect cancer cells for specific identification of such cancer cells, even when a cancer cell is present, for example, at a ratio of one infected cancer cell in a background often thousand non-cancer cells, thus further providing a reproducible and sensitive screening method for cancer detection, monitoring and prognosis.12-17-2009
20100009338Novel gold nanostructures and methods of use - The invention is drawn to novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors, conduits for fluids, and electronic conductors. The nanostructures can be used in microfluidic devices, for transporting fluids between devices and structures in analytical devices, for conducting electrical currents between devices and structure in analytical devices, and for conducting electrical currents between biological molecules and electronic devices, such as bio-microchips.01-14-2010
20100055671Method for Determining Transduction Efficiency and Virus Dosage of Baculovirus - A method for determining transduction efficiency of baculovirus includes: providing a recombinant baculovirus, in which the recombinant baculovirus includes an inducible promoter and a reporter gene positioned downstream the inducible promoter; adding the recombinant baculovirus to incubating environment of a mammalian cell for transduction; adding an inducer to promote expression of the reporter gene in the mammalian cell; and analyzing the percentage of the mammalian cell expressing the reporter gene to determine the transduction efficiency of the recombinant baculovirus. The method provides the ability to quantitatively analyze baculovirus transduction and is a simple and faster quantitative method applicable in transduction and other research study by including an inducible promoter and a reporter gene and thus prevents from imposing excessive metabolic burden to the cells. A method for determining virus dosage of baculovirus applied in genetic therapy is also disclosed.03-04-2010
20100062419Infectious, Chimeric Hepatitis C Virus, Methods of Producing the Same and Methods of Use Thereof - The present invention provides infectious recombinant Hepatitis C Viruses (HCV), and vectors, cells and animals comprising the same. The present invention provides methods of producing infectious recombinant HCV, and their use in identifying anti-HCV therapeutic agents, as well as sequences of HCV associated with HCV pathogenesis.03-11-2010
20100062416Immobilisation and application of antigenic carbohydrates to detect infective micro-organisms - The invention relates to the field of chemistry and diagnosis, more in particular to diagnosis of current and/or past and/or symptomless infections or of a history of exposure to a gram-negative-bacterium (such as an enterobacteriaceae or a 03-11-2010
20120244523System and Method for Detection of HIV Integrase Variants - An embodiment of a method for detecting low frequency occurrence of one or more HIV sequence variants associated with integrase is described that comprises the steps of: (a) generating a cDNA species from a plurality of RNA molecules in an HIV sample population; (b) amplifying a plurality of first amplicons from the cDNA species, wherein each first amplicon is amplified with a pair of nucleic acid primers capable of amplifying products from clades A, B, C, D, AE and G sub-types; (c) clonally amplifying the amplified copies of the first amplicons to produce a plurality of second amplicons; (d) determining a nucleic acid sequence composition of the second amplicons; (e) detecting one or more sequence variants that occur at a frequency of 5% or less in the nucleic acid sequence composition of the second amplicons; and (f) correlating the detected sequence variants with variation associated with HIV integrase.09-27-2012
20120244522COMPOSITIONS FOR USE IN IDENTIFICATION OF ALPHAVIRUSES - The present invention provides oligonucleotide primers and compositions and kits containing the same for rapid identification of alphaviruses by amplification of a segment of viral nucleic acid followed by molecular mass analysis.09-27-2012
20120244521Methods for identifying a virulent strain of a virus - The present invention relates to methods for identifying a virulent strain of a virus, particularly and influenza virus, by detecting specific mutations in the amino acid sequence of the hemagglutinin (HA) protein and by determining the case fatality rate for hospitalization (CFR/H) as the number of persons hospitalized for infection by the virus who die from the infection compared to the total number of persons hospitalized for infection, wherein the identification of mutations in the HA protean and/or an increasing CFR/H over time indicates a virulent strain of the virus.09-27-2012
20100055672100% SEQUENCE IDENTITY DETECTION METHODS FOR VARIABLE GENOMES - The present disclosure provides methods, reagents and kits for the detection of all known human variants of influenza A virus and at least 90% of avian and swine variants of influenza A virus in a biological sample, based on amplification primers and detection probes that are specific to a highly conserved region of the influenza A matrix gene.03-04-2010
20100055673TRANSPARENT MICROFLUIDIC DEVICE - A device for analysing the status of a biological entity. The device (03-04-2010
20110177494DEVICE AND METHOD FOR PRESSURE-DRIVEN PLUG TRANSPORT - The present invention provides microfabricated substrates and methods of conducting reactions within these substrates. The reactions occur in plugs transported in the flow of a carrier-fluid.07-21-2011
20090029347Method for Identifying Multiple Analytes Using Flow Cytometry - The present disclosure is directed to a method of using antibodies attached to different types of microspheres against different antigens located within a biological sample. Optical and electronic particle detection may be used to separate the microspheres via flow cytometry, allowing the subsequent measurement of multiple analytes in a single sample of body fluid by separating and gating such analytes based on the type of microsphere to which the analyte is coupled. According to the present disclosure, various biological components may be attached to microspheres of different volumes, shapes, conductivity, densities, and/or colors to detect biological components by gating on the type of microsphere and analyzing the biological component attached thereto.01-29-2009
20100062421COMPOSITIONS, METHODS, AND DEVICES FOR ISOLATING BIOLOGICAL MATERIALS - Compositions, methods, devices, and kits, which include an immobilized-metal support material comprising a substrate having a plurality of —C(O)O03-11-2010
20100062417ZEOLITE CRYSTALS WITH BIOLOGICAL MATERIAL - The invention provides a hybrid construct comprising at least a zeolite crystal and at least one biological moiety such as for example a cells bacteria or virus and a method for the production thereof.03-11-2010
20100062420Type I interferon-inducible proteins to detect viral infection - A method for determining the presence of a viral infection in an animal not known to have been infected with a virus or other disease-causing microbial organism by determining the level of Mx protein or other Type I Interferon-inducible protein in the animal.03-11-2010
20100062418INACTIVATED AND DRIED BIOLOGICAL PREPARATIONS - In one aspect, the present invention provides biological sample that includes a dry preparation comprising a stabilizer and stabilized, inactivated biological material. In certain embodiments, the biological material may be heat inactivated and/or heat dried. In another aspect, the present invention provides a method of making a dried biological preparation. Generally, the method includes collecting a sample of biological material, inactivating the biological material, suspending the sample in a volume of a stabilizer and allowing the stabilizer to dry. In certain embodiments, the biological material may be heat inactivated and/or heat dried.03-11-2010
20110097702Methods and compositions for in situ detection of microorganisms on a surface - Compositions and methods for in situ detection of one or more target microorganisms on a surface and preferably on a hard surface. Compositions and methods of the invention are based on the specificity of certain bacteriophage for target microorganisms. Bacteriophage are modified to express detectable biomarkers in the presence of the target microorganism, the detectable markers being detectable on the surface being tested using a portable detection device. Only living microorganisms are detected using the methods and compositions of the invention.04-28-2011
20110097703METHOD FOR CARRYING OUT A QUALITATIVE PRELIMINARY INSTANT DIAGNOSIS OF ONCOLOGIC DISEASES - The invention relates to medicine, in particular to a method for carrying out a preliminary instant diagnosis of oncologic diseases. The method involves sampling a patient's blood, mixing the sample with a reagent and recording reaction results. A supernatant liquid, which is produced by cultivating the finite cell line of a porcine embryo kidney culture in anaerobic conditions, is used as a reagent. The presence of oncologic disease is determined according to a positive reaction of erythrocytes and a negative or positive reaction of a citrated blood with the reagent. The inventive method makes it possible to make a preliminary conclusion about the presence of oncologic disease within a short time.04-28-2011
20100028860Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use - A method of predicting the virulence of a new or uncharacterized PRRS virus strain is provided wherein the strain is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus strain of known virulence, as a measure of the virulence of the new or uncharacterized strain.02-04-2010
20110081642Selection of B Cells with Specificity of Interest: Method of Preparation and Use - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides methods using a composition comprising an ordered and repetitive antigen or antigenic determinant array for visualization and selection of B cells specific for the antigen. These B cells are useful for the production of monoclonal antibodies used for therapy, diagnostic or research purposes.04-07-2011
20110081643Flow Focusing Method and System for Forming Concentrated Volumes of Microbeads, and Microbeads Formed Further Thereto - In a method and system for forming concentrated volumes of microbeads, a polymer solution and/or suspension includes a polymer dissolved and/or dispersed in a medium. Streams of a focusing fluid and of the polymer solution and/or suspension flow towards a fluid bath, and into intersection with one another, so &s to focus the polymer solution and/or suspension. The polymer solution and/or suspension stream forms microbeads in the fluid bath. Some of the focusing fluid is drawn from the fluid bath, so as to concentrate the microbeads in die fluid bath. The system includes a flow focusing apparatus and a liquid-containing cell. The focusing apparatus includes polymer and focusing nozzles. The cell contains the fluid bath and has an outlet port, through which the focusing fluid is drawn from the fluid bath.04-07-2011
20110081644CELL LINE STABLY EXPRESSING MUTATED ONCOPROTEIN E6 AND METHOD OF SCREENING ANTICANCER COMPOUND OF UTERINE CERVICAL CANCER USING THE SAME - Disclosed are a cell line that expresses protein of Seq. No. 1, and a method for screening an anticancer compound of uterine cervical cancer by using the same. The stable cell line that expresses oncoprotein E6 of a human papillomavirus type 16 variant strain is used to determine a difference in amounts of expression of tumor suppressor genes, such as p53, between E6 protein of the reference strain and E6 protein of a variant strain, thereby screening an anticancer compound of uterine cervical cancer, etc. Further, it is possible to develop an anticancer agent of uterine cervical cancer.04-07-2011
20100267007SOLID-FLUID COMPOSITION AND USES THEREOF - A nanostructure comprising a core material of a nanometric size surrounded by an envelope of ordered fluid molecules is disclosed. The core material and the envelope of ordered fluid molecules are in a steady physical state. Also disclosed, a liquid composition comprising liquid and the nanostructure.10-21-2010
20090215030Method - A method for detecting pathogens, particularly organisms associated with sexually transmitted diseases, especially Human papilloma virus genotypes is described. The method involves the use of real-time PCR using specially designed probes. The probes, kits for carrying out the method, and methods for designing primers suitable for use in the method of the invention are also described.08-27-2009
20090215027Method and system for colorimetric determination of a chemical or physical property of a turbid medium - A new method and a system for the simultaneous determination of a biological, chemical and/or physical property of a plurality of individual samples of a turbid is described. The invention relates to a system and colorimetric method for simultaneous determination and measuring properties, such as acidification or pH value, redox potentials, viscosity, diffusion, enzymatic activity, etc. of a plurality of individual samples of a turbid or opaque medium, such as, e.g. milk, whey and related products. In particular, this invention relates to a method for non-invasively and/or non-destructively scanning samples or an array of samples, and determine on the basis of the scanning a specific property, such as pH, of the samples. The method may also be used for multivariate determinations of chemical and/or physical properties.08-27-2009
20090258343Semi-quantitative immunochromatographic device and method for the determination of HIV/AIDS immune-status via measurement of soluble CD40 Ligand/CD154, A CD4+ T cell equivalent and the simultaneous detection of HIV infection via HIV antibody detection - A semi-quantitative, immunochromatographic dual test device for the simultaneous detection of HIV/AIDS immune status CD4+ T cell equivalents, such as soluble CD40 ligand/CD 154, and the detection of an HIV antibody, includes one or more support materials capable of providing lateral flow. The one or more support materials include at least one sample receiving area for receiving a biological sample containing a first target analyte, the first target analyte being a CD4+ T cell equivalent, such as soluble CD40 ligand/CD 154, and a second target analyte, the second target analyte being an HIV antibody. A second area, situated on the one or more support materials, has a movably contained detector ligand and or detector antigens, wherein the detector ligand and or detector antigens is capable of forming a mobile complex with the soluble CD40 ligand/CD 154 and or HIV antibodies, and at least a first capture area having a predetermined amount of a first immobile capture reagent, the first immobile capture reagent capable of specifically binding to the mobile complex formed by the soluble CD40 ligand/CD 154 protein and the detector ligand and providing a visible signal. The one or more support materials further have situated thereon at least a second capture area having a predetermined amount of a second immobile capture reagent that is capable of specifically binding to HIV antibodies present in the biological sample and providing a visible signal.10-15-2009
20110097707RNAi Agents Comprising Universal Nucleobases - One aspect of the present invention relates to an oligonucleotide agent comprising at least one universal nucleobase. In certain embodiments, the universal nucleobase is difluorotolyl, nitroindolyl, nitropyrrolyl, or nitroimidazolyl. In a preferred embodiment, the universal nucleobase is difluorotolyl. In certain embodiments, the oligonucleotide is double-stranded. In certain embodiments, the oligonucleotide is single-stranded. Another aspect of the present invention relates to a method of altering the expression level of a target in the presence of target sequence polymorphism. In a preferred embodiment, the oligonucleotide agent alters the expression of different alleles of a gene. In another preferred embodiment, the oligonucleotide agent alters the expression level of two or more genes. In another embodiment, the oligonucleotide agent alters the expression level of a viral gene from different strains of the virus. In another embodiment, the oligonucleotide agent alters the expression level of genes from different species.04-28-2011
20110097708ASSESSMENT OF HUMAN PAPILLOMA VIRUS-RELATED DISEASE - This invention provides novel methods for assessing HPV infection. Gene expression levels are used to assess the progression of HPV infection from benign to malignant growth. Also provided are kits for carrying out the methods of this invention.04-28-2011
20110097706MICRO-REACTOR FOR OBSERVING PARTICLES IN A FLUID - The invention relates to a micro-reactor for observing small particles, cells, bacteria, viruses or protein molecules in a fluid. The micro-reactor shows a first channel formed between two layers for containing the fluid, with an inlet and an outlet, the two layers separated by a first distance. A likewise second channel with an inlet and an outlet is placed adjacent to the first channel. A gap connects the first channel and the second channel, at the gap at least one layer showing a window transparent to the method of inspection and at the window the two layers being separated by a very small distance of, for example, 1 μm or less.04-28-2011
20110097705Surface-assisted hemagglutination and hemagglutination inhibition assays - Hemagglutination (HA) and hemagglutination inhibition (HAI) functional assays remain important instruments of analysis of virus-cell interaction and protecting efficacy of virus-specific antibodies and sera. However, they demonstrate limited sensitivity towards many viruses, and require significant volumes of viruses, erythrocytes, sera, and antibodies. The present invention comprises new and significantly more sensitive versions of the HA and HAI assays based on observing agglutination on activated surfaces of specifically opsonized plates and ELISA plates rather than in solution. A version of the new assay that uses ELISA plates additionally allows characterizing the affinity of functional antibodies in the tested sera and fluids, which is not possible in the classical HAI assay. The methods of the present invention can also be used to improve the sensitivity of agglutination methods based on latex beads and to develop agglutination methods using target cells other than erythrocytes.04-28-2011
20110097704COMPOSITIONS FOR USE IN IDENTIFICATION OF PICORNAVIRUSES - The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of viruses which are members of the Picornaviridae family by amplification of a segment of viral nucleic acid followed by molecular mass analysis.04-28-2011
20110076670DETECTION OF ANALYTES VIA NANOPARTICLE-LABELED SUBSTANCES WITH ELECTROMAGNETIC READ-WRITE HEADS - A first set of antibodies are bonded to a substrate, and are exposed to and bonded with target antigens. A second set of antibodies are bonded to nanoparticles, and the nanoparticle labeled antibodies are exposed to the targeted antigens. An electromagnetic write-head magnetizes the nanoparticles, and then a read-sensor detects the freshly magnetized nanoparticles. The substrate comprises a flexible film or a Peltier material to allow selective heating and cooling of the antigens and antibodies. Nanoparticles of different magnetic properties may be selectively paired with antibodies associated with different antigens to allow different antigens to be detected upon a single scan by the read-sensor.03-31-2011
20110081645COMPOSITIONS AND METHODS FOR DETECTING HEPATITIS B VIRUS - Compositions, methods and kits for detecting viral nucleic acids. Targets that can be detected in accordance with the invention include HBV and/or HIV-1 and/or HCV nucleic acids. Particularly described are oligonucleotides that are useful as hybridization probes and amplification primers that facilitate detection of very low levels of HBV nucleic acids.04-07-2011
20120149009VAPORIZATION DEVICE AND METHOD FOR IMAGING MASS SPECTROMETRY - Methods and apparatus for analyzing samples are disclosed. The samples are analyzed by vaporizing molecules from a sample in a sample area with a femtosecond laser beam under ambient conditions, ionizing the vaporized molecules with electrospray ionization under the ambient conditions to form ions; and analyzing and detecting the ions.06-14-2012
20120149011METHOD FOR DETECTING TARGET NUCLEIC ACIDS - The invention relates to a method for detecting target nucleic acids which are detected by means of a specific sequence tag which is not part of the target nucleic acid.06-14-2012
20110065092USE OF NONVIABLE PARTICLES COMPRISING AN INTERNAL CONTROL (IC) NUCLEIC ACID - The present invention relates to the use of non-viable particles (and in particular liposome particles, particles which are in the form of a viral protein coat, non-viable genetically modified organisms or particles made of synthetic polymers), comprising an internal control (IC) nucleic acid sequence as an internal control in nucleic acid-based analysis. The present invention further relates to non-viable particles comprising an IC nucleic acid and kits for carrying out the methods and uses of the invention.03-17-2011
20110076672Phage-Mediated Bioluminescent Detection of Yersinia Pestis - The present disclosure relates to compositions, methods, systems and kits for the detection of microorganisms of the 03-31-2011
20110065086Methods of producing homogeneous plastic-adherent aptamer-magnetic bead-fluorophore and other sandwich assays - Methods are described for assembly of DNA aptamer-magnetic bead (“MB”) conjugate plus aptamer-quantum dot (“QD”) aptamer-fluorescent nanoparticle or other aptamer-fluorophore, aptamer-chemiluminescent reporter, aptamer-radioisotope or other aptamer-reporter conjugate sandwich assays that enable adherence to glass, polystyrene and other plastics. Adherence to glass or plastics enables detection of surface-concentrated partitioning of fluorescence versus background (bulk solution) fluorescence in one step (without a wash step) even when the external magnetic field for concentrating the assay is removed. This assay format enables rapid, one-step (homogeneous) assays for a variety of analytes without wash steps that do not sacrifice sensitivity.03-17-2011
20110151437COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS VIRUSES - The present invention provides compositions, kits and methods for rapid identification and quantification of adventitious contaminant viruses by molecular mass and base composition analysis.06-23-2011
20110151435NOVEL ASSAYS FOR DETECTING ANALYTES IN SAMPLES AND KITS AND COMPOSITIONS RELATED THERETO - The present invention provides methods of detecting analytes using particles having different physico-chemical properties, such as buoyancy, size, density, spectral characteristics, and/or binding properties, in solution-based sandwich assays and solution-based competition assays. The methods can be performed using rotors and bench-top centrifuges and provide for rapid, qualitative and quantitative detection of analytes. The present invention also provides kits that can be used to perform the methods, and mixtures containing particles suitable for the methods.06-23-2011
20110151433METHODS FOR PRODUCTION OF UNSTRUCTURED RECOMBINANT POLYMERS AND USES THEREOF - The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.06-23-2011
20110065090Asymmetrically branched polymer conjugates and microarray assays - A method of detection comprising a conjugate of a randomly and asymmetrically branched dendritic polymer.03-17-2011
20110065089NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF - The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.03-17-2011
20110065094METHOD AND KIT FOR DETECTION/IDENTIFICATION OF VIRUS-INFECTED CELL - Disclosed is a means for specifically detecting and identifying a virus-infected cell in a floating cell system by a simple manipulation and with high sensitivity. A virus-infected cell can be detected and identified by the following steps (1) to (5): (1) adding a first labeled antibody which has been labeled with a first labeling substance and is directed against a cell surface antigen specific to a target cell to a sample and allowing the mixture to react; (2) immobilizing a protein in the presence of an RNAstabilizing agent; (3) treating the protein with a surfactant; (4) adding a labeled nucleic acid probe for a nucleic acid specific to a target virus to cause the hybridization; and (5) detecting a cell labeled with both the first labeled antibody and the labeled nucleic acid probe by flow cytometry.03-17-2011
20110065093NOVEL TOOL FOR THE ANALYSIS OF NEURAL CIRCUITS - The application relates to an isolated transsynaptic virus expressing an exogenous fluorescent activity sensor. Preferably, the transsynaptic virus is a rhabdovirus, e.g. rabies virus, or a herpesvirus, preferably an alphaherpesvirus, e.g. pseudorabies virus. The fluorescent exogenous activity sensor used in the transsynaptic virus can be a fluorescent protein Ca03-17-2011
20110065095ANTI-(INFLUENZA A VIRUS SUBTYPE H5 HEMAGGLUTININ) MONOCLONAL ANTIBODY - A method of immunoassay of H5 subtype influenza A virus by which the virus can be accurately assayed even in cases where a certain level of mutation has occurred in the H5 subtype influenza A virus, and a kit therefor, and a novel anti-H5 subtype influenza A virus monoclonal antibody which can be used for the immunoassay are disclosed. The antibody or an antigen-binding fragment thereof of the present invention undergoes antigen-antibody reaction with hemagglutinin of H5 subtype influenza A virus, and the corresponding epitope of the antibody or an antigen-binding fragment thereof is located in a region other than the receptor subdomain (excluding C-terminal region thereof consisting of 11 amino acids), which antibody or an antigen-binding fragment thereof does not have neutralizing activity against the influenza A virus.03-17-2011
20110065099METHOD OF PRETREATING SPECIMEN AND IMMUNOASSAY USING THE SAME - The present invention provides a method of pretreating a specimen, which allows measurement according to an immunoassay to be carried out on a specimen from nasal secretion while preventing non-specific reactions. According to this method, the specimen from nasal secretion is treated with a protease beforehand and then an immunoassay is performed. As the protease, it is preferable to use semi-alkaline protease (EC 3.4.21.63). Furthermore, it is preferable that a substance to be pretreated by the pretreatment method according to the present invention is an influenza virus contained in the specimen from nasal secretion. The immunoassay preferably is an immunoagglutination assay. Examples of the immunoagglutination assay include a turbidimetric immunoassay, a latex turbidimetric immunoassay, and a latex agglutination assay that is performed on a slide glass.03-17-2011
20110065098METHODS AND REAGENT KITS FOR IMPROVING ACCURACY OF SAMPLE CLASSIFICATION - The present invention relates to methods for increasing the accuracy of sample classification characterized by the detection of the protein YKL-40 and the protein MASP2 in the samples and methods for determining the efficacy of a drug in treating a cancer in an individual, as well as reagent kits for the same uses.03-17-2011
20110065097Apparatus and Method of Contaminant Detection for Food Industry - The present invention is a method and apparatus for contaminant detection in the food industry. Particularly, the method and apparatus involve collecting air samples containing aerosolized contaminate particles from a foodstuff and analyzing the sample for presence of a contaminate. Aerosol lab-on-a-chip and/or electronic nose devices are utilized for the detection of contaminant particles.03-17-2011
20110065096VIRAL DIAGNOSTIC METHOD AND WELL FOR USE IN SAME - The present invention relates to a single flat-based well suitable for use in a viral diagnostic method. More particularly, the well has a planar or flat base, as opposed to a curved base. The invention also relates to a viral diagnostic method that employs such single wells. In an embodiment of this method a specially developed tissue culture medium supplemented with hormones and enzymes is employed.03-17-2011
20120202194SUBSTANCE DETERMINING APPARATUS - The invention relates to a substance determining apparatus for determining a substance within a fluid. Particles, which have attached the substance, are bound to a binding surface (08-09-2012
20120149007METHOD FOR DETECTING ANALYTES - The invention provides an improved method for sensitive and specific detection of target molecules, cells, or viruses. The inventive method uses large area imaging to detect individual labeled targets complexed with a target-specific selection moiety. The invention eliminates wash steps through the use of target-specific selection through one or more liquid layers that can contain optical dye and density agents. By eliminating washes the invention simplifies instrumentation engineering and minimizes user steps and costs. The invention uses sensitive image analysis to enumerate individual targets in a large area, is scalable, and can be deployed in systems ranging in complexity from manual to highly automated.06-14-2012
20120149008CHROMATOGRAPHIC SYSTEM FOR NUCLEIC ACID DETECTION - The present disclosure provides a strip for separation and sequence specific detection of nucleic acids in a sample, a system for sequence specific detection of nucleic acids comprising the strip of the present disclosure and an epifluorescence detection device, and a method for qualitative and/or quantitative determination of a nucleic acid using the strip. The strip, system and method of the present disclosure is easy to use and provides accurate and reliable results due to its high sensitivity and specificity in a relatively short analysis time compared to the conventional assays.06-14-2012
20110033840VIRAL DETECTION LIPOSOMES AND METHOD - A method of generating pathogen detecting liposomes includes a step of providing molecular beacons with fluorescing components. The molecular beacons include either strands of RNA or DNA and the fluorescing components include an emitter and a quencher. The method further uses nanodroplet technology to encapsulate the molecular beacons within a lipid membrane. Subsequently, receptors are assembled in association with the membrane.02-10-2011
20110033838SURFACE ANTIGEN PROTEIN MUTANT OF HEPATITIS B VIRUS SURFACE ANTIGEN - The disclosure relates, in some embodiments, to sequences of a novel mutant or variant of the hepatitis B surface antigen (HBsAg) and methods for detecting this genome and protein variant, and antibodies directed against it, from patients' samples.02-10-2011
20100304363PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF - Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus.12-02-2010
20110256528ANALYTE DETECTION ASSAY - A rapid and sensitive analyte detection assay is based on whispering gallery modes of fluorescently labelled microspheroidal particles. Ligands for the analyte, such as nucleic acids, are anchored to the particles. The fluorescent labels may comprise fluorophores or quantum dots. In the latter case, the particles may comprise melamine formaldehyde. The assay may be used to detect analytes in aqueous samples.10-20-2011
20080254442Crystal structures of human peptide deformylase - The present invention provides the three-dimensional structure of human mitochondrial 10-16-2008
20100304362NEW DETECTION METHOD FOR CERVICAL HPVS - The invention describes a consensus PCR based method (i.e. HRE7-PCR) for the simultaneous detection of 14 Human Papilloma Virus types (i.e. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are classified as (probably) high-risk, relating to the causation of cervical cancer) and a candidate hrHPV type (i.e. HPV 67) using sets of 6 overlapping forward primers and 9 overlapping backward primers that together amplify a fragment of about (215) to (245) base pairs of the E7 open reading frame of these hrHPV types. For the detection of reaction products an EIA format can be used with the aid of a cocktail of type-specific oligoprobes as exemplified herein. Furthermore, we have developed a method for an efficient typing of these (15) HPVs that is compatible with the method for detection. This RLB typing system involves hybridisation of PCR products with immobilised type-specific oligoprobes.12-02-2010
20100304359MULTIANALYTE ASSAY - The invention provides compositions, systems and methods for detecting multiple analytes from a sample.12-02-2010
20100297607Reagents For HCV Antigen-Antibody Combination Assays - The present invention is directed to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a sample. The combination immunoassays of the present invention employ a non-ionic detergent that effectively exposes or releases the HCV core antigen from virions in a sample without interfering with the performance of other reagents such as the capture of anti-HCV antibodies by recombinant HCV antigens.11-25-2010
20100297611Method and Device For Combined Detection Of Viral And Bacterial Infections - A lateral flow assay detects and differentiates between viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In one preferred embodiment, the bacterial marker is CRP. In another preferred embodiment, the viral marker is MxA. In some embodiments, it is unnecessary to lyse the cells in the sample prior to applying it to the device.11-25-2010
20100297610MOLECULARLY IMPRINTED POLYMERS FOR DETECTING HIV-1 - The invention described herein provides molecularly imprinted polymers (MIPs) that are capable of binding to virus, and methods for detecting and/or identifying specific virus particles utilizing Molecularly Imprinted Polymers (MIPs). The virus particles of the invention include HIV-1, HIV-2, HTLV-1, HTLV-2, HPV, HBV, and HCV. The methods of the invention comprise detecting all or part, including epitopes, of macromolecules associated with a virus. The macromolecules of the invention include proteins, glycoproteins (e.g., envelope glycoproteins), peptides, and polypeptides associated with said virus. The invention also provides for methods of diagnosing a subject infected with a virus utilizing MIPs, in addition to diagnostic kits.11-25-2010
20100297606IgG BINDING PEPTIDE - The present invention provides a peptide capable of specifically binding to human IgG. In particular, the present invention relates to a human IgG binding peptide tag of 11 to 16 amino acids in length, comprising at least an amino acid sequence of the formula I:11-25-2010
20100285450COMPOSITIONS AND ASSAYS TO DETECT INFLUENZA VIRUS A AND B NUCLEIC ACIDS - Methods for detecting influenza virus A and influenza virus B nucleic acids in biological samples by using in vitro amplification and detection are disclosed. Compositions that are target-specific nucleic acid sequences and kits comprising target-specific nucleic acid oligomers for amplifying in vitro influenza virus A or influenza virus B nucleic acid and detecting amplified nucleic acid sequences are disclosed.11-11-2010
20100285449Human G-Protein Chemokine Receptor (CCR5) HDGNR10 - Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.11-11-2010
20090023133GENOMIC MARKERS OF HEPATITIS B VIRUS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA - The present invention provides methods of predicting a pre-disposition of HBV-infected individuals to develop hepatacellular carcinoma (HCC).01-22-2009
20110250586SYSTEM AND METHOD FOR CONCENTRATING SAMPLES - A system and method for concentrating samples. The system can include a first container adapted to contain a sample. The first container can include a first portion and a second portion adapted to be removably coupled to the first portion. The system can further include a second container comprising the second portion and a third portion adapted to be removably coupled to the second portion. The method can include centrifuging the first container in a first orientation toward the second portion of the first container; retaining a concentrate of the sample in the second portion of the first container; and centrifuging the second container in a second orientation toward the third portion of the second container, such that the concentrate retained in the second portion is moved into the third portion of the second container, the second orientation being different from the first orientation.10-13-2011
20110250585ORGAN MIMIC DEVICE WITH MICROCHANNELS AND METHODS OF USE AND MANUFACTURING THEREOF - System and method includes a body having a central microchannel separated by one or more porous membranes. The membranes are configured to divide the central microchannel into a two or more parallel central microchannels, wherein one or more first fluids are applied through the first central microchannel and one or more second fluids are applied through the second or more central microchannels. The surfaces of each porous membrane can be coated with cell adhesive molecules to support the attachment of cells and promote their organization into tissues on the upper and lower surface of the membrane. The pores may be large enough to only permit exchange of gases and small chemicals, or to permit migration and transchannel passage of large proteins and whole living cells. Fluid pressure, flow and channel geometry also may be varied to apply a desired mechanical force to one or both tissue layers.10-13-2011
20110250588METHOD FOR DETECTING CANCER CELLS IN BLOOD SAMPLE - A method for detecting cancer cells in a blood sample is provided comprising the steps of proliferating an oncolytic virus at least in the cancer cells by incubating the blood sample being suspected to contain the cancer cells with the oncolytic virus; mixing the blood sample obtained from the proliferating step with a fixing agent and a nonionic surfactant; and detecting the cancer cells in the blood sample obtained from the mixing step, in which the oncolytic virus has been proliferated.10-13-2011
20110250587NOVEL METHOD FOR GENERATION OF RNA VIRUS - The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus.10-13-2011
20110250584Method for Screening Cancer Therapeutic Agent Using Galectin-3, GSK-3Betta, and Fascin-1 - Disclosed is a method for screening a novel cancer therapeutic agent. The cancer therapeutic agent exhibits down-regulation of galectin-3 and fascin-1 or interferes with the interaction between galectin-3 and GSK-3β.10-13-2011
20110250583OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE BINDING, DETECTION, DIFFERENTIATION, ISOLATION AND SEQUENCING OF INFLUENZA A; INFLUENZA B; NOVEL INFLUENZA A/H1N1; AND A NOVEL INFLUENZA A/H1N1 RNA SEQUENCE MUTATION ASSOCIATED WITH OSELTAMIVIR RESISTANCE - Described herein are primers and probes useful for the binding, detecting, differentiating, isolating, and sequencing of influenza A, influenza B, 2009 influenza A/H1N1, and a 2009 influenza A/H1N1 RNA sequence mutation associated with oseltamivir resistance.10-13-2011
20080248460Composition and method for modulating an inflammatory response - The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling. LTβR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTβR complex proteins that act as LTβR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTβR, its ligands, LIGHT and LTβ1α2, or its intracellular binding partners, that function to regulate LTβR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTβR signaling is provided.10-09-2008
20080248459Multiplex detection of agricultural pathogens - Described are kits and methods useful for detection of seven agricultural pathogens (BPSV; BHV; BVD; FMDV; BTV; SVD; and VESV) in a sample. Genomic sequence information from 7 agricultural pathogens was analyzed to identify signature sequences, e.g., polynucleotide sequences useful for confirming the presence or absence of a pathogen in a sample. Primer and probe sets were designed and optimized for use in a PCR based, multiplexed Luminex assay to successfully identify the presence or absence of pathogens in a sample.10-09-2008
20110151436COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION - This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.06-23-2011
20110151431DETECTION OF XENOTROPIC MURINE LEUKEMIA VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV nucleic acid in a sample from a subject.06-23-2011
20100003667MULTIPLE LABELLING FOR ANALYTE DETECTION - Provided is use of a label in a method for detecting an analyte in a sample, for increasing the sensitivity of detection of the analyte, wherein, the analyte comprises a repeating protein unit, and wherein a plurality of label entities are capable of binding to a single analyte entity such that a signal obtained for an analyte from a plurality of labels is stronger than the signal obtained for an analyte with a single label.01-07-2010
20110151430VIRUS-SPECIFIC miRNA SIGNATURES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF VIRAL INFECTION - The present invention related to miRNA signatures and diagnostic and therapeutic applications of miRNA signatures. The miRNA signatures are defined by a test sample miRNA profile relative to an appropriate control miRNA profile. In some embodiments, the test sample is a sample isolated, obtained or derived from a virus-infected cell or organism. The present invention further relates to the use of miRNA signatures in the identification of druggable targets and antiviral agents. Kits and compositions are also provided.06-23-2011
20110151432METHODS AND SYSTEMS TO COLLECT AND PREPARE SAMPLES, TO IMPLEMENT, INITIATE AND PERFORM ASSAYS, AND TO CONTROL AND MANAGE FLUID FLOW - Methods and systems to related to sample collection, assays, and fluid control and management, including methods and systems to implement hand-held portable assays, to activate an assay system, to collect and prepare samples, to capture antibodies, and to trap or capture gas bubbles. Methods and systems disclosed herein, and portions thereof, may be implemented alone and/or in various combinations with one another.06-23-2011
20090317795METHOD OF DETECTING H5 OR H7 AVIAN INFLUENZA VIRUS - The present invention provides oligonucleotide primers specifically hybridizing to an arbitrary nucleotide sequence designed from the nucleotide sequence of hemagglutinin of an H5 or H7 avian influenza virus, a nucleic acid amplification method using the primers, a method for diagnosis of infection with an H5 or H7 avian influenza virus by detection of nucleic acid amplification, and a kit for influenza diagnosis.12-24-2009
20090286223Methods And Kits For In Situ Measurement of Enzyme Activity and Amount Using Single Measurement System - Disclosed are methods and kits for measuring in situ the activity and amount of an enzyme in a sample using a single measurement system. The method includes the steps of: (a) contacting a sample to a capturing agent having the capacity to bind to the enzyme to be analyzed and immobilized on a solid matrix; (b) measuring the activity of the enzyme captured by the capturing agent; (c) contacting a detection antibody specific to the enzyme captured by the capturing agent; and (d) detecting an antigen-antibody complex formed in the step (c). There is no need for separate measurement system to measure the activity and amount of an enzyme, as well as the above methods and kits permit to measure the precise activity and amount of an enzyme simultaneously because the measurement of enzyme activity and amount is carried out in a single and same measurement system as to the same sample in almost simultaneous manner.11-19-2009
20110151429Bioprobe, Method of Preparing the Bioprobe, and Analysis Apparatus and Method Using the Bioprobe - The present invention relates to a bioprobe including a substrate and inorganic nanoparticles attached to the surface of the substrate, a method of preparing the bioprobe, and an analysis apparatus and method using the bioprobe. In the bioprobe according to the present invention, inorganic nanoparticles introduced to the substrate serve as a linker to which a target-specific substance such as an antibody can be bound, and they also increase the surface area of the substrate, thus increasing a surface area where a target substance to be detected can contact the substrate. In this regard, the bioprobe can be effectively used for detection, dosing, or analysis of various biomolecules or other chemical substances.06-23-2011
20120202193DISPOSABLE DEVICE FOR STORING BIOLOGICAL LIQUIDS AND USE THEREOF TO DETECT MATERIALS, PARTICLES, AND/OR CELLS - The invention relates to a disposable device, in which the target substances are bound to solid carriers, preferably microparticles. A mechanism according to the invention enables the solid carriers to be easily concentrated to a volume of appropriate size. A further device according to the invention makes it possible for the solid carriers in the device to be subjected to known isolating, amplifying and/or detection reactions. The device is especially suitable for the enrichment and isolation and/or detection of substances in, or extracted from, biological liquids.08-09-2012
20120202191DETECTION METHOD BASED ON TIME RESOLVED REAL TIME FLUORESCENT ENERGY TRANSFER (TR-FRET) - A method for detecting the presence of a diagnostic moiety indicative of exposure to an infectious organism in a biological sample taken from a human or animal, said method comprising use of a first and second fluorescently labelled reagent which are capable of binding to a diagnostic moiety or to a binding partner in competition with a diagnostic moiety, wherein labels on the first and second labelled reagents act as fluorescent donors and acceptors to one another, the proximity of the reagents to one another being detectable by measuring the emission of fluorescent energy from at least one of the labels.08-09-2012
20120202189RAPID, SEMI-AUTOMATED METHOD TO DETECT RESPIRATORY VIRUS INFECTED CELLS IN DIRECT SPECIMENS - A novel cytometer system, methods and algorithms which provide a rugged, affordable and easy-to-use device in remote locations. All cells in a biological sample are fluorescently labeled, with target cells also magnetically labeled. Non-magnetically labeled cells are imaged for viability. Labeled sample is placed between two wedge-shaped magnets to selectively move the magnetically labeled cells for observation. A LED illuminates the cells and a CCO camera captures the images of the fluorescent light emitted by the target cells. Image analysis performed with a novel algorithm provides a cell count that can be related to the target cell concentration of the original sample.08-09-2012
20090136916METHODS AND MICROARRAYS FOR DETECTING ENTERIC VIRUSES - The present invention relates to methods, microarrays and kits for detecting one or more human astrovirus serotypes in a sample (e.g., a fecal sample) from an individual. The method includes amplifying nucleic acid molecules of the sample with one or more primers, to thereby obtain an amplified nucleic acid product; contacting the amplified nucleic acid product with one or more serotype specific probes having a nucleic acid sequence that is specific for only one astrovirus serotype in the group of astroviruses being assessed, wherein the nucleic acid sequence includes between about 9 and 25 nucleic acid bases (e.g., SEQ ID NO: 5-24); and detecting the hybridization complex. The presence of hybridization complexes with a serotype specific probe indicates the presence of one or more specific astrovirus serotypes, and the absence of hybridization complexes with a serotype specific probe indicates the absence of the specific astrovirus serotype. Identification of the astrovirus serotypes allows for one to diagnose an individual infected with the serotype. The present invention further includes microarrays having any one of the astrovirus specific probe, or kits having microarrays and reagents for carrying out the assay.05-28-2009
20090136914Identification and use of genes encoding holins and holin-like proteins in plants for the control of microbes and pests - This invention provides: 1) methods for the identification of broad-spectrum holins with a high level of nonenzymatic activity in membranes; 2) conditions required for maintaining and increasing the anti-microbial and anti-pest efficacy of holins in gene fusions; 3) a method for effective targeting of holins expressed in plants through use of a leader peptide to direct the holin protein to the plant apoplast and xylem; 4) methods for the control of bacterial and fungal diseases of plants and control of insect and nematode pests that attack plants by expression of gene fusions involving holins, C-terminal additions and leader peptides, and optionally, endolysins; 5) methods for increasing the shelf-life of cut flowers, and 6) transgenic plants useful for the production of novel antimicrobial proteins based upon holins.05-28-2009
20110177493USING HIGHLY SENSITIVE SUSPENDED CARBON NANOTUBES FOR MOLECULAR-LEVEL SENSING BASED ON OPTICAL DETECTION - A molecular sensor is provided that contains at least one carbon nanotube suspended on a suitable support structure. In one aspect, at least one receptor is attached to a surface of the suspended carbon nanotube. Also provided are methods of detecting an analyte in a sample by contacting a sample suspected of containing the analyte with the molecular sensor of this invention under suitable conditions that favor binding of the analyte to the receptor and detecting any analyte bound to the receptor, if present.07-21-2011
20110177492METHOD OF CLASSIFYING CHEMICALLY CROSSLINKED CELLULAR SAMPLES USING MASS SPECTRA - A method of analyzing cellular samples that include a chemically crosslinked analyte is provided. The analysis typically involves the use of mass spectrometry.07-21-2011
20080293036Monoclonal Antibodies to Hiv-1 and Methods of Using Same - The present invention provides monoclonal antibodies to HIV-1 Vpr and hybridoma cell lines that produce the monoclonal antibodies to HIV-1 Vpr. Methods for use of such antibodies in the detection of HIV-1 infection are also provided.11-27-2008
20090011403MICROPOROUS MATERIALS, METHODS OF MAKING, USING, AND ARTICLES THEREOF - Described herein are methods for separating one or more analytes present in a fluid sample. The methods involve passing the fluid through or into a microporous material, wherein the analytes are localized near the surface of the microporous material. Additional processing steps such as hybridization and amplification can be performed once the analyte is localized. In one method, once the analyte is localized, the analyte can be detected, counted, and correlated in order to determine the concentration of the analyte in the sample. In another method, the localized analyte is destabilized to make the localized analyte more accessible for chemical manipulation. Modified microporous materials and composite materials are also disclosed that can be used in any of the methods and articles described herein. The composite is composed of a microporous material and a pigment, wherein the pigment is incorporated in the microporous material. The pigments alter the optical properties of the microporous material, which enhances the detection of analyte once it is localized. Methods for making pigmented composites are also disclosed. In a further aspect, various kits and articles such as filtration devices containing any of the microporous materials described herein are provided.01-08-2009
20110256527RAPID AND SAFE TECHNIQUE FOR PERFORMING PCR AMPLIFICATIONS - This invention relates to methods for quick and safe identification of pathogens from biological samples. Iodinated resins may be employed to destroy a pathogen while leaving the pathogen's DNA in a state that can be analyzed. The DNA can then serve as a substrate for PCR analysis. The use of these iodinated resins work in a significantly quicker manner than prior art methods and allows scientists to spend a minimal time under Biosafety Level Three (BSL-3) conditions.10-20-2011
20110256526DETECTION OF HUMAN SOMATIC CELL REPROGRAMMING - The methods and kits described herein are based, in part, to the discovery phenotype representing a fully-reprogrammed iPS cell and several reprogramming intermediates. The methods and kits described herein permit identification of fully-reprogrammed iPS cells and further permits one of skill in the art to monitor the emergence of iPS cells during the reprogramming process. The methods/kits can also be performed using real time using live cell imaging. Also described herein are methods for screening candidate reprogramming agents by monitoring the emergence of fully-reprogrammed iPS cells in the presence and absence of such an agent.10-20-2011
20110256525COMPOSITIONS AND METHODS FOR PURIFYING AND CRYSTALLIZING MOLECULES OF INTEREST - A composition-of-matter is provided. The composition comprising at least one antibody binding moiety capable of binding an antibody-labeled target molecule, cell or virus of interest, said at least one antibody binding moiety being attached to at least one coordinating moiety selected capable of directing the composition-of-matter to form a non-covalent complex when co-incubated with a coordinator ion or molecule.10-20-2011
20080213748Method for Detection and Analysis of Macromolecular Complexes - The present invention relates to a method for the detection and/or analysis of the structure of macromolecular complexes and/or macromolecules comprising the steps of (a) purifying or separating said macromolecular complexes and/or macromolecules from a sample containing said macromolecular complexes and/or macromolecules by applying in a porous matrix a separation force in a first dimension (X-axis); (b) transferring in a second dimension (Z-axis) by adsorption forces the macromolecular complexes and/or macromolecules purified or separated in step (a) from the porous matrix onto a carrier wherein said carrier contacts the surface of the porous matrix and is positioned parallel to the surface of said matrix and parallel to the direction of the separation force applied in step (a); (c) immobilizing the macromolecular complexes and/or macromolecules on said carrier after transfer of step (b); and (d) assessing the structure of the macromolecular complexes and/or macromolecules on said carrier after immobilization of step (c).09-04-2008
20080213747FLUORESCENT POLYMER SUPERQUENCHING-BASED BIOASSAYS - A chemical composition including a fluorescent polymer and a receptor that is specific for both a target biological agent and a chemical moiety including (a) a recognition element, (b) a tethering element, and (c) a property-altering element is disclosed. Both the fluorescent polymer and the receptor are co-located on a support. When the chemical moiety is bound to the receptor, the property-altering element is sufficiently close to the fluorescent polymer to alter the fluorescence emitted by the polymer. When an analyte sample is introduced, the target biological agent, if present, binds to the receptor, thereby displacing the chemical moiety from the receptor, resulting in an increase of detected fluorescence. Assays for detecting the presence of a target biological agent are also disclosed.09-04-2008
20080254440Anti-Sars Virus Antibody, Hybridoma Producing the Antibody and Immunoassay Reagent Using the Antibody - A monoclonal antibody which specifically recognizes SARS virus is provided, and an immunoassay, immunoassay reagent and immunoassay device for detecting the SARS virus using the monoclonal antibody are disclosed. The monoclonal antibody according to the present invention is a monoclonal antibody against a nucleoprotein of a corona virus causing severe acute respiratory syndrome (SARS).10-16-2008
20080254444Immunoassay Devices and Use Thereof - An immunoassay device has a housing defining a first opening for receiving a solution and a second opening through which a liquid sample is deposited, a strip of sorbent material having a test site with immobilized antigen or antibody for the ligand to be tested, and a filter for filtering the sample. The filter is located at the second opening and directly above the test site. The sorbent material defines a horizontal flow path in the housing for the solution from the first opening to the test site. In use, the sample is first applied via the filter to the test site, and then, after the ligand has been captured, a buffer added through the first opening is used to cause a secondary specific binder conjugated to a marker to migrate horizontally by capillary action to the test site where it can bind to the already captured ligand. This immunoassay offer several advantages over the traditional chromatographic immunoassays.10-16-2008
20080254441Lateral-Flow Test Device Providing Improved Test Result Validity - The present invention refers to a lateral-flow test device providing improved test result validity comprising at least one indication means indicating whether a test result will be inconclusive and/or at least one indication means indicating that a test result is ready for read. It is further referred to a use of such lateral-flow test device and to a procedure for its manufacture.10-16-2008
20080254443Norovirus detection, methods and compositions therefor - A norovirus-permissive cell culture infected with a norovirus, and methods of culturing a norovirus, are disclosed. Norovirus-permissive cells include dendritic cell-lineage cells, and macrophage-lineage cells, such as dendritic cells, and macrophages having a deficiency in a cellular anti-viral pathway such as a STAT-1-dependent pathway, an interferon receptor-dependent pathway, or a PKR-dependent pathway. Also disclosed are methods of screening anti-viral compounds against norovirus-permissive cells infected with norovirus, and norovirus adapted to grow in fibroblasts as well as macrophages that are not deficient in a cellular anti-viral pathway. Methods of making a norovirus vaccine are also disclosed. A replicative form of norovirus as well as its use in the development of an anti-viral agent and a polypeptide expression system are also described. Further disclosed are methods of detecting norovirus in a sample.10-16-2008
20080206740Sampling Method and Device - Disclosed herein is test device and method for detection of sample analytes in which after sampling has occurred a closure is provided. Such a test device and method can be usefully employed to detect a variety of analytes including microorganisms.08-28-2008
20110020787NMR DEVICE FOR DETECTION OF ANALYTES - This invention relates generally to detection devices having one or more small wells each surrounded by, or in close proximity to, an NMR micro coil, each well containing a liquid sample with magnetic nanoparticles that self-assemble or disperse in the presence of a target analyte, thereby altering the measured NMR properties of the liquid sample. The device may be used, for example, as a portable unit for point of care diagnosis and/or field use, or the device may be implanted for continuous or intermittent monitoring of one or more biological species of interest in a patient.01-27-2011
20110020786PEPTIDE DENDRIMERS: AFFINITY REAGENTS FOR BINDING NOROVIRUSES - Noroviruses are recognized as the most common cause of outbreaks of acute gastroenteritis in humans. Therefore, the present invention relates to peptides or dendrimers that bind Noroviruses and the methods for identifying and synthesizing these peptides. It also relates to the detection of Noroviruses using said peptides or dendrimers formed by them.01-27-2011
20110053145QUANTITATION METHOD OF VIRUS - The present invention relates to a method of quantitatively determining the number of human herpesvirus (HHV) collected from a body fluid and a kit for performing the method. Conventionally, a trained technician has been required to accurately quantitatively determine a number of HHV collected from a body fluid. The method of the present invention is a novel method of quantitative determination that enables measurement of a number of HHV in a body fluid to be simply, accurately, and efficiently determined. The method of the present invention can enable continuous evaluation of the number of HHV in body fluids and, therefore, can be applied to quantitative evaluation of the accumulation of fatigue.03-03-2011
20110053142Binding Protein and Epitope-Blocking Elisa for the Universal Detection of H5-Subtype Influenza Viruses - Monoclonal antibodies and related binding proteins specific to influenza H5 subtype HA protein can be used in serological diagnosis of influenza H5 infection in mammalian and avian serum samples, including human serum samples. Each antibody reacts strongly with a wide variety of strains of H5 subtype and does not show cross-reactivity with non-H5 influenza subtypes.03-03-2011
20110053141Methods for ultrasensitive detection and quantification of mutant hepatitis B viruses - This invention provides compositions and methods for ultrasensitive detection and quantification of mutant hepatitis B viruses (HBV). The compositions and methods of the invention can be used to detect HBV mutations for diagnostic and prognostic purposes. This invention also provides new application of a TaqMan hydrolysis probe in asymmetric real time PCR and melting curve analysis.03-03-2011
20110053140Methods and reagents for diagnosing hantavirus infection - Novel methods and immunodiagnostic test kits for the detection of hantavirus infection are disclosed. The methods and kits employ combinations of recombinant N and/or G1 antigens from at least six different hantavirus serotypes, including Hantann (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV). Additional hantavirus antigens from these and other hantavirus types may also be present. The methods provide for highly accurate results and allow the detection of infection so that treatment can be administered and death avoided.03-03-2011
20110053138Universal multi-variant detection system - The present invention provides a method to diagnostically detect the variants of a given pathogen, such as HIV, hepatitis C, hepatitis B (HBV), Parvovirus B19, etc., with the use of a single detection probe.03-03-2011
20110053144PROCESS AND SYSTEM FOR DETECTING AND/OR QUANTIFYING BACTERIOPHAGES CAPABLE OF INFECTING A PREDETERMINED BACTERIAL HOST STRAIN, USE OF A MICROELECTRONIC SENSOR DEVICE FOR DETECTING SAID BACTERIOPHAGES AND MICROELECTRONIC SENSOR FOR CARRYING OUT SAID PROCESS - The process, system and device being claimed are based on the measurement of the changes in impedance produced in the interface of an electrode whereonto bacteria from a host strain have been previously adhered for detecting the desired bacteriophage. The changes produced in said electrode-bacteria interface originate in the phagic action of the bacteriophages on the bacteria adhered onto the surface of the work electrode of a microelectronic sensor device.03-03-2011
20110053143METHODS AND KITS FOR DETERMINING VIRAL LOAD IN CLINICAL SAMPLES - Methods and kits for determining load of an infectious agent in a sample are described, comprising performing at least one hybridization assay and calculating the load of the infectious agent in the sample from a detected nucleic acid. In particular, the methods and kits disclosed determine the load of human papillomavirus (HPV) in a sample.03-03-2011
20110027775DETECTION OF INFLUENZA VIRUS - A change in strain of flu and consequently pandemic potential can be determined by assessing the presence or absence of a PL motif. The 2009 swine flu illustrates the utility of such a test. The swine flu is a subtype H1N1 influenza A. Swine flu differs from the vast majority of influenza H1N1 subtype strains from 1981-2008 or H3N2 strains from 1985 to the present in that its NS1 protein lacks a PL motif. PDZ polypeptides can be used to identify such strains and distinguish them from strains in which PL motifs are present.02-03-2011
20110027772Antigen Detection Kit and Method - An antigen detection kit and an antigen detection method using the same are provided. The antigen detection kit comprises a capture antibody, a detection antibody bound to a single stranded DNA oligonucleotide, a single stranded RNA oligonucleotide complementary sequence to the DNA oligonucleotide, and an RNase.02-03-2011
20110027773MASS SPECTROMETRIC METHODS FOR DETECTING MUTATIONS IN A TARGET NUCLEIC ACID - Fast and highly accurate mass spectrometry-based processes for detecting particular nucleic acid molecules and mutations in the molecules are provided. In some embodiments, a process comprises: amplifying a nucleic acid from a biological sample; ionizing and volatilizing the amplified product; analyzing the product by mass spectrometry to determine an observed molecular mass of the product; and comparing the observed molecular mass of the product to a calculated molecular mass of at least one nucleic acid having a known sequence, wherein the calculated molecular mass of the at least one nucleic acid having a known sequence is derived from the base composition of the at least one nucleic acid having a known sequence; whereby the presence or absence of the target nucleic acid is detected based on the comparison.02-03-2011
20100285447Methods for Antimicrobial Resistance Determination - The present invention relates to methods and systems for determining the antibiotic-resistance status of microorganisms. The invention further provides methods for determining the antibiotic-resistance status of microorganisms in situ within a single system.11-11-2010
20100285443Diagnostic Methods for Diseases Caused by a HPV Infection Comprising Determining the Methylation Status of the HPV Genome - Methods and kits for diagnosing and/or monitoring the progression of or otherwise staging a disease caused by a human papillomavirus (HPV) infection in a test sample obtained from a subject comprise determining the methylation status of a HPV genome. The presence of hypermethylation of the HPV genome indicates a positive diagnosis of the disease and/or an increased level of methylation of the HPV genome indicates the progression of the disease to a more advanced form. Suitable diseases linked to HPV infection include cancers such as cervical cancer. High risk HPV types such as HPV16 are generally assessed in the methods and using the kits of the invention. The HPV16 methylome is provided.11-11-2010
20100285444HBV precore protein capable of forming particles - There is provided a HBV precore protein having an ability of forming particles, and a means for determining it. A novel HBV precore protein that forms the virus (like) particles of HBV was identified. The present invention provides this novel HBV precore protein. Furthermore, there are provided core-like particles and virus-like particles formed by this HBV precore protein. These virus-like particles can be used for vaccines and therapeutic agents. The present invention also provides a method of determining the HBV precore protein and a method of determining the anti-HBV precore protein antibody.11-11-2010
20100285446Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry - According to certain embodiments, a method of mass spectrometry may generally comprise subjecting a sample comprising at least one indicator to laser ablation electrospray ionization mass spectrometry; determining a relative intensity of the indicator; and comparing the relative intensity of the indicator to a standard indicator intensity. Subjecting a sample to laser ablation electrospray ionization mass spectrometry may comprise ablating the sample with an infrared laser under ambient conditions to form an ablation plume; intercepting the ablation plume by an electrospray plume; and detecting the indicator by mass spectrometry. The method of mass spectrometry may comprise classifying the sample as belonging to or not belonging to the standard indicator intensity. A sample not belonging to the standard indicator intensity may indicate that the sample is predicted to comprise a disease state.11-11-2010
20110136099Multiplexed Analyses of Test Samples - The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications.06-09-2011
20110136102Surface Impedance Imaging Methods and Apparatuses - Methods and apparatuses for imaging surface impedance.06-09-2011
20110136098METHODS FOR SIMPLIFYING MICROBIAL NUCLEIC ACIDS BY CHEMICAL MODIFICATION OF CYTOSINES - A method for detecting a microorganism comprising reducing the complexity of a microbial genome or microbial nucleic acid by generating a simplified form of the microbial genome or microbial nucleic acid in which substantially all of the positions naturally occupied by cytosines are occupied by uracil or thymine; and assaying for a microbial specific nucleic acid in the simplified form of the microbial genome or microbial nucleic acid, wherein presence of the microbial specific nucleic acid is indicative of the microorganism.06-09-2011
20100323345METHODS AND COMPOSITIONS FOR IDENTIFYING CELLS BY COMBINATORIAL FLUORESCENCE IMAGING - A method of identifying the classification of cells in situ involves labeling the cells with a set of nucleic acid probes and performing combinational fluorescence microscopic imaging. The set of probes contains groups of probes that bind to a taxon-specific or function-specific nucleotide sequence. Each probe of a group of probes is labeled with a distinct fluorescent label, and each group corresponds to a unique combination of labels, which can be detected across the image and serves to identify cells according to a unique taxonomic or functional classification. The combinational labeling and spectral imaging approach expands the number of different classifications that can be identified simultaneously in a single image of a collection of cells. The methods and probe sets of the invention can be used to rapidly identify microbes, study their ecological relationships, screen for novel antibiotics, and identify pathogens.12-23-2010
20100323343METHODS AND COMPOSITIONS FOR ANALYTE DETECTION - The present invention is directed to methods and apparatus for detection of one or more analytes. Analytes include agents or components of infectious agents such as pathogenic virus, as well as enzymes, proteins and biomarkers.12-23-2010
20100330550DETECTION OF HUMAN PAPILLOMAVIRUS - The present invention relates to in vitro methods of screening human subjects for the presence of human papillomavirus (HPV) which exhibits loss of regulation of E6/E7 mRNA expression and loss of replication and/or expression of a stabilized pre-mRNA encoding full length E6 protein. In particular, the invention provides in vitro methods of screening for persistent transforming HPV infection equivalent to persistent cell abnormalities or persistent CIN III lesions, cancer in situ or high-grade squamous intraepithelial lesions (HSIL). The methods are useful in the context of cervical cancer screening.12-30-2010
20100330549HETERODUPLEX TRACKING ASSAY - A change in viral tropism occurs in many HIV positive individuals over time and may be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus may be shifted back to CCR5-mediated entry soon after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment and clinical management of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CCR5- or CXCR4-specific strains. The diagnostic methods may be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. The methods of the invention include cell-based methods, including cell fusion assays, and molecular-based methods, including heteroduplex tracking assay, to both quantitatively and qualitatively analyze patient-derived HIV for coreceptor usage.12-30-2010
20090208925Methods and Compositions for Determining Hypersusceptibility of HIV-1 to Non-Nucleoside Reverse Transcriptase Inhibitors - This invention relates to methods for determining hypersusceptibility of HIV-1 viruses to non-nucleoside reverse transcriptase inhibitors (NNRTIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding reverse transcriptase of the HIV-1, the presence of a mutation at codon 65, 69, or 74 alone or in combination with one or more mutations at certain other codons. Combinations of mutation associated with hypersusceptibility to NNRTIs are also disclosed.08-20-2009
20090208924Generation of Replication Competent Viruses for Therapeutic Use - The present invention relates to the generation or replication-competent viruses having therapeutic utility. The replication-competent viruses of the invention can express proteins useful in the treatment of disease.08-20-2009
20110256524RECOMBINANT ADENOVIRUS COMPRISING TISSUE-SPECIFIC PROMOTER AND TUMOR-TARGETING TRANS-SPLICING RIBOZYME AND USES THEREOF - Disclosed herein are a recombinant adenovirus comprising tissue-specific promoters and trans-splicing ribozymes targeting tumor-specific genes, and uses thereof. More specifically, disclosed herein are a recombinant adenovirus comprising (1) a tissue-specific promoter, (2) a trans-splicing ribozyme acting on tumor-specific genes operably linked to the promoter, and (3) a therapeutic or reporter gene linked to 3′ exon of the ribozyme, an anticancer pharmaceutical composition comprising the same, and a composition for cancer diagnosis comprising the same.10-20-2011
20100173280Systems for Detection and Production of Respiratory, Herpes and Enteric Viruses - The present invention generally relates to the field of diagnostic microbiology, and, more particularly, to compositions and methods for detecting and differentiating one or more viruses or other intracellular parasites present in a specimen. The present invention also provides compositions and methods to evaluate the susceptibility of organisms to antimicrobial agents.07-08-2010
20110151434ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY - A method for detecting and isolating AAV sequences in a sample of DNA obtained from tissue or cells is provided, which sample contains DNA and proviral AAV. The method involves subjecting the sample containing DNA to amplification via polymerase chain reaction (PCR) using a first set of primers which specifically amplify a first AAV region. The first AAV region is characterized by having at least 250 nucleotides of AAV capsid nucleic acid sequence, a variable sequence flanked by a sequence of at least 18 nucleotides at the 5′ end of the first AAV region and a sequence of at least 18 nucleotides at the 3′ end of the first AAV region. Each of the 5′ and 3′ at least 18 nucleotides is the same over at least 9 consecutive nucleotides relative to corresponding sequences in an alignment of at least two AAV serotypes. Each of the sets of primers consist of a 5′ primer and a 3′ primer. The method is further useful for identifying AAV sequences in the sample by the presence of amplified proviral AAV sequences.06-23-2011
20100055670GROWTH OF WILD-TYPE HEPATITIS A VIRUS IN CELL CULTURE - The invention provides recombinant Hepatitis A Virus (HAV) nucleic acids and host cells that are permissive for their growth and replication. The recombinant Hepatitis A Virus nucleic acids not particularly limited, except that they incorporate at least one heterologous nucleic acid fragment. The heterologous nucleic acid can encode a selectable marker gene and such recombinant HAV nucleic acids are useful for selecting cells that are permissive for growth and replication of wild type HAV. Alternatively, the heterologous nucleic acid may encode a vaccine antigen or other expression product that is desirable to express in a cell harboring the recombinant HAV nucleic acid. The invention further provides cell lines permissive for growth and replication of wild type HAV or HAV having minimal mutations for growth in cell culture. The invention further provides methods for producing HAV vaccines and for monitoring environmental and patient samples for the presence of HAV.03-04-2010
20100255461METHOD FOR PRODUCTION OF MOLDED BODIES, IN PARTICULAR OPTICAL STRUCTURES AND USE THEREOF - The present invention relates to a method for manufacture a body from a thermoplastic plastic with a three-dimensionally structured surface, wherein molding is performed directly from a master made of glass coated with metal oxide, without deposition of further coatings on a surface of the master. The invention also relates to bodies manufactured with this method from a thermoplastic featuring a three-dimensionally structured surface, as well as to planar optical structures likewise manufactured with this method for generating evanescent-field measuring platforms and to a use thereof. The invention furthermore relates to a planar optical structure for generating an evanescent-field measuring platform, comprising a first essentially optical transparent, waveguiding layer (a) with refractive index n10-07-2010
20120028245Quantitative analyte assay device and method - The present invention relates to a quantitative assay device and a method for the determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains two bands having deposited on there high and low concentrations of different calibrator agents and a test band capable of reacting with conjugated analyte complexes giving rise to a measurable signal.02-02-2012
20100159444DEVICES FOR THE DETECTION OF MULTIPLE ANALYTES IN A SAMPLE - The present invention relates generally to an assay for detecting and differentiating multiple analytes, if present, in a single fluid sample, including devices and methods therefore.06-24-2010
20100159441MULTI-WAVELENGTH ANALYSES OF SOL-PARTICLE SPECIFIC BINDING ASSAYS - The present invention discloses methods for detecting the presence of a complex between a first reagent and a second reagent in solution. In particular, the invention provides methods for qualitative or quantitative detection of an analyte or its specific binding partner in complex biological samples. The invention further discloses algorithms using summary rate changes at selected wavelengths in the absorbance spectra of colloidal metal-labeled analytes or specific binding partners to identify intermolecular interactions between the analyte and its binding partner.06-24-2010
20100196877METHOD OF DETECTION OF MICROORGANISMS WITH ENHANCED BACTERIOPHAGE AMPLIFICATION - A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: combining with the sample an amount of bacteriophage capable of attaching to the target microorganism to create a bacteriophage exposed sample, and a substance which enhances bacteriophage amplification or sensitivity; providing conditions to the bacteriophage-exposed sample sufficient to allow the bacteriophage to infect the microorganism; and assaying the bacteriophage-exposed sample to detect the presence or absence of a bacteriophage marker to determine the presence or absence of the target microorganism.08-05-2010
20100196876Methods and Reagents for Genotyping HCV - The present invention is directed to methods and reagents for determining the genotype of a hepatitis C virus (HCV) species present in a test sample. The invention more particularly relates to mixtures of degenerate amplification and sequencing primers, and methods of using such primers, that are complementary to a plurality of HCV species, and are capable of generating nucleotide sequence information for a region of NS5B of HCV that is, for each species, indicative of the type and/or subtype, of the species present in the sample.08-05-2010
20100196875HUMAN ERYTHROVIRUS - Nucleic acid molecules derived from sequences of novel human parvovirus B19 variant genomes are provided. Also provided are assays and kits comprising the nucleic acid molecules.08-05-2010
20100196878DUAL-RECOGNITION IMMUNOASSAY FOR THE DETECTION OF ANTIBODIES - The invention relates to a dual-recognition immunoassay for the detection of antibodies specific to a target antigen in a sample which comprises contacting said target antigen with a sample suspected of containing said antibodies specific to said target antigen under conditions allowing the formation of an antigen-antibody complex; adding a conjugate comprising said target antigen and a marker under conditions allowing the formation of an antigen-antibody-antigen/marker complex; and detecting said antigen-antibody-antigen/marker complex. The immunoassay can be used, among other applications, in the diagnosis of infections caused by pathogenic organisms with high sensitivity and specificity.08-05-2010
20100068696UNIVERSAL BIOSENSOR AND METHODS OF USE - The present invention relates to methods for detecting or quantifying an analyte in a test sample including providing at least one test mixture including a test sample, at least one marker complex, wherein each marker complex includes a particle, a marker, and one member of a coupling group, a first binding material selected to bind to a portion of the analyte, a second binding material selected to bind with a portion of the analyte other than the portion of the analyte for which the first binding material is selected, analyte analog, and/or marker conjugate. The at least one test mixture is passed through a membrane. The amount of marker on the membrane is detected and correlated to the presence or amount of analyte in the test sample.03-18-2010
20100068698PRODUCTION OF INFECTIOUS HEPATITIS C VIRUS PARTICLES IN CELL CULTURE - The present invention provides for novel methods of producing high levels of infectious HCV genotype 1 virus particles in cell culture systems. The availability of HCV genotype 1 virus (principally associated with liver disease in most regions of the world) that can undergo the complete viral cycle in cultured cells is beneficial for the discovery and development of novel therapies for the treatment of HCV.03-18-2010
20090181363NON-INVASIVE DETECTION OF FISH VIRUSES BY REAL-TIME PCR - A real-time assay coupled with a non-invasive tissue sampling was developed for the detection and quantification of fish viruses. As a proof of principles, data were presented for the detection and quantification of infectious hypodermal necrosis virus (IHNV) in trout. The primers were designed for IHNV nucleocapsid (N), and surface glycoprotein (G) genes, and trout &bgr;-actin and elongation factor-l&agr; (EF-I &agr;) were used as internal control for the assay. The reaction conditions for the real-time RT-PCR were optimized using cDNA derived from IHNV-infected Epithelioma papulosum cyprinid (EPC) cells. Using both N- and G-gene primers, IHNV was successfully detected in liver, kidney, spleen, adipose tissue and pectoral fin samples of laboratory-challenged and wild samples. The dissociation curves with a single melting peak at expected temperature (85° C. for the N-gene and 86.5° C. for the G-gene) confirmed the specificity of the N- and G-gene amplicons. The IHNV N- and the G-gene expression levels in different tissues of laboratory challenged samples were in the order of spleen, liver, kidney, adipose tissue and pectoral fin, however in the field-collected samples the order of gene expression was liver, kidney, pectoral fin, adipose tissue, and spleen. The N- and G-gene expressions in spleen were found to be dramatically lower in the field-collected samples compared to the laboratory-challenged samples indicating a potential difference in the IHNV replication in the laboratory as opposed to field conditions. The real-time PCR assay was found to be rapid, highly sensitive, and reproducible. Based upon the ability to detect the virus in pectoral fins a non-invasive detection method for IHNV and other fish viruses is developed. Such a non-invasive tissue sampling coupled with real-time PCR assay is very valuable for large-scale virus screening of fish in aquaculture facilities as well as for epidemiological studies.07-16-2009
20120208175DETECTION OF HIV-RELATED PROTEINS IN URINE - A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed.08-16-2012
20090202983Method For Determining The Concentration of Virus Particles/Virus Antigens - The invention provides a method for determining the concentration of virus particles and/or virus antigens in a sample. In particular, the invention relates to determining the concentration of influenza virus particles/influenza virus antigens in a sample. The invention further relates to the use of an ion-exchange matrix for the determination of the concentration of virus particles and/or virus antigens in a sample.08-13-2009
20090197243Method and composition for rapid viability testing of cells - The present invention relates to a method for rapidly monitoring a stress response of a cell to a stressor and determining the magnitude of the stress response; a method for rapidly detecting the presence or absence of a cell by monitoring a stress response of the cell if said cell is present, or the absence of the stress response if said cell is absent or dead; and a method for determining a predictive outcome for the susceptibility of a cell to a selected concentration of a bio-active agent or environmental factor and a level of stress of the cell at the selected concentration of the bio-active agent. Also disclosed are kits for carrying out the methodology according to an embodiment of the invention.08-06-2009
20090176204Method for improved diagnosis of dysplasias - The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterising the proliferation properties of the respective cell. The characterisation of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.07-09-2009
20090176202Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIV - The invention comprises methods and cell lines for assaying APOBEC3G degradation and methods for identifying inhibitors of APOBEC3G degradation. The invention also provides methods of identifying inhibitors of HIV infection. The methods of the invention are useful for identifying inhibitors of viral infection, in particular, the methods of the invention are useful for treating retroviral infection.07-09-2009
20090176203Mutant HSV, Materials and Methods for Generation of Mutant HSV - A method of generating a mutant Herpes Simplex Virus (HSV) is disclosed, wherein the generated HSV genome comprises nucleic acid encoding a nucleic acid sequence of interest, the method comprising the steps of: i. providing a nucleic acid vector comprising nucleic acid encoding first and second site specific recombination sequences and a nucleic acid encoding a nucleic acid sequence of interest between said site specific recombination sequences; ii. providing an HSV, the genome of which comprises third and fourth site specific recombination sequences; iii. contacting said nucleic acid vector of (i) with said HSV of (ii) together with one or more recombinase enzymes capable of catalysing site specific recombination between the site specific recombination sequences of said nucleic acid vector and said HSV; iv. identifying HSV containing the nucleic acid sequence of interest, wherein steps i-iii are conducted in a cell-free system.07-09-2009
20120070820Probes and Methods for Hepatitis C Virus Typing Using Multidimensional Probe Analysis - This invention provides compositions and methods for HCV typing, e.g., genotyping and/or subtyping. The compositions and methods of the invention can be used to assign an HCV isolate to one of at least five HCV types (for example, selected from types 1, 2, 3, 4, 5 or 6), or to one of at least five subtypes (for example, subtypes 1a/b/c, 2a/c, 2b, 3a, 4a, 5a or 6a). These methods integrate the hybridization data from a plurality of HCV typing probes in a multidimensional analysis to make an HCV type assignment for an HCV in an experimental sample. The invention also provides related compositions, including, for example, the HCV typing probes and HCV typing diagnostic kits.03-22-2012
20110189656Method for Determining Presence or Absence of Abnormal Cell - A method for determining the presence or absence of an abnormal cell in a sample collected from the uterine cervix of a subject, and a method for predicting the progression of a lesion in the uterine cervix in a subject, each of which comprises measuring the frequency of methylation in the genomic DNA of human papillomavirus contained in the sample and determining the presence or absence of the abnormal cell or predicting the progression of the lesion based on the frequency; and a primer set which can be used in the above-mentioned methods.08-04-2011
20110189654DIAGNOSTIC REAGENT, CONTAINING BIOPARTICLES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF AS INTERNAL STANDARD IN NUCLEIC ACID PREPARATION AND NUCLEIC ACID DETECTION METHODS - A diagnostic reagent in the form of a composition dimensionally stable under standard conditions, comprising bioparticles and also customary pharmaceutical excipients, wherein the bioparticles are selected from the group consisting of bacteria, viruses, fungi, protozoa, bacteriophages, yeasts, spores, parasites, plant cells, animal or human cells, gametes, plasmids, and viroids.08-04-2011
20110189653DETECTION AND PROGNOSIS OF CERVICAL CANCER - The present invention relates to methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. These methods include determining the methylation status or the expression levels of particular genes, or a combination thereof.08-04-2011
20110189652VIRAL VARIANTS WITH ALTERED SUSCEPTABILITY TO NUCLOESIDE ANALOGS AND USES THEREOF - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.08-04-2011
20120308995VACCINIA VIRUS MUTANTS CONTAINING THE MAJOR GENOMIC DELETIONS OF MVA - The present invention provides modified vaccinia virus (VACV) genomes as well as vectors, especially viral vectors comprising the same. The present invention further provides modified vaccinia viruses. The present invention further provides methods for determining the effect of mutations in VACV with regard to competence for replication in certain cell types. The present invention further provides methods of preparing modified vaccinia viruses.12-06-2012
20120308992DRY STICK DEVICE AND METHOD FOR DETERMINING AN ANALYTE IN A SAMPLE - A method of preparing a dry stick test device for determining an analyte in a milk sample by chemical assay. At least one reagent pad is provided by impregnating a first porous material with an aqueous solution including a reagent capable of reacting with the analyte, a derivative of the analyte or an indicator compound for the analyte to provide a detectable signal when in a moistened state. The reagent pad is dried. A development pad is provided by impregnating a second porous material with an aqueous solution including at least one controlling compound which, when in a moistened state, is capable of providing a condition required for the reagent to react with the analyte to provide the detectable signal. The impregnated second porous material is dried. The first porous material is immobilized with the second porous material, on a solid support, to obtain the dry stick test device.12-06-2012
20110189655REAGENTS AND KITS FOR DETECTION OF INFLUENZA VIRUS AND THE LIKE - The present invention relates to reagents and methods for influenza virus detection. These reagents and methods disclosed in the present invention enable simple, rapid, specific and sensitive detection of influenza virus types A and B. These reagents are N-acetylneuraminic acid-firefly luciferin conjugates which can be cleaved by influenza virus neuraminidase.08-04-2011
20100028858 HIGH SENSITIVITY ASSAY FOR MOLECULAR TYPING OF BIOLOGICAL SAMPLE, PROBES AND A KIT THEREOF - The present invention relates to a high sensitivity assay for molecular typing of a biological sample using surface-enhanced Raman scattering (SERS) including resonance scattering (SERRS); capture probes for capturing nucleic acid; a detector probe to detect captured nucleic acid; a kit for molecular typing of biological sample using surface-enhanced Raman scattering (SERS) including resonance scattering (SERRS); and lastly a method of manufacturing said kit.02-04-2010
20100028856METHOD TO DETECT VIRUS RELATED IMMUNOLOGICAL MARKERS FOR THE DIAGNOSIS OF HEPATITIS B VIRUS INFECTION - This invention discloses using SPR technology to simultaneously and qualitatively measure the presence of HBV-associated immunological markers in a serum sample for the diagnosis of HBV infection. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of HBV related antigens or antibodies used for the diagnosis of HBV infection.02-04-2010
20100028854METHODS FOR MODELING INFECTIOUS DISEASE AND CHEMOSENSITIVITY IN CULTURED CELLS AND TISSUES - The present invention provides methods for utilizing a form of optimized suspension culture to examine the infectivity of pathogenic organisms and agents in human cells and tissues. Also provided are methods using a rotating wall vessel to predict Chemosensitivity of cells and tissues to toxins and chemotherapeutic agents. These culture conditions potentiate spatial colocalization and three-dimensional assembly of individual cells into large aggregates which more closely resemble the in vivo tissue equivalent. In this environment, dissociated cells can assemble and differentiate into macroscopic tissue aggregates several millimeters in size. These culture conditions allow for better cellular differentiation and formation of three-dimensional cellular aggregates, more efficient cell-to-cell interactions, the in in vivo-like exchange of growth factors and greater molecular scaffolding facilitating mechanical stability for cells. The suspension culture system offers a new approach for studying microbial infectivity from the perspective of the host-pathogen interaction and also for analyzing chemosensitivity to toxins and chemotherapeutic agents.02-04-2010
20100021882 METHOD TO DETECT VIRUS RELATED IMMUNOLOGICAL MARKERS FOR THE DIAGNOSIS OF RESPIRATORY TRACT INFECTIONS - This invention discloses using SPR technology to simultaneously and qualitatively detect the presence of respiratory tract viruses-related immunological markers in a serum sample, which can be used for the diagnosis of respiratory tract infections. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of representative antigens used to detect the respective respiratory tract viruses-related immunological markers (antibodies) in blood for the diagnosis of respiratory tract infections.01-28-2010
20080286755Immunoglobin IgG3 as a marker for protecting against infectious viral diseases, and the uses of the same - The invention relates to a novel variant of isolated and/or purified immunoglobulin IgG3 which can be used as a marker for protecting against infectious viral diseases such as AIDS, as a diagnostic tool, or as a preventative and curative medicament. The invention also relates to corresponding in vitro diagnostic methods.11-20-2008
20100028853OPTICAL DETERMINATION OF LIVING VS. NON LIVING CELLS - A method of determining whether a cell sample in a medium contains living or dead cells of a predetermined target cell type is disclosed. The method includes preparing a testing substrate by attaching a binding molecule thereto, the binding molecule having the property of immobilizing cells of the target cell type upon coming in contact therewith. The method also includes incorporating a colorimetric indicator onto the testing substrate, performing a first spectrographic analysis of the calorimetric indicator, determining a change in pH of the medium based upon a second spectrographic analysis of the colorimetric indicator as compared to the first, and determining the portion of live target cells in the medium based upon the change in pH.02-04-2010
20080318206DETECTION OF HERPES SIMPLEX VIRUS TYPES 1 AND 2 BY NUCLEIC ACID AMPLIFICATION - The present invention relates to a method of detecting the presence or absence of herpes simplex virus (HSV) in a sample based on amplifying a portion of the Glycoprotein G (US4) gene of HSV and detecting the presence of the amplified nucleic acid using primers and detector primers as described herewith. The method of the invention further identifies the type of HSV, either HSV-1 or HSV-2, in a sample. Also encompassed by the invention is a kit comprising the primers and detector primers which may be used with the amplification method described herewith.12-25-2008
20100151447METHOD FOR DOUBLE STAINING IN IMMUNOHISTOCHEMISTRY - The present invention relates to kits and methods for performing dual-staining immunohistochemistry (IHC) for the detection of specific cell populations in tissue samples containing heterogeneous populations of cells, which can be observed by a light microscope for co-localization of distinct pigments. The method includes providing a tissue sample comprising fixed cells; exposing the sample to first and second ligands that recognize different marker proteins found at the same cellular location, thereby forming a ligand-labeled sample; exposing the ligand-labeled sample to first and second labeling reagents, the first labeling reagent binding to the first ligand and the second labeling reagent binding to the second ligand, the first and second labeling reagents each forming distinct pigments; and identifying the number of cells that display only one particular pigment, or more than one pigment, by the different coloration of the cellular location labeled by the distinct pigment.06-17-2010
20100173284Method for Detection of HCV at the Real Time PCR with Intercalating Dye - The present invention relates to a composition for detection of HCV by a single step reaction, comprising a specific primer and probe. In particular, the present invention relates to a composition for detection of HCV by a single step reaction, comprising the primer sequences of SEQ ID NOs:1 and 2; a composition for detection of HCV by a single step reaction, comprising both the primer sequences and a probe of SEQ ID NOs:5 or 9; a method for detecting HCV by a single step reaction, comprising the steps of obtaining a sample from a subject, and amplifying and detecting HCV using the primer and probe; and a kit comprising the primer and probe, in which the HCV detection method is characterized by a single step reaction.07-08-2010
20090197244Method for typing and detecting HBV - The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG. 08-06-2009
20100055669Generation of Recombinant Genes in Bacteriophages - In vivo methods for generating and detecting recombinant DNA sequences in bacteriophages or plasmids containing bacteriophage sequences, methods for generating hybrid genes and hybrid proteins encoded by these hybrid genes by the use of bacteriophages and plasmids containing bacteriophage sequences, bacteriophages and plasmids that can be used in these methods, and kits comprising appropriate bacterial host cells and bacteriophages or plasmids are described.03-04-2010
20110008766Dual Variable Domain Immunoglobulins and Uses Thereof - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.01-13-2011
20100184018Detection of Herpes Simplex Virus - The invention provides methods to detect herpes simplex virus (HSV) in biological samples and further to distinguish between HSV-1 and HSV-2. Primers and probes for the differential detection of HSV-1 and HSV-2 are provided by the invention. Articles of manufacture containing such primers and probes for detecting HSV are further provided by the invention.07-22-2010
20100035231ANTIGEN CAPTURE ANTI-DENGUE IGA ELISA (ACA-ELISA) FOR THE DETECTION OF A FLAVIVIRUS SPECIFIC ANTIBODY - An antigen capture IgA Enzyme Linked Immunosorbent Assay (ACA-ELISA) was developed for the detection of anti-flavivirus IgA. The assay utilizes flavivirus lysate antigen, preferably dengue virus lysate antigen captured by a monoclonal antibody. Captured anti-flavivirus IgA from test sera are preferably detected using rabbit anti-IgA conjugated with a reporter group such as horseradish peroxidase (HRP). The assay was found to be at least 8 times more sensitive than anti-human IgA capture ELISA (AAC-ELISA). The ACA-ELISA, based either on serum or saliva, was found to be more sensitive and rapid compared to the “gold standard” anti-dengue IgM detection technique and can be utilized as a diagnostic tool for the confirmation of dengue in the early phase of infection.02-11-2010
20090176200Modified Human Hepatitis C Virus Genomic RNA That can be Autonomously Replicated - The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5′ untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3′ untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.07-09-2009
20090068639System and method of quantitatively determining a biomolecule, system and method of detecting and separating a cell by flow cytometry, and fluorescent silica particles for use in the same, and kit comprising plural kinds of the silica particles in combination - A system of quantitatively determining a biomolecule, which has: allowing fluorescent silica particles capable of emitting fluorescence detectable by a flow cytometer to capture a target biomolecule fluorescent-labelled for quantitative determination; detecting the fluorescence emitted from the fluorescent silica particles themselves by using the flow cytometer; and measuring the intensity of the fluorescence of the labelled target biomolecule, thereby quantitatively determining the target biomolecule.03-12-2009
20110117539Detection of an Analyte in a Sample - There is provided mechanisms for the detection of an analyte in a sample. The mechanisms utilize at least a first measurement channel comprising a detection reactant corresponding to the analyte to be detected, and at least a microstructure associated with the first measurement channel. When the mechanisms are in use, the sample is introduced into the first measurement channel and propagated by way of the first measurement channel towards the microstructure. If the analyte, if it is present in the sample, the analyte interacts with the detection reactant to form a networked product, and the microstructure is configured to filter the networked product.05-19-2011
20110117542REAL TIME ELECTRONIC CELL SENSING SYSTEM AND APPLICATIONS FOR CYTOTOXICITY PROFILING AND COMPOUND ASSAYS - The invention provides methods of investigating a mechanism of action of a compound, which includes providing a device for monitoring cell-substrate impedance; attaching the device to an impedance analyzer; adding cells to two or more wells; adding a test compound to at least one of the wells and providing at least one control well; monitoring impedance of the wells to obtain a series of impedance measurements; plotting impedance measurements to obtain impedance curves and comparing the impedance curves to determine a time frame at which the test compound has a significant effect on cell growth or behavior. Determining the time frame provides information on changes in cell status in response to the test compound, including cell attachment or adhesion status, cell growth or proliferation status, the number of viable or dead cells, cytoskeletal organization or structure, and the number of cells going through apoptosis or necrosis.05-19-2011
20110117540Highly Simplified Lateral Flow-Based Nucleic Acid Sample Preparation and Passive Fluid Flow Control - Highly simplified lateral flow chromatographic nucleic acid sample preparation methods, devices, and integrated systems are provided for the efficient concentration of trace samples and the removal of nucleic acid amplification inhibitors. Methods for capturing and reducing inhibitors of nucleic acid amplification reactions, such as humic acid, using polyvinylpyrrolidone treated elements of the lateral flow device are also provided. Further provided are passive fluid control methods and systems for use in lateral flow assays.05-19-2011
20100323342MICRO-DEVICE AND METHOD FOR SELECTIVE AND NON-INVASIVE SEPARATION AND EXTRACTION OF PARTICLES IN POLYDISPERSED SUSPENSIONS, MANUFACTURING PROCESS AND APPLICATIONS THEREOF - The present invention relates to a micro-device for selective and non-invasive separation of particles in polydispersed suspensions through the strategic use of ultrasounds, laminar flow and standing wave effects in a channel produced in a chip by means of microtechnology. Said device is a resonant multi-layer system with a modified lambda quarter-type treatment channel, which enables the particles to be channeled and separated in a flow inside the substrate channel without touching the walls of the device, in order to avoid problems of adherence. Said micro-device can be used in the field of biomedicine and/or biotechnology for the separation and concentration of cells, preferably human cells, applicable to research and medical processes for diagnosis and treatment.12-23-2010
20100233676HIGH AFFINITY FLUOROCHROME BINDING PEPTIDES - The present invention contemplates strategies comprising small molecule, cell permeable probes that allow site-specific protein labeling for visualizing biological processes. In one embodiment, the present invention contemplates a series of short peptide sequences comprising high affinity binding (i.e., for example, subnanomolar affinity (0.53 nM) for indocyanine fluorochromes. In one embodiment, the peptide sequences comprise a 5 pmol detection limit for indocyanine fluorochromes. In one embodiment, the present invention contemplates methods comprising high affinity peptide-fluorochrome binding pairs in biological applications including, but not limited to, enzyme linked immunoabsorbent assay (ELISA), fluorescence activated cell sorting (FACS), microscopy (i.e., for example scanning electromicroscopy), Western Blots, histochemistry, protein and cell based tracking both in vitro and in vivo.09-16-2010
20090081639Assay for sensitivity to chemotherapeutic agents - Diagnostic methods for assaying the efficacy of chemotherapeutic agents in vitro for the treatment of cancer and methods for identifying chemotherapeutic agents are provided. The methods employ reporter viruses. Combinations and kits for use in the practicing the methods are also provided.03-26-2009
20090220938VIRAL NUCLEOPROTEIN DETECTION USING AN ION CHANNEL SWITCH BIOSENSOR - The present invention provides a method of detecting viruses, such as respiratory-related viruses, in a sample with a sensitivity of at least 80%, and/or specificity of at least 90%, and/or with an accuracy of at least 90%. The method comprises contacting the sample with a biosensor. The present invention also provides a biosensor comprising a membrane and a solid conducting surface, with the membrane being attached to the solid conducting surface in a manner such that a reservoir exists therebetween. The membrane comprises first and second layers each comprising closely packed amphiphilic molecules; a plurality of first and second ionophores located in the first and second layers, respectively; and a plurality of antibodies or fragments thereof directed against nucleoproteins of respiratory-related viruses, more specifically, nucleoproteins of an influenza virus, and covalently attached to the second ionophores. The present invention further provides a device comprising an array of such biosensors.09-03-2009
20090208926DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESSMENT OF PROTEIN GLYCOSYLATION - Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.08-20-2009
20110033842 Skin Sampling Kit Which Stores Nucleic Acids In Stable Status, Genetic Test Methods By Using The Kit And Their Practical Application - The present invention relates to a new skin gene card for genetic test, a method for acquiring DNA and RNA and performing various genetic tests using the same, and practical applications thereof. More specifically, the inventors of the present invention have developed a skin gene card capable of acquiring samples from human skin, hair or mucosa simply, safely and quickly and enabling stable long-term storage and transport of DNA and RNA included in the acquired sample at room temperature. Various genetic tests may performed using the acquired DNA and RNA, including polymerase chain reaction (PCR), reverse transcription (RT)-PCR, real-time PCR, sequencing, hybridization, DNA chip analysis, single-nucleotide polymorphism (SNP) assay, gene mutation assay, promoter methylation assay, gene expression assay, etc. The genetic skin test result may be utilized for disease prognosis, nutrigenomic test, pharmacogenomic test, forensic test such as personal identification, diagnosis of genetic diseases, diagnosis of skin diseases, or the like. In addition, through an objective evaluation of the skin or hair condition, a personalized cosmetic and skin care system may be established for practical application in beauty care, cosmetology, dermatology, and clinical practice.02-10-2011
20090215029METHODS OF ISOLATING AND PURIFYING NUCLEIC ACID-BINDING BIOMOLECULES AND COMPOSITIONS INCLUDING SAME - The invention provides methods for isolating or purifying a biomolecule directly or indirectly bound to a region of interest of a nucleic acid in a cell, and methods for isolating or purifying a biomolecule that directly or indirectly binds to a region of interest of a nucleic acid in a cell. The invention further provides substantially cell free, isolated and purified biomolecule(s) that are fixed or cross-linked to a region of interest of a nucleic acid, which optionally reflects the interaction of the biomolecule(s) with the nucleic acid in the cell (e.g., in native chromatin) when fixed or cross-linked to the region of interest. Substantially cell free, isolated and purified biomolecules that are fixed or cross-linked to a region of interest of a nucleic acid can remain fixed or cross-linked to the region of interest of the nucleic acid when heated or treated with denaturing compounds or agents.08-27-2009
20110306038ASSAY FOR DETECTION OF HUMAN PARVOVIRUS NUCLEIC ACID - Nucleic acid oligomers specific for human parvovirus genomic DNA are disclosed. An assay for amplifying and detecting human parvovirus genotypes 1, 2 and 3 nucleic acid in biological specimens is disclosed. Compositions for amplifying and detecting the presence of human parvovirus genotypes 1, 2 and 3 genomic DNA in human biological specimens are disclosed.12-15-2011
20110306037OLIGONUCLEOTUIDE PROBES AND PRIMERS FOR DETECTION OF HEPATITIS B VIRUS - The present disclosure provides a method for the detection and quantification of Hepatitis B Virus. It discloses oligonucleotide probes set forth in SEQ ID Nos. 1 and 2 for detection of Hepatitis B Virus along with respective primers [sense and antisense] set forth in SEQ ID Nos. 3, 4, 5 and 6. It also provides a PCR reaction mixture for detection of Hepatitis B Virus and a kit for detection of HBV comprising said mixture along with an instruction package.12-15-2011
20110306035Methods and Compositions for Detection of a Pathogen, Disease, Medical Condition, or Biomarker Thereof - Provided are methods for detecting the presence or absence of a pathogen, disease, or medical condition, or biomarker thereof, using an enzymatic activity assay. In one embodiment, the method provided utilizes competitive inhibition of an enzyme for detecting a pathogen, disease, or medical condition, or biomarker thereof, in a subject. The method comprises providing a biological sample from the subject that may or may not contain an endogenous substrate. A test reaction is provided by contacting the biological sample with an enzyme indicative of the biomarker of a pathogen, disease, or medical condition and a substrate comprising a signaling moiety. The enzyme modifies the endogenous substrate and the substrate comprising the signaling moiety. Modification of the substrate comprising the signaling moiety by the enzyme produces a signal from the signaling moiety. Data from a control reaction comprising the enzyme and the substrate comprising the signaling moiety is further provided. The signal produced by the signaling moiety in the test reaction is detected. The presence of the biomarker of the pathogen, disease, or medical condition is indicated by a difference caused by the presence of the endogenous substrate in the biological sample between the signal produced in the test reaction and the data from the control reaction. In another embodiment, there is provide a method of detecting the presence or absence of enzymatic activity in a biological sample indicative of a pathogen, disease, or medical condition, or biomarker thereof, in a subject. The method comprises contacting a biological sample obtained from a subject that may or may not contain an enzyme with a substrate of the enzyme to be detected. The substrate comprises a signaling molecule such that when the enzyme is present in the biological sample, the enzyme modifies the substrate and the signaling moiety emits a signal, indicating the presence of a pathogen, disease, or a medical condition, or a biomarker thereof, in the subject.12-15-2011
20110306034METHOD FOR ISOLATING CELLS AND DISEASE VECTORS FROM BODILY FLUIDS - Embodiments provide one of a method, a device, and their use to isolate or analyze cells, including pathogens from body fluids by means of different separation methods.12-15-2011
20090162833TEST DEVICE FOR RAPID DIAGNOSTICS - Devices for detecting analytes or analogues thereof in a biological sample are disclosed. The device includes a solid support. The solid support has several juxtaposed zones. The sample is able to migrate from a sample receiving zone towards a detection zone. The analyte, if present, is detected in the detection zone. Both zones have material allowing a capillary flow of the sample through the zones. In between the zones, there is an intermediate zone of transport of the sample which is free from any capillary material. This allows the ample to migrate by gravitational forces on the support laid in a vertical position. Methods for detecting analytes or analogues thereof in a biological sample using the device are also disclosed.06-25-2009
20110065087NOVEL HIV TARGETS - A set of cellular genes that were identified by siRNA screening as being essential for Human Immunodeficiency Virus (HIV) infection. These genes are host cellular factors involved in DNA repair, specifically in the base excision repair pathway.03-17-2011
20090029348Kit for Detecting the Antibody of HCV and Its Preparing Method - A kit and its preparing method concerning dual-antigen sandwich method are used for detecting the antibody against HCV, and its detecting mode is ‘carrier-first antigen-antibody against HCV to be detected-second antigen-marker-distinguishable signal’. The kit ant its preparing method characterize in that the second antigen is the complex of a HCV and a tag.01-29-2009
20100221701VERSATILE THERMAL DETECTION - The present application discloses a method of detecting hybridization of complementary segments of nucleic acids by a heat generated upon aforementioned hybridization, a method of detecting the presence of a predetermined reactant in a sample suspected of containing the same, a method of detecting complex responses occur in biological systems by a heat generated upon triggering the same and a method of detecting the presence of a predetermined explosive material; an apparatus for detecting hybridization of complementary segments of nucleic acids by a heat generated upon aforementioned hybridization, an apparatus for detecting the presence of a predetermined reactant in a sample suspected of containing the same, and an apparatus for detecting the presence of a predetermined explosive material; a system for detecting complex responses occur in biological systems by a heat generated upon triggering of aforesaid biological systems; implementing a pyroelectric thermal sensor or a bolometric thermal sensor or a quantum well thermal sensor.09-02-2010
20100323344Detection of hepatitis C virus RNA - The methods and compositions of this invention provide a means for determining the presence of Hepatitis C virus (HCV) in a sample from an individual. This is accomplished by hybridization to tissue samples using a cRNA probe that is specific for HCV. These means allow superior detection of HCV infection by virtue of the RNA riboprobe.12-23-2010
20090298049METHODS FOR SAMPLE TRACKING - A method and apparatus are provided for identifying a biological sample obtained during either paternity screening, genetic screening, prenatal diagnosis, presymptomatic diagnosis, diagnosis to detect the presence of a target microorganism carrier detection analysis, forensic chemical analysis, or diagnosis of a subject to determine whether a subject is afflicted with a particular disease or disorder, or is at risk of developing a particular disorder, wherein the result obtained from the analysis is associated with the unique DNA fingerprint biological barcode of the genotype of the subject being analyzed. The methods and apparatus of the invention have application in the fields of diagnostic medicine, disease diagnosis in animals and plants, identification of genetically inherited diseases in humans, family relationship analysis, forensic analysis, and microbial typing.12-03-2009
20090092964Methods for Individualizing Cardiovascular Disease Treatment Protocols Based on Beta-1 Adrenergic Receptor Haplotype - A method is provided for determining whether a treatment protocol for a human patient who is suffering from heart failure, ischemic heart disease, cardiac arrhythmias, or hypertension includes administration of a beta blocker, the method including obtaining a biological sample from the patient, determining a β04-09-2009
20110111390METHOD FOR IN VITRO DETECTION AND/OR QUANTIFICATION AND/OR IDENTIFICATION OF INFECTIOUS COMPOUNDS IN A BIOLOGICAL MATERIAL - Method for in vitro detection and/or quantification and/or identification of infectious compounds present in a fluid medium M constituting a biological material, in which method a suspension of microbeads of solid polymer material capable of binding proteins is prepared; the microbeads are loaded with β2GPI proteins by coupling with a sufficient amount of β2GPI proteins; said microbeads are brought into contact with the fluid medium M while adding ions of at least one oxidizing metal, so as to bind the infectious compounds to the β2GPI proteins; the microbeads thus prepared are separated from their suspension medium, so as to obtain a residue; and the infectious compounds of the residue are detected and/or quantified and/or identified.05-12-2011
20110111388METHOD FOR THE SENSITIVE DETECTION OF POLYAMINO ACIDS AND OTHER MACRO-MOLECULES - The invention relates to a method for the detection of an analyte containing polyamino acid. The object of the invention is to detect polyamino acids in a highly sensitive manner. The object is achieved in that an LM is coupled to a protein after chemical activation, and is complexed using a lanthanoid ion. In order to detect polyamino acids, the time resolved fluorescence measurement is utilized after electrophoretic separation. The detection limit is 0.5 pg per spot (bovine serum albumin), wherein the linear region extends across six orders of magnitude. The invention also relates to analytes containing nucleic acid.05-12-2011
20100092943SCREENING METHOD WITH THE USE OF TBK1 KNOCKOUT MOUSE - The present invention provides a method for screening inductive promoting substances of anti-viral proteins such as IFN-β against LPS stimulation or viral infection by using TBK1 knockout mice, or the tissues or cells derived therefrom. The present invention also provides a method for screening substances promoting responses against LPS stimulation or viral infection which may comprise the steps of measuring/estimating the induction level of anti-viral proteins such as IFN-β against ligands recognized by TLR4 or substances containing thereof in mice wherein a part or a whole of TANK binding kinase-1 (TBK1) genes on its chromosome is deleted and is lacking the function to express TBK1 which is expressed in wild-type, or the tissues or cells derived therefrom; by using the mice, or the tissues or cells derived therefrom, a test substance, and the ligands recognized by TLR4 or substances containing thereof.04-15-2010
20120040337Conformational Epitope Initiated Signal Amplification - This invention relates to a method to generate a signal used to detect the presence or quantity of a biomarker in a sample. The signal generating reaction is initiated when the biomarker under assay interacts with a specific binding partner. The interaction produces a structural change in the binding partner that is recognized by additional binding partners capable of generating a signal. The reaction produces a localized cluster of signaling molecules that can be detected above background. The signaling cluster is detectable within minutes when interrogated in a chamber of specific dimensions. The presence of the signaling clusters is a qualitative indication of the presence of the analyte, while the number of signaling clusters detected is a direct quantification of the number of biomarker molecules in the sample. The reaction can be formatted to detect proteins, nucleic acids, cells or other informative biomarkers.02-16-2012
20120040336Lateral Flow Assays for Non-Diagnostic Analytes - Methods of determining whether a non-diagnostic analyte is present in a non-diagnostic sample are provided. Aspects of the methods include applying a non-diagnostic sample to a sample receiving region of a lateral flow assay device and reading a detection region to determine whether a non-diagnostic analyte is present in the non-diagnostic sample. Also provided are kits that find use in practicing methods of the invention.02-16-2012
20120040335Identification of Porcine Reproductive and Respiratory Syndrome Virus - An enzyme-linked immunosorbent assay (ELISA) is based on the non-structural protein 7 (nsp7) of porcine reproductive and respiratory syndrome virus (PRRSV) and provides for the simultaneous detection and differentiation of serum antibodies directed against Type 1 (European) and Type 2 (North American) PRRSV. The invention provides a serological assay for the detection and/or differentiation of serum antibodies directed against Type 1 and/or Type 2 PRRSV utilizing PRRSV nsp7 as an antigen, and provides a diagnostic method for the detection of PRRSV infection, epidemiological surveys, and outbreak investigations. The invention may be used either alone or as a follow-up assay to determine the true status of unexpected positive results that may occur using other assays, such as the IDEXX HERDCHEK PRRS ELISA.02-16-2012
20090081640Methods of using miRNA for detection of in vivo cell death - Described are non-invasive methods of detecting in vivo cell death by measuring levels of ubiquitous and tissue specific miRNA. The method can be applied for detection of pathologies caused or accompanied by cell death, as well as for diagnosis of infectious disease, cytotoxic effects induced by different chemical or physical factors, and the presence of specific fetal abnormalities.03-26-2009
20120149006CELLULOSE SUBSTRATES, COMPOSITIONS AND METHODS FOR STORAGE AND ANALYSIS OF BIOLOGICAL MATERIALS - The invention provides a method and article for storing genetic material or analytes from a biological sample by contacting said biological sample with a cellulose substrate comprising structural units of Formula I06-14-2012
20120149010BACULOVIRUS-BASED PRODUCTION OF BIOPHARMACEUTICALS FREE OF CONTAMINATING BACULOVIRAL VIRIONS - The present invention relates to methods for the production of biopharmaceuticals implementing a baculovirus-based system. These methods advantageously allow the production of biopharmaceuticals with reduced or no contaminating baculoviral virions.06-14-2012
20120301872SYSTEM AND METHOD FOR INCREASED FLUORESCENCE DETECTION - The invention relates to systems and methods for improving optical detection and sensitivity in situations in which emission of luminescent light is monitored. It is provided a sample carrier which achieves increased sensitivity of luminescent light detection. The sample carrier comprises a sample carrying part and a light reflecting part; wherein the light reflecting part is positioned to allow an optical collection and detection system to collect not only luminescent light emitted from the sample positioned on the sample carrying part in a direction of the optical collection and detection system, but also luminescent light emitted from the sample in a direction away from the optical collection and detection system and reflected in the direction of the optical collection and detection system via the light reflecting part. When an excitation light source is needed, the light reflecting part also allows the excitation light rays passing through the sample to hit the light reflecting part, and reflect back in the opposite direction thus the reflected excitation light also passes through the sample. Also provided are methods of using such a sample carrier.11-29-2012
20120301871COMPARATIVE LIGAND MAPPING FROM MHC POSITIVE CELLS - The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class II MHC molecules which may be uninfected, infected, or tumorgenic. The methodology of the present invention broadly allows for these peptide ligands and their comcomittant source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorgenic versus nontumorgenic cells with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.11-29-2012
20110020789METHODS FOR ASSESSING FATIGUE LEVEL AND APPLICATIONS THEREOF - Level of fatigue that accompanies everyday life or a disease can be simply, easily, and quantitatively assessed by obtaining a body fluid from a test subject and measuring the amount of human herpesvirus in the body fluid. Furthermore, the anti-fatigue potency of anti-fatigue substances and anti-fatigue food products can be measured.01-27-2011
20110091868NOVEL ANTIGEN CONSTRUCTS USEFUL IN THE DETECTION AND DIFFERENTIATION OF ANTIBODIES TO HIV - Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.04-21-2011
20100143881Selective detection of human rhinovirus - A process for detecting human rhinovirus nucleic acid in a biological sample, includes producing an amplification product by amplifying an human bocavirus nucleotide sequence using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and measuring said amplification product to detect human rhinovirus in said biological sample. Also provided are reagents and methods for detecting and distinguishing human rhinovirus from other viruses. A kit is provided for detecting and quantifying human rhinovirus in a biological sample.06-10-2010
20110081646DENGUE VIRUS ASSAY - Nucleic acid assays for detecting nucleic acids of Dengue virus serotypes 1-4.04-07-2011
20120308996METHOD AND SYSTEM FOR DISEASE DIAGNOSIS VIA SIMULTANEOUS DETECTION OF ANTIBODIES BOUND TO SYNTHETIC AND CELLULAR SUBSTRATES - The invention relates to a method and system for disease diagnosis that simultaneously detects antibodies bound to cellular and/or tissue substrates and antibodies bound to synthetic substrates, such as microparticles or beads coated with specific antigens, thereby providing a “one-step” method for the simultaneous detection and characterization of disease-associated antibodies at both low (cellular and/or tissue) and high (antigen) specificity.12-06-2012
20120308994SLPA AS A TOOL FOR RECOMBINANT PROTEIN AND ENZYME TECHNOLOGY - Disclosed are a recombinant DNA molecule encoding a fusion protein comprising a SlpA chaperone and a target polypeptide wherein human FK506 binding proteins (FKBPs) are excluded as target polypeptides, a corresponding expression vector encoding said fusion protein as well as host cells transformed with said expression vector. Also disclosed are a method for producing the fusion protein, a recombinantly produced fusion protein comprising a SlpA chaperone and a target polypeptide. A further aspect of the invention is the use of the recombinantly produced fusion protein, and a reagent kit containing a recombinantly produced fusion protein comprising a SlpA chaperone and a target polypeptide.12-06-2012
20120308993RESISTANT INFLUENZA A VIRUS DETECTION METHOD AND KIT THEREFOR - There is provided a method of detecting the presence of oseltamivir-resistant Influenza A virus in a sample, the method comprising detecting the presence of an amplicon, a fragment and/or a derivative thereof, wherein the amplicon, fragment and/or derivative thereof (a) is amplified by a primer (SEQ ID NO:1), a fragment, or derivative therefore and/or a primer (SEQ ID NO:2), a fragment, or derivative thereof. There are also provided primer(s) and/or probe as well as kit for the detection of the presence of Influenza A in a sample and/or in a subject.12-06-2012
20110318728SYSTEMS, DEVICES, METHODS AND KITS FOR FLUID HANDLING - Fluid handling devices, systems, methods and kits are disclosed. Fluid handling devices according to the disclosure comprise: an inlet for receiving a sample; a reagent layer comprising, a substrate having a first surface and an opposing second surface, at least one reagent storage compartment configured to hold a reagent, and a seal in communication with the at least one reagent storage compartment; and a reaction layer having a first surface and an opposing second surface comprising, a reaction area, and an outlet in communication with the reaction area, wherein the reagent layer and reaction layer are adapted and configured to permit movement of at least one of the reagent layer and the reaction layer in a plane relative to the other layer.12-29-2011
20110318729Rapid Bioluminescence Detection Assay - An assay is provided for detecting the activity of a reporter kinase comprising (i) adding said reporter kinase to an assay mixture wherein said reporter kinase is contacted with bioluminescent reagent no more than minutes after being contacted with ADP, and wherein, prior to contacting the reporter kinase with ADP, the assay mixture is substantially free from kinase other than reporter kinase; and (ii) detecting light output from the assay mixture. Methods for detecting the presence of an analyte in a sample and methods for validating a treatment process using the above assay are also provided. Further provided are devices for conducting these assays and methods.12-29-2011
20080233561Method for Measuring Cytopathic Effect Due to Viral Infection in Cells Using Electric Cell-Substrate Impedance Sensing - A method of measuring cytopathic effect in cells includes providing cells in culture, using electric cell-substrate impedance sensing (ECIS) to measure the resistance of current associated with the cells, and quantifying the cytopathic effect (CPE) associated with the cells based on the measured resistance. The cells may be identified as being infected with a virus if the CPE associated with the cells is above a predetermined level. Alternatively, the cells may be provided in a healthy monolayer and infected with a virus in order to measure the effect of the virus on CPE associated with the cells. Cells may also be treated with candidate antiviral agents and the effects of the agents on the virus-infected cells may be measured to screen for and identify actual antiviral agents.09-25-2008
20120045751Generic Sample Preparation - The present invention relates to the sample preparation of nucleic acids for diagnostic purposes. More precisely, the invention provides a process for simultaneously isolating at least a first and a second target nucleic acid from a plurality of different types of fluid samples and optionally amplifying said isolated nucleic acids in a simultaneous manner.02-23-2012
20090197245Rapid detection of dengue virus - One example of a solution provided here comprises providing a single-stranded oligonucleotide, the oligonucleotide being complementary to a portion of SEQ ID NO:1, and contacting the oligonucleotide with a nucleic acid comprising the sequence of SEQ ID NO:1, under conditions that permit hybridization of the oligonucleotide with the nucleic acid. Another example comprises providing a single-stranded oligonucleotide comprising the sequence of SEQ ID NO:4, and contacting the oligonucleotide with a nucleic acid comprising the sequence of SEQ ID NO:1, under conditions that permit hybridization of the oligonucleotide with the nucleic acid.08-06-2009
20120045754NOVEL GOLD NANOSTRUCTURES AND METHODS OF USE - The invention is drawn to novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors, conduits for fluids, and electronic conductors. The nanostructures can be used in microfluidic devices, for transporting fluids between devices and structures in analytical devices, for conducting electrical currents between devices and structure in analytical devices, and for conducting electrical currents between biological molecules and electronic devices, such as bio-microchips.02-23-2012
20120045752FIBER SAMPLER FOR RECOVERY OF BIOAEROSOLS AND PARTICLES - A bioparticle collection device and an aerosol collection system. The bioparticle collection device includes a collection medium including a plurality of fibers formed into a fiber mat and configured to collect bioparticles thereon, and includes a viability enhancing material provider disposed in a vicinity of the plurality of fibers and configured to provide a viability enhancing material to the collected bioparticles to maintain viability of the bioparticles collected by the fiber mat. The aerosol collection system includes an aerosol pumping device configured to entrain particles in an gas stream, an aerosol saturation device configured to saturate the particles in the gas stream with a biocompatible liquid, and an aerosol collection medium downstream from the aerosol saturation device and including a plurality of fibers formed into a fiber mat for collection of the saturated aerosol particles.02-23-2012
20120045750KIT FOR DETECTING HIV-2 AND METHOD FOR DETECTING HIV-2 USING THE SAME - A kit for detecting HIV-2 strains in a test sample is disclosed. In addition a method is described for the real-time detection of HIV-2 strains in a test sample using the kit. According to method of detection, the results of the detection can be rapidly identified with a reduced number of copies of a sample in real-time.02-23-2012
20120045748Particulate labels - A methodology for bioassays and diagnostics in which a particulate label (ranging in size from nm-scale molecular assemblages to organisms on the scale of tens or hundreds of microns), such as, but not limited to, nanoparticles, bacteria, bacteriophage, Daphnia, and magnetic particles, serve carriers for analytes bound by molecular recognition elements such as antibodies, aptamers, etc. The described methodology is generally applicable to most pathogen assays and molecular diagnostics and also leads to enhanced sensitivity and convenience of use.02-23-2012
20120003626SAMPLING DEVICES AND METHODS FOR CONCENTRATING MICROORGANISMS - The present disclosure describes methods for concentrating microorganisms with concentration agents in a sampling device and the sampling device described herein. More specifically, methods for concentrating microorganisms from large volume samples with concentration agents in a sampling device can provide for rapid, low cost, simple (involving no complex equipment or procedures), and/or effective processes under a variety of conditions.01-05-2012
20120003628Methods for Diagnosing Pervasive Development Disorders, Dysautonomia and Other Neurological Conditions - Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the individual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, 01-05-2012
20120003625METHODS AND KITS FOR DETECTING AN INFECTIOUS AGENT - The present invention provides methods and kits for determining the presence, absence, or level of an infectious agent in a sample. Specifically, the present invention provides methods and kits for detecting or quantifying certain target polynucleotides of the infectious agent. In certain embodiments, the present invention provides for such detection without the need for amplification (e.g., replication) of the target molecule and/or without the need for labor intensive purification procedures. In certain embodiments, the present invention provides positive control and housekeeping gene for normalization and quantatively detection of the copy numbers of infectious agent in a sample. In these or other embodiments, the invention allows for such detection with the desired sensitivity and/or specificity, even where the polynucleotide is present in the sample at low copy number.01-05-2012
20080233559Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein - Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.09-25-2008
20120003624STANDARDIZED METHOD AND KIT FOR THE QUANTIFICATION OF HEPATITIS A VIRUS - The present invention provides a standardized method and a kit for an accurate quantification of HAV in clinical and food samples. The general approach is based on the use of several controls to measure the efficiency of those critical steps of the quantification: the nucleic acids extraction and the RT-PCR reactions. The kit comprises: a Mengo virus mutant strain with the same growth properties than those of the wild-type Mengo virus and with no pathogenic capacity; a single stranded RNA molecule corresponding to a fragment of the HAV genome; primers that specifically bind to regions of the 5′ non coding region of the HAV genome; a detectable labeled probe that specifically binds to the amplimer resulting from the RT-PCR; and an appropriate molecule to generate an standard curve for the quantification of HAV.01-05-2012
20100216119Diagnostic Methods for HIV Infection - The invention relates to a method of aiding the diagnosis of a human immunodeficiency virus infection in a subject, said method comprising (i) providing a sample from the subject (ii) determining the level of ps20 in said sample (iii) comparing the level of ps20 of (ii) with the level of ps20 in an uninfected reference sample, wherein a higher level of ps20 in the sample from the subject compared to the uninfected reference sample indicates an increased likelihood of human immunodeficiency virus infection in said subject. The invention also relates to methods for assessing susceptibility of a subject to human immunodeficiency virus infection. Most suitably the ps20 level is determined via binding by an anti-ps20 antibody such as the 107 antibody. The invention also relates to kits for use in said methods.08-26-2010
20100196874 METHOD OF DRUG DESIGN - The description discloses that amiloride-like compounds inhibit enterovirus RNA replication by interaction with RNA dependent RNA polymerase (RdRP). The description discloses in silico and in vitro methods of screening for inhibitors of RdRP activity, amiloride-resistant enterovirus variants and amiloride-like compounds.08-05-2010
20090311666MICROFLUIDIC DEVICE FOR CRYSTALLIZATION AND CRYSTALLOGRAPHIC ANALYSIS OF MOLECULES - The present invention relates to a microfluidic device comprising at least one crystallization chamber adapted for comprising a solution in which at least one compound is present according to a concentration gradient, and wherein the geometry of said crystallization chamber allows for convection phenomena to be limited. The invention also relates to the use of said device, in particular for crystallization by counter diffusion and to a crystallization method.12-17-2009
20090317794BIOLOGICAL INDICATOR - A kinase is used in a biological indicator for validation of treatment processes designed to reduce the amount or activity of a biological agent in a sample. The indication can be used for validation of sterilisation treatment. The formation of ATP from a substrate comprising ADP is measured via the liciferin/luciferate system in a luminameter. Thermostable adenylate kinase from 12-24-2009
20110065091Coronavirus, Nucleic Acid, Protein, and Methods for the Generation of Vaccine, Medicaments and Diagnostics - A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.03-17-2011
20110065088METHOD AND DEVICES FOR RAPID DIAGNOSIS OF FOOT-AND-MOUTH DISEASE - A rapid immunoassay method and apparatus for detecting foot and mouth disease virus are disclosed. The method and test device permit pen-side testing of animals and provide test results within a relatively short time period. In a preferred embodiment, the method and apparatus provide a means for differentiating between FMDV-infected and FMDV-vaccinated animals.03-17-2011
20120208174Plasmonic System for Detecting Binding of Biological Molecules - Detection and characterization of molecular interactions on membrane surfaces is important to biological and pharmacological research. In one embodiment, silver nanocubes interfaced with glass-supported model membranes form a label-free sensor that measures protein binding to the membrane. The present device and technique utilizes plasmon resonance scattering of nanoparticles, which are chemically coupled to the membrane. In contrast to other plasmonic sensing techniques, this method features simple, solution-based device fabrication and readout. Static and dynamic protein/membrane binding are monitored and quantified.08-16-2012
20120208179COMPOSITIONS FOR USE IN IDENTIFICATION OF ORTHOPOXVIRUSES - Oligonucleotide primers and compositions and kits containing the same for rapid identification of orthopoxviruses by amplification of a segment of viral nucleic acid followed by molecular mass analysis are provided.08-16-2012
20120045749METHODS OF CATEGORIZING AN ORGANISM - The invention generally relates to methods of identifying and categorizing organisms and more specifically methods of generating and using patterns of chromosomal variation in order to classify organisms.02-23-2012
20120009563High-Risk Human Papillomavirus Detection - This invention provides compositions and methods for detecting HPV in a sample. This invention also provides related kits, systems, and computers.01-12-2012
20120009565COMPOSITIONS AND METHODS FOR DETECTION OF HEPATITIS A VIRUS NUCLEIC ACID - Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.01-12-2012
20120009561METHODS OF EVALUATING A TEST AGENT IN A DISEASED CELL MODEL - The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.01-12-2012
20120009564High-Risk Human Papillomavirus Detection - This invention provides compositions and methods for detecting HPV in a sample. This invention also provides related kits, systems, and computers.01-12-2012
20120009560Method For Purifying Nucleic Acids From Microorganisms Present In Liquid Samples - The present invention relates to a method for treating liquid samples with a view to detecting any possible pathogenic microorganisms in a very small amount. More specifically, this method comprises a generic step of capturing and concentrating microorganisms on an ion exchange surface, followed by an in situ lysis treatment carried out on the microorganisms and capture of the nucleic acids released during the lysis. The implementation of this method enables an extremely concentrated and purified solution of nucleic acids to be obtained. This method is suitable for a continuous treatment of liquid samples. The invention also relates to a device for analysing liquid samples for biology, health or the environment, which is suitable for the implementation of the method according to the invention.01-12-2012
20090029350RAPID DIAGNOSTIC METHOD FOR DISTINGUISHING ALLERGIES AND INFECTIONS AND NASAL SECRETION COLLECTION UNIT - A method for clinical scoring that involves evaluating certain parameters found in nasal secretia is disclosed. Contact of a nasal secretion with indicators for pH, protein content, leukocyte esterase activity, nitrite content, eosinophil content and/or TAME esterase activity permits diagnosis and differentiation between allergic, bacterial and viral conditions.01-29-2009
20090275014THERMAL CYCLING METHOD - This invention provides a method for carrying out nucleic acid amplification reactions involving heating and cooling of samples in sample vessels utilizing a heat block comprising a liquid. The method can be used to perform multiple nucleic acid amplification reactions simultaneously in which each of the reactions is performed so as to have temperature profiles. The apparatus can be used for performing PCR, and real time PCR in particular, with control and uniformity.11-05-2009
20120015350LATERAL FLOW STRIP AND USES THEREOF - The present invention relates to lateral flow strip assay system and uses thereof. In particular, the present invention relates to lateral flow assay systems for the simple and inexpensive detection of biomolecules.01-19-2012
20090111090METHOD FOR DETECTING INTEGRATED HPV DNA - A method for detecting integrated HPV DNA is described herein. This method comprises obtaining first and second samples, obtaining first and second information, and detecting, based on the first and second information, the HPV DNA integrated into the genome of a cell derived from a subject. The second sample comprises DNA derived from the cell, which is treated with an enzyme having exonuclease activity. The first information is related to the amount of HPV DNA in the first sample, and the second information is related to the amount of HPV DNA in the second sample.04-30-2009
20110033841METHODS AND KITS FOR DIAGNOSIS, PROGNOSIS OR MONITORING OF EPSTEIN-BARR VIRUS (EBV)-ASSOCIATED CANCER - Disclosed is a non-invasive method for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer by detecting and/or quantifying EBV associated nucleic acid fragments in a urine sample from an individual. Kits for diagnosis, prognosis or monitoring of cancer are also disclosed.02-10-2011
20120015349COMPOSITIONS FOR USE IN IDENTIFICATION OF PAPILLOMAVIRUS - The present invention relates generally to identification of HPV, and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.01-19-2012
20120015345Identification of Oligonucleotides for the Capture, Detection and Quantitation of West Nile Virus - West Nile virus capture oligonucleotides, primers and probes derived from conserved regions of the West Nile virus genome are disclosed. Also disclosed are nucleic acid-based assays using the capture oligonucleotides, primers and probes.01-19-2012
20120015348COMPOSITIONS AND METHODS FOR DETECTION OF HEPATITIS A VIRUS NUCLEIC ACID - Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed.01-19-2012
20120015344Methods, compositions, and apparatus for the detection of viral strains - The disclosure generally relates to a particulate composition formed from a conductive polymer bound to magnetic nanoparticles. The particulate composition can be formed into a biologically enhanced, electrically active magnetic (BEAM) nanoparticle composition by further including a binding pair member (e.g., an antibody or a fragment thereof that specifically recognizes a virus strain or a virus surface protein) bound to the conductive polymer of the particulate composition. The disclosure further provides compositions, kits, detection apparatus, and methods for detecting specific viral strains including those with pandemic potential. In the various embodiments, a triplex including the BEAM nanoparticle, a virus or virally derived material (e.g. strain- and/or strain subtype specific viral surface protein or fragments thereof), and a viral strain subtype-specific binding pair member (e.g., a glycan that recognizes a specific virus strain subtype) is formed and detected, such as by use of a biosensor.01-19-2012
20120208180METHOD FOR EARLY DIAGNOSIS OF CARCINOMAS OF THE ANOGENITAL TRACT - A method for the early diagnosis of carcinomas of the anogenital tract, preferably of the cervical carcinoma, and the preliminary stages thereof is described. The method is based on the determination of the methylation status of segments of the gene regions of ASTN1 (astrotactin 1) and ZNF671 (zinc finger protein 671, transcription factor). A DNA methylation in the promoter region or the 5′-region of these genes is indicative for carcinomas of the anogenital tract or severe preliminary stages thereof. The present invention also relates to kits which permit the conduction of the diagnostic method according to the invention,08-16-2012
20120208178PROBES COMPRISING FLUORESCENT ARTIFICIAL NUCLEOBASES AND USE THEREOF FOR DETECTION OF SINGLE BASE ALTERATION - The present invention relates to forced intercalation probes (FIT-probes) comprising at least one nucleoside analogue which comprises at least a fluorescent artificial nucleobase directly bound to a carbon of a modified sugar moiety wherein said modified sugar moiety is a carba-sugar or an amino acid nucleic acid (AANA). Thereby the nucleoside analogue is incorporated into DNA or RNA in the place of a single native base.08-16-2012
20090280474METHOD FOR DETECTING A VIRUS - This invention is related a method for increasing the sensitivity of detecting a viral target in a sample. The sensitivity may be increased by disrupting a complex comprising the target or by measuring the level of the target from a larger volume of the sample.11-12-2009
20110165558METHOD FOR IDENTIFYING INDIVIDUAL VIRUSES IN A SAMPLE - Individual viruses in any type of sample are identified quickly, unambiguously and reliably, and with the least possible preparation-related and technology-related expenditure, without necessitating immobilization using antibodies and without requiring an indication or at least a suspicion of potentially present viruses. This is accomplished by scanning the height profile of the sample, from which scanning sites suspected of containing viruses are selected, exposing those cites to monochromatic excitation light and spectroscopically analyzing the resulting Raman scattered light.07-07-2011
20110165556SYSTEM AND METHOD FOR DETECTION OF HIV TROPISM VARIANTS - An embodiment of a method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance is described that comprises the steps of: generating cDNA species from each RNA molecule in an HIV sample population; amplifying at least one first amplicon from the cDNA species, wherein each first amplicon comprises a plurality of amplified copies and is amplified with a pair of nucleic acid primers that define a locus of the first amplicon; clonally amplifying the amplified copies of the first amplicons to produce a plurality of second amplicons wherein a plurality of the second amplicons comprise an immobilized population of substantially identical copies from one of the amplified copies of first amplicons; determining a nucleic acid sequence composition of the substantially identical copies from at least 100 of the immobilized populations in parallel on a single substrate; and detecting one or more sequence variants that occur at a frequency of 5% or less in the nucleic acid sequence composition of the at least 100 immobilized populations; and correlating the detected sequence variants with variation associated with HIV tropism.07-07-2011
20110165557APPARATUS AND METHOD FOR DETECTING BIOMOLECULES - Provided are an apparatus and method for detecting biomolecules. The apparatus includes a FET having a substrate, a source electrode, a drain electrode, a channel region between the source and drain electrodes, and probe molecules fixed to the channel region, wherein the source and drain electrodes are separated on the substrate, a microfluid supplier selectively supplying one of a reference buffer solution of low ionic concentration and a reaction solution of high ionic concentration containing target molecules, to the channel region of the FET to which the probe molecules are fixed, and a biomolecule detector detecting the target molecules by measuring a first current value of the channel region of the FET, and a second current value of the channel region of the FET to which the target molecules and the probe molecules that bind to each other in the reaction solution of high ionic concentration are fixed.07-07-2011
20110165555Capillary-Column-Based Bioseparator/Bioreactor with an Optical/Electrochemical Detector for Detection of Microbial Pathogens - The present invention is directed to satisfying the need to detect microbial contamination of food products. The described bioseparator/bioreactor coupled with an optical/electrochemical biosensor was able to specifically detect 07-07-2011
20110165554METHODS AND BIOMARKERS FOR DIAGNOSING AND MONITORING PSYCHOTIC DISORDERS - A method of diagnosing or monitoring a psychotic disorder, or predisposition thereto, comprises measuring, in a sample taken from a subject, the levels of one or more peptide biomarkers listed herein.07-07-2011
20120058463HYDROPHOBIC, FUNCTIONALIZED PARTICLES - The present invention relates to a stable mixture comprising surface-modified particles which are obtained by reacting metal oxide or semimetal oxide particles with at least one compound selected from among silicon-comprising compounds bearing one, two or three alkoxy radicals and at least one solvent, at least one surface-active substance or a mixture thereof, the use of these particles in systems in which they are brought into contact with at least one solvent, where the mass ratio of solvent to modified particle is greater than 500, and also the use of these particles in agglomeration-deagglomeration cycles.03-08-2012
20120058461MOLECULAR DETECTION OF XMRV INFECTION - The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. In particular, the invention relates to XMRV-related nucleic acids having significant diagnostic and screening utilities and methods of using the same.03-08-2012
20120058466DIFFERENTIAL IMMUNOASSAY FOR PRRS VACCINE ANTIBODY - The present invention relates to immunoassays for serologically differentiating animals naturally infected with PRRS virus from animals vaccinated against PRRS. The immunoassays provide detection of at least a portion of the N terminal region of the 2b portion of PRRSV. The immunoassay is preferably an enzyme-linked immunosorbent assay (ELISA).03-08-2012
20120058465METHOD AND DEVICE FOR ASSAY - A device for assay can evenly develop solution, and performs highly accurate and sensitive measurement. A first device part (03-08-2012
20120058464Assay Methods Using Array of Test Zones - A method for assaying a sample for each of multiple analytes is described. The method includes contacting an array of spaced-apart test zones with a liquid sample (e.g., whole blood). The test zones disposed within a channel of a microfluidic device. The channel is defined by at least one flexible wall and a second wall which may or may not be flexible. Each test zone comprising a probe compound specific for a respective target analyte. The microfluidic device is compressed to reduce the thickness of the channel, which is the distance between the inner surfaces of the walls within the channel. The presence of each analyte is determined by optically detecting an interaction at each of multiple test zones for which the distance between the inner surfaces at the corresponding location is reduced. The interaction at each test zone is indicative of the presence in the sample of a target analyte. Capillary structures of the devices or used in the methods may comprise a matrix and the devices may comprise control elements and methods for assaying of sample may use corresponding controlling activities.03-08-2012
20120058462MOLECULAR DETECTION OF XMRV INFECTION - The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. In particular, the invention relates to XMRV-related nucleic acids having significant diagnostic and screening utilities and methods of using the same.03-08-2012
20120156670IN VITRO UROGENITAL CO-CULTURE MODELS - The invention is directed to co-culture systems comprising (i) rotating wall vessel (RWV)-cultured epithelial or differentiated tissue attached to microcarrier beads and (ii) the peripheral tissue equivalent (PTE) module of the MIMIC® system, and to methods of using the co-culture systems for assessing chemical or biological (bacterial or viral) insults. The system models mucosal exposure to chemicals, pathogens or antigen at various sites in the human body. The microcarrier and MIMIC® co-culture approach provides an in vitro co-culture model that simultaneously demonstrates mucosa-mediated antigen presentation and immunogenic responses. Models of the present invention can be used, for example, in assessments of disease pathogenesis and in pharmaceutical development, reproductive physiology, and immunological and toxicological evaluations. Models of the present invention can generate patient-specific localized mucosal immunology using primary cells, resembling the human physiological situation.06-21-2012
20120208177ASSAY METHODS FOR MDV-1 - A method for the quantification of a vaccine strain and/or a virulent strain of Wlarek's Disease Virus Serotype-1 (MDV-1) in a sample from a bird, comprising the steps of: (i) providing a biological sample from the bird and optionally isolating nucleic acid from the biological sample; (ii) subjecting the biological sample of (i) to real-time quantitative PCR (qPCR) comprising: (a) amplification of a region of the pp3B gene within the nucleic acid sample of (i), said region containing a consistent single nucleotide polymorphism (SNP) difference between vaccine and virulent strains of MDV-1; and (b) contacting the amplified nucleic acid of (a) with a detectable nucleic acid probe specific for the SNP of the vaccine strain of MDV-1 and/or a detectable nucleic aα′d probe specific for the SNP of the virulent strain of MDV-1; and (iii) Measuring changes in the detectable signal produced by the probe of (ii). Methods are also provided for the absolute quantification of vaccine and virulent viruses.08-16-2012
20120208176Multivalent Epitope in Complex with a Detection Marker for the Early Serodiagnosis of Infections - The present invention relates to a new method to determine the presence of antibodies to a pathogen in a serological sample using a new detection reagent which comprises at least two and preferably at least four copies of an antigen from the pathogen and a detectable marker. The present invention also relates to a new detection reagent which consists of at least two and preferably at least four antigenic peptides in a complex with a detectable marker via interacting multimerization domains upon both the antigenic peptides and detectable marker.08-16-2012
20120064514HIV-1-C RESISTANCE MONITORING - The present invention relates to methods for the evaluation of HIV-1 Subtype C (HIV-1-C) treatment. The methods are based on evaluating molecular events at the HIV-1-C gag-protease-reverse transcriptase (GPRT) resulting in altered therapeutic efficacy of investigated anti-retroviral compounds. The methods rely on providing HIV-1-C GPRT RNA and evaluating a treatment either through genotyping or phenotyping methods. Said methods may find a use in the field of diagnostics, drug screening, pharmacogenetics and drug development.03-15-2012
20120064510KIT INCLUDING TARGET SEQUENCE-BINDING PROTEIN AND METHOD OF DETECTING TARGET NUCLEIC ACID BY USING THE KIT - A kit including a target sequence-binding protein and a method of detecting a target nucleic acid by using the kit that may ensure efficient detection of the target nucleic acid in a biological sample are disclosed.03-15-2012
20120064511Generic Buffer For Amplification - The present invention relates to a method of amplifying a first and a second target nucleic acid in separate reaction receptacles, wherein said reaction receptacles comprise a solution comprising amplification reagents and oligonucleotides specific for said first or said second target nucleic acid, wherein said solution is the same for amplifying said first target nucleic acid and said second target nucleic acid.03-15-2012
20120064509Methods and compositions related thereto for detecting and identifying distinct species of nucleic acids from causative agents - Methods are described herein for detecting and identifying distinct species of nucleic acids, in a single container, for example, from a certain genus of infectious agents or otherwise causative agents comprising, for example, providing a forward PCR primer common to a homologous gene region between the distinct species, and providing a reverse PCR primer common to a homologous gene region between the distinct species, to thereby define a PCR target region amongst the species, and providing a first oligonucleotide probe specific to a nucleic acid sequence within the target region that is characteristic of a first species, providing a second oligonucleotide probe specific to a nucleic acid sequence within the target region that is characteristic of a second species, wherein the first and second oligonucleotide probes are each detectably labeled with distinctly different detectable labels, conducting a PCR reaction in the container by means of the primers to amplify the target region amongst the species, and detecting the distinct labels, thereby identifying distinct species of nucleic acids corresponding to distinct species of infectious agents. Methods are preferred, for example, wherein the infectious agent is a member of the Herpesviridae family.03-15-2012
20120064512GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.03-15-2012
20120064513Cell Sensor, And Monitoring Method Using Same For The Real-Time Monitoring Of Cell Capacitance - The present invention relates to a cell sensor for real-time monitoring of cell capacitance and a monitoring method using the same, and more particularly, to a cell sensor capable of monitoring an endocytosis process of a biomolecule through a cell surface receptor by attaching a cell between electrodes and then measuring in real time the capacitance between the electrodes over time, and a monitoring method using the same. A cell sensor for the real-time monitoring of cell capacitance according to an exemplary embodiment of the present invention includes a substrate; a first electrode and a second electrode that are formed on the substrate and spaced apart by a gap from each other, in which at least one or more cells are introduced to be attached onto the gap; and a passivation layer that is formed on each of the tops of the first electrode and the second electrode to prevent the cells from being attached onto the top of the first electrode and the second electrode. The cell sensor for the real-time monitoring of cell capacitance and the method for real-time monitoring of the cell condition using the same according to an exemplary embodiment of the present invention have the effect of being able to monitor an endocytosis process of a biomolecule through a cell surface receptor in real time, by attaching cells having a receptor for the particular biomolecule between electrodes and then measuring in real time the capacitance between the electrodes over time.03-15-2012
20090047664SPECIES DETECTION METHODS AND SYSTEMS - The disclosure provides methods, systems and kits for cellular and subcellular identification in a rapid, throughput manner.02-19-2009
20120070821Interference Control Panel for Evaluation of Analytical Assays For Samples Derived from Blood - The invention relates to quality control of analytical assays, particularly NAT assays of blood samples containing nucleic acids. A control panel containing quantified amounts of substances known to interfere with an analytical assay is used and compared with a reference sample in the analytical assay. A comparison of the assay results interference panel validates the assay and can serve as a periodic quality control check for the analytical assay as well as related methods and protocols. The use of the control panel of the invention can also determine whether interfering substances are present and establish under what conditions the analytical assay reliable.03-22-2012
20120070819Determination of Interactions of Constant Parts of Antibodies with FC-Gamma Receptors - The invention relates to a novel method for the exact determination of the binding of the Fc-part of IgG-antibodies to Fc-gamma receptors, and for the simultaneous examination of the antigen-specificity and the Fc-gamma-receptor activation, as well as specific materials for use in said method. The invention furthermore relates to a method for identifying substances that affect the binding of the Fc-part of IgG-antibodies to Fc-gamma receptors, on the basis of the method for the exact determination of the binding of the Fc-part.03-22-2012
20120070822METHOD FOR SIGNAL AMPLIFICATION DURING LATERAL-FLOW ANALYSIS - Provided is a signal amplifying method in a lateral flow analysis with high sensitivity, in which gold ions and a reductant are added and react to a seed of gold nano particles to amplify a signal, and a lateral flow analysis device using the same.03-22-2012
20110008767MICROFLUIDIC DEVICE - The present disclosure relates to microfluidic devices adapted for facilitating cytometry analysis of particles flowing therethrough. In certain embodiments, the microfluidic devices allow light collection from multiple directions. In certain other embodiments, the microfluidic devices use spatial intensity modulation. In certain other embodiments, the microfluidic devices have magnetic field separators. In certain other embodiments, the microfluidic devices have the ability to stack. In certain other embodiments, the microfluidic devices have 3-D hydrodynamic focusing to align sperm cells. In certain other embodiments, the microfluidic devices have acoustic energy couplers. In certain other embodiments, the microfluidic devices have phase variation producing lenses. In certain other embodiments, the microfluidic devices have transmissive and reflective lenses. In certain other embodiments, the microfluidic devices have integrally-formed optics. In certain other embodiments, the microfluidic devices have non-integral geographically selective reagent delivery structures. In certain other embodiments, the microfluidic devices have optical waveguides incorporated into their flow channels. In certain other embodiments, the microfluidic devices have optical waveguides with reflective surfaces incorporated into their flow channels. In certain other embodiments, the microfluidic devices have virus detecting and sorting capabilities. In certain other embodiments, the microfluidic devices display a color change to indicate use or a result.01-13-2011
20100112545TRANS-1,2-DIPHENYLETHLENE DERIVATIVES AND NANOSENSORS MADE THEREFROM - Novel trans-1,2-diphenylethylene derivatives are synthesized which can be used to form nanoparticles-monomer-nanomolecule-receptor nanosensors. These trans-1,2-diphenyl-ethylene derivatives are soluble in both water and organic solvents, highly fluorescent and can be synthesized in high yields. The trans-1,2-diphenylethylene derivatives are bonded to a nanoparticle, a nanomolecule bonded to the derivative and a receptor bonded to the nanomolecule to form a nanosensor that can be used to detect chemical and biological agents.05-06-2010
20110091869METHOD FOR CULTURE OF STEM CELL - The present invention enables efficient suspension culture of stem cells in a serum-free medium by comprising a step for quickly forming a homogenous aggregate of stem cells, and provides a method of selectively inducing the differentiation of nerves from a stem cell, a method of forming a cerebral cortical nerve network in vitro, and a method of producing a steric structure of a brain tissue in vitro, as well as a method of producing hypothalamic neuron progenitor cells, comprising culturing pluripotent stem cells as a suspended aggregate in a serum-free medium that substantially does not contain a Nodal signal promoter, a Wnt signal promoter, an FGF signal promoter, a BMP signal promoter, retinoic acid and an insulin, and isolating hypothalamic neuron progenitor cells from the culture.04-21-2011
20110091867METHOD TO IDENTIFY AND PREDICT DISEASE PROGRESSION OF HUMAN PAPILLOMA VIRUS-INFECTED LESIONS - The present invention provides a method for distinguishing benign human papilloma virus (HPV)-infected tissue from HPV-related lesions that have undergone malignant transformation. In one embodiment, the invention comprises a simple histochemical staining method and details a novel process for examining HPV-infected cells by determining susceptibility to enzymatic DNA digestion. Residual virion-associated DNA is seen only in benign HPV-infected lesions, while absence of residual DNA is seen with malignant transformation. In another embodiment, the invention comprises immunohistochemical assay methods for examining HPV-infected cells, utilizing antibodies to HPV L1 proteins. These methods can be used to predict biologic behavior of HPV-infected lesions. The invention can improve current cervical cancer screening programs, and improve clinical management of patients by defining malignant potential of HPV-infected tissue more accurately.04-21-2011
20110091866DETECTION OF POLYOMAVIRUS - Methods and kits are provided for testing for the presence or absence of a polyomavirus, such as BKV, in a sample. The methods and kits are useful for quantifying BKV and differentiating BKV from JCV.04-21-2011
20110091865MEASURING MULTIPLE ANALYTES OVER A BROAD RANGE OF CONCENTRATIONS USING OPTICAL DIFFRACTION - The invention relates to method, devices, and kits for measuring multiple analytes in a sample having a broad range of concentrations using optical diffraction. Devices, methods, and kits useful for monitoring and diagnosing diabetes, cardiovascular disease, thyroid disease, hormone-related conditions, and sepsis are also described.04-21-2011
20110104660MAL, A MOLECULAR DIAGNOSTIC MARKER FOR HPV-INDUCED INVASIVE CANCERS AND THEIR HIGH-GRADE PRECURSOR LESIONS - The inventors now have developed a (molecular) diagnostic marker based on MAL alterations, in particular reduced MAL mRNA and protein expression as well as MAL promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, and high-risk human papillomavirus (HPV)-induced precursor lesions of non-cervical invasive cancers within, cell material obtained via scraping, lavage or by other means and/or tissue. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the gene products thereof as marker for HPV-induced high-grade premalignant lesions, allowing early detection and better treatment option for the individual patient.05-05-2011
20110104659DEVICE FOR BIOCHEMICAL PROCESSING AND ANALYSIS OF A SAMPLE - A device including a sample compartment, a coil and an arm for mechanical manipulation of a sample vessel placed in the sample compartment and containing a sample is described. In at least one embodiment, the coil is surrounding the sample compartment and the sample compartment has an opening for insertion and removal of the sample vessel. A method, using the device according to at least one embodiment of the invention for detection of magnetic permeability, relative magnetic permeability or relative magnetic susceptibility, is also described.05-05-2011
20110104658Synthetic Microfluidic Blood-Brain Barrier - An apparatus and method for assaying blood-brain barrier properties for drug and drug delivery vehicle screening comprising of a microfluidic apparatus with gaps separating lumen and tissue space enabling formation of tight junctions similar to in vivo conditions using endothelial cells and brain cells.05-05-2011
20110104662Methods of Detecting Inhibitors of VIF-Mediated APOBEC3G Degradation and HIV - The invention comprises methods and cell lines for assaying APOBEC3G degradation and methods for identifying inhibitors of APOBEC3G degradation. The invention also provides methods of identifying inhibitors of HIV infection. The methods of the invention are useful for identifying inhibitors of viral infection, in particular, the methods of the invention are useful for treating retroviral infection.05-05-2011
20110104657METHOD OF DETECTING MALIGNANCY OF NASOPHARYNGEAL CARCINOMA AND A NASOPHARYNGEAL CARCINOMA MALIGNANCY BIOMARKER - A method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker are disclosed. Firstly, a specimen is obtained from a testee. Next, the specimen is tested for its MIP-3α expression level. Then, the MIP-3α expression level of the specimen is compared with that of a control. Finally, the malignancy of nasopharyngeal carcinoma is determined according to a relative MIP-3α expression level between the specimen and the control.05-05-2011
2010009294132142,21481,25964,21686, Novel dehydrogenase molecules and uses therefor - The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided.04-15-2010
20100092944DETECTION OF INFLUENZA VIRUS - The present application describes methods for detecting influenza A and/or influenza B and/or distinguishing between pathogenic and seasonal influenza A subtypes. Many of these preferred formats employ pan-specific antibodies (i.e., that react with all or at least multiple strains within an influenza type) to detect presence of influenza A and/or influenza B and PDZ domains in combination with panspecific antibodies to influenza A to distinguish pathogenic and seasonal influenza A subtypes.04-15-2010
20100092945TEST STRIP FOR A LATERAL FLOW ASSAY FOR A SAMPLE CONTAINING WHOLE CELLS - A test strip for conducting a lateral flow assay for detection of an analyte in a sample that contains cells and fluid is provided, as well as methods for making and using the test strip. This test strip is commercially usable, for example, in a diagnostic device at a point of care for detection of analytes in whole blood.04-15-2010
20100092940Method and Device for Detecting Feline Immunodeficiency Virus - A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV polypeptides and determining the binding of antibodies in the sample to the polypeptides. The determination of whether an animal is infected with FIV or has been vaccinated against FIV can be determined by measuring the animal's immune response to an FIV env polypeptide. A device for detecting FIV antibodies is provided.04-15-2010
20130011829DEVICE AND METHODS FOR QUANTIFYING ANALYTES - The present invention relates to devices and methods for measuring the quantity of multiple analytes in a sample. The device is designed such that each of the analyte sensing elements is configured to measure the quantity of a predetermined analyte and where the machine executable instructions are configured to select the proper analyte sensing element corresponding to the analyte to be measured.01-10-2013
20130011826METHODS AND KITS FOR DECREASING INTERFERENCES FROM LEUKOCYTES IN SPECIFIC BINDING ASSAYS - The present disclosure describes methods and kits for reducing interferences in immunoassays performed on solid phase and on samples containing serum or plasma, by adding an effective amount of a polycationic derivative of dextran to the assay.01-10-2013
20120122080FLUORESCENCE ENERGY TRANSFER BY COMPETITIVE HYBRIDIZATION - A method is provided for detecting the presence of nucleotides or monitoring nucleotide amplification. It utilizes fluorescence energy transfer by competitive hybridization. Competitive hybridization is achieved by using unequal length complementary probes which have a fluorophore on one probe and a quencher on the other. The fluorophore and quencher are juxtaposed in a manner wherein the proximity of the quencher to the fluorophore produces quenching of the fluorescence of the fluorophore.05-17-2012
20120122079INFECTION DETECTION METHODS AND SYSTEMS AND RELATED COMPOUNDS AND COMPOSITIONS - A compound, or a pharmaceutically acceptable salt, ester, hydrate or solvate thereof, comprising formula IV:05-17-2012
20120122082METHOD AND KIT FOR DETECTION OF MICROORGANISM - Live cells of microorganism in a test sample are detected by distinguishing the live cells from dead cells or injured cells by the following steps of: 05-17-2012
20120122081DIFFERENTIATING PICORNA VIRUSES, NUCLEIC ACIDS THEREFOR, USE THEREOF AND BIOASSAY METHODS EMPLOYING THEM - A nucleic acid comprising a 13 base sequence selected from the group consisting of tcGg TtccgCt Gc, tcGgTtccgCc Ac, tcGgTcCcaTcCc, tcGgTtCcaTcCc, ttGgTcCcaTcCc, ttGgTtCcaTcCc, tcGgTcccgTcCc, and tcGgTtccgTcCc, where A and a are adenine, C and c are cytosine, G and g are guanine, and T and t are thymine or uracil, and complementary sequences thereof; provided that only a very limited number of additional bases are included at the 5′ and 3′ ends of the sequences. The use of these nucleic acids for differentiating picornaviruses, and bioassay methods employing these nucleic acids in nucleic acid amplification assays, are also disclosed.05-17-2012
20120122078METHODS AND SYSTEMS FOR PREDICTING WHETHER A SUBJECT HAS A CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) LESION FROM A SUSPENSION SAMPLE OF CERVICAL CELLS - Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.05-17-2012
20110129814PROCESS AND SYSTEM FOR DETECTING AND/OR QUANTIFYING BACTERIOPHAGES, USE OF A MICROELECTRONIC SENSOR DEVICE FOR DETECTING SAID BACTERIOPHAGES AND MICROELECTRONIC SENSOR DEVICE FOR CARRYING OUT SAID PROCESS - The present invention relates to a process and system for detecting and/or quantifying bacteriophages capable of infecting a predetermined bacterial host strain, which is based on the surface plasmon resonance technique that takes place on the conductive material surface of an optical sensor device, and also relates to a microelectronic sensor device for carrying out this process and to the use of this microelectronic sensor device for detecting and/or quantifying bacteriophages.06-02-2011
20090130654METHOD FOR SCREENING HIV DRUG SENSITIVITY - A method for monitoring ARV resistance, to determine viral fitness, and to forecast possible drug failure utilizes two nucleic acid sequences. One nucleic acid includes a retroviral nucleic acid devoid of at least a majority of the sequence for one of the two long terminal repeat regions. A second nucleic acid, includes a retroviral nucleic acid sequence devoid of the sequences encoding an envelope gene and the second long terminal repeat region of the retrovirus. The method allows the rapid cloning of an amplicon into an HIV-1 genome vector through recombination/gap repair in organisms such as yeast. The vectors can be directly passed to a mammalian cell line which has been specifically engineered to produce replication competent HIV-1 particles. The susceptibility of an isolate to any of several ARVs, i.e. PRIs, NRTIs, NNRTIs, T20, as well as entry and integrase inhibitors in developmentlclinical trials, may be tested.05-21-2009
20090130651VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.05-21-2009
20100248217ROUNDWORM COPROANTIGEN DETECTION - A composition, device, kit and method for detecting the presence or absence of roundworm in a fecal sample. The composition, device, kit and method of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm.09-30-2010
20100248215SAMPLE PREPARATION CONTAINER AND METHOD - A system and method for preparing and delivering samples for analyte testing. The system can include a sample preparation system and a sample delivery system coupled to the sample preparation system. The sample preparation system can include a deformable self-supporting receptacle comprising a reservoir adapted to contain a liquid composition comprising a source and a diluent. The sample delivery system can include a valve positioned in fluid communication with the reservoir and adapted to control the removal of a sample from the sample preparation system. The method can include applying pressure to the deformable self-supporting receptacle to remove a sample from the sample preparation system via the sample delivery system.09-30-2010
20100248213COLLECTION/EXTRACTION CONTAINER FOR BIOLOGICAL MATERIAL IN FORENSIC SAMPLES - Relates to a collection/extraction container (09-30-2010
20100248216SAMPLE PREPARATION CONTAINER AND METHOD - A system and method for preparing and analyzing samples. The system can include a sample preparation system and a sample detection system coupled to the sample preparation system. The sample preparation system can include a deformable self-supporting receptacle comprising a reservoir adapted to contain a liquid composition comprising a source and a diluent. The sample detection system can be positioned in fluid communication with the reservoir, and can be adapted to analyze a sample of the liquid composition for an analyte of interest. The system can further include a fluid path defined at least partially by the reservoir and the sample detection system. The method can include applying pressure to the deformable self-supporting receptacle to move a sample of the liquid composition in the fluid path to the sample detection system, and analyzing the sample for the analyte of interest with the sample detection system.09-30-2010
20100248210Nucleic acid primer set for detection of drug-resistant strain of hepatitis B virus, assay kit, and method of detecting drug-resistant strain of hepatitis B virus - The invention provides a method of detecting a drug-resistant strain of hepatitis B virus, including amplifying a hepatitis B virus nucleic acid in a sample solution by LAMP with a primer set to yield an amplification product, and hybridizing the amplification product with a probe containing a polynucleotide derived from a drug-resistant strain and/or a probe containing a polynucleotide derived from a drug-nonresistant strain, to detect a drug-resistant strain of hepatitis B virus.09-30-2010
20100248211METHOD FOR ANALYSIS OF HEPATITIS B VIRUS S ANTIGEN - An object of the present invention is to enable to accurately quantify HBs antigen in the samples for which measured values are low or false-negative results by the conventional assaying method of HBs antigen. In the method of assaying HBs antigen according to the present invention, at least one inner capture probe that binds to a first inner region peptide consisting of 26th to 80th amino acid residues of HBs antigen and at least one outer capture probe that binds to a second outer region peptide consisting of 98th to 156th amino acid residues of HBs antigen are used as capture probes; and at least one inner detection probe which binds to the first inner region and at least one outer detection probe which binds to the second outer region are used as detection probes.09-30-2010
20100248212DETECTION CONJUGATE - The invention relates to a detection conjugate composed of a filament fragment, e.g. a cytoskeletal filament such as actin filaments or microtubules, and recognition elements bound to this fragment as well as kits comprising said detection conjugate and methods how to use said detection conjugate as well as the use for the detection of one or more compounds present within a sample, such as a biological sample.09-30-2010
20100248214MICROORGANISM CONCENTRATION PROCESS - A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a particulate concentration agent that comprises gamma-FeO(OH); (b) providing a fluid sample comprising at least one microorganism strain; and (c) contacting the concentration agent with the sample such that at least a portion of the concentration agent is dispersed in the sample and at least a portion of the at least one microorganism strain is bound to or captured by the concentration agent.09-30-2010
20100248209Three-dimensional integrated circuit for analyte detection - The embodiments of the invention relate to a device having a first substrate comprising a transistor; a second substrate; an insulating layer in between and adjoining the first and second substrates; and an opening within the second substrate, the opening being aligned with the transistor; wherein the transistor is configured to detect an electrical charge change within the opening. Other embodiments relate to a method including providing a substrate comprising a first part, a second part, and an insulating layer in between and adjoining the first and second parts; fabricating a transistor on the first part; and fabricating an opening within the second part, the opening being aligned with the transistor; wherein the transistor is configured to detect an electrical charge change within the opening.09-30-2010
20130171621METHODS OF IN SITU DETECTION OF NUCLEIC ACIDS - Methods of detecting the presence or absence of a class of nucleic acid targets in single cells through direct or indirect capture of labels to the nucleic acids are provided, where such labels to the class of nucleic acid targets are indistinguishable from each other. Also described are methods of detecting individual cells, particularly a cell of a specific type from large heterogeneous cell populations, through detection of one or more of nucleic acid targets, where the labels to the one or more of nucleic acid targets are indistinguishable from each other. Related kits are also described.07-04-2013
20110183317DETERMINING THE SENSITIVITY OF A CELL TO A DRUG - The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase, a deoxyribonucleoside kinase transcription promoter and a dephosphorylating agent; and (vi) measuring the bioluminescence of each of the mixtures from steps (iii) to (v), wherein the comparative levels of bioluminescence of each of the mixtures provides a measure of the resistance or sensitivity to the drug.07-28-2011
20120164624SERS Nanotag Assays - Methods and systems for the use of Surface Enhanced Raman Scattering nanotags (SERS nanotags) to create homogeneous (no-wash), heterogeneous or sequence detection assay platforms. In certain embodiments the SERS nanotags are used in combination with magnetic particles. Multiplexed assay platforms are also disclosed. In certain embodiments, the assay is useful for clinical proteomics. Assay platforms suitable for use within a biological matrix, for example within whole blood or serum are also disclosed. The assay formats described herein may be used to detect any analyte of interest including but not limited to the detection of cells, viruses, bacteria, proteins, DNA, RNA, or small molecules in any type of biological (animal or plant kingdom) or environmental samples including but not limited to whole blood or serum, occult samples, urine, feces, air, drinking water, phage, any organism, multicellular clumps of cells, for example, cancer tissue homogenate.06-28-2012
20110183315DETECTION OF WEST NILE VIRUS NUCLEIC ACIDS IN THE VIRAL 3' NON-CODING REGION - Methods for detecting flavivirus nucleic acids. Particularly described are methods for detecting West Nile virus nucleic acids in the 3′ non-coding region.07-28-2011
20110183316METHODS FOR DETECTING ORGANISMS AND ENZYMATIC REACTIONS USING RAMAN SPECTROSCOPY - The present disclosure provides systems for the rapid and sensitive detection of organisms and molecules in samples. Reactants that produce Raman-active products are used in combination with Raman light scattering. The present disclosure can also be used to measure enzyme-kinetics.07-28-2011
20120129154METHODS AND COMPOSITIONS FOR THE DETECTION OF BACTERIAL BLIGHT - Methods and compositions relating to the detection of bacterial blight are provided. In one embodiment, a detection system is provided comprising a phage operable to infect a 05-24-2012
20120129157Methods and Devices for Rapid Detection and Identification of Live Microorganisms by Aptamers and/or Antibodies Immobilized on Permeable Membranes - The invention provides methods, devices and kits for rapid detection and identification of one or more live target microorganisms in a liquid sample or grown on plates containing nutrient media. The invention includes mixing one or more target microorganisms with one or more aptamers and/or one or more antibodies, each conjugated to a reporter compound and specific for a first site on one or more target microorganisms to form a mixture. The mixture is placed on a permeable membrane having immobilized thereon one or more aptamers linked to an amine compound, and/or one or more antibodies, each specific for a second site on one or more target microorganisms or a site on the aptamer conjugate and/or antibody conjugate. A detection solution is added to the membrane and detection and identification of one or more target microorganisms is achieved in about one hour or less.05-24-2012
20120129156BARRIERS FOR FACILITATING BIOLOGICAL REACTIONS - The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes.05-24-2012
20120129155METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS - A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO:12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.05-24-2012
20120129153Diagnostic method for the prediction of the development and control of the effectiveness of the treatment of oncological illnesses - A diagnostic method, in which patient tissue samples are taken, microassay are prepared, specific anti-viral immunoglobulins are processed, the number of cells infected by two or more viruses before the beginning of treatment are determined, and the dynamic of the change in the number of infected cells and their interrelationships are established: if the number of blood cells infected by any two or more viruses exceeds 50±10% in patients without signs of oncological pathology, a diagnostic conclusion is drawn of a high danger of oncological illness in connection with immune system ineffectiveness; if the number of cells infected by any two or more viruses exceeds 50±10% in patients with diagnosed oncological illnesses, a diagnostic conclusion of the cancer tumor's low sensitivity to chemotherapy and the perspective of quick tumor metastasis is drawn.05-24-2012
20120129152Diagnostic method for the prediction of the development of and control over the effectiveness of treatment of cardiovascular illnesses - A diagnostic method for the prediction of the development and control of the effectiveness of the treatment of cardiovascular diseases, in which patient tissue samples are taken, microassay are prepared, specific antiviral immunoglobulins are processed, the number of cells infected by two or more viruses before the beginning of treatment are determined, and the dynamic of the change in the number of infected cells and their interrelationships are established: when the number of cells infected by cytomegalovirus and any other viruses decreases by more than 50±10% in patients without symptoms of cardiovascular pathology, a diagnostic conclusion is high danger of the development of atherosclerosis; if the number of cells infected by cytomegalovirus and any other viruses exceeds 50±10% in patients with demonstrated clinical signs of cardiovascular system pathology, a diagnostic conclusion is drawn of the danger of the development of complications such as arrhythmia, thrombolytic embolism.05-24-2012
20120129151Quantitative Real-Time Assay For Noroviruses And Enteroviruses With Built In Quality Control Standard - A method is provided for reverse transcription-polymerase chain reaction (RT-PCR) accomplished by: a) amplifying a reverse transcribed cDNA in a mixture containing Norovirus Genogroup I and Norovirus Genogroup II primers and probes, in which the Norovirus primers and probes can distinguish between Genogroup I and Genogroup II viruses; b) quantifying virus; and c) normalizing data based on a universal internal RNA control. Optionally, the method may also include primers and probes for Enteroviruses. The present invention also provides a reaction mixture comprising containing Norovirus Genogroup I and Norovirus Genogroup II primers and probes, in which the Norovirus primers and probes can distinguish between Genogroup I and Genogroup II viruses and universal internal RNA control primers and probes.05-24-2012
20110183313Genome Wide Visual Identification of Human Co-Factors of HIV-1 Infection - The present invention relates to the identification of human host factors involved in the early stage of HIV infection. Furthermore, it relates to the use of the identified genes for the elucidation of the mechanism of HIV-infection, as drug targets, and for identifying a compound useful in the treatment of HIV.07-28-2011
20110183314BACTERIOPHAGE-BASED MICROORGANISM DIAGNOSTIC ASSAY USING SPEED OR ACCELERATION OF BACTERIOPHAGE REPRODUCTION - A method of determining the presence or absence of a target microorganism in a sample to be tested, the method comprising: combining with the sample an amount of bacteriophage capable of infecting the target microorganism to create a bacteriophage-exposed sample; and measuring the time rate of change of the amount of said bacteriophage or the change in the rate of change of the amount of said bacteriophage as an indication of the presence or absence of the target microorganism as a function of time.07-28-2011
20100190148Electrophoretic Interactive Spectral Methods and Devices for the Detection and/or Characterization of Biological Particles - Methods for identifying a biological particle in a sample medium include generating an Electrophoretic Quasi-elastic Light Scattering (EQELS) spectrum for the biological particle in the sample medium. The EQELS spectrum is compared to a reference database comprising a plurality of spectra, and each of the plurality of spectra correspond to an EQELS spectrum for one of a plurality of known biological particles. The biological particle in the sample medium is identified from the comparison.07-29-2010
20120164628AFFINITY CAPTURE OF CIRCULATING BIOMARKERS - Methods, devices and systems for capturing biomarkers are provided. In particular, methods, compositions, and systems that utilize affinity capture devices comprising a processing chamber, affinity capture agent and porous membrane are provided.06-28-2012
20120164629Antibodies For Oncogenic Strains Of HPV And Methods Of Their Use - The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.06-28-2012
20120164625METHODS FOR RAPID IDENTIFICATION OF PATHOGENS IN HUMANS AND ANIMALS - The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.06-28-2012
20120164626DETECTION OF HIGH GRADE DYSPLASIA IN CERVICAL CELLS - Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture.06-28-2012
20120214153Detection of an Analyte in a Sample - There is provided mechanisms for the detection of an analyte in a sample. The mechanisms utilize at least a first measurement channel comprising a detection reactant corresponding to the analyte to be detected, and at least a microstructure associated with the first measurement channel. When the mechanisms are in use, the sample is introduced into the first measurement channel and propagated by way of the first measurement channel towards the microstructure. If the analyte is present in the sample, the analyte interacts with the detection reactant to form a networked product, and the microstructure is configured to filter the networked product.08-23-2012
20120315626METHOD OF EVALUATING ELIMINATION OF MICROOGANISMS AND APPARATUS FOR EVALUATING ELIMINATION OF MICROORGANISMS - The sterilizing effect of particle irradiation on microorganisms for the sterilizing treatment thereof can be evaluated. The evaluation can be done by supplying microorganisms in the space inside a container (12-13-2012
20120315622SYSTEM FOR DETECTING AND ENUMERATING BIOLOGICAL PARTICLES - The invention discloses a system to detect and enumerate diverse biological particles through the use of microbial spores that in the presence of a redox substrate rapidly respond to germination signals by forming discrete intracellular fluorescent formazan granules. The disclosed system enables ultrasensitive detection and enumeration of different analytes including microorganisms, viruses, nucleic acids, polypeptides, and natural or man-made particles bearing analytes.12-13-2012
20120164627METHODS AND DEVICES FOR MICROFLUIDIC POINT-OF-CARE IMMUNOASSAYS - Microfluidic methods and devices for heterogeneous binding and agglutination assays are disclosed, with improvements relating to mixing and to reagent and sample manipulation in systems designed for safe handling of clinical test samples.06-28-2012
20120214154GENETICALLY ENGINEERED BIOLOGICAL INDICATOR - The disclosed technology relates to a genetically engineered biological indicator, comprising: at least one test organism and at least one reporter gene suitable for producing an indicator enzyme, the reporter gene being taken up by the test organism; and at least one repressor gene that inhibits expression of the reporter gene until the reporter gene is exposed to at least one inducer. A process and an apparatus for using the biological indicator are disclosed.08-23-2012
20120214152RNASCOPE.RTM. HPV ASSAY FOR DETERMINING HPV STATUS IN HEAD AND NECK CANCERS AND CERVICAL LESIONS - The present invention provides a method and a kit for determining whether a head and neck cancer is HPV-related. In one embodiment, an RNAscope® HPV assay was designed to detect the presence of E6/E7 mRNA of certain high-risk HPV subtypes related to head and neck cancer. The present invention also provides a method and a kit for determining whether a cervical lesion is a benign lesion or a cervical intraepithethial neoplasm lesion. The present invention further provides a method for determining the progression of cervical intraepithethial neoplasm based on the spatial pattern and levels of the E6/E7 mRNA of certain high-risk HPV subtypes. The present invention also provides a method for determining the risk of developing cervical cancer in a human diagnosed with cervical intraepithethial neoplasm based on presence and absence of the certain subgroups of high-risk HPV subtypes.08-23-2012
20120214151DETECTION OF HIV-RELATED PROTEINS IN URINE - A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed.08-23-2012
20120135396Multi-Shell Microspheres With Integrated Chromatographic And Detection Layers For Use In Array Sensors - The development of miniaturized chromatographic systems localized within individual polymer microspheres and their incorporation into a bead-based cross-reactive sensor array platform is described herein. The integrated chromatographic and detection concept is based on the creation of distinct functional layers within the microspheres. In this first example of the new methodology, complexing ligands have been selectively immobilized to create “separation” layers harboring an affinity for various analytes. Information concerning the identities and concentrations of analytes may be drawn from the temporal properties of the beads' optical responses, Varying the nature of the ligand in the separation shell yields a collection of cross-reactive sensing elements well suited for use in array-based micro-total-analysis systems.05-31-2012
20120135398Method of Detection and Related Detection Device - A method that uses an (DOPC) surfactant based biofilm that reacts with a material in a known manner, and a device that utilizes such a biofilm, to detect a material of interest is provided. The principles of the present invention are particularly useful in detecting/measuring a material that is harmful to a human or to property.05-31-2012
20120135397HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) DETECTION METHOD AND KIT THEREFOR - The invention provides oligonucleotide(s) derived from the gene sequence encoding the gag region of HIV-I for simple, specific and/or sensitive test(s) for the presence of HIV-I. In particular, the present invention provides oligonucleotide(s) for test(s) for HIV-I. Kit(s) comprising the oligonucleotide(s) for use as probe(s) and/or primer(s) useful in the test(s) are also provided.05-31-2012
20120135395Methods and Compositions for Determining Altered Susceptibility of HIV-1 to Anti-HIV Drugs - This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.05-31-2012
20120135394APPARATUS FOR INTEGRATED REAL-TIME NUCLEIC ACID ANALYSIS, AND METHOD FOR DETECTING A TARGET NUCLEIC ACID USING SAME - Provided are an apparatus for integrated real-time nucleic acid analysis and a method for detecting target a nucleic acid using the same, and more particularly an integrated real-time nucleic acid analysis for simultaneously performing qualitative analysis or quantitative analysis on genes from various kinds of plural biological samples and a method for detecting target a nucleic acid using the same. The apparatus for integrated real-time nucleic acid analysis and the method for detecting target a nucleic acid using the same according to the present invention, perform tests of various targets required from various samples through a single step promptly and accurately, and thus, can be efficiently used by hospitals or the like needing to rapidly diagnose diseases.05-31-2012
20120135393REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV-1 RESISTANCE TO ANTIVIRAL DRUGS - Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.05-31-2012
20100261155METHODS AND COMPOSITIONS RELATING TO VIRAL FUSION PROTEINS - Provided herein are isolated paramyxovirus pre-triggered fusion proteins, or functional fragments thereof, which contain one or more CRAC domains in a location that is away from the transmembrane domain. Also provided herein is a computer model of the structure of the pre-triggered F protein. Compositions that directly or indirectly bind and interfere with the normal activity or binding of the pre-triggered F proteins, or the CRAC domains, are useful as antiviral agents in the treatment of paramyxovirus infections. Thus, disclosed herein are methods of screening for antiviral agents, using the isolated pre-triggered F protein, or functional fragments thereof.10-14-2010
20120219941Identification of Oligonucleotides for the Capture, Detection and Quantitation of Hepatitis A Viral Nucleic Acid - Hepatitis A virus-specific primers and probes derived from conserved regions of the hepatitis A virus genome are disclosed. Also disclosed are nucleic acid-based assays using the capture oligonucleotides, primers and probes.08-30-2012
20100173283METHOD OF PREDICTING POTENTIAL SEVERITY OF HEPATITIS E, PROBE SETS, AND PRIMER SETS - The present invention provides a method of predicting potential severity of hepatitis, includes determining that hepatitis in a subject is potentially severe when it is detected that any amino acid is mutated to an amino acid of genotype-4, the any amino acid being amino acid of an amino acid sequence in a region encoded by ORF1 of an HEV genome RNA of genotype 3, and the HEV genome RNA being contained in a specimen nucleic acid taken from the subject infected with genotype-3 HEV.07-08-2010
20100173279DETECTION USING PRIMERS TO REPETITIVE DNA AND TRANSCRIPTION-BASED AMPLIFICATION THEREBY - The present invention concerns identifying organisms based on detecting distinguishing patterns produced following RNA amplification that originates via a DNA template. In particular, the methods and compositions of the invention concern obtaining ds DNA from the organism in question, amplifying at least part of the DNA via RNA molecules from transcription using primers that target repetitive DNA, and detecting a hallmark pattern of the amplified RNA.07-08-2010
20100173282MUTATIONAL PROFILE IN HIV-1 GAG CLEAVAGE SITE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE - The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e. correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management.07-08-2010
20120252006Methods and Systems for Multiple Control Validation - The invention provides methods for validating a multiplex binding assay that results in a reduced number of false invalidations. The invention further provides systems for validating a multiplex binding assay that results in a reduced number of false invalidations. The invention further provides a computer readable medium containing program instructions for validating a multiplex binding assay that results in a reduced number of false invalidations.10-04-2012
20120252007OPTIMIZED REAL TIME NUCLEIC ACID DETECTION PROCESSES - This invention provides for compositions for use in real time nucleic acid detection processes. Such real time nucleic acid detection processes are carried out with energy transfer elements attached to nucleic acid primers, nucleotides, nucleic acid probes or nucleic acid binding agents. Real time nucleic acid detection allows for the qualitative or quantitative detection or determination of single-stranded or double-stranded nucleic acids of interest in a sample. Other processes are provided by this invention including processes for removing a portion of a homopolymeric sequence, e.g., poly A sequence or tail, from an analyte or library of analytes. Compositions useful in carrying out such removal processes are also described and provided. Paneling and multiplex analyses of more than one nucleic acid analyte using one sample are also provided.10-04-2012
20120252004HIGHLY SENSITIVE IMMUNOCHROMATOGRAPHY METHOD - Provided is an immunochromatography method that enables highly sensitive detection by reducing the background density of a non-measurement site in the immunochromatography method. The immunochromatography method includes developing a complex of a substance to be tested and a labeling substance containing a metal modified with a first binding substance for the substance to be tested on an insoluble carrier in the presence of a surfactant having a steroid skeleton while the substance to be tested and the labeling substance form the complex; and detecting the complex of the substance to be tested by capturing the substance to be tested and the labeling substance on a detection site of the insoluble carrier containing a second binding substance for the substance to be tested or a substance that can bind to the first binding substance for the substance to be tested.10-04-2012
20120252005MULTI-WAVELENGTH ANALYSES OF SOL-PARTICLE SPECIFIC BINDING ASSAYS - The present invention discloses methods for detecting the presence of a complex between a first reagent and a second reagent in solution. In particular, the invention provides methods for qualitative or quantitative detection of an analyte or its specific binding partner in complex biological samples. The invention further discloses algorithms using summary rate changes at selected wavelengths in the absorbance spectra of colloidal metal-labeled analytes or specific binding partners to identify intermolecular interactions between the analyte and its binding partner.10-04-2012
20120252003Bacteria Identification by Phage Induced Impedance Fluctuation Analysis - Methods for detection and identification of bacteria within a sample include the step of inserting a pair of electrodes into the sample. A first impedance across the electrodes is established with a first AC voltage source having a first frequency. A phage is introduced into the sample, and impedance fluctuations that are caused by ion release by the bacteria due to the phage introduction are measured. The use of impedance fluctuations instead of voltage fluctuations to detect and identify bacteria minimizes 1/f noise effects and increases system sensitivity. To further increase system sensitivity by eliminating thermal noise, a second impedance across the electrodes can be established using a second AC voltage source at a second frequency. Second impedance fluctuations are cross-correlated to the first impedance fluctuations, and the cross-correlation results are analyzed to determine whether or not bacteria are present in the sample based on phage electrical activity.10-04-2012
20120171661Detection of Antigens - The invention discloses a method for detecting at least one antigen, comprising the following steps: providing magnetic beads, which are coated with antibodies specific for at least one antigen to be detected; bringing the magnetic beads in contact with a washing buffer that comprises at least 8% BSA and incubating the mixture with a sample; isolating the magnetic beads by means of a magnetic separator; and detecting the antigens bound to the magnetic beads by the antibodies. Washing buffers, primers, kits and devices that can be used for said method are also disclosed.07-05-2012
20120171660METHOD FOR SCREENING AND PURIFYING ENTEROVIRUS, METHOD FOR MASS-PRODUCING ENTEROVIRUS, AND METHOD FOR MANUFACTURING ENTEROVIRUS VACCINE - The present invention relates to methods for screening or purifying enteroviruses, a method for mass-producing enteroviruses, and a method for manufacturing an enterovirus vaccine. The method for screening enteroviruses in a sample comprises the following steps: (A) providing a sample and a carrier, wherein monosaccharides such as glucose or galactose are bound to the surface of the carrier, and the monosaccharides have binding affinity to enterovirus; (B) contacting the sample with the carrier; (C) removing components of the sample that do not bind to the carrier; (D) providing a detection unit and contacting the detection unit with the carrier, wherein the detection unit binds to the sample bound on the carrier; and (E) measuring a signal of the detection unit, wherein when the signal of the detection unit is detected, it represents that the enterovirus exists in the sample.07-05-2012
20120171664METHODS AND DEVICES FOR DETECTION OF THE STRAIN OF A PATHOGEN - Provided are methods and devices for determining the strain of a pathogen in a sample.07-05-2012
20120171662Simplified Device for Nucleic Acid Amplification and Method for Using Same - The present invention relates to a disposable device (07-05-2012
20120214155DIAGNOSTIC ASSAYS FOR CHORDOPOXVIRUSES - This disclosure relates to compositions and methods of their use in detection and identification of a chordopoxvirus in a sample, such as diagnosis of an infection in a subject. The compositions and methods allow for detection and identification of all non-avian low-GC content chordopoxviruses, identification of most known high-GC content chordopoxvirus, and species-specific detection of Canarypox virus, Fowlpox virus, and Sealpox virus.08-23-2012
20120077185DETECTION OF GENETIC ABNORMALITIES AND INFECTIOUS DISEASE - The present invention provides assay systems and related methods for detecting genetic abnormalities and infectious agents in maternal samples. Exemplary maternal samples for analysis using the assay systems of the invention include maternal blood, plasma or serum.03-29-2012
20120077184ELECTROMAGNETIC MULTIPLEX ASSAY BIOSENSOR - A method is provided for determining the presence of multiple different target analytes in a liquid sample using electrophoretic separation and magnetic labels within a self-contained reaction cartridge and an external magnetic sensor for detection. Magnetic labels are bound to target analytes through specific binding elements. By electrophoretic separation, the multiple different targets can be sorted according to their specific sizes and inherent molecular charges for better detection resolution and specificity. After the separation process, the target analytes are then recognized and trapped by the detection binding elements within the reaction cartridge. A magnetic field generator provides a changeable magnetic field that causes the bounded magnetic labels and target analytes to produce a resonance disruption detectable by a magnetic sensor. The sensor can provide a digital binary value to indicate whether or not a label particle is bound and that determines the presence of target analytes.03-29-2012
20120315625SELF-ASSEMBLED MONOLAYERS AND METHODS FOR USING THE SAME IN BIOSENSING APPLICATIONS - Cross-linked amphiphile constructs that form self-assembled monolayers (SAMs) on metal surfaces such as gold surfaces are disclosed. These new SAMs generate well packed and highly oriented monolayer films on gold surfaces. A method for using the SAMs in the fabrication of biomolecule sensors is also disclosed.12-13-2012
20120315623DETECTION OF CONDUCTIVE POLYMER-LABELED ANALYTES - The disclosure relates to the detection of analytes (e.g., biological pathogens such as bacteria or viruses) using a conductive polymer label. The disclosed detection system utilizing the conductive polymer label generally involves the formation of an analyte conjugate between the target analyte and a conductive polymer moiety conjugated to the target analyte. The conductive polymer portion of the analyte conjugate is electrically activated to form an electrically activated analyte conjugate having an increased electrical conductivity relative to the analyte conjugate as originally formed. The electrically activated analyte conjugate can then be detected by any suitable means, such as by conductimetric or electrochemical detection.12-13-2012
20120315624Using LNA Flow-Fish to Quantitatively Monitor Viral Infections in Infected Cells and Test the Efficacy of Antiviral Medications - As described herein, locked nucleic acids are used with flow cytometric-fluorescence in situ hybridization (LNA flow-FISH) detection of viral RNA in infected cells. This technique represents a straightforward way to monitor viral infection in cells and can be used to measure efficacy of potential antiviral compounds.12-13-2012
20120315621PERSONAL GLUCOSE METERS FOR DETECTION AND QUANTIFICATION OF A BROAD RANGE OF ANALYTES - A methodology for developing highly sensitive and selective sensors that can achieve portable, low-cost and quantitative detection of a broad range of targets using only a personal glucose meter (PGM) is disclosed. The method uses recognition molecules specific for a target agent, enzymes that can convert an enzyme substrate into glucose, and a PGM. Also provided are sensors, which can include a solid support having attached thereto a recognition molecule that permits detection of a target agent, as well as an enzyme that can catalyze the conversion of a substance into glucose, wherein the enzyme is attached directly or indirectly to the recognition molecule, and wherein in the presence of the target agent the enzyme can convert the substance into glucose. The disclosed sensors can be part of a lateral flow device. Methods of using such sensors for detecting target agents are provided.12-13-2012
20100047768AMPLIFICATION OF SINGLE VIRAL GENOMES - The present invention relates, e.g., to a method for amplifying the genome of a single virus particle from a mixture of virus particles, comprising (a) subjecting the mixture of virus particles to flow cytometry and identifying a sorted sample that putatively contains a single virus particle, (b) imbedding the sorted sample comprising the putative single viral particle in a solid matrix (e.g., low melting agarose); (c) visualizing the embedded virus particle (e.g., by EFM and/or confocal microscopy) to confirm that a single particle is embedded; and (d) exposing the nucleic acid from the visualized, embedded single, discrete viral particle (e.g., by alkali treatment) and amplifying the genomic viral nucleic acid in situ (e.g., by MDA).02-25-2010
20100047766ANALYTE MANIPULATION AND DETECTION - Provided is a method for separating two or more analytes in a fluid, which method comprises: 02-25-2010
20100047765MOLECULAR DETERMINANTS ASSOCIATED WITH ENHANCED ABILITY TO ENTER CELLS EXPRESSING CXCR4 - The invention provides a method for determining whether a human immunodeficiency virus is likely to be have enhanced ability to enter a cell expressing CD4 and CXCR4 relative to a reference HIV. In certain aspects, the methods comprise detecting one or more amino acid in an envelope protein of the HIV associated with enhanced ability to enter CD4- and CXCR4-expressing cells and determining that the HIVs ability to enter such cells is enhanced relative to a reference HIV, e.g., an HIV that does not comprise such amino acid(s).02-25-2010
20100047764Novel surface protein (HBsAg) variant of the hepatitis B virus - The invention relates to sequences of a novel variant of the Hepatitis B surface antigen (HBsAg) and to methods for detecting, in patient samples, nucleic acids, antigens, and antibodies directed against the same.02-25-2010
20100047763Plasmid Expression Vectors for Expression of Recombinant Rotavirus and Astrovirus Proteins or Epitopes - The present invention refers to the production of specific recombinant viral proteins intended for use in the construction of a diagnostic kit for the simultaneous detection of the two most important gastroenteric viruses, namely rotavirus and astrovirus.02-25-2010
20100279276METHODS FOR DETERMINING THE PRESENCE OF SARS CORONAVIRUS IN A SAMPLE - Methods for determining the presence of SARS-CoV in a test sample that include targeting the SARS-CoV 5′ leader sequence or the SARS-CoV 3′ terminal sequence.11-04-2010
20120315627METHOD FOR DETERMINING THE EFFECTIVENESS OF STERILIZATION AND/OR DISINFECTION PROCESS - A method for determining the effectiveness of a sterilization and/or disinfection process is disclosed.12-13-2012
20120178079Human Bocavirus and Methods of Diagnosis and Treatment - Human parvovirus, genus 07-12-2012
20120178078Methods and Compositions for Nucleic Acid Detection - The present application relates to Multicomponent Nucleic Acid Enzymes (MNAzymes), which may be used for detecting, identifying and/or quantifying targets. More particularly, this application provides methods of designing and making more reliable MNAzymes, as well as compositions comprising MNAzyme components and methods of using MNAzymes.07-12-2012
20110104661DEGRADABLE POLYACRYLAMIDE GEL - A degradable polyacrylamide gel for analyzing or separating at least one macromolecule in a sample using electrophoresis includes a polyacrylamide cross-linked with at least one degradable cross-linker having a ketal or acetal group with the formula (I), wherein R05-05-2011
20100273144NOVEL USE OF GRP 94 IN VIRUS INFECTION - A novel use of GRP 94 in treatment of virus infection is provided. More specifically, a method of inhibiting virus infection by inhibiting expression of GRP 94 and/or inactivating activity of GRP 94, and a method of developing drugs for preventing and/or treating virus infection and/or diseases caused by virus infection by using GRP 94 as a target are provided.10-28-2010
20100216117OLIGONUCLEOTIDES, USE, METHOD OF DETECTION AND KIT FOR DIAGNOSING THE PRESENCE OF THE CHIKUNGUNYA VIRUS E1 GENE - The present invention concerns oligonucleotides intended to enable the amplification and the detection of a target sequence located in the E1 gene of the Chikungunya virus. These oligonucleotides are between 10 and 50 nucleotides in length and comprise at least one fragment of 10 consecutive nucleotides derived from the following sequences: SEQ ID No. 1: 5′-CTCTTACCGGGTTTGTTGC-3′ or SEQ ID No. 2: 5′-GCCTGGACACCTTTCGAC-3′, or the sequence complementary thereto. The invention also concerns the oligonucleotide which enables detection of the amplicons, the use of these oligonucleotides, a method of detection and a kit for diagnosing the presence of the E1 gene of the Chikungunya virus. The invention has a preferred use in the diagnostics field.08-26-2010
20100009343COMPOSITIONS AND METHOD FOR RAPID, REAL-TIME DETECTION OF INFLUENZA A VIRUS (H1N1) SWINE 2009 - Disclosed are oligonucleotide amplification primers and detection probes specific for the amplification and detection of pathogenic organisms, including for example, specific Influenza A H1N1 viral isolates. Also disclosed is a biological organism identification kit including the disclosed nucleic acid probes and primers, as well as thermal cycling reagents that is both portable and durable, and may also be self-contained for remote, or in-field analysis and identification of particular influenza isolates from a variety of biological specimen types.01-14-2010
20100009340COMPOSITIONS AND METHODS FOR THE ANALYSIS AND TREATMENT OF AIDS WASTING SYNDROME AND IMMUNE CELL DYSFUNCTION - The present invention relates to aberrant cell signaling by the HIV type I envelope glycoprotein. In particular, the present invention provides compositions and methods for identification of inhibitors of melanocortin receptor pathway stimulation by HIV-I gp120 and its degradation products. The inhibitors so identified are contemplated to be suitable for treating HIV-related cachexia, T cell hyperactivation and central nervous system disease.01-14-2010
20100009339Detection method for influenza viruses - A method of rapid detection of influenza viruses and/or virus particles comprising a hemagglutinin and a neuraminidase component, said method comprising the steps of:01-14-2010
20100009342CONTROL OF CHEMICAL MODIFICATION - Provided is a method for controlling the degree of labeling (DOL) of a carrier molecule or solid support by the addition of a reactive label competitor to the labeling reaction. When the reactive label competitor is added to the labeling solution the competitor competes with the carrier molecule or solid support for the label, reducing the number of labels available to conjugates to the carrier molecule or solid support. This provides for a facile method that predictably alters the DOL of a carrier molecule or solid support.01-14-2010
20090061418DISPOSABLE ANALYTICAL MICROPROCESSOR DEVICE - The present invention generally relates to the determination of an analyte concentration (quantitative determination) or whether an analyte threshold level has been passed (qualitative determination) in a biological sample through employment of a disposable analytical microprocessor device. The device can include a batch-specific, self-executable algorithm for the calculation of the analyte concentration.03-05-2009
20090061420MUTATIONAL PROFILES IN HIV-1 PROTEASE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE - The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis03-05-2009
20090061416Surfaces and methods for biosensor cellular assays - Disclosed is an apparatus for measuring ligand-induced cell activity as defined herein, the apparatus including: an optical biosensor having a contact surface including a compatibilizer zone, an optional surface modifier zone, and a live cell zone. The disclosure also provides a method of making the apparatus and methods for measuring ligand-induced live cell activity with the apparatus.03-05-2009
20090061419GENOMIC MARKERS OF HEPATITIS B VIRUS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA - The present invention provides methods of predicting a pre-disposition of HBV-infected individuals to develop hepatacellular carcinoma (HCC).03-05-2009
20090061414Method for quantification of recombinant viruses - Titration is an important and critical step in dosing recombinant virus for gene therapy. A relatively fast, convenient and sensitive method that allows for precise quantification of recombinant retrovirus is presented. The method is based on PCR amplification of a foreign gene by the PRINS (primer in situ DNA synthesis) technique. The PRINS technique is based on the sequence-specific annealing of unlabeled oligonucleotide DNA it situ. This oligonucleotide operates as a primer for in situ chain elongation catalyzed by the Taq I polymerase. Using -labeled nucleotides as a substrate for chain elongation, the neo-synthetic DNA is labeled by an FITC-conjugated anti-antibody. To avoid the possibility of false positives, the puromycin resistance gene, which is associated with the transgene in the same viral vector and is not normally present in mammalian cells was amplified. The retroviral titer was evaluated by counting FITC-positive cells after PRINS labeling, while knowing the number of cells that were transduced with different amounts of viral supernatant. A comparable viral concentration of 1×1003-05-2009
20090061417INFLUENZA A VIRUS DETECTION METHOD AND KIT THEREFORE - The invention provides oligonucleotides for a simple, specific and/or sensitive test for the presence of Influenza A. In particular, the present invention provides a primer(s), probe(s) and/or test(s) for Influenza A Subtype H5N1. Kits comprising probe(s) and/or primer(s) useful in the test are also provided.03-05-2009
20090061415Sequences Diagnostic For Shrimp Pathogens - Primers have been isolated that are diagnostic for the detection of the taura syndrome virus (TSV). The primers are based on a new portion of the TSV genome and may be used in primer directed amplification or nucleic acid hybridization assay methods.03-05-2009
20090061413ISOTHERMAL SCREENING OF HIV-1 RELATED NUCLEIC ACIDS - The presently described technology relates generally to the art of molecular diagnostics and more particularly to point-of-care diagnostic methods and materials. The diagnostic methods and materials of the presently described technology are suitable for a variety of uses including but not limited to the bedside or field diagnosis of infectious or noninfectious diseases.03-05-2009
20100291547FLUOROGENIC HYDRAZINE-SUBSTITUTED COMPOUNDS - The present disclosure is directed to fluorogenic schiff base-forming dyes capable of detecting analytes containing aldehyde and ketone groups. The dyes contain nucleophilic hydrazinyl appendages and are capable of binding and detecting analytes in situ.11-18-2010
20100291546METHOD FOR DETECTION OF HEPATITIS B VIRUS - To provide a method for detection or quantification of hepatitis B virus (HBV) antigens in serum and a simple and highly user-friendly method for sample treatment for use in the detection or quantification thereof. The method for treatment of a sample containing hepatitis B virus (HBV) is characterized in that release of HBV antigens and disruption of antibodies that bind to HBV antigens are carried out by treating a sample containing HBV with a treatment agent containing (1) an acidifying agent and (2) a protein denaturant or an amphoteric surfactant or cationic surfactant having an alkyl group and a tertiary amine or a quaternary ammonium salt within a molecule.11-18-2010
20100291545ANTIBODY HAVING INHIBITORY ACTIVITY ON INFECTION WITH HEPATITIS C VIRUS (HCV) AND USE THEREOF - The objection of the invention is to provide an antibody that inhibits infection with hepatitis C virus (HCV). To this end, this invention provides an antibody that recognizes the hepatitis C virus (HCV) particle obtained from the hepatitis C virus (HCV) genome comprising the following (i) and (ii) ligated to each other as an antigen and has an inhibitory activity on infection with hepatitis C virus (HCV): (i) (a) the 5′-untranslated region, the core protein-encoding sequence, the E1 protein-encoding sequence, the E2 protein-encoding sequence, and the p7 protein-encoding sequence of the JFH-1 strain of the hepatitis C virus (HCV) or (b) the 5′-untranslated region, the core protein-encoding sequence, the E1 protein-encoding sequence, the E2 protein-encoding sequence, and the p7 protein-encoding sequence of the J6CF strain the hepatitis C virus (HCV); and (ii) the NS2 protein-encoding sequence, the NS3 protein-encoding sequence, the NS4A protein-encoding sequence, the NS4B protein-encoding sequence, the NS5A protein-encoding sequence, the NS5B protein-encoding sequence, and the 3′-untranslated region of the JFH-1 strain.11-18-2010
20100291544COMPOSITIONS FOR USE IN IDENTIFICATION OF STRAINS OF HEPATITIS C VIRUS - The present invention provides compositions, kits and methods for rapid identification and quantification of strains of hepatitis C viruses by molecular mass and base composition analysis.11-18-2010
20100291543HOMOGENEOUS IN VITRO FEC ASSAYS AND COMPONENTS - Reporter fragments, reporter components, and systems adapted to detect analytes in homogeneous in vitro assays are provided, such assays employing these systems, and methods of making and using same. Particular embodiments include isolated and purified reporter fragments displaying enhanced solubility, reduced aggregation, resistance to inhibitors, and enhanced suitability for use in homogeneous in vitro assays.11-18-2010
20100291542RAPID IMMUNOCHROMATOGRAPHIC DETECTION BY AMPLIFICATION OF THE COLLOIDAL GOLD SIGNAL - The present invention relates to a method for rapid immunochromatographic detection of a target in a sample by double sandwich immunoassay detection, wherein the target is an antibody and/or an antigen, using different colloidal gold conjugates conjugated with a first and a second specific antibody or antigen, respectively, to a rapid immunochromatographic detection device, to uses of the method for detecting diseases or specific conditions, and to a method for the manufacture of the device as well as to a kit which comprises the device.11-18-2010
20100291541BACTERIOPHAGE IMMOBILIZATION FOR BIOSENSORS - A method is disclosed for anchoring a bacteriophage on a substrate, the bacteriophage having a phage amine moiety, the method comprising: producing a free amine terminal moiety on the substrate by chemical modification of the substrate; activating the free amine terminal moiety with a cross-linking agent to produce an active functional group to couple to the phage amine moiety; and anchoring the bacteriophage to the substrate using the active functional group. A sensor is also disclosed comprising: a substrate; an anchor group attached by chemical modification to the substrate and having an active functional group produced by the activation of a free amine terminal moiety; and a bacteriophage having a phage amine moiety coupled to the active functional group to anchor the bacteriophage to the substrate.11-18-2010
20100291540CARBOHYDRATE BINDING MODULE AND USE THEREOF - The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.11-18-2010
20100291539METHODOLOGY FOR DETECTION, ENUMERATION, PROPAGATION AND MANIPULATION OF BACTERIOPHAGES - A method to propagate, enumerate and quantify bacteriophage(s) in a water sample or other aqueous sample was designed which contains ingredients to stimulate the growth of select bacterial species which are susceptible to infection by specific bacteriophage(s), in which interfering background organisms are either inhibited or inconsequential. Important features of the medium include oxidation-reduction compounds producing colored and/or fluorescent products, chromogenic and/or fluorogenic enzyme substrates, and temperature-independent gelling agent(s). A preferred combination is the growth medium containing 2,3,5-triphenyl tetrazolium chloride, 5-bromo-4-chloro-3-indolyl-B-D-galactoside, and appropriate gelling agents, which (when properly used) produces a dark red bacterial lawn containing teal blue-green, irregularly circular spots representing individual phage plaque, all discernible to the eye in visible light. The procedure can also be readily applied towards automatic counting systems under artificial illumination. The procedure can be employed with water samples and with elution buffers that can retain bacteriophages in suspension following contact by the buffer with foods, soils, hard surfaces and other solids that may be contaminated by bacteriophages.11-18-2010
20100291538ARTIFICIAL CALIBRATION VIRUS TO CONTROL HIV VIRAL LOAD TESTS BY PCR IN REAL TIME - The present invention refers to the design of an artificial calibrating virus (ACV), as well as a methodology quality guarantee system, which has controlling characteristics in the performance of all the stages carried out during a detection and/or quantification molecular test. More specifically, the referred to ACV is used for the validation and calibration of quantitative determinations of circulating viruses in blood plasma samples by means of polymerase chain reaction (PCR) technology in real time (or ‘real time PCR’).11-18-2010
20100291537METHODS AND COMPOSITIONS RELATED TO PHAGE-NANOPARTICLE ASSEMBLIES - Embodiments of the invention include additional compositions and related methods and devices for the use of phage-nanoparticle assemblies. Embodiments of the invention include compositions, methods and devices related to phage-nanoparticle assemblies and their use in a variety of methods including detection methods, in vitro and in vivo diagnostic methods, direct and/or indirect therapeutic methods, or combinations thereof. Phage-nanoparticle assemblies of the invention comprise a plurality of nanoparticles complexed with one or more phage particles to form a phage-nanoparticle assembly. In certain aspects, the phage-nanoparticle assembly may also include other agents, including but not limited to organizing agents and/or therapeutic agents.11-18-2010
20100297602Apparatus and method of contaminant detection - The present invention is a method and apparatus for contaminant detection of body parts, such as hands, and or their coverings, such as clean room suits or gloves, and small objects. Particularly, the method and apparatus involve collecting air samples containing aerosolized contaminate particles from the objects and analyzing the sample for presence of a contaminate. Aerosol lab-on-a-chip and/or electronic nose devices are utilized for the detection of contaminant particles.11-25-2010
20120225422METHOD AND DEVICE EMPLOYING A NON-RECEPTOR LIGAND INTERACTION WITH NANOPARTICLES OR OTHER SOLID PHASE FOLLOWED BY SPECIFIC DETECTION - A method and apparatus for conducting specific binding assays are claimed. This invention relates to an initial non-receptor ligand interaction with nanoparticles or other solid phases followed by specific detection methods used for detecting biological, chemical or environmental entities. This invention employs an on-device ligand attachment to nanoparticles or other solid phase followed by the specific capture in discrete zones on the device. The ligand-bound complexes assemble on the ligand specific capture zone leading to a visible diagnostic result, if colored solid phases are employed.09-06-2012
20120225421KIT AND METHOD FOR SEQUENCING A TARGET DNA IN A MIXED POPULATION - Methods and kits for sequencing a target DNA sequence in a sample having a related reference sequence are provided herein. In particular, kits and methods for sequencing cancer and cancer therapy associated mutations are described. Also provided are kits and methods for detecting mitochondrial mutations and for differentiating between closely related viral strains.09-06-2012
20120258445METHODS FOR USING NANOWIRE SENSORS - Methods for using nanowire sensors are described. In one embodiment, the nanowire sensor may be field effect transistor having a nanowire and a functionalized control electrode. One method of using such a nanowire sensor includes exposing the functionalized control electrode to a test sample and an enhancing reagent. In another embodiment, the nanowire sensor may be a field effect transistor having a gate electrode and a functionalized nanowire. One method of using such a nanowire sensor includes exposing the functionalized nanowire to a test sample and an enhancing reagent. The use of an enhancing reagent increases the sensitivity of the nanowire sensor to a substance to be detected or quantified.10-11-2012
20120258442DETERMINING TUMOR ORIGIN - The disclosure provides methods for the use of gene expression measurements to classify or identify among 54 cancer types in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.10-11-2012
20120190010Generic Matrix for Control Nucleic Acids - The present invention belongs to the field of in-vitro diagnostics. Within this field, it particularly concerns the amplification of at least a first target nucleic acid that may be present in at least one fluid sample using an internal control nucleic acid for qualitative and/or quantitative purposes and at least one external control nucleic acid in an aqueous buffer. It further provides an analytical system comprising an internal control nucleic acid for qualitative and/or quantitative purposes and at least one external control nucleic acid in an aqueous buffer.07-26-2012
20120329037BIOSENSOR - Embodiments of the present disclosure set forth a biosensor for detecting a target. One example sensor includes a first electrode. The first electrode includes a first electron conducting molecule and a first probe. The first probe includes a second electron conducting molecule. The first probe is configured to bind to the target of interest in solution. The first and second electron conducting molecules are different.12-27-2012
20120258448MUTATIONAL PROFILE IN HIV-1 GAG CLEAVAGE SITE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE - The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management.10-11-2012
20120190008GENERIC PCR - The present invention provides a method for the amplification of at least a first and a second target nucleic acid that may be present in a fluid sample. The invention further provides a kit and an analytical system for carrying out said amplification.07-26-2012
20120190011COMPOSITIONS AND METHODS FOR MAMMALIAN GENETICS AND USES THEREOF - The invention provides compositions and methods for performing mammalian cell genetics, e.g., genetic screens, using near-haploid cells. The invention further provides genes and gene products isolated using the inventive methods and methods of use thereof.07-26-2012
20120190009Viral Modulators and Processes Thereof - A viral modulator and process thereof. A method may include contacting one or more viral modulators to one or more biological systems. A biological system may be configured to be infected by one or more virus. A virus may include an HIV virus, a VEEV virus and/or the like. A viral modulator may include a viral inhibitor and/or a viral activator.07-26-2012
20120190007METHOD AND SYSTEM FOR MONITORING AND RECORDING A VIRAL INFECTION PROCESS AND THAT FOR SCREENING VACCINES - The present invention relates to a method and system for monitoring and recording a viral infection process and that for screening vaccines, which is characterized by providing a microcantilever detection device, which comprises a microcantilever comprising a contact area having an macromolecular material attached thereon; allowing host cell to be attached to the macromolecular material; allowing a sample containing a test virus or vaccine to be loaded into the contact area to make the test virus or vaccine to contact the host cells attached to the macromolecular material so as to produce a deflection of the microcantilever; and recording the deflection in a time course manner so as to obtain a deflection profile that can used as a basis for determining the viral infection process or the potential efficacy of the vaccines.07-26-2012
20120190006OPTOELECTRONIC DETECTION SYSTEM - The invention relates to optoelectronic systems for detecting one or more target particles. The system includes a reaction chamber, a specimen collector, an optical detector, and a reservoir containing cells, each of the cells having receptors which are present on the surface of each cell and are specific for the target particle to be detected, where binding of the target particle to the receptors directly or indirectly activates a reporter molecule, thereby producing a measurable optical signal.07-26-2012
20120264109LYMPHOCYTE ANALYSIS FOR MONITORING THE PROGRESSION OF IMMUNODEFICIENCY VIRUS - The present disclosure describes a method of monitoring disease progression in a mammal positive for immunodeficiency virus which includes collecting blood cells from a mammal to obtain a first blood sample adding antibodies such as CD4 and CD8 to the first blood sample scanning the blood sample to produce a first multivariate dot plot which may be used to quantify at least CD410-18-2012
20090035747Nucleic Acid and Gene Derived from Novel HCV Strain and Replicon-Replicating Cell Using Said Gene - The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV replicon-replicating cell transfected with the replicon RNA. When the HCV replicon RNA and the HCV replicon-replicating cell of the present invention are used, HCV proteins can be continuously produced in a large amount.02-05-2009
20090017449COMPOUNDS AND METHODS FOR ASSAYING FUSION OF AN INDIVIDUAL, ENVELOPED VIRUS WITH TARGET MEMBRANE - Compositions and methods for monitoring viral fusion are provided. Methods of labelling virions are also provided. A novel, detectable label is provided. A mobile lipid bilayer is also provided.01-15-2009
20120329040MICROFLUIDIC DEVICES AND METHODS FOR SEPARATING AND DETECTING CONSTITUENTS IN A FLUID SAMPLE - Microfluidic devices and methods for using the same are provided. Aspects of the present disclosure include microfluidic devices that include a separation medium having functional groups which covalently bond to one or more analytes of interest, e.g., proteins, in a sample upon application of an applied stimulus, e.g., light. Also provided are methods of using the devices as well as systems and kits that include the devices. The devices, systems and methods find use in a variety of different applications, including diagnostic and validation assays.12-27-2012
20120329041REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV-1 RESISTANCE TO ANTIVIRAL DRUGS - Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein.12-27-2012
20120329039SUBSTANCE DETERMINING APPARATUS - The invention relates to a substance determining apparatus for determining a substance within a fluid. Particles attach the substance and bind to a binding surface (12-27-2012
20120329038Multivolume Devices, Kits and Related Methods for quantification of Nucleic Acids and Other Analytes - Provided are devices comprising multivolume analysis regions, the devices being capable of supporting amplification, detection, and other processes. Also provided are related methods of detecting or estimating the presence nucleic acids, viral levels, and other biological markers of interest.12-27-2012
20110123979DETECTION OF MICROORGANISMS - A method of collecting, detecting and enumerating microorganisms in a fluid comprising subjecting a sample of the fluid to dielectrophoresis and collecting the microorganisms onto a microelectrode, scanning the microelectrode using a scanning laser and determining the number of microorganisms present on the microelectrode. Alternatively, the microorganisms may be spun onto a substrate which has been pre-treated with a polycationic electrolyte.05-26-2011
20110123978HUMAN PAPILLOMA VIRUS (HPV) DETECTION USING NUCLEIC ACID PROBES, MICROBEADS AND FLUORESCENT-ACTIVATED CELL SORTER (FACS) - The present invention relates generally to the field of diagnostic and detection assays. More particularly, the present invention provides methods, and reagents including biochips for detecting the presence of, or distinguishing between, one or more analytes in a sample.05-26-2011
20110123977METHOD FOR TAKING A PLURALITY OF SAMPLES - The invention provides a method for taking a plurality of samples (05-26-2011
20120231446METHOD FOR SELECTIVELY ENRICHING AND ISOLATING MICROBIAL AND OPTIONALLY ADDITIONAL VIRAL NUCLEIC ACIDS - The present invention relates to a method for selectively enriching and/or isolating microbial and optionally additionally viral nucleic acids from samples that contain a mixture of microbial cells, freely circulating nucleic acids and higher eukaryotic cells, and optionally additionally viruses, in a liquid, and to a kit for selectively enriching and/or isolating intracellular and extracellular microbial nucleic acids, and optionally additionally viral nucleic acids, from samples that contain a mixture of microbial and higher eukaryotic cells, freely circulating nucleic acids, in particular extracellular microbial nucleic acids, and optionally additionally viruses in a liquid.09-13-2012
20120231445OLIGONUCLEOTIDES AND PROCESS FOR DETECTION OF SWINE FLU VIRUS - A rapid, sensitive and cost effective process of detection of swine flu virus H1 type in a sample is provided herein. The present invention further provides highly specific oligonucleotides useful for rapid detection of swine flu virus in a sample. Swine flu virus specific isothermal gene amplification assay disclosed in the present invention is highly specific and sensitive and is useful for early clinical diagnosis of H1N1 human patients. The oligonucleotides disclosed in the present invention provide amplification of the target gene in highly sensitive and specific manner showing no cross amplification.09-13-2012
20100323341HETERODUPLEX TRACKING ASSAY - A change in viral tropism occurs in many HIV positive individuals over time and may be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus may be shifted back to CCR5-mediated entry soon after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment and clinical management of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CCR5- or CXCR4-specific strains. The diagnostic methods may be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. The methods of the invention include cell-based methods, including cell fusion assays, and molecular-based methods, including heteroduplex tracking assay, to both quantitatively and qualitatively analyze patient-derived HIV for coreceptor usage.12-23-2010
20100323340HETERODUPLEX TRACKING ASSAY - A change in viral tropism occurs in many HIV positive individuals over time and may be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus may be shifted back to CCR5-mediated entry soon after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment and clinical management of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CCR5- or CXCR4-specific strains. The diagnostic methods may be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. The methods of the invention include cell-based methods, including cell fusion assays, and molecular-based methods, including heteroduplex tracking assay, to both quantitatively and qualitatively analyze patient-derived HIV for coreceptor usage.12-23-2010
20080299544Hcv Multiple Epitope Fusion Antigens With Modified Proteolytic Cleavage Sites And Uses Thereof - Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.12-04-2008
20080299545CHROMATOGRAPHIC METHODS FOR ASSESSING ADENOVIRUS PURITY - Methods for determining the quantity, quality and purity of a previously purified virus sample are disclosed. Such methods, which include the use of high performance size exclusion chromatography to determine these attributes are also disclosed.12-04-2008
20120264114Disposable Device for the Detection of Particles of Interest, Such as Biological Entities, Detection System Comprising Said Device and Method for Using Same - The invention relates to a disposable device comprising all of the reagents necessary for the detection of one or more particles of interest, and which can be incorporated in a detection system including simple means for the automatic management of fluids. For this purpose, the invention relates to a disposable device for the detection of one or more particles of interest present in a liquid sample, said device comprising a substrate provided with: a chamber for capturing the particle(s) of interest to be detected; a fluid channel connecting, upstream, the capture chamber to a buffer solution container, a liquid sample injection means and a container of labelling probes that can be secured to the particle(s) of interest to be detected; and a fluid channel connecting, downstream, the capture chamber to a container for the recovery of liquids which, during use, can flow from the capture chamber.10-18-2012
20120264113USE OF SUPERHYDROPHOBIC SURFACES FOR LIQUID AGGLUTINATION ASSAYS - This invention relates to the use of thermodynamically incompatible surfaces in agglutination assays for the express purpose of using the sample as a key component of the detection instrument. Specifically, the invention relates to formation of a lense and a virtual container for rapid mixing via thermal energy by a sample liquid disposed on a superhydrophobic surfaces, and a subsequent specific analyte or overall protein concentration assay using particles agglutination for use in the industrial, environmental, and clinical laboratory test fields.10-18-2012
20120264112METHOD OF MEASURING HUMAN CYP3A INDUCIBILITY - A method for measuring human CYP3A inducibility upon administration of a test drug, characterized in that a non-human animal to which a test drug is administered or a population of human cells cultured in a medium containing a test drug is infected with viruses (A) and (B); virus (A) being an adenovirus which is used as a vector and engineered by incorporating thereto a detectable reporter gene and at least 3 human PXR binding regions falling within an untranslated region of a human CYP3A gene, and virus (B) being an adenovirus which is used as a vector and engineered by incorporating thereto a human PXR cDNA; and subsequently expression level of the reporter gene is determined in the non-human animal or the cultured human cells.10-18-2012
20120264110AUTOMATED PAP SCREENING USING A PLURALITY OF BIOMARKERS AND MULTI-SPECTRAL IMAGING - An automated screening method for detecting abnormalities in a sample. The method includes steps of staining a sample with a histologic or cytologic stain for transmission light microscopy to provide a stained sample; exposing the stained sample to a plurality of differentially-labeled biomarkers, wherein each of the biomarkers is labeled with a distinct transmission stain or fluorescence probe; at a first location, generating at least one multi-spectral image of the stained sample using signals obtained from the plurality of differentially-labeled biomarkers and the histologic or cytologic stain; and automatically determining whether the first location requires further pathologist review or interpretation.10-18-2012
20120264108Intracellular Molecular Delivery Based On Nanostructure Injectors - There is disclosed a method and device for the delivery of molecules into individual cells. A device for injecting a biological molecule into a target cell comprises a microscopic tip attached to a mechanical scanning device for positioning the tip relative to the target cell and for moving the tip into the target cell; a nanostructure, such as a carbon nanotube, fixed on an end of the microscopic tip; and a biological molecule attached to the nanotube by a cleavable electrostatic or chemical linker linking the biomolecule to the nanotube, said chemical linker having a chemical linkage which is cleaved in an intracellular environment. The biological molecule may be one or more of proteins, nucleic acids, small molecule drugs, and optical labels, and combinations thereof. Exemplified are multiple walled carbon nanotubes to which a polycyclic aromatic compound is adsorbed, the aromatic compound having a side chain containing a cleavable disulfide linkage and a biotin functionality for coupling to a streptavidin-linked payload.10-18-2012
20110003280IMMUNOASSAY APPARATUS AND IMMUNOASSAY METHOD - The present invention relates to an immunoassay apparatus comprising a measurement unit 01-06-2011
20110003278H5 Subtype-Specific Binding Proteins Useful for H5 Avian Influenza Diagnosis and Surveillance - The invention provides monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes of avian influenza virus (“AIV”). The monoclonal antibodies and related binding proteins are useful for the detection of H5 subtypes of AIV, including the pathogenic H5N1 subtypes. Virus may be detected in formalin preserved, paraffin embeded specimens as well as frozen specimens and biological fluids. Accordingly, the invention provides means for the diagnosis and surveillance of dangerous viral infections.01-06-2011
20120264111HYDROPHOBIC, FUNCTIONALIZED PARTICLES - The present invention relates to a stable mixture comprising surface-modified particles which are obtained by reacting metal oxide or semimetal oxide particles with at least one compound selected from among silicon-comprising compounds bearing at least one metaloxy radical and optionally further alkoxy and/or hydroxy radical(s) and at least one solvent, at least one surface-active substance or a mixture thereof, a process for producing the mixture, the use of these particles in systems in which they are brought into contact with at least one solvent, where the mass ratio of solvent to modified particle is greater than 500, and also the use of these particles in agglomeration-deagglomeration cycles.10-18-2012
20110039256DETECTION METHOD - A method for detecting the presence of a diagnostic moiety indicative of exposure to an infectious organism in a biological sample taken from a human or animal, said method comprising; (a) adding to said sample a first fluorescently labelled reagent which binds said diagnostic moiety, and a second fluorescently labelled reagent which either binds said diagnostic moiety in addition to said first fluorescently labelled reagent, or which binds the first fluorescently labelled reagent or a complex comprising the first fluorescently labelled reagent in competition to the said diagnostic moiety, wherein a label on one of the first or second fluorescently labelled reagent acts as a fluorescent energy donor compound and wherein the other of the first or second fluorescently labelled reagent acts as a fluorescent energy acceptor compound which is able to accept fluorescent energy from said donor compound; (b) exciting the fluorescent energy donor compound by illuminating with light of a wavelength which is absorbed by said fluorescent energy donor compound; (c) measuring fluorescent signal emitted by said fluorescent energy acceptor compound as a result of its absorption of the fluorescent energy from the donor compound after a time delay; and (d) relating the results to the presence or absence of diagnostic moiety in said sample.02-17-2011
20110039255METHOD AND SYSTEM FOR DETECTION OF A SELECTED TYPE OF MOLECULES IN A SAMPLE - The present invention refers to a method for detecting molecules and/or substances within a sample based on the use of a microcantilever system. The method comprises the variation of a certain condition such as humidity so as the mechanical feature analysed varies with a characteristic pattern while the target molecule is bound to the detector. The invention also refers to the system used to carry out such method.02-17-2011
20120322050USING IMPEDANCE-BASED CELL RESPONSE PROFILING TO IDENTIFY PUTATIVE INHIBITORS FOR ONCOGENE ADDICTED TARGETS OR PATHWAYS - Use of impedance devices in methods of generating a time dependent cellular profiles (TCRP) for the modulation of oncogene addicted cells and comparing the impedance-based TCRP to controls or knowns to identify signature time dependent cellular profiles.12-20-2012
20120322051METHODS AND COMPOSITIONS FOR IDENTIFYING AND CHARACTERIZING HEPATITIS C - The invention provides novel methods and compositions for amplifying portions of the HCV genome. The nucleic acid sequences set forth as SEQ ID NOS:1-64 derived from HCV cDNA and functional equivalents thereof, kits containing same, and methods employing same, are useful for the identification and characterization of HCV in biological samples.12-20-2012
20120322049MATERIALS AND METHODS FOR DETECTION OF HPV NUCLEIC ACIDS - Provided are nucleic acids capable of hybridizing to HPV 16 and/or HPV 18 nucleic acids, in particular, mRNA encoding E2 and E6-7 gene products. Such nucleic acids are useful in methods of isolating RNA from a biological sample, methods and means for determining the presence of particular RNA splice-form variants in a biological sample, methods and means for determining the relative ratio of RNA ratios in a biological sample, methods and means for predicting the progression of precancerous cervical lesions, and methods and means for detecting disruption of genes or gene expression.12-20-2012
20120322052SYSTEM AND METHOD FOR PREPARING SAMPLES - A system and method for preparing samples for analyte testing. The sample preparation system can include a freestanding receptacle. The method can include providing a liquid composition comprising a source and a diluent, and positioning the liquid composition in a reservoir defined by the freestanding receptacle. The method can further include filtering the liquid composition to form a filtrate comprising an analyte of interest, removing at least a portion of the filtrate from the sample preparation system to form a sample, and analyzing the sample for the analyte of interest.12-20-2012
20120322053CROSS-COUPLED PEPTIDE NUCLEIC ACIDS FOR DETECTION OF NUCLEIC ACIDS OF PATHOGENS - The present invention concerns methods for detecting a nucleic acid comprising (i) contacting a solution comprising a first PNA having a first cross-reactive functional group with a substrate having a second PNA affixed thereto, the second PNA having a second first cross-reactive functional group, wherein the first PNA has a reporter molecule attached thereto and the first and second PNAs being complementary to different portions of a target DNA; (ii) contacting a sample suspected of containing the nucleic acid with the first and second PNAs; and (iii) determining the presence of the reporter molecule on the substrate.12-20-2012
20110045456COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS CONTAMINANT VIRUSES - The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of viruses by amplification of a segment of viral nucleic acid followed by molecular mass analysis.02-24-2011
20120270205HIGH-FLUX CHEMICAL SENSORS - The present invention relates to the field of chemical detection. Specifically, the invention provides devices that respond quickly to various target chemical analytes present in the environment. Responses are based on a change in an electrical property (such as impedance or resistance) caused by adsorption or absorption of the target analyte(s) to or in a substrate-free chemical sensing element. The chemical sensing element is composed of a thin, electrically conductive polymer material (due to doping of structural polymer material(s) with electrically conductive particles and/or the use of electrically conductive polymer material(s)), which can allow vapors to pass through with little pressure drop. The chemical sensing material is either suspended in the environment, or emplaced adjacent to one or between two porous membranes, resulting in a sensing patch capable of high gas or vapor flux through the chemical sensing element.10-25-2012
20120270207ANALYTE DETECTION - The present disclosure provides methods and/or kits for detecting an analyte in a sample. Some embodiments provide a method for detecting a non-nucleic acid analyte in a sample using a solid substrate comprising a bound immobilisation agent and an antibody capture agent and a detectable agent, which can bind to the analyte. The antibody capture agent comprises, at a plurality of sites, a ligand for the immobilisation agent. A complex between the analyte, the antibody capture agent and a detectable agent is formed and immobilised on the solid substrate by binding between the immobilisation agent and the ligand. In some embodiments, the ligand and the immobilisation agent are a binding pair comprising a peptide tag and an anti-peptide tag antibody.10-25-2012
20120322048Materials and Methods for Assessing and Mapping Microbes and Microbial Biofilms on Wounds - The subject invention provides point-of-care assays for assessing the topographical distribution of microbial biofilm and/or specific microorganisms in wounds.12-20-2012
20120270208SYNTHETIC ANTIGENS FOR THE DETECTION OF ANTIBODIES TO HEPATITIS C VIRUS - Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.10-25-2012
20120270206Systems and Methods for Analyzing Nucleic Acid Sequences - The invention relates to systems and methods for analyzing clinically relevant nucleic acid sequences.10-25-2012
20090311668In situ detection of early stages and late stages HPV einfection - Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. The anti-HPV antibodies are used in performing immunological assays on clinical samples. Various immunological assays and kits for detecting HPV infection, cervical cancer, other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression are also provided.12-17-2009
20090186336Immuno-PCR method for detecting nasopharyngeal carcinoma markers and kit thereof - The present invention is related to an immuno-PCR method for detecting nasopharyngeal carcinoma (NPC) and kit thereof, especially related to an immuno-PCR method for detecting markers of early stage NPC and kit thereof. The present invention includes providing a substrate whereon protein markers immobilized; applying a patient's specimen to the substrate; adding a solution which has biotinylated anti-human IgA secondary antibody and incubating the solution; adding a solution with a linker and biotinylated target DNA; proceeding a polymerase chain reaction; and finally, detecting the target DNA fragments via electrophoresis.07-23-2009
20110129815METHOD FOR PRETREATING SAMPLE FOR DETECTION HCV CORE PROTEIN, REAGENT KIT FOR DETECTION OF HCV CORE PROTEIN, METHOD FOR DETERMINING THE PRESENCE OR ABSENCE OF HEPATITIS C VIRUS IN SAMPLE, AND METHOD FOR IMMUNOASSAY OF HCV - There are provided: a method for pretreating a sample for HCV core protein detection by an immunoassay using particles, which includes treating a sample suspected of containing hepatitis C virus (HCV) with an alkaline material-containing reagent and neutralizing the sample with an acid material-containing reagent, wherein at least one of the reagents contains a reducing agent; a reagent kit for HCV core protein detection; a method for determining the presence or absence of hepatitis C virus in a sample; and a method for immunoassay of HCV.06-02-2011
20090155769DETECTION METHOD FOR LJUNGAN VIRUS - The present invention relates to a method for specifically detecting Ljungan virus (LV). In particular, the present invention relates to a method of detecting LV using quantitative real-time reverse transcriptase PCR. The present invention also provides kits for performing the method of the invention.06-18-2009
20100190149CROSS-REACTIVE HYBRIDIZATION PROBE FOR DETECTING HIV-1 AND HIV-2 NUCLEIC ACIDS IN THE p31 GENE SEQUENCE - Cross-reacting hybridization probe for detecting HIV-1 and HIV-2 nucleic acids. The probe advantageously exhibited uniformly high signal-to-noise ratios when hybridized to HIV-1 and HIV-2 target nucleic acids. The probe can be used, for example, in screening applications for detecting donated blood contaminated with either of the two analytes.07-29-2010
20110236884MICROBUBBLES FOR AFFINITY SEPARATION - The present invention relates to methods, compositions and kits for affinity isolation, affinity purification and affinity assay based on microbubbles coated with an affinity molecule. Particularly, the invention provides protein microbubbles coated with an affinity molecule. In addition, the invention provides glass microbubbles coated with an affinity molecule. Methods of using the microbubbles of the invention for isolating analytes and cells are specifically provided.09-29-2011
20110236883DETECTION OF HERPES SIMPLEX VIRUS TYPES 1 AND 2 BY NUCLEIC ACID AMPLIFICATION - The present invention relates to a method of detecting the presence or absence of herpes simplex virus (HSV) in a sample based on amplifying a portion of the Glycoprotein G(US4) gene of HSV and detecting the presence of the amplified nucleic acid using primers and detector primers as described herewith. The method of the invention further identifies the type of HSV, either HSV-1 or HSV-2, in a sample. Also encompassed by the invention is a kit comprising the primers and detector primers which may be used with the amplification method described herewith.09-29-2011
20110236882QUANTITATIVE MEASUREMENT OF NANO/MICRO PARTICLE ENDOCYTOSIS WITH CELL MASS SPECTROMETRY - Methods for detecting the presence of nanoparticles or microparticles by cell mass spectrometry (CMS) are provided. CMS methods are provided for determining the number of nanoparticles or microparticles in each cell. Nanoparticles whose intracellular concentration can be determines by the CMS methods of the invention include polymeric nanoparticles (NPs), liposomes, viral-based NPs, carbon nanotubes, diamond NPs, polymeric micelles, nanocarriers, liposomes, and viral nanoparticles. Determination of the efficiency of drug delivery and intracellular titer of pathogens according to the invention is disclosed. Methods for determining intracellular uptake of virus particles are provided.09-29-2011
20100167272Method for Detecting and Analyzing Pathogens in a Sample - The present invention relates to a method and kits thereof for detecting the presence and/or the specific serogroup of a prokaryote selected from the group consisting of & 07-01-2010
20100167271METHOD FOR SCREENING BLOOD USING A PRESERVATIVE THAT MAY BE IN A SUBSTANTIALLY SOLID STATE FORM - Methods and devices useful for screening a blood product for a transfusion, pursuant to which leukocytes in drawn whole blood are contacted with a formaldehyde releaser screening preservative so that the presence of any residual leukocytes can be screened. A substantially solid state form preservative for one or more blood components (e.g., leukocytes) and use thereof is also described.07-01-2010
20100233678TUNABLE AFFINITY LIGANDS FOR THE SEPARATION AND DETECTION OF TARGET SUBSTANCES - Conformationally tunable affinity ligands are rationally designed and selected for the ability to switch under operator-defined environmental conditions between or among structurally distinct states that have different affinities for a given target substance. Tunable affinity ligands are incorporated into reagents, separation media, assays, sensors, devices, kits and systems for sorting, separating, detecting, sensing, quantifying, identifying and monitoring target substances. Applications include biomedical research, diagnostics, drug discovery, bioproduction and processing and environmental, industrial, chemical, agricultural and military use.09-16-2010
20100233677FULL GENOME SEQUENCES OF HUMAN RHINOVIRUS STRAINS - Infection by human rhinovirus (HRV) causes upper and lower respiratory tract disease with varying degrees of virulence. The molecular basis of diversity was examined by completing the genome sequences for all known serotypes (n=99) as well as novel field samples. Superimposition of capsid crystal structure and optimal-energy RNA configurations established the alignments. The phylogeny revealed conserved motifs, Glade-specific diversity including a potential new species (clade-D), pan-genome mutations in field isolates, and unexpected recombination that contributes to heterogeneity. A spacer tract near a 5′-UTR cloverleaf was hypervariable, and in analogy with poliovirus, may be associated with virulence. A previously unidentified configuration consistent with non-scanning internal ribosome entry may account for rapid protein translation. The data density from complete sequences of the HRV reference serotypes provided high resolution for this degree of modeling, and serves as a platform for full genome-based epidemiologic studies, for viral diagnostics and prognostics, and for antiviral compounds and vaccines.09-16-2010
20100233675ANALYTE MANIPULATION AND DETECTION - Provided is a method for separating two or more analytes in a fluid, which method comprises: (a) binding each different analyte to a different functional particle in one or more binding zones, to produce two or more bound analytes; (b) allowing the bound analytes to move through a separating conduit to two or more separate functional zones; wherein, each different functional particle has, or can be controlled to have, a different function in the fluid as compared with the other functional particles; and wherein the separating conduit separates into two or more functional conduits, such that the separating conduit serves to separate the bound analytes into the separate functional conduits by means of the different functions of the different functional particles. Also provided is an apparatus for separating two or more analytes in a fluid, which apparatus comprises: (a) a binding zone; (b) two or more functional conduits; (c) a separating conduit connecting the binding zone to the two or more functional conduits; (d) a transporter for transporting the analyte through the separating conduit from the binding zone to the two or more functional conduits; and (e) optionally one or more concentrating zones in connection with at least one of the functional conduits.09-16-2010
20100233674Cells for detection and production of influenza and parainfluenza viruses - The invention provides cell lines that are useful for the rapid detection and production of influenza and parainfluenza viruses. In particular, the invention relates to transgenic cells with increased sensitivity to infection by influenza A, influenza B, or parainfluenza 3 viruses, or which are capable of enhanced productivity of infectious virions. The invention is suitable for use in culturing clinical influenza and parainfluenza virus isolates and for the production of influenza and parainfluenza virus for vaccine formulations, as antigen preparations for diagnostic applications, and for screening antiviral drugs.09-16-2010
20100203501Assay to detect HCV receptor binding - Identification of HCV receptor target cells using HCV receptor-binding ligands and cell separation by flow cytofluorimetry is described. HCV receptor target cells are employed to conduct assays for HCV receptor-binding ligands in order to identify potential HCV vaccine candidates. HCV receptor target cells are used to measure antibody neutralisation to monitor vaccine development, as a diagnostic of HCV infection and to develop neutralising antibodies for passive immunisation.08-12-2010
20100203500METHOD FOR DETECTION OF HOP LATENT VIRUS, PRIMER SET FOR THE DETECTION, AND KIT FOR THE DETECTION - The invention provides a detection method for hop latent virus that comprises an extraction step in which hop latent virus RNA is extracted from a specimen, an amplification step in which a primer set containing 4 different oligonucleotides consisting of the nucleotide sequences represented by SEQ ID NO: 1-4 of the Sequence Listing is used for amplification of cDNA by RT-LAMP using the RNA as template, and a judging step in which hop latent virus is judged to be present when amplification of cDNA containing the nucleotide sequence represented by SEQ ID NO: 8 of the Sequence Listing has occurred in the amplification step.08-12-2010
20100203499Electrophoretic Interactive Spectral Methods and Devices for the Detection and/or Characterization of Biological Particles - Methods for identifying a biological particle in a sample medium include generating an Electrophoretic Quasi-elastic Light Scattering (EQELS) spectrum for the biological particle in the sample medium. The EQELS spectrum is compared to a reference database comprising a plurality of spectra, and each of the plurality of spectra correspond to an EQELS spectrum for one of a plurality of known biological particles. The biological particle in the sample medium is identified from the comparison.08-12-2010
20120276526METHOD AND SYSTEM FOR MONITORING AND RECORDING VIRAL INFECTION PROCESS AND SCREENING FOR AGENTS THAT INHIBIT VIRUS INFECTION - The present invention relates to a method for monitoring and recording a viral infection process, which is characterized by providing a microcantilever detection device, which comprises a microcantilever comprising a contact area having an macromolecular material attached thereon; loading host cells to the contact area to allow the host cells to be attached to the macromolecular material; loading virus to the contact area to make the virus to contact the host cells attached thereto whereby a deflection level of the microcantilever is produced; and recording the deflection level in a time course manner so as to obtain a deflection curve that can be used as a basis for monitoring and recording the viral infection process. The method of the invention can also be used for screen for an agent that inhibits virus infection.11-01-2012
20120276523LIQUID DROP DIAGNOSTIC ASSAYS - The present invention provides simple and inexpensive assays for the detection of virtually any analyte in any sample that is in liquid form or that can be solubilized. The assays utilize the fluid dynamics of drop evaporation whereby soluble materials, including analytes and particles binding thereto, are drawn to the edge of the drop and ultimately form a concentrated residual ring. The presence or absence of certain reagents can then be detected through a number of different approaches.11-01-2012
20120276525METHOD AND SYSTEM FOR PREVENTING VIRUS-RELATED OBESITY AND OBESITY RELATED DISEASES - A method for preventing obesity related to infection by an adipogenic adenovirus includes assaying a sample from a person to determine whether the person has been previously infected with an adipogenic adenovirus, and if the person has not been previously infected, providing the person with at least one sensor positioned to detect when a person's hand approaches a predetermined distance from the person's face. By warning the person of undesired hand-to-face contacts, the person is able to reduce the incidence of obesity related infections. Other embodiments are directed to a kit for preventing obesity caused by infection with an adipogenic adenovirus, such kit including a container for assaying an agent indicating the presence of antibodies to Ad-36, and a sensor positioned on an item selected from the group consisting of one of a hat, a writing instrument, eye glasses, a belt, sunglasses, a bra, a shirt, and a tie.11-01-2012
20120276524GENOTYPING METHOD - The present invention relates to a genotyping method, and more particularly to an ID sequence, which is assigned to each genotype, and a multiplex genotyping method which uses the ID sequence. When pyrosequencing is performed using the ID sequence, a unique and simple pyrogram can be obtained for each genotype. Thus, the use of the ID sequence makes it possible to genotype viral genes, disease genes, bacterial genes and identification genes in a simple and efficient manner. In addition, a genotyping primer of the invention can be used in various genotyping methods which are performed using dispensation orders and sequencing methods.11-01-2012
20120276520ASSAY FOR MUTATIONS IN STEM CELLS AND THEIR DERIVATIVES - The present invention provides methods to assess the genetic safety of stem cells, whether endogenous embryonic stem cells, somatic or adult stem cells, or artificially induced stem cells from non-pluripotent cells, and their differentiated derivatives for use in human medicine, and the applications of modified stem cells to testing environmental or potential genetic or epigenetic modulators such as culture media formulations, substrates or scaffolds, additives, reagents, processes, and processing materials used to prepare stem cells for use.11-01-2012
20120276522Methods and Compositions for Determining Virus Susceptibility to Integrase Inhibitors - Methods and compositions for the efficient and accurate determination of HIV susceptibility to an integrase inhibitor and/or HIV replication capacity are provided. In certain aspects, the methods involve detecting in a biological sample a nucleic acid encoding an HIV integrase that comprises a primary mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the HIV has a decreased susceptibility to an integrase inhibitor or altered replication capacity relative to a reference HIV. In certain embodiments, the HIV also contains one or more secondary mutations in integrase. Also provided are methods for determining the selective advantage of a mutation or mutation profile based on the difficulty to create the mutation, and its effect on susceptibility to an integrase inhibitor or replication capacity.11-01-2012
20120276521ORAL FLUID RAPID ASSAY FOR HEPATITIS C VIRUS (HCV) ANTIBODIES USING NON-ANTIBODY LABELING OF lgA MOLECULES RECOGNIZING HCV PEPTIDE EPITOPES - A method and device to detect Hepatitis C (HCV) antibodies in oral fluid is provided. This method introduces a non-antibody detection molecule that labels all classes of patient antibodies in oral fluid, followed by the specific concentration of labeled anti-HCV antibodies by selective capture in a trapping zone consisting of peptide antigens derived from the HCV genome. Signal generated by the labeled antibodies present in the trapping zone is proportional to the number of anti-HCV antibodies bound to the antigens present in the trapping zone. Presence of signal derived from the capture of antibody/detection molecule complexes in the trapping zone is indicative of past exposure to HCV.11-01-2012
20100203498METHODS AND COMPOSITIONS FOR IDENTIFYING ANTI-HCV AGENTS - The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.08-12-2010
20090068637MONOCLONAL ANTIBODIES BINDING TO AVIAN INFLUENZA VIRUS SUBTYPE H5 HAEMAGGLUTININ AND USE THEREOF - The present application provides monoclonal antibodies that specifically bind to the hemagglutinin of avian influenza virus subtype H5, as well as monoclonal antibodies capable of blocking at least 50% of the hemagglutinin binding activity of these monoclonal antibodies. Such antibodies are useful, for example, in the detection, diagnosis, prevention, and treatment of avian influenza virus. Also provided herein are hybridoma cell lines, isolated nucleic acid molecules, and short peptides related to the monoclonal antibodies provided herein, and pharmaceutical compositions and kits containing the monoclonal antibodies provided herein.03-12-2009
20120088231Biological Specimen Collection/Transport Compositions and Methods - Disclosed are compositions for collecting, storing, and transporting populations of nucleic acids from biological specimens, and clinical, forensic, or environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. In particular embodiments, the invention provides a single, one-step, sample collection/transport/storage formulation containing a known quantity of a non-genomic, nucleic acid carrier molecule that serves as an internal reference control to monitor the fidelity of the collection/transportation medium, and measure the integrity of nucleic acids subsequently isolated and purified from the processed sample.04-12-2012
20120088230System And Method For Cell Analysis - A system for enumeration of objects such as cells in a sample is disclosed. The system uses a low-cost cartridge and a reader instrument, based on planar waveguide imaging technology. Cells of a blood sample may be stained with fluorescence-tagged antibodies and are loaded onto the cartridge where the differentially labeled cells may be distinguished and quantified.04-12-2012
20120088229SURFACE PLASMON RESONANCE SENSOR - The application relates to a sensor using a gold layer (04-12-2012
20120088226NUCLEIC ACID EXTRACTION METHOD - The present invention relates to a nucleic acid extracting apparatus, and the nucleic acid extracting apparatus can include a pipe-shaped tube having an open outlet at one side thereof, and a hydrogel column that is provided inside the tube and filters impurities excluding an extraction target material.04-12-2012
20100203497SYSTEM AND METHOD FOR DETECTION OF HIV DRUG RESISTANT VARIANTS - In one embodiment of the invention a method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance is describe that comprises generating cDNA species from RNA molecules in an HIV sample population; amplifying first amplicons from the cDNA species, wherein each amplicon comprises amplified copies and is amplified with a pair of nucleic acid primers that define a locus; clonally amplifying the amplified copies of the first amplicons to produce second amplicons that comprise an immobilized population of substantially identical copies from one of the amplified copies of first amplicons; determining a nucleic acid sequence composition from at least 100 of the immobilized populations in parallel on a single instrument; detecting one or more sequence variants that occur at a frequency of 5% or less in the nucleic acid sequence composition of the at least 100 immobilized populations; and correlating the detected sequence variants with variation associated with HIV drug resistance.08-12-2010
20100203496Fluorescent Multiplex HPV PCR Assays - The present invention relates a fluorescent multiplex PCR assay for detecting the presence of a nucleic acid sequence of an HPV type in a sample using multiple fluorophores to simultaneously detect a plurality of HPV genes of the same HPV type, wherein the HPV type is selected from the group consisting of: HPV31, HPV45, HPV52, and HPV58. The present invention also relates to oligonucleotide primers and probes specific to said HPV types for use in the methods of the present invention.08-12-2010
20100173281HCV NS3 protease replicon shuttle vectors - The present invention provides for novel HCV NS3 protease replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility.07-08-2010
20090286225METHOD AND APPARATUS FOR BACTERIOPHAGE-BASED DIAGNOSTIC ASSAYS - Bacteriophage are combined with a test sample in an incubator, and the bacteriophage-exposed test sample is conjugated and applied to a sample pad in contact with a lateral flow strip to determine the presence or absence of a target bacterium. The conjugation may be performed in the sample pad or prior to application of the bacteriophage-exposed test sample to the pad. The incubator comprises a bacteriophage container and an incubation container separated by a valve. The test sample may be inserted into the incubation chamber using a swab or a rod with a piercing tip and a sample collection eye. The valve comprises a breakable stem. An antibiotic may be added to the test sample to determine the antibiotic resistance or susceptibility of the bacterium.11-19-2009
20090298048NON-FLUORESCENT, NON-ENZYMATIC, CHEMILUMINESCENT AQUEOUS ASSAY - This invention provides for nonfluorescent, nonenzymatic, chemiluminescent aqueous assays in which the binding of two ligands is determined by a water soluble label system that emits light upon contact with a chemical energy transferring composition.12-03-2009
20120100529Biological Specimen Collection and Transport System and Methods of Use - Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.04-26-2012
20120100528METHOD FOR DETECTION OF HUMAN PAPILLOMAVIRUS (HPV) TYPE - The present invention describes a method for detection of human papillomavirus (HPV) types and a kit for detection of said HPV types.04-26-2012
20120100527METHOD OF DETECTING H5 OR H7 AVIAN INFLUENZA VIRUS - The present invention provides oligonucleotide primers specifically hybridizing to an arbitrary nucleotide sequence designed from the nucleotide sequence of hemagglutinin of an H5 or H7 avian influenza virus, a nucleic acid amplification method using the primers, a method for diagnosis of infection with an H5 or H7 avian influenza virus by detection of nucleic acid amplification, and a kit for influenza diagnosis.04-26-2012
20120100526IDENTIFICATION AND DIFFERENTIATION OF NUCLEIC ACID SEQUENCE USING TEMPERATURE-DEPENDENT HYBRIDIZATION - Oligonucleotide probes are provided that are capable of hybridizing to different target nucleic acid sequences in a temperature-dependent manner allowing for detection of more than one target sequence by the same probe or by different probes having reporter labels with identical or similar detection characteristics. Also provided is a method for detecting target nucleic acid sequences using an oligonucleotide probe capable of hybridizing to the sequences in a temperature-dependent manner or using different probes having reporter labels with identical or similar detection characteristics.04-26-2012
20120288852Force Mediated Assays - A sensitive and specific method of detecting chemical species, viruses and microorganisms is presented to improve performance of molecular-recognition-based assays utilizing particles decorated with molecular recognition agents such as antibodies and DNA probes, and observing analyte-dependent changes in the response of the particles to forces such as magnetic or gravitational forces or Brownian thermal fluctuations.11-15-2012
20120288851Measurement System, Measurement Method, Program for Implementing the Method, and Recording Medium for the Program - The invention relates to a measurement system MS11-15-2012
20120288850METHODS FOR DIAGNOSIS OF IMMUNE RESPONSES AGAINST VIRUSES - The present invention relates to methods for diagnosis of a cellular immune responses against a virus using an inactivated virus. In the method of the invention a cellular immune response against the virus is detected in a subject by incubating PBMCs from the subject with a preparation of inactivated virus and subsequently detecting the expression of at least one T cell specific cytokine in the subject's PBMCs, preferably by flow cytometry. Advantageously in the method, inactivated virus is used for incubation with PBMCs from the subject so as to make feasible that the method is performed in laboratories without BSL-3 classification. Preferably the method is a method for detecting a CD4+ and/or CD8+ T cell response against an influenza virus by detecting expression of one or more of CD107, IFN-γ, IL-2, IL-10 and TNF-α, using formalin inactivated influenza virus. The invention further pertains to kits comprising components that are useful for detecting a cellular immune responses in a subject against a virus.11-15-2012
20100055675METHOD FOR DETECTING MEASLES VIRUS, MEMBRANE ASSAY TEST DEVICE, AND MEMBRANE ASSAY TEST KIT - Method for detecting a measles virus in an analyte, comprising forming a complex of a first monoclonal antibody being capable of binding to a first epitope of a measles virus nuclear protein and being immobilized on a solid phase, a second monoclonal antibody being capable of binding to a second epitope of a measles virus nuclear protein different from the first epitope and being labeled, and a measles virus nuclear protein contained in the analyte, on the solid phase; and detecting the measles virus based on the amount of the label of the complex formed on the solid phase, is disclosed. Membrane assay test device, and membrane assay test kit are also disclosed.03-04-2010
20100190147METHOD OF DETERMINING IMMUNE ENHANCEMENT OF VIRUS INFECTIVITY USING FC RECEPTOR-TRANSFECTED CELL LINES - The present invention relates to a method of detecting immune enhancement of virus infectivity, a method of determining neutralization and immune enhancement of virus infectivity, a method of identifying a virus epitope that displays immune enhancement, a method of identifying a compound that modulates activity of an Fc receptor, and a method of identifying a compound that modulates intracellular signaling of an Fc receptor. DNA constructs, cells, and kits relating to these assays are also disclosed.07-29-2010
20100167266Compositions and Methods for Determining Whether a Subject Would Benefit from Co-Receptor Inhibitor Therapy - The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.07-01-2010
20130011828Use - The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.01-10-2013
20130011830FAST RESULTS HYBRID CAPTURE ASSAY AND SYSTEM - The present invention comprises a method that provides fast and reliable results for detecting the presence of a target nucleic acid molecule in a sample.01-10-2013
20130011827METHODS AND KITS FOR DECREASING INTERFERENCES IN PLASMA OR SERUM CONTAINING ASSAY SAMPLES OF SPECIFIC BINDING ASSAYS - Methods and kits are provided for decreasing interferences and inaccuracies due to nonoptimal sample handling of blood samples in plasma or serum containing assay samples of specific binding assays by addition of a large polycation to the assay sample during the specific binding assay.01-10-2013
20090170067Simian tropic, recombinant human immunodeficiency-1 viruses - The present invention relates to a vector for producing recombinant human immunodeficiency virus 1 (HIV-1) that is capable of infecting simian cells and monkeys. The recombinant HIV-1 overcomes blocks to infection mediated by simian cell gene products. Such recombinant viruses are useful for evaluating the effectiveness of antiretroviral therapies and vaccines.07-02-2009
20100129786AGENTS AND METHODS FOR SPECTROMETRIC ANALYSIS - Disclosed herein are agents, methods, and kits for determining the presence or concentration of a target, or multiple targets, in a sample, in a uniplexed or multiplexed fashion. In general, the methods enable the analysis of small molecules produced or consumed in liquid-phase that may be analyzed using gas or vapor phase detection methods.05-27-2010
20100129788METHOD FOR EVALUATING THE RESPONSE OF AN INDIVIDUAL TO A TREATMENT WITH A TYPE I INTERFERON (IFN) - A method for evaluating the in vivo presence of a factor that prevents the biological effect of a type I (IFN) in an individual that is under treatment with type I interferon is described. The in vivo presence of antibodies directed against a type I interferon (IFN) is evaluated in an individual that is under treatment with type I interferon. The method includes incubating a blood sample of the individual in vitro with a suitable amount of the type I interferon for a suitable period of time, and determining mRNA levels of a biological marker of IFN activity, preferably M×A, in the blood sample. The treatment may involve a treatment of multiple sclerosis, HCV or HBV using a type I interferon.05-27-2010
20100129787AGENTS AND METHODS FOR SPECTROMETRIC ANALYSIS - Disclosed herein are agents, methods, and kits for determining the presence or concentration of a target, or multiple targets, in a sample, in a uniplexed or multiplexed fashion. In general, the methods enable the analysis of small molecules produced or consumed in liquid-phase that may be analyzed using gas or vapor phase detection methods.05-27-2010
20100129789Automated assay and system - An automated assay processing method including transferring a first number of samples from respective sample containers to a first intermediary vessel, determining the testing adequacy of a second number of samples in a second intermediary vessel, preparing a third number of samples in a third intermediary vessel for downstream testing; and transferring a fourth number of samples from a fourth intermediary vessel to an output sample tray. These steps are all performed essentially simultaneously within the duration of a single clock cycle and are repeated during one or more subsequent clock cycles. The clock cycle may be relative to each intermediary vessel. The clock cycle also may be universal to the first, second, third and fourth intermediary vessels.05-27-2010
20130017536WESTERN BLOT KIT FOR DETECTION OF VACCINATED POULTRYAANM Madani; RasoolAACI KarajAACO IRAAGP Madani; Rasool Karaj IRAANM Rezayat; Seyed MahdiAACI TehranAACO IRAAGP Rezayat; Seyed Mahdi Tehran IRAANM Sarkar; SaeedAACI TehranAACO IRAAGP Sarkar; Saeed Tehran IRAANM Emami; TaraAACI KarajAACO IRAAGP Emami; Tara Karaj IR - Modified western blot membranes with silver nanoparticle allow the small peptides of the NS1 protein of the poultry influenza virus to be kept in the membrane and not to diffuse during transferring from the Tricine SDS PAGE. These peptides may differentiate infected from vaccinated poultry.01-17-2013
20130017535INSTRUMENT AND PROCESS FOR THE AUTOMATED PROCESSING OF LIQUID SAMPLESAANM Frey; RolfAACI EbikonAACO CHAAGP Frey; Rolf Ebikon CHAANM Schacher; GottliebAACI KriensAACO CHAAGP Schacher; Gottlieb Kriens CH - An automated instrument and process for processing samples is presented. The instrument comprises a sampling area for receiving samples and reaction vessels; an analytical area with a first device resource comprising at least one analyzer; a reaction area comprising a conveyor for reagent containers; an incubator; a second device resource comprising first functional devices, the first functional devices having access to the sampling area and the incubator such as to transfer reaction vessels from the sampling area to the incubator and/or to pipette samples and/or reagents into the reaction vessels; a third device resource comprising second functional devices, the second functional devices having access to the incubator and the analytical area such as to transfer the reaction vessels from the incubator to the analytical area and/or to dispense liquids or withdraw liquids from the reaction vessels.01-17-2013
20130017534DEVICE AND METHOD FOR IDENTIFYING MICROBES AND COUNTING MICROBES AND DETERMINING ANTIMICROBIAL SENSITIVITY - A method of determining antimicrobial activity of an agent can include providing a well, wherein the well contains at least one antimicrobial agent, the well further including at least two electrodes. A sample of a microbe can be added into the well and a voltage pulsed between the electrodes. An electrical property can be sampled and recorded. In another aspect, a method of identifying at least one microbe includes taking a sample containing the at least one microbe, isolating the at least one microbe from the sample, dividing the at least one microbe into a at least one well, wherein each well contains at least one antimicrobial agent and at least two electrodes. A voltage is pulsed between the at least two electrodes, an electrical property is sampled during the pulsing and recorded. In another aspect, a diagnostic device for detecting at least one microbe is presented.01-17-2013
20110159477PRODUCTS AND ANALYTICAL METHOD - The present invention describes product and analysis method for analysis of a substance, a virus, a bacteria or a cell which binds to carbohydrate structures. One or more carbohydrates, or carbohydrate derivatives, is bound to spherical or non-spherical polymer beads (for example microspheres or nanospheres). Formed carbohydrate-polymer beads or carbohydrate-polymer particles, can bind to with more or less specific affinity to the substance, bacteria, virus or cell which shall be detected. The carbohydrate beads is contacted with a sample containing the substance, bacteria, virus or cell (completely or partially isolated, or not purified, in a non-diluted or diluted solution). The resulting mixture is optionally added to a gel, or a column containing a gel, through which the resulting mixture (of carbohydrate beads or carbohydrate particles bound to the substance, virus, bacteria or cell), is allowed to migrate. Detection of aggregates is made visually or using apparatus for detection.06-30-2011
20100167270METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS FOR PROPAGATING VIRUS - The invention relates to improved strains of mammalian negative strand RNA virus, 07-01-2010
20100167269Detection method for human pappilomavirus (HPV) and its application in cervical Cancer - Embodiments of the invention provide methods, assays, and kits for detecting HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with pre-malignant and malignant epithelial cell lesions. Detection of HPV DNAs, genomes, and/or oncoproteins by nucleic acid hybridization assays and immunological assays can be used in early clinical screening for HPV infection and diagnosis for cervical cancer. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.07-01-2010
20100167268SEROCONVERSION ASSAYS FOR DETECTING XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS - Methods of detecting, diagnosing, monitoring or managing an XMRV-related disease such as an XMRV-related neuroimmune disease such as chronic fatigue syndrome or an XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity of antibodies against XMRV in a sample from a subject.07-01-2010
20100167267Mass Spectrometric Quantitation - Provided is a method of assaying for an analyte, which method comprises: a) combining a test sample, which may comprise the analyte, with a calibration sample comprising at least two different aliquots of the analyte, each aliquot having a known quantity of the analyte, wherein the sample and each aliquot are differentially labeled with one or more isobaric mass labels each with a mass spectrometrically distinct mass marker group, such that the test sample and each aliquot of the calibration sample can be distinguished by mass spectrometry; b) determining by mass spectrometry the quantity of the analyte in the test sample and the quantity of the analyte in each aliquot in the calibration sample, and calibrating the quantity of the analyte in the test sample against the known and determined quantities of the analytes in the aliquots in the calibration sample.07-01-2010
20100167265VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, ANTIBODIES AND METHOD OF DIAGNOSIS - A vaccine for treating and/or preventing infectious diseases where the infectious agent has at least one intracellular phase in the host during its multiplication cycle, is disclosed. The vaccine comprises at least one cryptic epitope of a cellular element that is carried along by an intracellular infectious agent as it leaves the cell, and revealed by said infectious agent. A composition for treating and/or preventing HIV infections, antibodies to a peptide of interest, and a diagnostic method, are also disclosed.07-01-2010
20130022961ASSAY FOR JC VIRUS ANTIBODIES - The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.01-24-2013
20130022964Use of Ribozymes in the Detection of Adventitious Agents - The present invention provides a method of detecting adventitious agents in a composition comprising a microorganism by using ribozyme-expressing indicator cells, as well as indicator cells useful in such detection.01-24-2013
20130171618POROUS MEMBRANES HAVING A POLYMERIC COATING AND METHODS FOR THEIR PREPARATION AND USE - A modified porous membrane comprising a polymer coating grafted to a porous membrane is described. The polymer coatings grafted to the porous membranes generally comprise a polymer of variable length of an electron beam (e-beam) reactive moiety, designated “poly-(A)07-04-2013
20130171619POROUS MEMBRANES HAVING A HYDROPHILIC COATING AND METHODS FOR THEIR PREPARATION AND USE - A modified porous membrane comprising a polymeric hydrophilic coating grafted to a porous membrane is described. The polymeric hydrophilic coatings grafted to the porous membranes comprise, for example, a PEG moiety such as a PEGMA, a PEGDA, or a TMPET, wherein the polymeric hydrophilic coating on the porous membrane decreases non-specific binding of unwanted material to the porous membrane and increases the signal to noise ratio in immunoassays, in vitro diagnostic tests, and point of care tests. Methods of making these modified porous membranes are also disclosed.07-04-2013
20130171620VIRAL VARIANTS AND METHODS FOR DETECTING SAME - The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents.07-04-2013
20080248461PNA Probes, Kits, and Methods for Detecting Genotypes of Human Papillomavirus - Disclosed are PNA probes capable of genotype specifically binding with Human Paillomavirus (HPV) DNA, kits for detecting HPV genotypes comprising the probes, and methods for detecting HPV genotypes by using the kits, which enables the accurate detection of all 24 genotypes of HPV found in cervix, diagnosis of combined infection with more than one HPV genotype, and detection of HPV genotypes with high specificity and sensitivity.10-09-2008
20080241821ASSAY FOR PORCINE CIRCOVIRUS PRODUCTION - The present invention provides methods for the determination of the viral titer of a culture of host animal host cells infected with a circovirus. The FACS-based methods of the invention may include determining the viability of the host cells in a cell culture medium supernatant and of those cells that remain adherent to a solid support. Detecting and measuring the percentage of cells that expressed the viral antigens ORF1 and ORF2 may determine the viral load of the cultured host cells. The yield of the virus may be established by the detection and measurement of both antigens in supernatant cells, for example 5 to 7 days from when the host cells are transferred to a serum free medium. The methods of the invention may yield rapid quantitative data. This allows the repeated in-process monitoring of the viral production throughout the incubation period, and ready selection of the most appropriate harvesting point.10-02-2008
20080241820MULTIPLEX CELLULAR ASSAYS USING DETECTABLE CELL BARCODES - We describe herein a cell-based multiplexing technique called detectable cell barcoding (DCB). In DCB, each individual sample is labeled with a different DCB signature that distinguishes each sample by one or both of detected intensity or type of detection characteristic. The samples are then combined and analyzed for a detectable characteristic of interest (e.g., presence of an analyte). By employing multiple distinct DCB labels at varying concentrations, one can perform multiplex analyses on up to hundreds or thousands (or more) of cell samples in a single reaction tube. DCB reduces reagent consumption by factors of 100-fold or more, significantly reduces data acquisition times and allows for stringent control sample analysis.10-02-2008
20080241819METHOD AND APPARATUS FOR ENHANCED BACTERIOPHAGE-BASED DIAGNOSTIC ASSAYS BY SELECTIVE INHIBITION OF POTENTIAL CROSS-REACTIVE ORGANISMS - A sample to be tested for the presence of a target microorganism is exposed to bacteriophage and conditions are provided to inhibit phage attachment to or replication in a potentially cross-reactive, non-target microorganism. The sample is incubated and assayed to detect the presence or absence of a bacteriophage marker to determine the presence or absence of the target microorganism. The inhibiting may comprise the addition of an inhibiting substance or the use of an inhibiting process. It may include inhibiting the growth of potentially cross-reactive bacteria while allowing growth of the target bacteria, selectively removing or blocking potential cross-reactive bacteria using selective binding agents or selectively destroying potentially cross-reactive bacteria.10-02-2008
20080233560DNA-transfection system for the generation of infectious influenza virus - The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.09-25-2008
20130143202COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION - This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.06-06-2013
20110262894VACCINE AGAINST INFECTIOUS AGENTS HAVING AN INTRACELLULAR PHASE, COMPOSITION FOR THE TREATMENT AND PREVENTION OF HIV INFECTIONS, ANTIBODIES AND METHODS OF DIAGNOSIS - A vaccine for treating and/or preventing infectious diseases where the infectious agent has at least one intracellular phase in the host during its multiplication cycle, is disclosed. The vaccine comprises at least one cryptic epitope of a cellular element that is carried along by an intracellular infectious agent as it leaves the cell, and revealed by said infectious agent. A composition for treating and/or preventing HIV infections, antibodies to a peptide of interest, and a diagnostic method, are also disclosed.10-27-2011
20080241818Method and microarray for detecting herpesviruses - The present invention relates to a method and to a microarray for detecting herpesviruses. The invention provides new primers and oligonucleotides for detecting herpesviruses, in particular herpesviruses selected from the group comprising HSV-1, HSV-2, CMV, EBV, VZV, HHV-6A, HHV-6B and HHV-7. By using the method of the invention several different herpesviruses can be detected simultaneously from the same biological sample.10-02-2008
20080220412Method and Means for Determining the Replication Rate of a Viral Population - The present invention relates to methods and means for determining the replication rate of a viral population. More specifically, the invention provides methods and means for determining the replication rate of a viral population by performing a linear regression on signal data generated by cells infected with dilutions of the viral population. The methods are useful for monitoring the progression of diseases associated with viruses, identifying effective drug regimens for the treatment of viral infections, and identifying and determining the biological effectiveness of potential therapeutic compounds.09-11-2008
20080220411NON-LINEAR ROTATION RATES OF REMOTELY DRIVEN PARTICLES AND USES THEREOF - The present invention relates to biological sensors. In particular, the present invention relates to the use of remotely driven nonlinear rotation of particles (e.g., magnetic particles) for detection of cells such as microorganisms (e.g., bacteria and viruses). The present invention further relates to the use of remotely driven nonlinear rotation of particles for measurement of physical properties of a solution (e.g., viscosity).09-11-2008
20080220410METHOD FOR REPLICATING THE HEPATITIS C VIRUS - The invention concerns the use of cells capable of carrying out a process of prenylation of proteins coded by the hepatitis C virus (HCV) genome, such as prenylation of the NS5A protein, for replicating and, if required, the production of HCV or derivative viable mutants, in a suitable culture medium.09-11-2008
20080220409Antigen of Dengue Virus Type 1 - Antigens and B-cell epitopes derived from dengue virus type 1 are provided. The antigens are specifically immunoreactive with sera from individuals infected with dengue virus type 1 but not reactive with sera from healthy individuals and individuals infected with dengue virus type 2. The antigens and epitopes are useful for development of diagnostic kits and reagents, and are useful tools as well in determining whether an individual is infected with dengue virus type 1, and for distinguishing infection from dengue virus type 2.09-11-2008
20080220408Protein Scaffolds and Viral Particles For Detecting Analytes - The present invention relates to compositions and methods for detecting analytes using detectably labeled fluorescent protein scaffolds. In certain embodiments of the invention, the scaffolds are viral particles in which the capsid viral structure provides a scaffold to attach detectably labeled fluorescent dyes and capture moieties that can be utilized to determine the presence of a desired analyte in a sample using any suitable method. The protein scaffold can contain amino acids carrying reactive groups (e.g., amines and thiols) that are spatially distributed on it with large enough separation to enable the attachment of a greater number of fluorescent label molecules without quenching09-11-2008
20130143203COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS VIRUSES - The present invention provides compositions, kits and methods for rapid identification and quantification of adventitious contaminant viruses by molecular mass and base composition analysis.06-06-2013
20130143204DETERMINATION OF IN VIVO DNA DOUBLE-STRAND BREAK LOCALIZATION AND APPLICATION THEREOF - The present invention relates to a method for determining the in vivo localization of double-strand breaks in a host cell, comprising incubating a host cell suspected to comprise DNA double-strand breaks and a linear polynucleotide comprising a known sequence, detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, and assessing the in vivo localization of double-strand breaks. Further envisaged by the present invention is a method for obtaining an endonuclease with altered in vivo specificity. Finally, the present invention is directed to a kit for determining in vivo specificity of an endonuclease.06-06-2013
20130143205HIGHLY SENSITIVE METHOD FOR DETECTION OF VIRAL HIV DNA REMAINING AFTER ANTIRETROVIRAL THERAPY OF AIDS PATIENTS - Methods for detecting polynucleotides, especially the DNA replicated from samples obtained from subjects infected with pathogenic viruses such as human immunodefiency virus, by detecting electromagnetic signals (“EMS”) emitted by such polynucleotides, and methods for improving the sensitivity of the polymerase chain reaction (“PCR”).06-06-2013
20130171622COMPOSITIONS AND METHODS FOR DETECTING VIRAL INFECTION USING DIRECT-LABEL FLUORESCENCE IN SITU HYBRIDIZATION - The present invention relates generally to assays for the detection of viral infection and/or prognosis of viral infection and associated disease states. In particular, the invention relates to directly labeled viral-related nucleic acids having significant diagnostic, prognostic, and screening utilities and methods of using the same.07-04-2013
20130171623Binding Assays Utilizing Time-Resolved Up-Converting Luminescence Detection - This invention describes a general binding assay method to detect the presence and quantity of analyte in a sample. The method uses time-resolved up-converting fluorescence detection technique to provide highly sensitive detection without using expensive optical components such as band-pass optical filters. The method uses pulsed long wavelength light for excitation and time-delayed luminescence detection, resulting in little interferences from sample matrices. Furthermore, the usage of long wavelength excitation light requires simpler sample preparation and processing such as removal of red blood cells, which otherwise will significantly interfere with excitation efficiency of the luminescence probes.07-04-2013
20130171624Magnetic Binding Assays Utilizing Time-Resolved Up-Converting Luminescence Detection - This invention describes a general magnetic binding assay method to detect the presence and quantity of analyte in a sample. The method uses magnetic particles for separating and concentrating analytes of interest from complex samples and use time-resolved up-converting fluorescence detection technique to provide highly sensitive detection without using expensive optical components such as band-pass filters. The method uses pulsed long wavelength light for excitation and time-delayed luminescence detection, resulting in little interferences from sample matrices. Furthermore, the usage of long wavelength excitation light requires simpler sample preparation and clean-up such as removal of red blood cells, which otherwise will significantly interfere with excitation efficiency of the fluorescence probes.07-04-2013
20120252002FLUORESCENT NANOPARTICLE COMPOSITES THEMSELVES, PROCESS FOR THE PREPARATION OF SUCH COMPOSITES, AND USE IN RAPID DIAGNOSIS SYSTEMS WITH AFFINITY TO BIOLOGICAL MOLECULES - The present invention provides fluorescent nanoparticle composites themselves, the process of preparing such composites, to systems for rapid diagnosis (as “kits”) containing such composites, and to the use of such composites. In a preferential embodiment, the composites of the present invention have an affinity for biological molecules, such as DNA. The present invention also comprises the preparation of probes containing biological material, upon which are added fluorescent nanoparticle composites, making viable a rapid and economic biological diagnosis of, for example, diseases and genetic traits, notably in the medical and veterinarian fields. There is yet the fact that the absorption of radiation in the ultraviolet and visible regions, with the emission of light in the near ultraviolet and visible range, including in the colors of deep blue and/or green, provides advantageous use of its fluorescent properties in photovoltaic or electroluminescent devices, such as organic LEDs, or for the increase in luminous gain of fluorescent lamps, which represents another characteristic of the invention.10-04-2012
20080213752Bacteriophages as Selective Agents - Compositions containing bacteriophages and methods of using bacteriophages in microorganism detection assays and microbial growth and plating media are disclosed. The lytic ability of these phages to control the growth of non-target populations provides superior sensitivity and specificity to detection assays and reduces false negative and false positive results. The removal of contaminating bacteria reduces the microbial competition for nutrients in the growth media thereby increasing the efficiency and productivity of the culture. The phage treatment of the sample increases the proportion of target microorganisms in the sample over contaminating bacteria thereby requiring less time for enrichment to obtain a significant signal improving overall signal to noise ratio in assays and providing for higher yield of end product in microbiological production systems.09-04-2008
20080213749Compositions and methods for detecting human metapneumovirus - Disclosed are oligonucleotides useful in methods for determining whether a sample contains a human metapneumovirus or has an increased likelihood of containing a human metapneumovirus, a virus which is a causative agent of respiratory tract disease in humans. These oligonucleotides, which have nucleotide sequences derived from a coding segment of the gene encoding the fusion protein of a human metapneumovirus, are useful as forward and reverse primers for a polymerase chain reaction using reverse transcripts of RNA from a biological sample as templates, and as probes for detecting any resultant amplicon. Detection of an amplicon indicates the sample contains a human metapneumovirus or has an increased likelihood of containing a human metapneumovirus.09-04-2008
20110269117Methods For Direct Fluorescent Antibody Virus Detection In Liquids - The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.11-03-2011
20130137089HUMAN GASTROINTESTINAL STEM CELL-DERIVED PRIMARY INTESTINAL EPITHELIAL CELL SYSTEM AND METHODS OF USE THEREOF - The present invention relates to an intestinal primary epithelial cell system for detecting gastrointestinal segment-specific activation or suppression of a Toll-like receptor (TLR) by a target agent. The cell system includes an isolated human intestinal primary epithelial cell (HIPEC) line that expresses at least one TLR, where the HIPEC line is derived from a differentiable adult human gastrointestinal stem cell (ahGISC) line. Also disclosed are various methods of using the cell system, a kit that includes the cell system, and an isolated cell culture including an isolated HIPEC line derived from a differentiable ahGISC line.05-30-2013
20130115590MATERIALS AND METHOD FOR IMMOBILIZING, ISOLATING, AND CONCENTRATING CELLS USING CARBOXYLATED SURFACES - The present disclosure relates to immobilization of a cell using a carboxylated surface by contacting the carboxylated surface with a sample comprising the cell for a sufficient time to permit the cell to bind to the carboxylated surface. The immobilized cell may then be separated from the remainder of the sample and further manipulated to isolate, concentrate, and/or analyze the cell or a component thereof.05-09-2013
20130171625BIOCHIPS AND RELATED AUTOMATED ANALYZERS AND METHODS - The present invention provides biochips that include: (a) a plurality of cards, each card having a plurality of card apertures extending therethrough, each respective card aperture having one or more cross sectional areas; and (b) a plurality of gaskets, at least one gasket residing intermediate two neighboring cards, each gasket having a plurality of gasket apertures extending therethrough. At least some of the gasket apertures have an area that is greater than that of at least one adjacent card aperture. Different sets of the gasket apertures and card apertures define a plurality of fluidic flow channels. Also provided herein are methods of making and using biochips.07-04-2013
20130095470ASSAY FOR DETECTION OF HUMAN PARVOVIRUS B19 NUCLEIC ACID - Nucleic acid oligomers specific for human parvovirus B19 genomic DNA are disclosed. An assay for amplifying and detecting human parvovirus B19 nucleic acid in biological specimens is disclosed. Compositions for detecting the presence of parvovirus B19 genomic DNA in human biological specimens are disclosed.04-18-2013
20130115592MODIFIED HUMAN HEPATITIS C VIRUS GENOMIC RNA THAT CAN BE AUTONOMOUSLY REPLICATED - The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5′ untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3′ untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.05-09-2013
20130115591MOLECULAR METHOD FOR UNIVERSAL DETECTION OF CITRUS VIROIDS - The present invention provides methods for universally detecting 05-09-2013
20130115589Pharmaceutical Composition for Treatment and Prevention of Herpes Virus Infections - An object of the present invention is to find a protein expressed in a variety of cells and functioning as a receptor for herpesvirus and provide a preventive or remedy for herpesvirus infections capable of inhibiting binding of the receptor to herpesvirus and thereby preventing entry of the virus to cells.05-09-2013
20130101990MICROFLUIDIC SYSTEM FOR AMPLIFYING AND DETECTING POLYNUCLEOTIDES IN PARALLEL - The present technology provides for an apparatus for detecting polynucleotides in samples, particularly from biological samples. The technology more particularly relates to microfluidic systems that carry out PCR on nucleotides of interest within microfluidic channels, and detect those nucleotides. The apparatus includes a microfluidic cartridge that is configured to accept a plurality of samples, and which can carry out PCR on each sample individually, or a group of, or all of the plurality of samples simultaneously.04-25-2013
20130101988COMPOSITIONS, METHODS AND KITS TO DETECT HERPES SIMPLEX VIRUS NUCLEIC ACIDS - The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Herpes Simplex Virus (HSV) nucleic acid (eg. HSV-1 and/or HSV-2 nucleic acid). Compositions include amplification oligomers, detection probe oligomers and/or target capture oligomers. Kits and methods comprise at least one of these oligomers.04-25-2013
20130101987Detection of feline Immunodeficiency Virus - Method, device and kit for the detection of antibodies directed to Feline Immunodeficiency Virus (FIV). The method includes contacting the felid biological sample with FIV env polypeptide and detecting whether the polypeptide substantially binds to the antibody in the biological sample. The method will detect FIV antibodies in a sample from animals that have been naturally infected but the method will not detect antibodies in a sample from animals that have not been infected and that have not been vaccinated with an FIV vaccine after within about the previous five to eight weeks.04-25-2013
20130101986In Vitro Method for obtaining Intrahepatic Fibroblasts Infected with Hepatitis C Virus - The present invention relates to in vitro methods for obtaining intrahepatic fibroblasts infected with hepatitis C virus, to the infected intrahepatic fibroblasts obtained by means of these methods, and also to methods for screening for anti-fibrogenesis molecules and for anti-HCV molecules using these cells.04-25-2013
20130101992Diagnostic Assay For Type 1 Diabetes - There is an association between enteroviruses and type 1 diabetes (T1D). The present invention is based on the finding that particular enterovirus serotypes are T1D risk serotypes, while others are protective against the disease. The present invention relates to a diagnostic assay for type 1 diabetes (T1D), and especially to an assay for predicting the risk of contracting the disease. It also relates to a method of monitoring the efficacy of antiviral treatments aiming at prevention of T1D. The invention still further relates to a diagnostic kit.04-25-2013
20130101993MICROCHEMICAL CHIP, PRODUCING METHOD THEREOF AND METHOD FOR USING THE MICROCHEMICAL CHIP - According to the microchemical chip of the present invention, the sample introducing port 04-25-2013
20130101991MICROFLUIDIC ASSAY IN IDEALIZED MICROVASCULAR NETWORK FOR SELECTION AND OPTIMIZATION OF DRUG DELIVERY VEHICLES TO SIMULATED TUMORS - An apparatus for assaying a tumor drug delivery vehicle and or drug can include an idealized microvascular network (IMN) of one or more interconnected idealized flow channels in fluid communication through a porous wall with a tissue space (e.g., idealized tissue space) containing animal cells and means for quantifying drug delivery through the IMN to the animal cells.04-25-2013
20130101989Diagnostic Method for Predicting the Response of a Patient to Chemovirotherapy or Radiovirotherapy - Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15.04-25-2013
20130101985METHODS FOR THE DETECTION OF JC POLYOMA VIRUS - Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.04-25-2013
20130115593SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS - Embodiments of substrates and processes for chromogenic detection, and in particular pyrazolyl dihydrogen phosphate compounds, are disclosed.05-09-2013
20130130231Bioinformatically detectable group of novel viral regulatory genes and uses thereof - The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic address genes” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.05-23-2013
20130130232SELF-LOADING MICROFLUIDIC DEVICE AND METHODS OF USE - Microfluidic devices and methods for conducting chemical assays and biological assays using microfluidic devices are disclosed. The microfluidic devices do not require external connections, tethers, tubing, valves and actuators. The microfluidic devices are useful in methods for analyzing a wide variety of chemical and biological assays such as, for example, molecule-molecule interactions, enzyme-substrate interactions, molecule identification, minimum inhibitory concentrations, therapeutically effective amounts, and toxic amounts.05-23-2013
20130130233MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS AND USES THEREOF - The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.05-23-2013
20130130234POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA - The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.05-23-2013
20110217694FLOW CYTOMETRY-BASED SYSTEMS AND METHODS FOR DETECTING MICROBES - In various embodiments, the present disclosure describes methods and systems for detecting microbes in a sample. The methods are generally applicable to quantifying the number of target bacteria in a sample counted from a detection region of a flow cytometer histogram. The detection methods can be employed in the presence of other microorganisms and other non-target microbe components to selectively quantify the amount of a target microbe. The methods are advantageous over those presently existing for testing of foodstuffs and diagnostic evaluation in their speed, accuracy and ease of use. Various swab collection devices and kits useful for practicing the present disclosure are also described herein.09-08-2011
20130157258HCV NS5B PROTEASE MUTANTS - The invention provides polypeptides comprising an amino acid sequence comprising at least one variation from wild-type HCV NS5B polymerase, the at least one variation selected from the group consisting of cysteine, isoleucine, valine, or proline at amino acid position 419; alanine, valine, or asparagine at amino acid position 482; valine, isoleucine, threonine, or serine at amino acid position 486; and isoleucine at amino acid position 494, as the amino acid positions are defined in SEQ ID NO: 1, and having Hepatitis C Virus (HCV) NS5B polymerase activity. Polynucleotides encoding the polypeptide, antibodies, host cells, compositions, and methods for detecting an HCV NS5B polymerase having resistance to a polymerase inhibitor also are provided.06-20-2013
20130157256Method for Determining the Presence of an Analyte by Means of Small Magnetic Particles, and Corresponding Device - The invention relates to a method for determining the presence of an analyte by means of a distribution of small magnetic particles. According to said method, the magnetisations of the small particles are oriented in relation to each other by means of an outer magnetic focusing field; once the focussing field has been terminated, the magnetisations of the small particles are rotated asynchronously to the magnetic field by means of an outer magnetic field of suitable field intensity and rotational frequency, which rotates about a longitudinal axis (z); the temporal course of the superpositioned transverse magnetisation of the set of particles is detected; and the presence of the analyte is deduced from the detected temporal course. The invention also relates to a corresponding device (06-20-2013
20130157255METHOD FOR SIMULTANEOUSLY DETECTING AN ANTIGEN OF, AND AN ANTIBODY AGAINST, AN INFECTIOUS MICROORGANISM - The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method.06-20-2013
20130157254Method and apparatus for two-step surface-enhanced raman spectroscopy - A SERS method and apparatus employ a sample device having support structure including a first material containing a SER-active metal functionalized with a binding agent having specific capability for binding a designated target analyte. An analyte sample is introduced upon the functionalized SER-active metal; conditions to effect binding of the target analyte to the binding agent are maintained; unbound chemicals, biochemicals, or biologicals are removed; a second SER-active material is introduced to cause it to attach to the bound target analyte; the support structure is irradiated to generate a SER spectrum, with the first and second SER-active materials acting in concert; and the SER spectrum is detected and analyzed to determine the presence and quantity of the target analyte. Alternatively, the second SER-active material may be functionalized with a binding agent, with the procedure being modified accordingly.06-20-2013
20130157253DETECTION OF CYTOMEGALOVIRUS DNA USING AMPLIFICATION FROM BLOOD SAMPLES - Described are methods and kits for detecting cytomegalovirus DNA in liquid and dried blood samples. Primer and probe combinations for CMV detection are described as well as methods for isolating DNA from blood samples.06-20-2013
20080199852Detection method for human pappilomavirus (HPV) and its application in cervical cancer - Embodiments of the invention provide methods, assays, and kits for detecting HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with pre-malignant and malignant epithelial cell lesions. Detection of HPV DNAs, genomes, and/or oncoproteins by nucleic acid hybridization assays and immunological assays can be used in early clinical screening for HPV infection and diagnosis for cervical cancer. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.08-21-2008
20080199851METHODS AND COMPOSITIONS FOR ANALYTE DETECTION - The present invention is directed to methods and apparatus for detection of one or more analytes. Analytes include agents or components of infectious agents such as pathogenic virus, as well as enzymes, proteins and biomarkers.08-21-2008
20110223584Oligonucleotides For Detecting Human Papilloma Virus In A Test Sample - Oligonucleotides targeted to HPV Type 16 and/or Type 18 nucleic acid sequences which are particularly useful to aid in detecting HPV type 16 and or 18 are described. The oligonucleotides can aid in detecting HPV Type 16 and/or Type 18 in different ways such as by acting as hybridization assay probes, helper probes, and/or amplification primers.09-15-2011
20130203043PORTABLE RAPID DIAGNOSTIC TEST READER - A portable rapid diagnostic test reader system includes a mobile phone having a camera and one or more processors contained within the mobile phone and a modular housing configured to mount to the mobile phone. The modular housing including a receptacle configured to receive a sample tray holding a rapid diagnostic test. At least one illumination source is disposed in the modular housing and located on one side of the rapid diagnostic test. An optical demagnifier is disposed in the modular housing interposed between the rapid diagnostic test and the mobile phone camera.08-08-2013
20130203044SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR THE ORGANISM-SPECIFIC DIAGNOSIS OF SEPTICEMIA IN INFANTS - A method, system, and computer program product for producing an organism specific diagnosis of septicemia in infants is disclosed. The method involves measuring the levels of one or more biomarkers against redefined threshold values and interpreting these levels to arrive at the diagnosis. Other techniques may introduce a preliminary step of identifying higher risk subjects, as well as the integration of such methods into the final diagnostic methodology. One aspect of a technique of this method may involve measuring one more cytokines to detect specific classes of infective organisms, such as Gram-negative bacteria.08-08-2013
20110229876BIOMARKERS FOR THE DETECTION OF HEAD AND NECK TUMORS - A method of detecting the presence of specific human papilloma virus and host cell biomarkers associated with head and neck tumors in biological samples, like saliva, blood or biopsy tissue, obtained from a subject.09-22-2011
20130137085Method for Real-Time Measurement of the Individual Secretions of a Cell - The present invention relates to a method for real-time measurement of the secretion of at least one compound by at least one individual cell, comprising: 05-30-2013
20130137086HPV DNA Methylation Patterns of Diagnostic or Prognostic Significance in Cervical Cancer Screening - Disclosed are methods, compositions, devices, and systems for assessing cancer potential, state, stage, risk of progression, prognosis, etc. of a subject based on determining the methylation state of human papillomavirus (HPV) in a sample from the subject. The cancers assessed generally can be cancer associated with or caused by HPV. For example, cervical cancer, vulvar cancer, penile cancer, anal cancer, and head and neck cancer can be associated with HPV. It has been discovered that certain patterns, profiles, and sets of methylation of HPV genomes are correlated with different cancer potential, state, stage, risk of progression, prognosis, etc.05-30-2013
20130137083Detection of H5N1 Influenza Infection - A combination of H5N1 influenza peptides that provide for H5N1 diagnosis with a high level of sensitivity and specificity is described.05-30-2013
20130149694METHODS, DEVICES, KITS AND COMPOSITIONS FOR DETECTING ROUNDWORM, WHIPWORM, AND HOOKWORM - Methods, devices, kits and compositions for detecting the presence or absence of one or more helminthic coproantigens in a sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm, whipworm and/or hookworm in a fecal sample from a mammal and may also be able to distinguish between one or more helminth infections. Confirmation of the presence or absence of roundworm, whipworm and/or hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.06-13-2013
20130149695METHOD FOR DETECTING GENETIC MUTATION BY USING A BLOCKING PRIMER - The present invention provides a method for detecting a gene mutation, comprising the step of performing PCR using generic PCR primers together with a blocking primer which competes with the generic primers and was modified at one end, and a method of diagnosing gene mutation-related diseases using the same. According to the invention, detection sensitivity and specificity can be increased by blocking the amplification of normal DNA and selectively amplifying mutant DNA.06-13-2013
20130149696HIGH-THROUGHPUT METHOD FOR DETERMINING THE PRESENCE OF PAPILLOMAVIRUS-NEUTRALIZING ANTIBODIES IN A SAMPLE - The present invention relates to a method for the determination of the presence of PV-neutralizing antibodies in a sample, comprising a) contacting said sample with infectious PV particles comprising a reporter gene, wherein the gene product of said reporter gene is secreted into the growth medium, b) contacting the PV particles from a) with host cells, and c) determining PV-neutralizing antibodies based on the amount of gene product from said reporter gene, wherein, preferably, a lower amount of said gene product as compared to a reference amount is indicative of the presence of PV-neutralizing antibodies. It further relates to a host cell strongly adhering to multi-cluster plates for use in a method for diagnosing anti-PV immunity comprising the method of the present invention.06-13-2013
20130149697DETECTION OF HPV - The present invention provides compositions and methods for the detection and characterization of HPV sequences. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of HPV sequences. The present invention also provides compositions, methods and kits for screening sets of HPV sequences in a single reaction container.06-13-2013
20110275060DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING COMPLEMENT COMPONENTS ON WHITE BLOOD CELLS - The invention is related to methods of diagnosing inflammatory diseases or conditions by determining levels of components of the complement pathway on the surface of white blood cells.11-10-2011
20110275059Diagnostic Transcript and Splice Patterns of HR-HPV in Different Cervical Lesions - The present invention relates to a method for differentiating in a subject with HR-HPV between a severe form of HR-HPV infection and a mild form of HR-HPV infection. It further is concerned with a composition comprising a probe oligonucleotide mixture, a device, and a kit for use in conjunction with the method of the invention.11-10-2011
20110275058SELF-CONTAINED BIOLOGICAL ASSAY APPARATUS, METHODS, AND APPLICATIONS - A self-contained, fully automated, biological assay-performing apparatus includes a housing; a dispensing platform including a controllably-movable reagent dispensing system, disposed in the housing; a reagent supply component disposed in the housing; a pneumatic manifold removably disposed in the housing in a space shared by the dispensing platform, removably coupled to a fluidic transport layer and a plurality of reservoirs, wherein the fluidic transport layer, the reservoirs, and a test sample to be introduced therein are disposed in the housing in the space separate from the dispensing platform; a pneumatic supply system removably coupled to the pneumatic manifold in the housing in a space separate from the dispensing platform; and a control system coupled to at least one of the dispensing platform and the pneumatic supply system, disposed in the housing.11-10-2011
20100285448RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS, IN PARTICULAR ASSOCIATED WITH MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES - An isolated polynucleotide having a nucleotide sequence selected from the group consisting of (a) SEQ ID NO: 21, (b) the full-length sequences encoding a polypeptide having a peptide sequence selected from the group consisting of SEQ ID NOs: 25 and 26, and (c) the full-length complementary sequences to the sequences set forth in (a) or (b).11-11-2010
20100285445CHIMERIC CONSTRUCT OF MUNGBEAN YELLOW MOSAIC INDIA VIRUS (MYMIV) AND ITS USES THEREOF - A recombinant DNA construct, recombinant vectors and host cells comprising the dimers of DNA A and DNA B of Mungbean Yellow Mosaic India Virus (MYMIV) in a single Ti plasmid are provided herein.11-11-2010
20120258447REAL-TIME MULTIPLEXING DETECTION OF TARGET NUCLEIC ACID SEQUENCES WITH ELIMINATION OF FALSE SIGNALS - The present invention relates to the real-time multiplex detection of at least three target nucleic acid sequences with elimination of false positive signals. Unlikely to conventional real-time multiplex PCR methods, the present invention comprises two different amplification reactions in different reaction vessels from each other: a primary multiplex PCR for obtaining amplicons and a secondary nested real-time multiplex PCR using the amplicons. The present invention permits to eliminate the false positive signals generated by the dimer formation of labeled primers, false positive signals10-11-2012
20120258446Universal Multi-Variant Detection System - The present invention provides a method to diagnostically detect the variants of a given pathogen, such as HIV, hepatitis C, hepatitis B (HBV), Parvovirus B19, etc., with the use of a single detection probe.10-11-2012
20120258444ACOUSTIC WAVE (AW) SENSING DEVICES USING LIVE CELLS - In one embodiment according to the invention, there is provided a method of sensing a response of a living cell or virus to a change in conditions. The method comprises applying an essentially constant external electromotive force that causes oscillation of an acoustic wave device at essentially constant amplitude and frequency under steady state conditions. The acoustic wave device has attached at least one living cell or virus. A combined oscillating system including the acoustic wave device and the living cell or virus exhibits a fundamental frequency and at least one harmonic frequency of the combined oscillating system. The living cell or virus is exposed to a change in an environmental condition while oscillating the combined oscillating system under the essentially constant external electromotive force, whereby a response of the living cell or virus to the change in environmental condition will be indicated by a change in at least one of frequency and amplitude of the oscillation of at least one harmonic frequency of the combined oscillating system.10-11-2012
20120258443METHODS FOR THE DETECTION OF JC POLYOMA VIRUS - Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants, by determining whether the subject harbors a JCV variant with reduced binding for sialic acid relative to a normal JCV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided.10-11-2012
20100297612OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION, SCREENING, QUANTITATION, ISOLATION AND SEQUENCING OF CYTOMEGALOVIRUS AND EPSTEIN-BARR VIRUS - Described herein are primers and probes useful for detecting, screening, quantitating, isolating and sequencing CMV and EBV viral strains, and methods of using the described primers and probes.11-25-2010
20130122485METHOD OF ANALYZING BIOMATERIALS USING A MAGNETIC BEAD - Provided are methods of analyzing biomaterials using a magnetic bead. The method may include preparing a bio material including a target material, preparing first and second magnetic beads, the second magnetic bead having a size smaller than that of the first magnetic bead, forming a binding element including the target material bound on the first and second magnetic beads, separating the first magnetic bead from the binding element by using a magnet, and quantifying the target material bound on the second magnetic bead.05-16-2013
20100311039NON-TARGET AMPLIFICATION METHOD FOR DETECTION OF RNA SPLICE-FORMS IN A SAMPLE - Provided are methods of isolating RNA from a biological sample, methods and means for determining the presence of particular RNA splice-form variants in a biological sample, methods and means for determining the relative ratio of RNA ratios in a biological sample, and methods and means for predicting the progression of precancerous cervical lesions.12-09-2010
20100316992DIAGNOSTIC TEST - Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.12-16-2010
20100316991HUMAN PARAINFLUENZA VIRUS TYPE 3 EXPRESSING THE ENHANCED GREEN FLUORESCENT PROTEIN FOR USE IN HIGH-THROUGHPUT ANTIVIRAL ASSAYS - Disclosed herein is a recombinant human parainfluenza virus expressing the enhanced green fluorescent protein. Methods of making and methods of using a recombinant human parainfluenza virus expressing the enhanced green fluorescent protein are also disclosed. A recombinant human parainfluenza virus expressing the enhanced green fluorescent protein was rescued and evaluated for its use in antiviral assays. Without limiting the invention, in one example, there is provided a cDNA clone of SEQ ID NO: 1.12-16-2010
20100316990Biomarkers for HPV-Induced Cancer - Biomarkers that correlate with progression to neoplasia in human papillomavirus (HPV) induced cancer, for example cervical cancer have been identified. These biomarkers can be used to diagnosis or assist in the diagnosis of HPV-induced cancer. They can also be used to increase the positive predictive value of current screening modalities. In addition, they can provide insights into the biology of HPV-induced cancer and thus provide leads for the development of nonsurgical therapies. Exemplary biomarkers include cornulin, PA28 β, DJ-1, actin, transthyretin, HSPB1, CV intracellular channel 1, cytokeratin 8, transferrin, Hsρβ6 (HSP20), aflatoxin reductase, α2 type I collagen, creatine kinase B, cytokeratin 13 GST π, PA28 α, Manganese SOD, lamin A/C, serpin B1 (elastase inhibitor), serpin B3 (SCAA1), cytokeratin 10, cytokeratin 6A, and trp-tRNA synthetase. Preferred biomarkers for HPV-induced cancer include cornulin, DJ-1, PA28 α, and PA28 β, trp-tRNA synthetase, HSPβ6, creatine kinase B, aflatoxin reductase, GST π, transthyretin, transferrin, α2-type 1 collagen, and combinations thereof.12-16-2010
20100316989METHOD FOR SCREENING AN INHIBITORY AGENT OF HBV PROLIFERATION BY USING THE INTERACTION BETWEEN HBV CAPSID AND SURFACE PROTEINS BASED ON CELLULAR IMAGING - The present invention relates to a method for screening an inhibitory agent of HBV proliferation by measuring the interaction (binding strength) between capsid protein and surface protein, necessary for the proliferation of HBV, by using cellular imaging, more precisely a method for measuring changes on cellular imaging caused by the interaction between a fusion protein containing PreS domain of HBV surface protein and PH (Pleckstrin homology) domain sequence and a fusion protein containing capsid protein and fluorescence protein (GFP) interacting with the said fusion protein. The method of the present invention detecting the interaction between proteins necessary for HBV proliferation at cellular level can be effectively used for the screening of a novel inhibitory agent of HBV proliferation at cellular level.12-16-2010
20130157259METHOD OF AMPLIFYING DNA FROM RNA IN SAMPLE AND USE THEREOF - Provided are methods of efficiently amplifying DNA from RNA in sample, methods of efficiently estimating an amount of RNA in a sample, and compositions for efficiently amplifying DNA from RNA in a sample.06-20-2013
20120282596Sensor for Biomolecules - A method for sensing biomolecules in an electrolyte includes exposing a gate dielectric surface of a sensor comprising a silicon fin to the electrolyte, wherein the gate dielectric surface comprises a dielectric material and antibodies configured to bind with the biomolecules; applying a gate voltage to an electrode immersed in the electrolyte; and measuring a change in a drain current flowing in the silicon fin; and determining an amount of the biomolecules that are present in the electrolyte based on the change in the drain current.11-08-2012
20120282595HIGH THROUGHPUT CELL-BASED HPV IMMUNOASSAYS FOR DIAGNOSIS AND SCREENING OF HPV-ASSOCIATED CANCERS - Methods for quantifying an HPV protein expression in a clinical sample are disclosed. The quantifying methods include the process for obtaining the clinical sample. Such a clinical sample is consisted of a population of cells that are susceptible to infection by an HPV. The quantifying methods also include the process for depositing the clinical sample into a container. The clinical sample is contacted with the first antibody that specifically binds to an HPV protein which is expressed by an HPV-infected cell under a condition that promotes specific binding of the first antibody to the HPV protein expressed by the population of cells. The methods further include the process for quantifying the specific binding of the first antibody and thereby quantifying the HPV protein expression in the clinical sample. The assay provides an objective test to identify patients with high-grade precursor from cytology samples before biopsy.11-08-2012
20120282594METHOD OF ENHANCED DETECTION FOR NANOMATERIAL-BASED MOLECULAR SENSORS - Sensors based on single-walled carbon nanotubes and graphene which demonstrate extreme sensitivity as reflected in their electrical conductivity to gaseous molecules, such as NO, NO11-08-2012
20120282593Method and Kit for Detecting Virulent Strains of Influenza Virus - The present invention is a kit and method for determining the virulence of an influenza virus based upon the presence or absence of leucine at position 62, arginine at position 75, arginine at position 79 and leucine at position 82 of the polymerase basic 1-F2 protein amino acid sequence.11-08-2012
20090202985METHOD AND APPARATUS FOR DETECTING AN ELECTRIC FIELD FLUCTUATION ASSOCIATED WITH THE PERMEABILIZATION OF A BACTERIAL CELL WALL - A sensor for detecting an electric field fluctuation associated with the permeabilization of a bacterial cell wall comprises a substrate, at least two electrodes integrated on the substrate, an amplifier integrated on the substrate, and a processor electrically connected to the amplifier to analyze the amplified signal. The substrate and the at least two electrodes define a well between the at least two electrodes, and the at least two electrodes being configured to generate a signal in response to an electric field fluctuation in close proximity to the well or the electrodes triggered when at least one antibacterial agent associated with the well contacts a cognate target. The amplifier is configured to generate an amplified signal in response to the signal. In addition, the processor is electrically connected to the amplifier to analyze the amplified signal.08-13-2009
20130157257Compositions Comprising the NC2 Domain of Collagen IX and Methods of Using Same - The present invention relates to the newly identified timerization initiating and stagger determining capacity of the NC2 domain of collagen IX. The invention further relates to a hexavalent molecular building block wherein the linkage of additional moieties to the amino and carboxyl terminals of monomers comprising the NC2 domain of collagen IX promotes the directed association of those moieties via the trimerization initiating and stagger determining capacity of the NC2 domain of collagen IX.06-20-2013
20130183661STABILIZED LEUKOCYTES AND THEIR USE IN HIV-DIAGNOSIS AND THERAPY - A method of producing extremely stable leukocytes from human blood samples which are stable for long period of time under extraordinary temperature conditions. The method also relates to producing and stabilizing the leukocytes with formaldehyde release agents. The method is directed at the use of the stabilized leukocytes as a control in assays for determining CD4+ and HIV diagnosis and therapy.07-18-2013
20130183660Apparatus for Disease Detection - Among others, the present invention provides apparatus for detecting a disease, comprising a system delivery biological subject and a probing and detecting device, wherein the probing and detecting device includes a first micro-device and a first substrate supporting the first micro-device, the first micro-device contacts a biologic material to be detected and is capable of measuring at the microscopic level an electric, magnetic, electromagnetic, thermal, optical, acoustical, biological, chemical, physical, or mechanical property of the biologic material.07-18-2013
20130183659MICROFLUIDIC DEVICES - The present invention provides novel microfluidic substrates and methods that are useful for performing biological, chemical and diagnostic assays. The substrates can include a plurality of electrically addressable, channel bearing fluidic modules integrally arranged such that a continuous channel is provided for flow of immiscible fluids.07-18-2013
20130183658Methods and Devices for Rapid Detection of Live Microorganisms by Aptamers and/or Antibodies Immobilized on Permeable Membranes - The present invention provides methods, devices and test kits for rapid detection and identification of one or more live target microorganisms in a liquid sample or grown on plates containing solid nutrient media. The invention includes mixing the one or more target microorganisms with one or more aptamers and/or one or more antibodies, each conjugated to a reporter compound and specific for a first site on the one or more target microorganisms to form a mixture. The mixture is placed on a permeable membrane having immobilized thereon one or more aptamers linked to an amine compound, and/or one or more antibodies, each specific for a second site on the one or more target microorganisms or a site on the aptamer conjugate and/or antibody conjugate. A detection solution is added to the membrane, and detection and identification of the one or more target microorganisms is achieved in less than one hour.07-18-2013
20130183657MATERIALS AND METHOD FOR DETECTING CYTOMEGALOVIRUS (CMV) - Methods and kits for amplifying cytomegalovirus (CMV) nucleic acid sequences in a sample comprising pairs of primers for amplification of UL34 and UL80.5 nucleic acid sequences or one or more reagents.07-18-2013
20110281258Human Immunodeficiency Virus And Uses Thereof - The present invention relates to Human Immunodeficiency Virus-1 (HIV-1) Group P of the strain designated 06CMU14788 and fragments thereof, primers which are derived from HIV-1 Group P, immunogenic regions thereof, immunoassays and nucleic acid based assays for the detection of Human Immunodeficiency Virus (HIV) that employ said HIV-1 Group P or fragments thereof and therapeutic compositions containing said HIV-1 Group P or fragments thereof.11-17-2011
20110287407INTEGRATED METHODS AND SYSTEMS FOR PROCESSING A MOLECULAR PROFILE - An automated and integrated matching of a biological specimen to an individual, can include a collector having substrate materials and configured to selectively collect and release at least one bio-molecular species from a biological specimen; a self-contained mobile automated testing instrument configured to receive the biological specimen and further configured to generate, store and output a molecular profile of the at least one predetermined bio-molecular species; a processor based system communicatively coupled to the self-contained mobile automated testing instrument and configured to receive the molecular profile; and wherein the processor based system is configured to provide a quantitative comparative analysis and report of the molecular profile with a selected molecular profile. In one approach, at least one predetermined bio-molecular species and stored pre-selected molecular profile is for a predetermined sequence of interest, such as a DNA-profile as defined by a Combined DNA Index System (CODIS) system.11-24-2011
20130122488METHOD OF DETECTING SPARSE PARTICLES IN A SOLUTION USING A LIGHT-EMITTING PROBE - There is provided an optical analysis technique enabling the detection of the condition or characteristic of a particle to be observed contained at a low concentration or number density in a sample solution using a light-emitting probe. The inventive optical analysis technique uses an optical system capable of detecting light from a micro region in a solution, such as an optical system of a confocal microscope or a multiphoton microscope, to detect the light from the light-emitting probe having bound to a particle to be observed while moving the position of the micro region in the sample solution (while scanning the inside of the sample solution with the micro region), thereby detecting individually the particle crossing the inside of the micro region to enable the counting of the particle(s) or the acquisition of the information on the concentration or number density of the particle.05-16-2013
20130122486Compositions Comprising Human Embryonic Stem Cells and Their Derivatives, Methods of Use, and Methods of Preparation - The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.05-16-2013
20130122484DIAGNOSTIC METHOD FOR DETERMINING ANIMALS PERSISTENTLY INFECTED (PI) WITH BOVINE VIRAL DIARRHEA VIRUS (BVDV) - The present specification relates to methods and kits for detection of animals that are persistently infected (PI) with a Bovine Viral Diarrhea Virus (BVDV) and/or transiently infected (TI) with BVDV. Some embodiments describe methods to distinguish a PI animal from a TI animal using a single one-time testing protocol.05-16-2013
20110306036RT-LAMP assay for the detection of pan-serotype dengue virus - The invention relates to a reverse transcription loop-mediated isothermal amplification (LAMP) assay for the detection of dengue virus. The assay is capable of simultaneous detection of dengue 1-4 serotypes in a single reaction.12-15-2011
20090098530Cell Line For Producing Coronaviruses - The invention relates to the production of coronaviruses. In particular, the invention relates to methods for producing SARS-CoV by using cells expressing a functional SARS-CoV receptor04-16-2009
20110311962METHOD FOR HIGH-RESOLUTION DETECTION OF NANOPARTICLES ON TWO-DIMENSIONAL DETECTOR SURFACES - The invention relates to a surface plasmon resonance spectrometer comprising a radiation source that emits substantially monochromatic radiation, a sensor surface, an optical arrangement for lighting the sensor surface by the radiation emitted from the radiation source such that surface plasmons can be created in the sensor surface, a detector having a plurality of image elements and observation optics for depicting the radiation reflected by the sensor surface on the detector, characterized in that the resolution capability of the observation optics and of the detector is larger than the resolution that can be obtained by the deflection-limited radiation source.12-22-2011
20110311961DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUSES - Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.12-22-2011
20130189673Assay Device Having Controllable Sample Size - Disclosed is an assay device which comprises a liquid sample addition zone, a reagent zone, a detection zone, and a wicking zone, all defining a fluid flow path. The device further comprises a reagent addition zone along and in fluid communication with the fluid flow path downstream of the sample addition zone and upstream of the detection zone. An interrupting wash is added at this reagent addition zone in accordance with the method of the subject invention to control sample volume. The interrupting wash fluid is added at a predetermined fill volume on the chip device and also serves to wash the detection channel and fill the remaining chip volume.07-25-2013
20130189672Assay Device Having Multiple Reagent Cells - An assay device includes: a liquid sample zone; a reagent zone downstream and in fluid communication with the sample zone. The reagent zone includes at least two reagent cells containing a reagent material and arranged in the reagent zone such that each reagent cell experiences substantially the same flow conditions of sample from the sample zone. The reagent cells divide the sample flow from the sample zone into multiple flow streams. Also includes are: one or more flow control elements disposed downstream from the reagent zone which combine the multiple flow streams into fewer flow streams; a detection zone in fluid communication with the reagent zone; and a wicking zone in fluid communication with the detection zone having a capacity to receive liquid sample flowing from the detection zone. The sample addition zone, the detection zone and the wicking zone define a fluid flow path.07-25-2013
20090087832Nucleic acids and new polypeptides associated with and/or overlapping with hepatitis C virus core gene products - DNA encoding core+1 polypeptides of hepatitis C virus (HCV), nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.04-02-2009
20110318727GENETIC MARKER FOR DETECTION OF HUMAN PAPILLOMAVIRUS - The invention provides compositions and methods for the differential detection of high risk forms of HPV from a urine sample provided by a patient. Specifically, the invention provides primers and probes that specifically recognize and bind sequences within the E1 gene of HPV. Detection of high risk forms of HPV identify individuals at risk of developing or in the early stages of cervical carcinoma.12-29-2011
20080286753Wicking Cassette Method and Apparatus for Automated Rapid Immunohistochemistry - A sample processing system that may be configured to achieve automatic withdrawal of a substance at the end of appropriate processing sequences such as histochemical processing may involve a plurality of samples for which substances removed by moving a wicking cartridge that may have sequentially advanced absorbsant material on rolls that are advanced an appropriate amount based upon usage in sequences such as repeated elimination and reapplication of a fluidic substance perhaps through the action of capillary motion in order to refresh a microenvironment adjacent to a sample such as a biopsy or other such sample. Snap in wicking cassettes and perhaps antibody and other substances may be included to ease operator actions and to permit location specific substance applications perhaps by including single container multiple chamber multiple fluidic substance magazines, linearly disposed multiple substance source, and primary antibody cartridges.11-20-2008
20120009566LUMINESCENCE ASSAY METHOD - A bioassay employing a first group including a lanthanide ion carrier chelate and a first recognition element, a second group including an antenna ligand and a second recognition element; where the lanthanide ion carrier chelate binds strongly to lanthanide, or the lanthanide ion carrier chelate binds moderately to lanthanide, and an agent complexing the lanthanide ion is additionally employed at a concentration of at least 1 pmol/l. The antenna ligand binds weakly to the lanthanide ion. Analyte recognition by the first recognition element and by the second recognition element results in either chelate complementation and increased fluorescence, or chelate discomplementation and decreased fluorescence.01-12-2012
20120009562High-Risk Human Papillomavirus Detection - This invention provides compositions and methods for detecting HPV in a sample. This invention also provides related kits, systems, and computers.01-12-2012
20120015347Methods for Assaying Cellular Binding Interactions - There are provided methods, and devices for assaying for a binding interaction between a protein, such as a monoclonal antibody, produced by a cell, and a biomolecule. The method may include retaining the cell within a chamber having an aperture; exposing the protein produced by the cell to a capture substrate, wherein the capture substrate is in fluid communication with the protein produced by the cell and wherein the capture substrate is operable to bind the protein produced by the cell; flowing a fluid volume comprising the biomolecule through the chamber via said aperture, wherein the fluid volume is in fluid communication with the capture substrate; and determining a binding interaction between the protein produced by the cell and the biomolecule.01-19-2012
20120015346INFLUENZA VIRUS DETECTION AND DIAGNOSIS - The invention discloses compositions comprising nucleic acid(s) for rapid detection, identification, differentiation, and/or diagnosis of certain Influenza virus A subtypes, e.g., H1N1, H3N2 and A(2009 H1N1)pdm, and methods of use thereof, e.g., Short-run RT-PCR, including an RT-PCR assay kit, comprising the disclosed composition(s).01-19-2012
20080280283Methods For Assessing Fatigue Level and Applications Thereof - Level of fatigue that accompanies everyday life or a disease can be simply, easily, and quantitatively assessed by obtaining a body fluid from a test subject and measuring the amount of human herpesvirus in the body fluid. Furthermore, the anti-fatigue potency of anti-fatigue substances and anti-fatigue food products can be measured.11-13-2008
20120021407Methods and Devices for Rapid Urine Concentration - The present invention provides a device for the concentration of one or more target analytes contained in a urine sample. The device comprises a tube comprising an upper portion defining an opening for receiving the urine sample and a lower tapered portion terminating in collection reservoir. The tube contains a predetermined amount of a particulate binding agent which specifically binds the one or more target analytes and of a predetermined amount of a binding buffer. The device comprises means for seating the opening of the tube. The present invention further provides methods and kits for concentrating one or more target analytes in murine sample.01-26-2012
20120021406METHOD FOR MONITORING A STERILIZATION PROCESS - The disclosed invention relates to a method for monitoring a sterilization process. The method comprises: (A) exposing an article to be sterilized and a biological indicator to a sterilization medium during a sterilization process, the biological indicator comprising a cell with a plasma membrane; and (B) measuring the membrane potential of the cell to detect the viability of the cell.01-26-2012
20120021405Single Chain Antibody for the Detection of Noroviruses - The present invention concerns compositions and methods for detecting Norovirus or Norovirus particles. In particular, the present invention encompasses antibodies for detecting Norovirus or Norovirus particles, including, for example, monoclonal antibodies that have broad specificity of binding to various genogroups of norovirus.01-26-2012
20120021404Method for Diagnosis and Monitoring of Viral Infection by Analysis of Viral Transrenal Nucleic Acids in Urine - The present invention relates to methods for diagnosis or monitoring of viral infection by detecting the presence of transrenal viral nucleic acids or nucleic acids of viral origin in urine sample, with or without isolation of nucleic acids from a urine sample. The analysis of the nucleic acids is performed through hybridization of the nucleic acids with specific probes, or through a chain amplification reaction with specific primers. The methods are applicable to all viral pathogenic agents, including RNA, DNA, episomal, or integrated viruses.01-26-2012
20120021403Human Endogenous Retrovirus with Foamy-Like Properties and Uses Thereof - The invention relates to the discovery of a human endogenous retrovirus (HERV) family, Type I HERV-K (HML-2) which appear to be active in vitro and in vivo, infectious, and which have the have the salient features and properties of foamy retroviruses. Based on its natural replication in humans, and that it protects the host from viral and tumor transformation, this non-pathogenic endogenous virus could be developed as a replication competent gene therapy vector. It also is expected to have much higher efficacy than other vectors as it crosses the bloodbrain barrier and infects almost all cell types in the host (proliferating or not). It may naturally lyse tumor cells or infected cells, and thus could even be used without genetic modification. Of course, this vector could be used in traditional ways with it ability to replicate genetically removed. In addition to its value as a vector, as it is reactivated with infection, its detection could also be used to monitor the safety of gene therapy (irrespective of vector type used), as well as other biological therapies including vaccination, blood transfusion, transplantation and xenotransplantation. Finally it may be used to screen for new therapeutic and prophylactic treatments for a wide variety of diseases.01-26-2012
20120021402BIOSENSOR APPARATUSES AND METHODS THEREOF - A biosensor has one or more field effect transistors each comprising a source region and a drain region separated by a channel region and a gate positioned offset and spaced from the channel region. The biosensor also has one or more molecular probes coupled to at least one of the channel region and the offset gate, the one or more molecular probes configured to mate with at least one target. A method for detection of a target is also disclosed. One or more targets are immobilized as an electric field shunt between an offset gate and a channel region for one or more biosensors. A target measurement value is determined in proportion to a number of the one or more biosensors having the electric field shunt.01-26-2012
20120028247PLASMON SENSOR AND MANUFACTURING METHOD THEREFOR, AND METHOD FOR INSERTING SAMPLE INTO PLASMON SENSOR - A plasmon sensor includes a first metal layer and a second metal layer having an upper surface facing a lower surface of the first metal layer. The upper surface of the first metal layer is configured to receive an electromagnetic wave. A hollow space is provided between the first and second metal layers, and is configured to be filled with a test sample containing a medium. This plasmon sensor has a small size and a simple structure.02-02-2012
20120028246KIT FOR DETECTING HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS SUBTYPE H5N1 - Disclosed by the invention are an immunoassay kit and an immunoassay method for detecting highly pathogenic avian influenza virus subtype H5N1 rapidly, conveniently and specifically. Also disclosed are an immunochromatographic detection kit and an immunochromatographic detection method for detecting the virus subtype H5N1 rapidly, conveniently and specifically. It is found that a monoclonal antibody 4G6 produced by using the virus subtype H5N1 as an immunogen does not react with the subtype H5N2 virus or a subtype H5N3 virus and reacts only with a subtype H5N1 virus specifically. It is also found that only an avian influenza virus subtype H5N1 can be detected specifically by an immunoassay utilizing the monoclonal antibody 4G6. It is further found that the sensitivity of the detection of immunochromatography can be increased by adding a nonionic surface and a water-soluble vinyl polymer having a polar group containing an oxygen atom and a nitrogen atom to a developing solution to be used in the immunochromatography.02-02-2012
20120028244Anti-Viral Azide Containing Compounds - Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.02-02-2012
20120028243AMPLIFICATION GENIQUE STATISTIQUE POUR L'IDENTIFICATION SANS A PRIORI DE MICRO-ORGANISMES PAR SEQUENCAGE SANS ETAPE DE CLONAGE - A pair of hexamers and a pair of primers specifically for identifying, without preconceptions, microorganisms in a sample, and a method for identifying one or more microorganisms, and a microorganism identification kit that uses the abovementioned hexamers and primers.02-02-2012
20120028242BIOSENSOR FOR DETECTING MULTIPLE EPITOPES ON A TARGET - The present invention encompasses a method for detecting a target comprising a repeating epitope.02-02-2012
20130196308MULTIPARAMETER ASSAY - The present invention is related to the field of pathogenic diagnostics and provides the means for typing and assessing the physical status of a pathogenic infection in a host. It is in particular directed to the determination of human papilloma virus (HPV) and the application of the assays according to the invention in monitoring the disease progression of HPV related cancer, i.e. in the differentiation between regressive and progressive HPV infected lesions.08-01-2013
20130196309WOVEN HYDROGEL BASED BIOSENSOR - A porous hydrogel sensor that is responsive to the presence of one or more target compounds in solution is synthesized based on demixing of certain molecules in the presence of a target compound. The porous hydrogel sensor may include fluorescently tagged antibodies that are noncovalently bound to the gel and then released in the presence of the target antigen. The porous hydrogel sensor may alternatively include dissolvable cross-links using polymerized antibody and antigen complexes so that, in the presence of the target antigen, the cross-links will be displaced and the hydrogel will dissolve.08-01-2013
20130196310Method and Device for Combined Detection of Viral and Bacterial Infections - A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample.08-01-2013
20130196311Method and Device for Combined Detection of Viral and Bacterial Infections - A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample.08-01-2013
20120040334Diagnostic Transcript and Splice Patterns of HPV16 in Different Cervical Lesions - The present invention relates to a method for differentiating in a subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on determining the amount of a first gene product and a second gene product in a sample of a subject and calculating a ratio of the amount of said first gene product and the amount of said second gene product. Further envisaged by the present invention is a composition comprising an oligonucleotide mixture. Also envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention.02-16-2012
20120045753SEQUENCES DIAGNOSTIC FOR SHRIMP PATHOGENS - Primers have been isolated that are diagnostic for the detection of the white spot syndrome virus (WSSV). The primers are based on a new portion of the WSSV genome and may be used in primer directed amplification or nucleic acid hybridization assay methods.02-23-2012
20080261198Diagnostic Primers and Method for Detecting Avian Influenza Virus Subtype H5 and H5n1 - The present invention provides primers directed to conserved regions of the HA and NA genes of avian influenza virus subtypes H5 or H5N1, and provides a method for detecting avian influenza subtype H5 or H5N1.10-23-2008
20130203047Increasing Confidence of Allele Calls with Molecular Counting - Aspects of the present invention include methods and compositions for determining the number of individual polynucleotide molecules originating from the same genomic region of the same original sample that have been sequenced in a particular sequence analysis configuration or process. In these aspects of the invention, a degenerate base region (DBR) is attached to the starting polynucleotide molecules that are subsequently sequenced (e.g., after certain process steps are performed, e.g., amplification and/or enrichment). The number of different DBR sequences present in a sequencing run can be used to determine/estimate the number of different starting polynucleotides that have been sequenced. DBRs can be used to enhance numerous different nucleic acid sequence analysis applications, including allowing higher confidence allele call determinations in genotyping applications.08-08-2013
20130203046SYSTEM AND METHOD INCLUDING ANALYTICAL UNITS - Systems and methods for processing and analyzing samples are disclosed. The system may process samples, such as biological fluids, using assay cartridges which can be processed at different processing locations. In some cases, the system can be used for PCR processing. The different processing locations may include a preparation location where samples can be prepared and an analysis location where samples can be analyzed. To assist with the preparation of samples, the system may also include a number of processing stations which may include processing lanes. During the analysis of samples, in some cases, thermal cycler modules and an appropriate optical detection system can be used to detect the presence or absence of certain nucleic acid sequences in the samples. The system can be used to accurately and rapidly process samples.08-08-2013
20130203045METHOD FOR DETECTING NUCLEIC ACIDS BASED ON AGGREGATE FORMATION - The invention provides methods to detect or determine the presence or amount of a pathogen, such as a virus or bacterium, in a sample or the amount of cells based on the detection of their genomic DNA. The method employs magnetic substrates and subjects the sample and the magnetic substrate to forms of energy so as to induce aggregate formation and detects the aggregates.08-08-2013
20120094277Methods of producing competitive aptamer FRET reagents and assays - Methods are described for the production and use of fluorescence resonance energy transfer (FRET)-based competitive displacement aptamer assay formats. The assay schemes involve FRET in which the analyte (target) is quencher (Q)-labeled and previously bound by a fluorophore (F)-labeled aptamer such that when unlabeled analyte is added to the system and excited by specific wavelengths of light, the fluorescence intensity of the system changes in proportion to the amount of unlabeled analyte added. Alternatively, the aptamer can be Q-labeled and previously bound to an F-labeled analyte so that when unlabeled analyte enters the system, the fluorescence intensity also changes in proportion to the amount of unlabeled analyte. The F or Q is covalently linked to nucleotide triphosphates (NTPs), which are incorporated into the aptamer by various nucleic acid polymerases, such as Taq or Deep Vent Exo04-19-2012
20120094276METHODS AND DEVICES TO ENHANCE SENSITIVITY AND EVALUATE SAMPLE ADEQUACY AND REAGENT REACTIVITY IN RAPID LATERAL FLOW IMMUNOASSAYS - Methods and devices for rapid lateral flow immunoassays to detect specific antibodies within a liquid sample while also validating the adequacy of the liquid sample for the presence of immunoglobulin and the integrity and immunoreactivity of the test reagents that detect the antibodies of interest, without requiring instrumentation. The methods and devices provide for delivery of a diluted liquid sample to a single location that simultaneously directs the liquid flow along two or more separate flow paths, one that serves as a positive control to confirm that all critical reagents of the test are immunoreactive, and that the sample being tested is adequate, and the other to detect specific antibodies if present.04-19-2012
20120094275METHODS AND KITS FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PANCREATIC PATIENTS USING POLYSPECIFIC CAPTURE AND COCKTAIL DETECTION REAGENTS - A highly sensitive assay is disclosed which combines immunomagnetic enrichment with multiparameter flow cytometric or image cytometry to detect, enumerate and characterize carcinoma cells in the blood. The present invention incorporates the conjugation of different antibodies to the same ferrofluid. This has the effect of making the ferrofluid polyspecific with respect to the antigens that the ferrofluid will bind. The multiple antibodies present on the same ferrofluid do not appear to block or otherwise interfere with each other. Such ferrofluids have the highly desirable effect of being able to bind specifically to more than one type of cell. The assay is especially useful to enable the capture of CTCs that have low EpCAM expression, but high expression of other tumor markers; Accordingly, the assay facilitates the biological characterization and staging of carcinoma cells.04-19-2012
20120094274IDENTIFICATION OF SWINE-ORIGIN INFLUENZA A (H1N1) VIRUS - The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of viruses (e.g., swine-origin influenza A (H1N1) virus) which are members of the influenza virus family by amplification of a segment of viral nucleic acid followed by molecular mass analysis.04-19-2012
20120094273IMMUNOLOGICAL METHOD FOR DETECTING ACTIVE JCV INFECTION - The invention relates to an immunological method for detecting an extra renal active infection by JC virus in a patient candidate for a treatment with an immunosuppressive treatment or during the course of this treatment.04-19-2012
20120094272SIGNAL ENHANCEMENT SYSTEM WITH MULTIPLE LABELED-MOIETIES - Dipstick tests for detecting analyte are described. In a preferred embodiment, a multiple biotinylated antibody capable of binding analyte is bound to an anti-biotin antibody labelled with colloidal gold and wicked up the dipstick with test solution thought to contain analyte. Complex formed between analyte, biotinylated anti-analyte antibody, and colloidal gold labelled anti-biotin antibody is captured at a capture zone of the dipstick. Presence of colloidal gold label at the capture zone indicates the presence of analyte in the test solution. The sensitivity of analyte detection using such methods is an order of magnitude higher than for comparable methods in which biotinylated anti-analyte antibody bound to analyte is wicked up the dipstick in a first step, and a colloidal gold labelled anti-biotin antibody is wicked up the dipstick in a separate step. Kits for performing the tests of the invention are also described.04-19-2012
20120094271SELECTING FOR COOPERATIVELY INTERACTING MOLECULES - The present invention provides method of identifying molecules that cooperatively and positively interact with either a ligand or a target molecule of a ligand/target molecule pair, or molecules that interact with a ligand/target molecule complex.04-19-2012
20120094270SELF-EXCITING, SELF-SENSING PIEZOELECTRIC CANTILEVER SENSOR FOR DETECTION OF AIRBORNE ANALYTES DIRECTLY IN AIR - A method for detection of airborne biological agent using a piezoelectric cantilever sensor that includes a piezoelectric layer and a non-piezoelectric layer. A recognition entity is placed on one or both of the two layers. The antibody that recognizes and binds to the airborne species may be chemically immobilized on the cantilever sensor surface. In one embodiment, the cantilever sensor is attached to a base at only one end. In another embodiment, the sensor includes first and second bases and at least one of the piezoelectric layer and the non-piezoelectric layer is affixed to each of the first and second bases to form a piezoelectric cantilever beam sensor. In this embodiment, resonance is measured via stress on the piezoelectric layer and it has been demonstrated that such sensors are robust and exhibit excellent sensing characteristics in gaseous media with sufficient sensitivity to detect airborne species at relatively low concentrations.04-19-2012
20130209989OLIGONUCLEOTIDE PRIMER COMPOSITION - Oligonucleotide primer useful for synthesizing a cDNA copy of HIV-1 nucleic acids from a broad range of HIV-1 subtypes, including M group and O group variants.08-15-2013
20130209987OLIGONUCLEOTIDE SETS FOR DETECTION OF HUMAN PAPILLOMAVIRUS - Disclosed are methods and kits for detecting high risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, that are known to cause abnormal cell growth and cancer. The disclosed methods and kits allow a rapid and quantitative real-time PCR detection of all high risk strains of HPV in a single PCR reaction. The procedure promises to facilitate the rapid high throughput detection of high risk strains of HPV in a cost effective and reliable manner.08-15-2013
20130209988MICROFLUIDIC DEVICES FOR THE CAPTURE OF BIOLOGICAL SAMPLE COMPONENTS - Methods and systems for selectively capturing analytes, such as cells, e.g., circulating tumor cells (CTCs), from fluid samples are disclosed. The methods include contacting the sample with an analyte binding moiety that selectively binds to the analytes; optionally separating first components of the sample including a majority of the analytes bound to the binding moieties from second components of the sample using size-based separation, e.g., in a microfluidic channel; adding to the first components of the sample a plurality of binding agents under conditions that enable a plurality of the binding agents to be linked to the analyte binding moieties to form multivalent tagging agents bound to the analyte; passing the first components of the sample past a surface to which is attached a plurality of capture agents that selectively bind to the binding agents; and capturing the analytes by providing conditions that enable the multivalent tagging agents bound to the analytes to bind to one or more of the capture agents.08-15-2013
20130209990DETECTION OF NUCLEIC ACIDS BY TYPE-SPECIFIC HYBRID CAPTURE METHODS - Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid sequences. The method produces DNA/RNA hybrids which can be detected by a variety of methods.08-15-2013
20130209991WIRELESS SWNT SENSOR INTEGRATED WITH MICROFLUIDIC SYSTEM FOR VARIOUS LIQUID SENSING APPLICATIONS - Sensors based on single-walled carbon nanotubes (SWNT) are integrated into a microfluidic system outfitted with data processing and wireless transmission capability. The sensors combine the sensitivity, specificity, and miniature size of SWNT-based nanosensors with the flexible fluid handling power of microfluidic “lab on a chip” analytical systems. Methods of integrating the SWNT-based sensor into a microfluidic system are compatible with the delicate nature of the SWNT sensor elements. The sensor devices are capable of continuously and autonomously monitoring and analyzing liquid samples in remote locations, and are applicable to real time water quality monitoring and monitoring of fluids in living systems and environments. The sensor devices and fabrication methods of the invention constitute a platform technology, because the devices can be designed to specifically detect a large number of distinct chemical agents based on the functionalization of the SWNT. The sensors can be combined into a multiplex format that detects desired combinations of chemical agents simultaneously.08-15-2013
20130209992METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS - Methods for capturing a target nucleic acid from a sample by using a capture probe that binds nonspecifically to the target nucleic acid and binds specifically to an immobilized probe via a specific binding pair that has one member on the capture probe and one member on the immobilized probe are disclosed. Compositions that include a capture probe that binds nonspecifically to a target nucleic acid and specifically to an immobilized probe via binding of members of a specific binding pair in a solution phase of a reaction mixture are disclosed.08-15-2013
20130209993SAMPLE COLLECTION SYSTEM AND METHOD FOR USE THEREOF - A sample collection system capable of collecting, storing and dispensing a liquid sample is disclosed. The collection system includes a collector composed of a material which has the unique ability to express constituents of interest at levels which are much more concentrated than their levels in the fluid samples from which they are expressed, where the expressed highly concentrated sample can then be used with modern rapid screening/testing protocols, such as solid phase assays, to test for the constituents of interest. Thus, it is now possible to obtain analytes of interest, such as the HIV protein antibodies, from saliva samples at concentrations that are detectable with systems and/or devices that are typically utilized only for blood serum or plasma testing. The collector is sized and shaped to fit within a recovery container, which, in turn, is sized and shaped to fit within a collection tube. The recovery container includes an aperture which does not permit passage of fluid under ambient conditions, but facilitates transfer thereof when subjected to pressure. An optional channel within the collection tube facilitates dispensing of the sample for further processing.08-15-2013